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Chapter 1
General introduction and outline o f the thesis

The main focus o f this thesis is the identification o f novel genes and functional protein 
networks contributing to four neurodevelopmental disorders: developmental dyslexia 
(DD), attention deficit hyperactivity disorder (ADHD), motor coordination problems 
(MCP) and autism spectrum disorders (ASDs). In this introduction, the phenotype, 
prevalence, heritability, gene identification methods and neuroanatomical findings for 
these disorders are briefly described, followed by a paragraph discussing the comorbidity 
and genetic overlap between them. In addition, the overall and specific aims o f the thesis 
are presented as they are examined in each chapter.
Phenotype
All neurodevelopmental disorders that are studied in this thesis have a distinct phenotype, 
a set o f cognitive and behavioural symptoms and traits that defines them and sets them 
apart from other, related and often comorbid (see below) disorders.
Developmental dyslexia (DD) is a neurodevelopmental learning disorder that can be 
defined as a specific and significant impairment in reading ability that cannot be explained 
by deficits in either intelligence, learning opportunity, motivation or sensory acuity 
(Grigorenko et al., 1997; Fisher et al., 2002; Francks et al., 2004).
Attention deficit hyperactivity disorder (ADHD) is characterised by age-inappropriate 
levels o f hyperactive, impulsive and inattentive behaviours and leads to significant clinical 
and psychosocial impairments (American Psychiatric Association, 2000). In clinical 
practice, three subtypes can be discerned: a hyperactive/impulsive subtype, an inattentive 
one, and a combined subtype, which shows impairments in both domains. The most 
effective and commonly used medications to treat ADHD are the stimulants 
methylphenidate and amphetamine and the nonstimulant drug atomoxetine (Wilens, 2006; 
Antshel et al., 2011).
M otor coordination problems (MCP), referred to as developmental coordination disorder 
(DCD) in the DSM -IV-TR (American Psychiatric Association, 2000), are clinically 
heterogeneous in that some children predominantly manifest delays in acquiring motor
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milestones such as walking and crawling, while others display hypotonia and/or 
clumsiness (Green et al., 2008; W ilson and Larkin, 2008).
Autism spectrum disorders (ASDs) are a group o f pervasive disorders that are 
characterized by qualitative impairments in reciprocal social interaction and verbal and 
nonverbal communication as well as restricted, repetitive and stereotyped patterns of 
behaviour, interests and activities. The ASDs include autism, Asperger’s syndrome (AS) 
and pervasive developmental disorder not otherwise specified (PDD-NOS) (American 
Psychiatric Association, 2000). People with autism show impairments in all three core 
symptom domains and an onset o f symptoms before age 3 years. AS is characterized by 
impairment in social interaction and restricted, repetitive and stereotyped patterns of 
behaviour, interests and activities in the absence o f marked impairments of 
communication and with an apparently normal development o f language and cognitive 
skills before age 3 years. PDD-NOS is diagnosed in people who present with impairments 
in social interaction, communication and/or restricted and stereotyped behaviours that are 
similar to those in autism but fail to meet the full set o f criteria for autism or AS, and/or 
show a late age o f onset (American Psychiatric Association, 2000; Volkmar et al., 2004). 
To date, only two drugs have been approved by the Food and Drug Administration (FDA) 
for the treatment o f ASDs, i.e. the neuroleptics risperidone and aripiprazole for the 
treatment o f severe irritability associated with ASDs (http://www.fda.gov/).
Prevalence and heritability
DD, ADHD, MCP and ASDs all have a relatively high prevalence in the general 
population. All disorders are also more frequent in males than in females. Table 1 
summarizes the prevalences and male to female ratios for DD (De Kovel et al., 2004; 
Petryshen and Pauls, 2009; Flannery et al., 2000; Scerri and Schulte-Korne, 2010), ADHD 
(Polanczyk et al., 2007; Kessler et al., 2006; Fayyad et al., 2007; M uller et al., 2011a; 
M uller et al., 2011b; Kooij et al., 2005), MCP/DCD (Kirby and Sugden, 2007; Lingam et 
al., 2009; M issiuna et al., 2008) and ASDs (Chakrabarti and Fombonne, 2005; Baird et al., 
2006; Fombonne, 2009; Volkmar and Pauls, 2003; Volkmar et al., 2004).
All four disorders have a multifactorial (or complex) etiology in which combinations of 
genetic and environmental factors contribute to disease risk.
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Evidence from family and/or twin studies suggests that the disorders have a (very) high 
heritability, which implies that a (very) large proportion o f the phenotypic variance can be 
explained by genetic factors. Table 1 also shows the heritabilities o f DD (Fisher et al., 
2002; Francks et al., 2004; De Kovel et al., 2004), ADHD (Biederman and Faraone, 
2005), MCP/DCD (Martin et al., 2006) and ASDs (Bailey et al., 1995; Volkmar and Pauls, 
2003; Freitag, 2007).
The most plausible underlying genetic model for these disorders is a polygenic one in 
which multiple genetic factors, all o f small to moderate individual effect size, contribute to 
disease etiology in the majority o f patients (Francks et al., 2004; Petryshen and Pauls, 
2009; Faraone et al., 2005; Franke et al., 2009; Martin et al., 2006; Abrahams and 
Geschwind, 2008).
Table 1. Prevalence, male : female ratio and heritability for the four studied neurodevelopmental 
disorders.
Disorder Prevalence Male : female ratio Heritability
Dyslexia 3.6 - 10% 2 : 1 75%
ADHD Children: 5 - 6% 
Adults: 1 - 4%
Children: 7 : 1 
Adults: 1 - 1.6 : 1
76%
MCP/DCD 5% 3 : 1 69%
ASDs 0.5 - 1% 4 : 1 90%
Gene identification methods
Broadly speaking, two types o f genetic variants are thought to contribute to the 
susceptibility for polygenic diseases, such as the four conditions studied in this thesis: 
common and rare variants.
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Common genetic variants are found in > 1 % o f the general population. The most frequent 
types o f common variants are single nucleotide polymorphisms (SNPs), which constitute a 
single base pair change and are located within or within the vicinity o f genes, and DNA 
repeat-type variants (Attia et al., 2009). The role o f common variants in a disorder can 
best be assessed by association testing, a powerful tool to identify genetic variants of 
limited effect. Association testing can be performed for individual variants or genes, or in 
a genome-wide manner. A candidate gene-based association study assesses the over- or 
underrepresentation o f one or more SNPs in cases compared to controls and is hypothesis- 
driven, as it is based on the known or postulated biological function o f the gene/variant 
and/or its location within a genomic region o f interest. In recent years, many genome-wide 
association studies (GWASs) have also been carried out for polygenic disorders, including 
psychiatric and neurodevelopmental disorders. The advent o f the GWAS method has 
revolutionized the search for genetic influences on complex disorders in which both 
genetic and environmental factors are implicated (McCarthy et al., 2008; Stranger et al., 
2011). In a GWAS, hundreds o f thousands o f SNPs across the entire genome are tested 
independently for their association with a trait or disorder (Attia et al., 2009). Importantly, 
GWASs are performed in a hypothesis-free manner and therefore can generate entirely 
new ideas about the biology behind a disorder.
A second hypothesis-free method to identify common variants for polygenic disorders is 
genetic linkage analysis, which is aimed at detecting chromosomal regions that contain 
genes predisposing to the investigated disorder, using pairs o f siblings who are both 
affected with the disorder in question (Teare and Barrett, 2005). However, linkage 
analysis is most powerful for the identification o f genetic variants o f larger effect size, 
which are rare in polygenic disorders.
Rare genetic variants occur at a frequency o f (much) less than 1% in the general 
population (Attia et al., 2009). Notable examples o f rare variants are actual gene mutations 
which can be identified through: 1) several gene sequencing approaches (including 
targeted sequencing as well as the novel methods o f exome and whole genome sequencing 
(Kuhlenbaumer et al., 2010)); 2) genetic linkage analysis in large pedigrees with multiple 
affected individuals (Teare and Barrett, 2005); and 3) methods directed at identifying rare 
chromosomal aberrations, including copy number variations (CNVs).
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CNVs constitute deletions or duplications o f (one to multiple) genes. Rare CNVs can be 
detected through cytogenetic and molecular genetic approaches in individual cases or 
families and/or by using a genome-wide array-based hybridization approach in larger 
cohorts (Dhawan and Padh, 2009; W arden et al., 2011). That being said, it is not always 
clear what the pathogenic (and hence clinical) relevance is o f a rare CNV found in one or 
more patients with a specific polygenic disorder, as such variants -  although individually 
rare -  occur very frequently throughout the human genome. Therefore, and in order to 
maximise the power to detect genetic variation contributing to the susceptibility for 
polygenic disorders (including neurodevelopmental disorders), new and more 
sophisticated bioinformatics approaches will need to be developed that integrate and 
consider all types o f common and rare genetic variants (Lee and Scherer, 2010; Chapter 
7).
Neuroanatomy
The neuroanatomical substrates o f all four neurodevelopmental disorders have been 
investigated through structural and/or functional neuroimaging studies. For many years, 
these studies have been carried out with the traditional aim o f identifying localized brain 
lesions and/or abnormalities. However, in recent years, there is increasing consideration 
that the key to understanding the neural basis o f these neurodevelopmental disorders lies 
in abnormal structural and/or functional connectivity between various brain regions rather 
than in local abnormalities.
DD
Results from structural and functional neuroimaging studies together with 
neuropathological findings in postmortem brains o f individuals with DD indicate that 
three regions in the left cerebral hemisphere are important for fluent reading, suggesting 
that structural anomalies and/or altered activation patterns o f these regions are implicated 
in DD. These regions are an ‘anterior’ system, i.e. the inferior frontal gyrus (Broca’s area), 
and two ‘posterior’ systems, the dorsal parietotemporal and ventral occipitotemporal 
systems (Shaywitz and Shaywitz, 2008; Hoskyn, 2008; Caylak, 2009; Richlan et al., 2009; 
Raschle et al., 2010).
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ADHD
Structural neuroimaging studies in children and adults with ADHD show similar 
neurodevelopmental brain anomalies, i.e. a decreased total brain volume and folding, 
decreased cortical gray matter, and altered cortical thickness (Valera et al., 2007; Wolosin 
et al., 2009; Shaw et al., 2009; Cubillo and Rubia, 2010), which indicate that - 
neuroanatomically - ADHD is a disorder o f early brain development. In addition, specific 
neuroimaging modalities such as diffusion tensor imaging (Ashtari et al., 2005; Makris et 
al., 2007; Pavuluri et al., 2009), (resting-state) functional M agnetic Resonance Imaging 
(fMRI) (Cao et al., 2008; W ang et al., 2009; Castellanos et al., 2009), and EEG (Mazaheri 
et al., 2010) show that both in children and adults, the structural and functional 
connectivity o f the frontostriatal brain regions are predominantly affected (Makris et al., 
2009; Cubillo and Rubia, 2010; Konrad and Eickhoff, 2010).
MCP/DCD
At the moment, little is known about the neuroanatomical substrates o f MCP/DCD, but the 
few (functional) neuroimaging studies that have been carried out point to an important and 
central role for the cerebellum and brain circuits involving the cerebellum in the etiology 
o f this disorder (Querne et al., 2008; Zwicker et al., 2010; Zwicker et al., 2011; Marien et 
al., 2010; Kashiwagi et al., 2009). However, MCP/DCD should not be seen as merely a 
problem of the brain. In fact, a whole range o f functional processes that take place in 
peripheral motor neurons, neuromuscular junctions, muscle ‘balance’ sensors and muscle 
cells also play a role in motor coordination (Raynor, 2001; Schoemaker et al., 2001; 
Visser, 2003; Geuze, 2005; Smits-Engelsman et al., 2008), and a deficiency in one or 
more o f these processes may underlie MCP/DCD.
ASDs
Although there are many inconsistencies in the literature, the most consistent finding from 
the many neuroimaging studies in people with ASDs is that o f an abnormal developmental 
trajectory o f brain growth. This affects both grey and white matter and is characterized by 
an accelerated brain volume growth in early childhood that is probably followed by a
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prolonged growth plateau in subsequent years (Amaral et al., 2008; Anagnostou and 
Taylor, 2011). Furthermore, volumetric abnormalities o f specific brain regions including 
the cerebellum, amygdala, corpus callosum and caudate nucleus have been reported, and 
these are associated with a disturbed structural and functional brain connectivity 
(Verhoeven et al., 2010; Anagnostou and Taylor, 2011; Schipul et al. 2011). The most 
consistently replicated neuroanatomical findings from postmortem studies o f ASD brains 
is a loss o f cerebellar volume and, more specifically, a loss o f cerebellar Purkinje neurons 
(Amaral et al., 2008; W hitney et al., 2008; W hitney et al., 2009; M artin et al., 2010).
Comorbid symptoms and genetic overlap
DD, ADHD, MCP and ASD are each highly comorbid with each other, which means that 
children (or adults) with one disorder often also have symptoms o f one or more o f the 
three other disorders. For instance, children with MCP often also display symptoms o f DD 
(Crawford and Dewey, 2008), ASDs (Reiersen et al., 2008; Rommelse et al., 2009) and/or 
ADHD. The latter is particularly frequent, with 30-50% of the children with ADHD also 
suffering from MCP/DCD (Gillberg et al., 2004; Fliers et al., 2008). DD and ADHD are 
also often comorbid (Chadwick et al., 1999), as well as ADHD and ASDs (Rommelse et 
al., 2009) and DD and ASDs (Jones et al., 2009; M iniscalco and Dahlgren, 2010). This 
clinical overlap could be partially explained by the fact that the currently used diagnostic 
instruments, such as standardized questionnaires, and classification systems, such as 
DSM -IV or ICD-10, in part measure or consider certain symptoms or “traits” that are 
shared between different disorders. For instance, motor deficits can be a part o f DCD, 
ADHD and ASDs (Rommelse et al., 2009). More importantly, the clinical overlap 
between the different disorders seems to be due - at least in part - to shared genetic risk 
factors. Disorders showing considerable shared heritability are DD and ADHD (Stevenson 
et al., 1993), ADHD and ASDs (Rommelse et al., 2010) as well as ADHD and MCP/DCD 
(Martin et al., 2006; Fliers et al., 2009).
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Aims o f this thesis
The overall aim o f this thesis is to identify novel genes and protein networks for DD, 
ADHD, MCP and ASDs, which is key in elucidating the core biological processes 
underlying each disorder. Ultimately, and based on the identification o f so-called “protein 
targets”, this could lead to the development o f novel disorder-specific drugs and/or non- 
pharmacological treatments.
Therefore, the two specific aims o f this thesis are:
1. To identify novel genes and gene/protein networks for DD, ADHD, MCP and ASDs by 
both finding novel rare and common genetic variants (CNVs and SNPs) and integrating 
the genes implicated through different types o f genetic studies into functional protein 
networks for all four disorders.
2. To identify the underlying, shared and specific biological process(es) for each o f the 
four disorders, with the goal o f finding psychopharmacological (or “druggable”) protein 
targets for existing/new disorder-specific medications as well as protein targets that could 
lead to novel, non-pharmacological interventions.
These specific aims o f the thesis are addressed in the following chapters:
Chapter 2 describes the identification o f four new DD candidate genes through the 
detailed molecular genetic analysis o f a CNV, i.e. a very small deletion o f chromosome 
region 21q22.3, that cosegregated with dyslexia in a father and his three sons.
Chapter 3 sets out the findings o f the first GWAS for MCP that was conducted in a group 
o f children with ADHD and aimed at discovering candidate genes for this disorder in a 
hypothesis-free way. Based on bioinformatics and literature analyses, a functional network 
is described that contains the proteins encoded by the top-ranked genes from the GWAS.
In Chapters 4, 5 and 6, applying a similar “network building approach” to the one used in 
Chapter 3 and based on genetic data from the literature (including available GWAS data), 
functional protein networks are described for DD, ADHD and ASD, respectively.
Chapter 7 presents a summary and general discussion o f the thesis findings together with 
suggestions for future research.
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ABSTRACT
Dyslexia is the most common childhood learning disorder and it is a significantly heritable 
trait. At least nine chromosomal loci have been linked to dyslexia, and additional 
susceptibility loci on other chromosomes have been suggested. Within two of these loci, 
D Y X 1C 1  (15q21 ) and R O B O 1  (3p12) have recently been proposed as dyslexia candidate 
genes through the molecular analysis of translocation breakpoints in dyslexic individuals 
carrying balanced chromosomal translocations. Moreover, genetic association studies have 
indicated a cluster of five dyslexia candidate genes in another linkage region on 
chromosome 6p22, although there is currently no consensus about which of these five 
genes contributes to the genetic susceptibility for dyslexia. In this article, we report the 
identification of four new dyslexia candidate genes (PC N T, DIP2A, S 100B  and PRM T2) 
on chromosome region 21q22.3 by FISH and SNP microarray analyses of a very small 
deletion in this region, which cosegregates with dyslexia in a father and his three sons.
Key words: dyslexia; candidate genes; chromosome region 21q22.3
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INTRODUCTION
Dyslexia (or specific reading disability) is defined as a specific and significant impairment 
in reading ability that cannot be explained by deficits in either intelligence, learning 
opportunity, motivation or sensory acuity. Dyslexia is the most common childhood 
learning disorder (Gigorenko et al., 1997 ; Fisher et al., 2002). A recent survey has 
assessed the prevalence of dyslexia to be 3,6 %  of all primary school children in the 
Netherlands. In the same survey, a M/F ratio of around 2:1 was found (de Kovel et al.,
2004). The available evidence from family and twin studies further suggests that dyslexia 
is a significantly heritable trait (Fisher et al., 2002 ; Francks et al., 2004). Numerous 
linkage studies for dyslexia have been carried out and at least eight loci have been 
repeatedly linked to dyslexia : D YX 1  on 15q15-q21 (Grigorenko et al., 1997), D Y X 2  on 
6p21.3-p22 (Grigorenko et al., 1997), D Y X 3  on 2p11-p16 (Fagerheim et al., 1999 ; 
Francks et al., 2002 ; Anthoni et al., 2007 ; de Kovel et al., 2008), D Y X 5  on 3p12-q13 
(Nopola-Hemmi et al., 2001), D Y X 6  on 18p 11.2 (Fisher et al., 2002), D Y X 7  on 11p15.5 
(Hsiung et al., 2004), D Y X 8  on 1p35-p36 (Rabin et al., 1993 ; Grigorenko et al., 2001 ; 
Tzenova et al., 2004; Miscimarra et al., 2007; de Kovel et al., 2008) and D Y X 9  on Xq26- 
q28 (Fisher et al., 2002 ; de Kovel et al., 2004). Additional significant multipoint linkage 
findings on chromosome regions 6q12 (D Y X 4) (Petryshen et al., 2001), 7q32.2 (Kaminen 
et al., 2003), 13q22.1, 18q22.2-q22.3 and 21q21-q22 (Fisher et al., 2002) have been 
reported, but these results have not been replicated yet. In 2003, Taipale et al. reported the 
identification of a candidate gene for dyslexia (D Y X 1C 1) on 15q21. D Y X 1C 1  was 
disrupted by the 15q21 translocation breakpoint in four dyslexic members of an earlier 
described family, carrying a translocation between chromosomes 2 and 15, 
t(2;15)(q11;q21) (Nopola-Hemmi et al., 2000). By applying a similar “positional cloning” 
approach, the R O B O 1  gene was recently found to be disrupted at the 3p12 translocation 
breakpoint in an individual with both dyslexia and a translocation between chromosomes 
3 and 8, t(3;8)(p12;q11) (Hannula-Jouppi et al., 2005). In addition, a cluster of five genes 
in the D Y X 2 locus (VM P, D C D C 2, K IAA 0319, TTRAP, and THEM2) has been consistently 
reported to be associated with dyslexia (Londin et al., 2003 ; Deffenbacher et al., 2004), 
although it is currently not clear which of these five genes would be (a) dyslexia candidate 
gene(s) (Francks et al., 2004 ; Cope et al.,2005 ; Meng et al., 2005 ; Paracchini et al., 2006 
; Schumacher et al., 2006 ; Brkanac et al., 2007 ; Luciano et al., 2007).
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In this article, we describe a family in which a very small deletion in chromosome band 
21q22.3 cosegregates with dyslexia in a father and his three sons. By further cytogenetic 
(fluorescent in situ hybridization, FISH) and SNP microarray analyses of the deletion in 
our family, we have identified PCN T, D IP2A, S 100B  and P R M T 2  as dyslexia candidate 
genes.
M ATERIALS AND M ETHODS 
Case Reports
The pedigree of our family is shown in Figure 1. The proband, III.2, is a 16-year-old male 
and he firstly presented at our genetics clinic with severe dyslexia. His two brothers, III.1 
(18 years old) and III.3 (14 years old) were found to have similar learning difficulties, 
with specific delays in the acquisition of reading and writing skills. The three brothers 
have attended specialized schools for the whole or a part of their primary school career. 
III.1 and III.2 are physically healthy, III.3 has motoric sequellae of a traffic accident. 
The proband (III.2) and his older brother (III. 1) suffer from a recurrent major depressive 
disorder, which responds well to treatment with fluoxetine in III.2, but is more treatment 
resistant in III.1. The father of the three boys, II.3, has attended a regular primary school 
and later vocational training, and he repeated 2 years during his school career. He does not 
recall having had any major learning difficulties whilst he was at school. However, he 
states that he is currently “not very good at reading and writing”. The other paternal 
family members (I.1, I.2, II.1, and II.2) and the mother of the boys (II.4) are all healthy 
individuals with no history of reading/writing difficulties or other learning problems.
A scertainm ent and Testing of Cases
Informed consent was obtained from all tested family members. The father of the proband 
was given the WAIS intelligence test (Stinissen et al., 1970) and his three sons were given 
a Raven Progressive Matrices test (Raven, 1976). All four subjects also underwent 
specific diagnostic tests for dyslexia. Single-word reading (SWR) and spelling abilities 
were assessed using standardized tests (Brus and Voeten, 1973 ; Kleijnen, 1992; Kleijnen, 
1997). Three other key component skills of the reading process, namingly phoneme 
awareness (PA), phonological decoding (PD) and orthographic coding (OC) (Fisher et al.,
2002) were also assessed with Dutch standardized tests (Evers and Lucassen, 1983, 1991 ; 
Van Luijn-Hindriks, 1992a ; Van Den Bos et al., 1994).
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PA, the ability to reflect on and manipulate the phonemes of words (Fisher et al., 2002), 
was assessed in our family by a phoneme-removal task in pronounceable non-words (Van 
Luijn-Hindriks, 1992b). PD, the skill to convert written sublexical letter units (or 
graphemes) into their corresponding phonemes (Fisher et al., 2002) was measured through 
the oral reading of pronounceable non-words (Van Den Bos et al., 1994). Lastly, OC, 
which can be defined as the ability to recognize the specific letter patterns (or 
orthography) of whole words (Fisher et al., 2002), was measured with an OC-choice task, 
in which the correct spelling of a word has to be chosen between two phonologically 
identical words (Evers and Lucassen, 1983, 1991).
OC is a particularly important skill in English, in which frequently the same word sounds 
can be represented by different letter patterns (Fisher et al., 2002) . In this respect, it 
should be noted that orthographic coding is less difficult in Dutch than in English, as the 
Dutch language contains (much) less irregularities of grapheme to phoneme 
correspondences than exist in English. Dyslexics usually show deficits in one or more of 
PA, PD and OC skills. Dyslexia should therefore be regarded as a continuum, in which 
mostly all the components of the reading process are affected to some extent. Moreover, 
the three hypothesized component skills seem to be genetically correlated with one 
another and with IQ and SWR skills (Fisher et al., 2002 ; Francks et al., 2004). The results 
of the three boys were compared with their IQ, age and level of education. Based on their 
scores for the different subtests, standard deviations for the different components of the 
normal reading process were calculated (Struiksma et al., 1995). As for the father, 
standard deviations for SWR, PD and OC were calculated by comparison with the adult 
mean scores (Kuijpers et al., 2003), but the calculated standard deviations on his spelling 
and PA tests are based on the adolescent mean scores (Struiksma et al., 1995), as adult 
norms are currently not available for these tests. The results and standard deviations of the 
four subjects are given in table I. The cut-off for the diagnosis of dyslexia was defined as a 
standard score of below -  2 standard deviations for at least two different components of 
the reading process in the three boys and a standard score of below -  1.5 standard 
deviations for at least two different components in the father (Struiksma et al., 1995 ; 
Fisher et al., 2002).
Cytogenetics and Fluorescent In  Situ Hybridization (FISH)
Chromosomes were prepared from peripheral blood lymphocyte cultures following 
standard procedures. Chromosome banding was performed by treatment with trypsin
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followed by staining with Giemsa to obtain a GTG-banded pattern. FISH was performed 
with a set of subtelomeric probes, which are designed to detect deletions near the 
chromosomal telomeres (NIH & IMMC, 1996). The additional smaller probes we used to 
cover the broader chromosome region surrounding subtelomeric probe CTB-63H24 (other 
name : telomereC3), were provided by the Sanger Institute (Cambridge, UK) and the 
Department of Human Genetics of the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. The identity and exact position of all probes were checked 
before we used them in further determining the size of the deleted region (cfr. Results).
SNP M icroarray Analysis
SNP Microarray analysis was carried out according to the protocols of the manufacturer 
using the NspI array (~262,000 SNPs) from the Affymetrix GeneChip® Human Mapping 
500K Array Set (Affymetrix, Inc., Santa Clara, California, USA, 
http://www.affymetrix.com).
RESULTS 
Neurocognitive Testing
The proband of our family (III.2), his two brothers (III. 1 and III.3) and their father (II.3) 
were given an intelligence test and standardized tests of reading and writing skills (see 
Materials and Methods Section). The results of these tests are summarized in table I. All 
four subjects have a normal to borderline normal intelligence. As can also be seen in table
I, the three boys scored below -  2 SD and the father below -  1.5 SD for at least two 
different components of the reading process, thus establishing the diagnosis of dyslexia in 
all of them (Struiksma et al., 1995 ; Fisher et al., 2002). Moreover, all tested subjects score 
below -  1.5 SD for PD and SWR, two genetically and conceptually correlated components 
of the normal reading process (Fisher et al., 2002). All four relatives also score above -  2 
SD for the phoneme awareness component of the normal reading process.
Cytogenetics and FISH
All the available family members (Fig. 1) were karyotyped. Analysis of 10 GTG-banded 
metaphases of the proband (III.2) showed a 46,XY karyotype in all the metaphases 
examined.
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However, subsequent FISH analysis with a routinely used set of subtelomeric probes (NIH 
& IMMC, 1996) showed that, for subtelomeric probe CTB-63H24, a fluorescent signal on 
only one of the chromosomes 21 could be detected, which indicates a deletion in 
chromosome band 21q22.3. (Fig. 2). Chromosome analysis of GTG-banded chromosomes 
of the grandparents (I.1 and I.2) , the parents (II.3 and II.4) , the uncle and aunt (II. 1 and
II.2) and the two brothers (III.1 and III.3) of the proband initially showed a normal 
karyotype. Subsequent FISH analysis with probe CTB-63H24 on metaphases of the 
grandparents, the mother, and the uncle and aunt of the proband also showed fluorescent 
signals on both chromosomes 21. However, FISH with probe CTB-63H24 on metaphases 
of the father (II.3) and the two brothers of the proband (III.1 and III.3) showed that they 
are also carriers of the chromosome 21 deletion in chromosome band q22.3 (Fig. 2).
To determine the size of the deleted region further, FISH was performed on chromosomal 
material of the father (II.3) with additional smaller probes, which cover the region 
surrounding probe CTB-63H24 (Fig. 3). FISH analysis with probes CTD-2205B09 and 
RP11-124P01 showed a fluorescent signal on both chromosomes 21 of II.3. However, 
FISH with probes RP11-618M06 and RP11-457P07 showed a fluorescent signal on only 
one of the chromosomes 21 of II.3 (Fig. 3).
Combining the results of the analysis of GTG-banded metaphases and the results of the 
additional FISH analysis, we can ascertain the exact karyotype of II.3 and his three sons as 
46,XY,del(21)(q22.3q22.3)(RP11-618M06-, RP11-457P07-).
SNP M icroarray Analysis
Using the Affymetrix GeneChip® Human Mapping 500K Array Set, NspI array, copy 
numbers of 20 SNPs in the deleted region identified by the FISH analysis were analysed 
(Table II). This microarray analysis indicated that the deletion minimally encompasses the 
region from base pair position 46.678.820 (rs2839259) to 46.854.893 (rs9982863), which 
are the most proximal and distal genotyped SNPs in the deleted region showing only one 
allelic copy (Table II and Fig. 3). The most distal SNP showing two allelic copies 
(rs2 8 3 9 2 3 2 ) is located at base pair position 46.617.302 (Table II and Fig. 3).
Combining the results of the FISH and SNP microarray analyses and information from the 
E nsem bl H um an G enom e B row ser, version  4 5  (http://www.ensembl.org/Homo_sapiens), 
we determined that four known genes are located within this deleted region, namely 
PCN T, D IP2A, S100B, and P R M T 2  (Fig. 3).
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DISCUSSION
Identification of Dyslexia Candidate Genes
We have identified a family in which a deletion in chromosome band 21q22.3 
cosegregates with dyslexia in a father and his three sons. By further FISH and SNP 
microarray analyses of the chromosomal material of individual II.3, we have refined the 
deletion to a region in which four known genes are located (PC N T, D IP2A, S100B, and 
PRM T2). Because of the cosegregation of the deletion with dyslexia, our hypothesis is that 
haploinsufficiency of at least one of these four genes would result in less gene expression 
and thus reduced gene function, which would in turn contribute to the dyslexia phenotype 
in the described family.
In 2002, Fisher et al. reported that they had found modest linkage between dyslexia and a 
marker on chromosome band 21q22.3 in a sample of US dyslexic patients. Marker 
D21S266, for which they found a P-value of 0.026 for PD (Fisher et al., 2002), maps 
approximately 5 megabases (Mb) proximally from our deleted region. Given the 
imprecision of genetic linkage for multifactorial phenotypes, the deleted region might 
correspond to the linked locus for dyslexia on chromosome band 21q22.3. Alternatively, 
there might be two loci for dyslexia in this chromosomal region. In this respect, it should 
be noted that the D Y X 1C 1  gene (cfr. supra) maps about 7 Mb distally from the maximal 
linked signal on 15q (DYX1), which could also either be due to imprecise genetic linkage 
or to the fact that there are two seperate loci for dyslexia in D YX 1  (Taipale et al., 2003 ; 
Scerri et al., 2004 ; Wigg et al., 2004 ). In addition, both positive and negative association 
findings have been reported between SNPs in D Y X 1C 1  and dyslexia, which might also 
indicate that more than one gene in 15q21 contributes to the genetic risk for dyslexia 
(Taipale et al., 2003 ; Scerri et al., 2004 ; Wigg et al., 2004 ; Bellini et al., 2005 ; Marino 
et al., 2005, 2007 ; Brkanac et al., 2007). Lastly, this genetic heterogeneity (or the fact that 
more than one gene in a linked region may contribute to the genetic risk for a disorder) 
could possibly explain the at first sight contradictory genetic association findings for the 
cluster of five dyslexia candidate genes in the D Y X 2  locus on 6p22 (Francks et al., 2004 ; 
Cope et al.,2005 ; Meng et al., 2005 ; Paracchini et al., 2006 ; Schumacher et al., 2006 ; 
Brkanac et al., 2007 ; Luciano et al., 2007), but more research will be needed to further 
elucidate whether or not there is more than one dyslexia susceptibility gene in this region.
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P C N T , D IP 2A , S 100B , and P R M T 2  as Dyslexia Candidate Genes
The P C N T  gene is only partially deleted (see Table II and Fig.3). P C N T  (other name : 
P C N T 2) encodes the Pericentrin (other name : Kendrin) protein. The Pericentrin protein is 
ubiquitously expressed in the centrosomes and it is important for the normal functioning 
of the centrosomes and the cytoskeleton, and for cell-cycle progression (Takahashi et al.,
2002). The Disrupted-In-Schizophrenia 1 (DISC1) protein localizes to the centrosome by 
binding to the Pericentrin protein (Miyoshi et al., 2004) which suggests a possible role for 
the P C N T  gene in the pathogenesis of brain disorders. We therefore think that the P C N T  
gene is a valid dyslexia candidate gene.
The D IP2A  and S 100B  genes are mainly and highly expressed in the brain (and more 
specifically in the hippocampus) (Yu et al., 2001 ; Rothermundt et al., 2003), making them 
both valid dyslexia candidate genes.
The D IP2A  gene (other name : GRIP1B) encodes the GRIP1b protein, an alternatively 
spliced, human variant of GRIP1 (Glutamate Receptor Interacting Protein 1) (Yu et al., 
2001). GRIP1b is involved in the AMPA Glutamate Receptor recycling pathway in brain 
cells through its ability to bind these receptors (Dong et al., 1999 ; Hanley et al., 2002 ; 
Collingridge and Isaac, 2003). The AMPA receptor recycling pathway seems to be very 
important in the regulation of the so-called “synaptic plasticity”, which could be defined 
as the amount of AMPA receptors that are available at the synapse for downstream signal 
transduction (and which are thus not present in the intracellular pool) (Hanley et al., 2002 ; 
Collingridge and Isaac, 2003). Synaptic plasticity is important during hippocampal- 
dependent cognitive processes such as learning and memory (Collingridge and Isaac,
2003), which have been suggested to be impaired in dyslexia (Swanson et al., 2006). In 
this respect, it is interesting that D Y X 1C 1  and R O B O 1  (the two other dyslexia candidate 
genes that were identified by the “positional cloning” approach, cfr. supra) are 
functionally implicated in processes of neuronal migration and/or connectivity (such as 
synaptic plasticity) as well (Taipale et al., 2003 ; Hannula-Jouppi et al., 2005 ; Fisher and 
Francks, 2006 ; Wang et al., 2006 ; Rosen et al., 2007).
The S 100B  gene codes for a calcium-binding peptide that is mainly produced by astrocytes 
and that exerts paracrine and autocrine effects on neurons and glial cells. The 
concentration of the S100B peptide has been found to be increased in blood and 
cerebrospinal fluid in various clinical brain conditions, including psychiatric disorders 
such as schizophrenia and Tourette’s syndrome, but the mechanism by which this is 
brought about is currently unknown (Rothermundt et al., 2003).
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Lastly, the P R M T 2  gene encodes a protein (the HRMT1L1 protein) that is involved in the 
mRNA metabolism. The P R M T 2  gene is ubiquitously expressed, but since it is only 
expressed to a rather limited extent in the brain and thus not brain-specific 
(Kzhyshkowska et al., 2001), we did not think it to be a particularly valid dyslexia 
candidate gene. However since, for example, some XLMR (X-linked mental retardation) 
genes are ubiquitously expressed and thus not entirely brain-specific either, we have 
decided to include the P R M T 2  gene in our proposed genetic association study (cfr. infra).
CONCLUSION AND FUTURE RESEARCH
We have identified four putative dyslexia candidate genes (PC N T, D IP2A, S100B, and 
PRM T2) by FISH and SNP microarray analyses of a very small deletion of chromosome 
region 21q22.3, which cosegregates with dyslexia in a father and his three sons. Of the 
four possible candidates, the D IP2A  gene seems to be the most likely dyslexia 
susceptibility gene, because of its function in the regulation of neuronal connectivity. 
However, a further genetic association study is needed to determine which of the four 
candidate genes (or possibly which combination of these genes ?) would, if  reduced in 
function or haploinsufficient, contribute to the dyslexia phenotype in the wider dyslexic 
population. In this respect, we have started a genetic association study for the four 
candidate genes in a sample of dyslexic children from the Netherlands.
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Table I. Results of the IQ and dyslexia tests in II.3 and his three sons (III. 1, III.2 and
III.3). The score is either a standard score (IQ, SWR, Spelling, PD and OCchoice ) or a 
rough score (PA).
Score Standard Deviation Score Standard Deviation
II.3 (father) III.2 (proband)
IQ (WAIS) 104 +0.3 SD IQ (Raven) 91 - 0.6 SD
SWR 2 -1.5 SD SWR 1 - 3.0 SD
Spelling 4 - 0.5 SD Spelling 1 - 2.0 SD
PA 16 - 0.2 SD PA 16 - 0.2 SD
PD 1 - 2.0 SD PD 1 -3.0 SD
OCw '- 'c h o ice 4 - 0.5 SD OCw '- 'c h o ice 1 -2.0 SD
III.1 (oldest son) III.3 (youngest son)
IQ (Raven) 81 - 1.3 SD IQ (Raven) 90 -0.7 SD
SWR 1 - 3.0 SD SWR 1 -3.0 SD
Spelling 1 - 2.0 SD Spelling 1 -2.0 SD
PA 15 - 0.5 SD PA 12 -1.6 SD
PD 1 - 3.0 SD PD 1 -3.0 SD
OCw '- 'c h o ice 4 - 0.5 SD OCw '- 'c h o ice 1 -2.0 SD
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Table II. Microarray analysis results for 20 SNPs in the deleted region that were 
genotyped with the Affymetrix GeneChip® Human Mapping 500K Array Set, NspI array 
(~262,000 SNPs). The most proximal (rs2839259) and the most distal (rs9982863)  
genotyped SNPs of which only one allelic copy was present, are marked in bold.
SNP *Physical location (bp) Position in gene gene allelic copy number
rs2839193 46.522.771 Intron 5 MCM3AP 2
rs16979065 46.573.884 Intron 2 PCNT 2
rs4819241 46.606.492 Intron 14 PCNT 2
rs2839227 46.610.952 Exon 16 PCNT 2
rs2839232 46.617.302 Intron 16 PCNT 2
rs2839259 46.678.820 Intron 39 PCNT 1
rs11702704 46.692.749 5’ Upstream DIP2A 1
rs4274674 46.698.696 3 ’ Downstream PCNT 1
rs8132320 46.711.224 Intron 1 DIP2A 1
rs2839282 46.727.250 Intron 1 DIP2A 1
rs2839299 46.749.105 Intron 6 DIP2A 1
rs1892692 46.762.493 Intron 8 DIP2A 1
rs2839308 46.779.155 Intron 13 DIP2A 1
rs2070435 46.786.139 Exon 18 DIP2A 1
rs17302525 46.788.563 Intron 18 DIP2A 1
rs1697937 46.798.483 Intron 25 DIP2A 1
rs762254 46.808.108 Intron 34 DIP2A 1
rs9983698 46.842.971 Exon 3 S100B 1
rs8133385 46.853.888 5’ Upstream PRMT2 1
rs9982863 46.854.893 5’ Upstream PRMT2 1
* position as mapped onto the Ensembl Human Genome Browser, version 45.
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Figure 1. Pedigree of the family studied. There is a cosegregation of a deletion of 
chromosome band 21q22.3 with dyslexia in the father (II.3) and his three sons (III.1,III.2 
and III.3)
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Figure 2. FISH with probe CTB-63H24 showing a subtelomeric deletion in 
chromosome 21.
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Figure 3. FISH analysis with probes covering the region surrounding probe CTB-63H24 
(other name: telomereC3). FISH with the probes CTD-2205B09 and RP11-124P01 
showed a fluorescent signal on both chromosomes 21 of II.3. However, analysis with the 
probes RP11-618M06 and RP11-457P07 showed a fluorescent signal on only one of the 
chromosomes 21 of II.3. Further microarray analysis with the Affymetrix GeneChip® 
Human Mapping 500K Array Set, NspI array indicated that the deletion minimally 
encompasses the region from base pair position 46.678.820 (rs2839259) to 46.854.893 
(rs9982863), which are the most proximal and distal genotyped SNPs in the deleted region 
showing only one allelic copy (see Table II). The positions of these SNPs are indicated 
with red arrows. The black arrow shows the location of the most distal SNP (rs2839232 , 
bp position 46.617.302) showing two allelic copies (see Table II).
Taken together, the results of the FISH and SNP microarray analyses indicate that the 
deletion contains four known genes: P C N T (partially deleted), DIP2A, S100B, and P R M T 2  
(E n sem bl H um an G enom e B row ser, version  45).
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A bstract
O bjectives:
Motor coordination problems are frequent in children with attention deficit/hyperactivity 
Disorder (ADHD). We performed a genome-wide association study to identify genes 
contributing to motor coordination problems, hypothesizing that the presence of such 
problems in children with ADHD may identify a sample of reduced genetic heterogeneity.
M ethods:
Children with ADHD from the International Multicentre ADHD Genetic (IMAGE) study 
were evaluated with the Parental Account of Children’s Symptoms. Genetic association 
testing was performed in PLINK on 890 probands with genome-wide genotyping data. 
Bioinformatics enrichment-analysis was performed on highly ranked findings. Further 
characterization of the findings was conducted in 313 Dutch IMAGE children using the 
Developmental Coordination Disorder Questionnaire (DCD-Q).
R esults:
Although none of the findings reached genome-wide significance, bioinformatics analysis 
of the top-ranked findings revealed enrichment of genes for motor neuropathy and 
amyotrophic lateral sclerosis. Genes involved in neurite outgrowth and muscle function 
were also enriched. Among the highest ranked genes were M A P 2K 5, involved in restless 
legs syndrome, and CH D6, causing motor coordination problems in mice. Further 
characterization of these findings using DCD-Q subscales found nominal association for 
15 SNPs.
C onclusions:
Our findings provide clues about the etiology of motor coordination problems, but 
replication studies in independent samples are necessary.
Key words: M o to r  coord in a tion  prob lem s, AD H D , g en o m e-w id e  associa tion  s tu d y  
(GWAS), n eu rite  outgrow th , sk e le ta l m uscle  function
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Introduction
With a prevalence of 5% at school age, motor coordination problems are common in 
children and are usually referred to as developmental coordination disorder (DCD) 
(American Psychiatric Association 2000; Kirby and Sugden 2007; Missiuna et al. 2008; 
Lingam et al. 2009). DCD is a heterogeneous condition. Motor milestones such as 
crawling and walking may be delayed, while some children show marked hypotonia 
and/or clumsiness (Green et al. 2008; Wilson and Larkin 2008). The motor problems lead 
to difficulties in everyday living and often have an effect on academic performance, 
sports, play and self-esteem (Cummins et al. 2005; Polatajko and Cantin 2005; Miyahara 
and Piek 2006; Piek et al. 2008). Delay of brain maturation as well as functional 
deviations in basal ganglia, parietal lobe and cerebellum have been suggested as the 
dominant source of neuropathology in motor coordination problems (Zwicker et al. 2009). 
DCD is considered a multifactorial disorder in which genetic factors and environmental 
factors such as perinatal adversity play a role (Pearsall-Jones et al. 2009). The one study 
formally examining the heritability of DCD is a population-based twin study (Martin et al. 
2006) and estimated it to be 0.69. In our study of sib pairs, we found a familial component 
(comprising genetic and environmental effects) of 0.47 (Fliers et al. 2009). The genetic 
component appears polygenic, with many genes of small effect thought to causing the 
disorder in unfavourable environmental circumstances.
Children with motor coordination problems usually have problems in other areas of 
development as well, including dyslexia, autistic spectrum disorders and attention 
deficit/hyperactivity disorder (ADHD). The other way around, we and others have found 
that of children with ADHD, 30 to 50% also suffer from motor coordination problems 
(Gillberg et al. 2004; Fliers et al. 2008). The combination of ADHD and motor 
coordination problems has previously been named deficits of attention and motor 
perception, DAMP (Kadesjo and Gillberg 1998; Gillberg et al. 2004). At present, we can 
only speculate about the underlying neurobiological mechanisms for this comorbidity, but 
a dopamine-induced imbalance of basal ganglia neurocircuits may play a role (Arnsten 
2006).
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Previous work on the familiality of these two disorders identified a possible shared 
etiological background. In the Dutch sample of the International Multicenter ADHD 
Genetics (IMAGE) study, we found that ADHD and motor coordination problems have a 
common basis that may be due to genetic factors and/or shared environmental factors. The 
familial correlation between motor performance measures and ADHD was found to be 
0.38 (Fliers et al. 2009). These results are in line with a twin study of the shared 
background of ADHD and DCD, in which a shared heritability of between 29% and 51% 
was observed (Martin et al. 2006).
Despite the considerable familial component involved in motor coordination problems 
(Fliers et al. 2009), little is known about the specific genetic factors involved. Since such 
knowledge may help to better understand the etiology of motor coordination problems, we 
set out to perform a hypothesis-generating genome-wide association study (GWAS) to 
search for DNA variation contributing to the condition. Genome-wide association studies 
are a powerful tool to identify genetic factors of limited effect size (McCarthy et al. 2008). 
In GWAS, hundreds of thousands of single nucleotide polymorphisms (SNPs) across the 
genome are tested independently for their association with a trait/disorder. This method 
has revolutionized the search for genetic influences on complex traits such as ADHD, in 
which both genetic and environmental factors work together (Franke et al. 2009). The 
SNPs analyzed in GWAS are selected to “tag” or capture the majority of genetic variation 
in their vicinity, which is possible because the human DNA is organized in blocks of 
genetic material that is transmitted together across generations. This means that if  we 
genotype one given SNP, we will be able to flag or predict the variation of several other 
SNPs including those contributing to the trait/disease.
We hypothesized that studying motor coordination problems in a sample of ADHD- 
affected children might reduce the phenotypic and genetic heterogeneity of motor 
problems. In the current study, 890 children from the IMAGE study were included. 
We performed bioinformatics analysis on the highest ranked findings to test for 
enrichment of gene functional groups. Findings were further characterized in more detail 
using a second phenotyping instrument in the Dutch IMAGE subsample.
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M ethods
P a rtic ip a n ts
Children with ADHD and their siblings were recruited for the IMAGE study that aims at 
identifying genes that increase the risk for ADHD using QTL linkage and association 
strategies (Brookes et al. 2006; Kuntsi et al. 2006). Families were identified through 
ADHD probands aged 5-17 years attending outpatient clinics at the data collection sites in 
Europe (Belgium, Germany, Ireland, The Netherlands, Spain, Switzerland, and the United 
Kingdom) and Israel. Families of European Caucasian ancestry were recruited based on 
having one child with ICD-10 or DSM-IV ADHD and at least one other child who would 
provide DNA and quantitative trait data. In addition, both parents had to be available for 
DNA-sampling. The ADHD diagnosis was based on DSM-IV criteria using both parent 
and teacher questionnaires and standardized interviewing. Diagnostic instruments used 
were the Parental Account of Childhood Symptoms (PACS) interview (see below), 
Conners’ Parents and Teachers long versions, and the SDQ (Strengths and Difficulties 
Questionnaire).
Exclusion criteria included an IQ < 70, known genetic syndromes (Down, Turner, Fragile 
X), autism, seizures (current or in the past), brain disorders (such as periventricular 
haemorrhage, cerebral palsy and epilepsy), and disorders mimicking ADHD symptoms. 
When children were using medication to treat their ADHD symptoms, the parents were 
asked to report on their children’s behaviour off medication. For additional details about 
the clinical characteristics and the diagnostic process , see Brookes et al. 2006; Kuntsi et 
al. 2006; Chen et al. 2008; Christiansen et al. 2008; Zhou et al. 2008; Mulligan et al. 2009.
The following disorders co-occur with ADHD in the IMAGE sample: mood disorder 
(15%), anxiety disorder (44%), oppositional defiant disorder (64%) and conduct disorder 
(24%) (Muller et al. 2011). Both the mean and median IQs were 98. Children with and 
without motor problems did not differ according to age, gender and also severity of 
ADHD symptoms (Fliers, 2008).
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M o to r  m easu res
P a ren ta l A ccou n t o f  C h ild ren ’s  Sym ptom s (PACS) interview .
The PACS, a semi-structured, standardized, investigator-based interview (Taylor et al. 
1986), was administered to all parents. To ensure cross-site consistency in measurement 
and coding, all interviewers attended a 5-day PACS training course in the UK. The sites’ 
chief investigator additionally attended annual inter-rater reliability exercises. The mean 
kappa coefficient across all sites was high (0.88). The PACS also includes questions 
regarding motor development of which we analysed the question “does your child have 
motor coordination problems”, with three possible answers: “no”, “maybe”, or “yes 
definitely” as the primary phenotype for genetic analysis.
D evelo p m en ta l C oordination  D iso rd er  Q uestionnaire (D CD -Q ).
In the Dutch participants of IMAGE, we collected additional data on motor performance 
with the DCD-Q, completed by parents (Fliers et al. 2008). The DCD-Q identifies children 
with motor coordination problems in daily life and is widely used in international studies 
(Wilson et al. 2000, 2009; Loh et al. 2009) The Dutch DCD-Q has been validated 
(Schoemaker et al. 2006). The internal consistency of the questionnaire is high (a = 0.88). 
The DCD-Q contains 17 items that are rated on a five-point scale (1 = not at all like this 
child; 5 = extremely like this child) and four subscales: motor control in motion, fine motor 
control/handwriting, gross motor control/planning and general coordination. In this study, 
DCD-Q scores (on a continuum) were tested as secondary phenotypes in the genetic 
analysis of candidate SNPs. We tested five traits: the total score on the DCD-Q (range from 
17 to 85), and the four subscale scores.
G enetic  A n alysis
The IMAGE consortium is a part of the Genetic Association Information Network 
(GAIN), a public-private partnership of FNIH (Foundation for the National Institutes of 
Health, Inc.) (http://www.fnih.org). A total of 958 affected proband-parent trios from 
IMAGE were initially selected for genome-wide genotyping conducted at Perlegen 
Sciences using their genotyping platform of approximately 600,000 tagging SNPs 
designed to be in high linkage disequilibrium with untyped SNPs for the HapMap 
populations.
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Quality control of the genotype data was performed by NCBI (The National Center for 
Biotechnology Information) using the GAIN QA/QC Software Package (version 0.7.4). 
Details of the genotyping and data cleaning process for the ADHD GAIN study (Study 
Accession, phs000016.v1.p1) have been reported elsewhere (Neale et al. 2008). Briefly, 
we selected only SNPs with minor allele frequency (MAF) > 5% and Hardy-Weinberg 
equilibrium (HWE) P  >  1.00E-06. Genotypes causing Mendelian inconsistencies were 
identified by PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) and removed (Purcell et 
al. 2007). We additionally removed SNPs that failed the quality control metrics for the 
other two GAIN Perlegen studies (major depression disorder (dbGAP Study Accession 
phs000020.v1.p1) and psoriasis (dbGAP Study Accession phs000019.v1.p1)). With this 
filtering, 384,401 autosomal SNPs were retained in the final dataset. To increase coverage 
in the targeted genomic areas, we used the imputation approach implemented in PLINK 
(v1.04), which imputes genotypes of SNPs that are not directly genotyped in the dataset, 
but that are present on a reference panel. The reference panel used consisted of 2,543,285 
polymorphic autosomal SNPs genotyped on the 60 HapMap Caucasian (CEU) founders 
which are publicly available for download from the HapMap website (HapMap r23 build, 
http://www.hapmap.org). A threshold of 0.95 confidence level was set for a hard genotype 
call to be included in association testing. Most likely genotypes for imputed SNPs were 
then used in association analyses.
S ta tis tica l A n alysis
For statistical analysis, the PACS motor answers “no motor problems” and “possible 
motor problems” were combined into an “unaffected” category creating a binary outcome 
variable. We chose this rather strict way of analysis because standard deviations of motor 
scores were overlapping for the groups “no motor problems” and “possible motor 
problems” whilst the definitely affected category formed a truly different group (not 
shown). An ANOVA was performed with the binary PACS trait as independent and 
DCD-Q total scores as dependent variables to validate the motor question in a sample of 
313 Dutch IMAGE participants for whom scores from both PACS and DCD-Q were 
available. Of these, 296 also had complete data for covariates required for the genetic 
analysis. Association analysis of 890 ADHD probands with motor data was conducted 
using the logistic procedure implemented in PLINK with the motor variable from PACS 
as a binary outcome.
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The analysis was adjusted for age, gender, Conners’ hyperactive/impulsive score, 
Conners’ inattentive score and the country in which the motor variable had been 
measured.
SNPs showing association P-values < 10.00E-05 in the GWAS were tested for their 
association with the four subscales (fine and gross motor scores, general coordination and 
control during movement) of the DCD-Q. This association analysis was conducted in 296 
Dutch ADHD probands using the linear procedure implemented in PLINK. Each DCD-Q 
variable was a continuous outcome and the models were adjusted for age, gender, 
Conners’ hyperactive/impulsive score and Conners’ inattentive score. In order to control 
for multiple testing, an extra permutation step was added to the linear test by applying the 
max(T) permutation approach implemented in PLINK. A total of 10,000 permutations 
were done for the subset of SNPs passing the P  value threshold to determine empirical 
(EMP) P  values for association.
B ioin form atics an alysis
To detect significantly enriched gene functional groups in 97 genes from the GWAS 
containing at least one SNP showing association with the PACS motor variable at 
P  < 10.00E-04, we performed functional analyses using Ingenuity Pathway Analysis 
(http://www.ingenuity.com). In the presentation of the results of these analyses, only gene 
categories with significant enrichment (i.e. false discovery rate corrected P  < 0.05) and 
containing more than one gene were taken into account. The Ingenuity software package 
uses information from the published literature as well as many other sources, including 
gene expression and GO (gene ontology) terms databases, to assign genes to different 
groups and categories of functionally related genes. “Ingenuity genes” are assigned to one 
or more of three groups of gene functional categories, i.e. “diseases and disorders”, 
“canonical pathways” and “physiological systems development and function”. Each main 
category can be further divided into many subcategories (http://www.ingenuity.com).
In this study, we specifically looked at the five top-ranked “diseases and disorders” gene 
functional categories and subsequently at the five top-ranked subcategories within the 
“neurological disease” gene functional category.
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In addition, we looked at the top five “canonical pathways” and “physiological systems 
development and function” gene functional categories.
The NCBI databases (http://www.ncbi.nlm.nih.gov/sites/entrez/), the UCSC Genome 
Browser (http://genome.ucsc.edu), the HapMap project website (http://www.hapmap.org) 
and the website of the Sullivan Lab Evidence Project (http://slep.unc.edu) were used to 
retrieve information on gene function and prior association of the genes of interest with 
psychiatric disorders.
Results
A sample of 890 children with ADHD combined type had complete data. The mean age of 
the sample was 10.8 years (SD 2.8, age range 5 to 17 years) and 85.3% was male (see 
Table 1). O f these, 199 children (22.4%) were reported by their parents to have definite 
motor problems, and 225 (25.3%) were noted with possible motor problems. Scores for 
the DCD-Q were available for 313 Dutch IMAGE individuals (Table 1). Groups based on 
PACS motor scores showed a significant difference in DCD-Q motor scores, both in total 
score (F  = 36.89, P <  0.001) and subscale-scores (motor control in motion F  =  16.45, 
P  < 0.001; fine motor control/handwriting F  = 13.93, P  < 0.001; gross motor 
control/planning F  = 14.27, P  < 0.001; general coordination F  = 8.40, P  = 0.004). 
Of those children showing definite motor problems in PACS (n=92), 66 children (72%) 
also scored clinically on the DCD-Q total score (in the lowest 15th percentile of the 
normal population) (see Table 2). The Spearman correlation between the scores on the 
motor coordination item of the PACS and the DCD-Q total score was -0.340 (P  < 0.001).
A total of 580 SNPs showed association with PACS motor score at P  values < 10.00E-04. 
The most significant association was observed for an intronic SNP in SL C 7A 2  (P-value = 
1.90E-06), 58 additional SNPs showed association P  values < 10.00E-05 (Table 3). Of the 
580 PACS-associated SNPs, 174 were located in 97 genes (Supplementary Table 1). 
Bioinformatics analysis using the Ingenuity program revealed that 45 of the 97 genes from 
the GWAS fell into the “neurological disease” gene category (P  = 6.57E-06; Table 4). 
These 45 genes were most significantly enriched in five subcategories of the “neurological 
disease” category: “neurodegenerative disorder” (22/97 genes; P  =  6.57E-06),
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“progressive motor neuropathy” (23/97 genes; P  = 2.10E-05), “amyotrophic lateral 
sclerosis” (15/97 genes; P  = 5.42E-05) and two psychiatric disorders, “bipolar affective 
disorder” (19/97 genes; P  = 7.40E-04) and “schizophrenia” (10/97 genes; P  = 1.01E-02) 
(Table 5).
Other gene functional subcategories found significantly enriched in the 97 top candidate 
genes were “synaptic long term depression” (6/97 genes; P =  1.54E-02) and “nervous 
system development and function” (6/97 genes; P  = 4.00E-02) (Table 6).
Further characterization of the 59 SNPs showing P  values < 10.00E-05 for association 
with the PACS motor score using a more elaborate measure of motor coordination, the 
DCD-Q, revealed 15 SNPs associated with different subscales with P  values < 0.05 
(Table 3). Permutation testing showed that two SNPs had significant empirical P  values: 
rs11002745 for the gross motor scale (EMP P  = 0.045) and rs2839083 for the fine motor 
scale (EMP P =  0.014). While most DCD-Q subscale-associated SNPs influenced only 
one of the subscales, one SNP near the CO L6A 1  gene influenced control during movement 
and fine motor control (Table 3).
Of the 59 SNPs (Table 3), 17 were located within exonic, intronic or untranslated regions 
of nine different genes (see Supplementary Table 2 for information regarding gene 
function and published association with psychiatric disorders). A comprehensive search of 
the literature and databases indicated that eight of the nine encoded proteins function in a 
signalling network that operates in functional processes linked to neurite outgrowth, as 
recently also implicated in ADHD etiology (Poelmans et al. 2011). Interestingly, the same 
eight proteins are expressed in skeletal muscle, where they play important roles in basic 
muscle function (see Figure 1 and Supplementary File 1).
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D iscussion
This report describes the first GWAS of motor coordination problems. Although none of 
the associations reached genome-wide significance, i.e. a P-value < 7.20E-08 (Dudbridge 
and Gusnanto 2008), the findings are intriguing and can give input to further hypothesis- 
driven follow-up studies.
The finding that eight of the nine proteins encoded by the top-ranked findings from our 
GWAS (with P  values < 10.00E-05) function in a signalling network operating in neurite 
outgrowth is in line with another recent study of our group finding that 45 of the 85 top- 
ranked ADHD candidate genes from the five reported GWAS for ADHD are involved in 
neurite outgrowth (Poelmans et al. 2011). The finding that the same eight genes/proteins 
are also involved in muscle function is in line with the view that motor coordination 
problems should not be viewed merely as a neuronal problem. They are related to the 
whole range of functional processes located in the cerebrum, cerebellum, motor neurons, 
neuromuscular junctions, muscle sensors and muscle cells. Motor skills are also the result 
of many different processes such as perceptual, feedback and learning processes, motor 
preparation and movement execution processes. These processes rely on the visual system, 
memory, attention, the balance system, the kinaesthetic system (“feeling one's body”) and 
the motor effector system (Raynor 2001; Schoemaker et al. 2001; Visser 2003; Geuze 
2005; Smits-Engelsman et al. 2008). Any defect in one of these processes or systems may 
lead to motor coordination problems. Thus, our findings of motor coordination associated 
genes that are expressed in both nerve tissue and muscle may provide a rationale for 
further studies of basic muscle function in DCD.
Forty-five of the 97 genes identified by the GWAS (P  < 10.00E-04) fell into the 
“neurological disease” functional gene category. Among the most significantly enriched 
subcategories were “progressive motor neuropathy” and “amyotrophic lateral sclerosis” . 
Indeed, a relationship between ADHD and amyotrophic lateral sclerosis (ALS), an adult 
onset, polygenic disease of motor neuron degeneration (Ravits and La Spada 2009; 
Valdmanis et al. 2009; Van der Graaff et al. 2009), has been hypothesized (Lule et al. 
2008). Many patients developing ALS seem to have fulfilled clinical characteristics of 
ADHD earlier in their lives. At the neurobiological level, there is evidence for
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hyperactivity of the glutamatergic system and a dopaminergic hypoactivity in both ADHD 
and ALS (Lule et al. 2008). Therefore, our finding provides further input to the hypothesis 
that ADHD may be a risk factor for the development of ALS. However, whether children 
with ADHD and motor coordination problems might be at a particularly high risk for 
developing ALS in later life needs to be explored in further studies.
The Ingenuity analysis further showed that the categories “synaptic long term depression” 
and “nervous system development and function” were significantly enriched in the 97 top- 
ranked genes. Long-term depression of neurotransmission leads to physical changes in 
neuronal circuits (Johnston 2009) and this neuronal plasticity allows reorganization of 
neuronal networks and learning. Given that motor learning disturbances such as 
difficulties in mastering new motor skills like swimming and riding a bicycle are a 
hallmark of motor coordination problems in children (Sugden 2007), our results are 
particularly interesting.
Apart from the enrichment of motor neuropathy and ALS genes in the top-ranked findings 
from the GWAS, more evidence of genes involved in motor dysfunction is present in our 
data: CO L6A 1  codes for a collagen found in most connective tissues and important in 
organizing extracellular matrix components. Mutations in this gene are known to cause 
motor problems in Bethlem myopathy and Ullrich scleroatonic muscular dystrophy 
(Lampe and Bushby 2005; Baker et al. 2007; Nadeau et al. 2009). Several patients with 
autosomal recessive myosclerosis also have mutations in this gene (Merlini et al. 2008). 
The M A P 2 K 5  gene, a member of the mitogen-activated protein kinase family, has been 
consistently associated with restless legs syndrome (RLS) - a neurological disorder 
characterized by uncomfortable and unpleasant sensations in the legs that occur at rest and 
induce an irresistible desire to move the legs - in GWAS (Winkelmann 2008; Kemlink et 
al. 2009; Trenkwalder et al. 2009). A large population-based study has reported a 
prevalence of RLS of 2% in children and adolescents without ADHD (Picchietti and 
Picchietti 2008), whereas up to 44% of children with ADHD have symptoms of RLS 
(Cortese et al. 2005). Several authors have already suggested that RLS and ADHD share 
common risk genes (Schimmelmann et al. 2009; Reif 2010). Lastly, CH D6, one of our 
other main findings, is linked to motor behaviour, as a deletion of exon 12 of this gene 
leads to motor coordination problems in a mouse model (Lathrop et al. 2010).
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The association analysis of the candidate genes with the DCD-Q subscales provided 
insight into the sources of motor impairment at an additional level, in that it allowed us to 
characterize the movement “domain” that was influenced by the genetic variants 
identified. For 15 out of 59 tested SNPs, we found DCD-Q associations with P  values 
<0.05. The intergenic SNP rs11002745, located on chromosome 10, and SNP rs2839083, 
located 18.7 kb downstream of the CO L6A 1  gene on chromosome 21, survived multiple 
testing correction. The former SNP showed association with gross motor problems, the 
latter SNP was associated with fine motor problems and control during movement. As 
children with motor coordination problems show a heterogeneous phenotype, with some 
of them being mainly disturbed in fine and others in gross motor performance (Polatajko 
and Cantin 2005; Green et al. 2008), it is not surprising that we find these different 
associations.
This is the first GWAS of motor coordination problems and should be viewed as only a 
first step in identifying genetic factors contributing to these problems. Our study was 
underpowered, even though we collected a large sample of children with motor 
coordination problems in which we tried to maximize genetic homogeneity of the motor 
coordination problems by just focusing on children with ADHD. Another potential 
limitation of our study is the sparseness of the motor assessment in the international 
IMAGE sample, with only one question pertaining to motor problems in the PACS. 
Recognizing this, we chose a conservative approach in pooling the unaffected and 
possibly affected individuals together as non-affected, which has probably reduced the 
power of our study. Still, the affected group might show different types of motor 
problems, as is also suggested by the fact that 28% of people scoring positive for motor 
problems on PACS scored negative on the more extensive DCD-Q. The overall correlation 
of the PACS item with the total DCD-Q score was thus modest, which supports the 
validity of the PACS item but also indicates that this item and the DCD-Q measure 
somewhat different movement problems. In addition, it would have been preferable to use 
objective motor tests in our study. However, these tests are time-consuming, expensive 
and less compatible with testing large samples of children, as was done in our study. 
Nevertheless, the substantial evidence of the involvement of the genes from the top-ranks 
of this GWAS in other movement disorders strongly validates our approach.
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Replication studies in independent samples are necessary to confirm or refute the 
presented results. In addition, replication of these findings is needed in samples of children 
with DCD who were not primarily selected as suffering from ADHD. However, despite 
extensive efforts from our side to find such samples, at the current time, they do not seem 
to be available in the international research community.
Taken together, our findings raise the intriguing possibility that motor coordination 
problems are associated with genes expressed in both nerve tissue and skeletal muscle.
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Table 1. Descriptives of the study population measured with the PACS (n=890) and the DCD-Q 
(n=313)
Sample of children with ADHD and PACS (n) 890
Age (years mean (SD)) 10.8 (2.8)
Gender (% male) 85.3
Conners score (mean (SD)) hyperactivity/impulsivity 78.8 (10.3)
Conners score (mean (SD)) inattentiveness 71.3 (9.0)
Sample of children with DCD-Q scores (n) 313
DCD-Q total score (SD) 53.7 (9.5)
DCD-Q control during movement (SD) 19.9 (5.4)
DCD-Q fine motor (SD) 11.2 (3.2)
DCD-Q gross motor (SD) 13.1 (2.9)
DCD-Q general coordination (SD) 9.6 (2.8)
Table 2. Comparison PACS and DCD-Q motor affection in 
part of IMAGE
296 children participating in the Dutch
N children DCD-Q unaffected DCD-Q affected
PACS motor-unaffected 121 83
PACS motor-affected 26 66
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Table 3. Top single SNPs with P<  10.00E-05 from the GWAS for motor coordination problems in children with ADHD and DCD-Q results. The 24 SNPs showing a 
significant P  value for one of the DCD-Q results are indicated in bold.
chr SNP Position 
(base pair)
P  values Position ~ gene Gene P  values 
DCD-Q 
control
P  values 
DCD-Q 
fine motor
P  values 
DCD-Q 
gross 
motor
P  values 
DCD-Q 
general coord
1 rs6687919 111198699 9.29E-05 < 20 kb upstream CD53 7.24E-01 9.47E-01 3.29E-02 6.02E-01
1 rs6687898 111198839 9.29E-05 < 20 kb upstream CD53 7.24E-01 9.47E-01 3.29E-02 6.02E-01
1 rs6690536 111198974 9.29E-05 < 20 kb upstream CD53 7.24E-01 9.47E-01 3.30E-02 6.02E-01
2 rsl7762507 85247495 1.98E-05 intron TCF7L1 1.09E-01 5.72E-02 4.66E-01 4.44E-01
2 rs6733332 231346384 8.99E-05 intron CAB39 9.42E-01 5.41E-01 9.56E-01 5.40E-01
3 rs6550788 23734941 3.43E-05 < 100 kb upstream UBE2E1 3.78E-01 2.52E-01 2.22E-01 2.29E-01
4 rsl2643829 16989235 5.26E-05 < 100 kb upstream CLRN2 3.81E-01 3.21E-01 5.92E-01 4.20E-01
4 rs7442317 29512150 3.62E-06 intergenic - 3.83E-01 7.65E-01 7.69E-01 6.94E-01
4 rsl6882428 29512172 3.62E-06 intergenic - 3.83E-01 7.65E-01 7.69E-01 6.94E-01
4 rs7690092 29516307 3.62E-06 intergenic - 3.83E-01 7.65E-01 7.69E-01 6.94E-01
4 rs953797 29523996 3.62E-06 intergenic - 3.83E-01 7.65E-01 7.69E-01 6.94E-01
4 rsl0023178 29526536 3.62E-06 intergenic - 3.83E-01 7.65E-01 7.69E-01 6.94E-01
4 rs 1503 966 29538600 1.93E-05 intergenic - 3.81E-01 1.84E-01 7.49E-01 7.42E-01
4 rs6837917 29558689 7.87E-05 intergenic - 8.80E-01 1.40E-01 1.07E-01 9.44E-01
4 rsl2511112 85895123 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.59E-02 8.23E-01
4 rs3098928 85898827 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.59E-02 8.23E-01
4 rs6858666 85948960 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.59E-02 8.23E-01
4 rs6531775 85949938 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.59E-02 8.23E-01
4 rs6835046 85973968 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.59E-02 8.23E-01
4 rs2046402 85981409 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.60E-02 8.23E-01
4 rs2869216 85984565 9.16E-05 intron WDFY3 2.28E-01 1.09E-01 7.60E-02 8.23E-01
4 rsl 1097028 86088807 5.61E-05 intron WDFY3 8.57E-01 3.08E-01 4.72E-03 9.10E-01
4 rs6820517 86089649 5.61E-05 intron WDFY3 8.57E-01 3.08E-01 4.72E-03 9.10E-01
4 rsl2502559 86094664 5.61E-05 intron WDFY3 8.57E-01 3.08E-01 4.72E-03 9.10E-01
4 rsl0012888 182392020 7.21E-05 intergenic - 5.09E-02 2.98E-01 3.74E-01 4.94E-01
5 rsl0462643 7720153 8.40E-05 intron ADCY2 4.90E-01 1.16E-01 3.45E-01 1.92E-02
5 rs747243 7736784 8.40E-05 intron ADCY2 4.90E-01 1.16E-01 3.45E-01 1.92E-02
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5 rsl366414 7743296 8.40E-05 intron
5 rs6895553 114849566 8.63E-05 <30 kb downstream
6 rs4413658 2313641 3.37E-05 100 kb upstream
6 rs7449538 2314638 3.37E-05 100 kb upstream
6 rs9503158 2315074 3.37E-05 100 kb upstream
6 rsl883587 2319820 3.37E-05 100 kb upstream
6 rsl883588 2319887 3.37E-05 100 kb upstream
6 rs4507577 19564453 3.38E-05 intergenic
7 rs2075000 150764725 4.99E-05 intron
7 rsl2534366 150769315 5.27E-05 intron
7 rsll766792 152862485 1.20E-05 intergenic
8 rs7819754 16125110 6.75E-05 < 50 kb upstream
8 rsl0090333 16131941 6.37E-05 < 50 kb upstream
8 rs2248010 17460770 1.90E-06 intron
9 rsl3283363 34832242 2.66E-05 < 10 kb upstream
9 rs 12726 35394840 9.45E-05 exon
10 rs l1002745 80370924 1.98E-05 intergenic
10 rs6480913 80379260 7.26E-05 intergenic
10 rs7092666 125267555 1.01E-05 intergenic
11 rsl 3 93 878 13869322 7.27E-05 <100 kb upstream
15 rsl6951001 65641295 6.78E-05 intron
15 rsl 1638507 65661099 6.72E-05 intron
15 rsl7241403 65662816 6.72E-05 intron
15 rsl878699 65687937 6.72E-05 intron
15 rsl7811219 85564053 2.35E-05 intergenic
17 rsl4003 17045439 5.37E-05 exon
17 rs9894565 17047909 6.74E-05 exon
17 rsl736217 17068881 6.74E-05 intron
18 rs4800802 23179814 6.49E-05 intergenic
20 rs4812506 39487624 1.80E-05 intron
20 rs761024 39490051 1.98E-05 intron
21 rs2839083 46268084 8.87E-05 < 20 kb downstream
ADCY2 4.90E-01 1.16E-01 3.45E-01 1.92E-02
FEMIC 9.30E-01 2.27E-02 2.21E-01 9.16E-01
GMDS 3.19E-02 2.79E-01 4.69E-01 2.58E-01
GMDS 3.20E-02 2.79E-01 4.69E-01 2.58E-01
GMDS 3.20E-02 2.79E-01 4.69E-01 2.58E-01
GMDS 3.20E-02 2.79E-01 4.69E-01 2.58E-01
GMDS 3.19E-02 2.79E-01 4.69E-01 2.58E-01
- 2.76E-01 5.78E-01 3.46E-01 4.19E-01
CRYGN 2.90E-02 1.55E-01 3.32E-01 5.02E-01
CRYGN 3.43E-02 1.95E-01 2.53E-01 5.62E-01
- 9.08E-01 2.16E-01 9.24E-02 4.33E-03
MSR1 3.06E-01 3.96E-01 3.12E-01 6.64E-01
MSR1 1.07E-01 3.21E-01 3.94E-01 2.39E-01
SLC7A2 7.00E-02 6.55E-01 2.71E-01 4.29E-01
C90RF144 7.86E-01 1.29E-01 7.67E-01 2.48E-01
UNC13B 2.78E-01 1.42E-01 2.37E-01 8.92E-01
- 6.53E-01 4.89E-01 4.49E-03 1.86E-01
- 5.13E-01 4.87E-01 4.93E-02 3.14E-01
- 1.16E-01 4.38E-01 2.49E-01 7.95E-01
SP0N1 2.03E-01 3.23E-01 8.02E-01 8.25E-01
MAP2K5 9.61E-02 9.53E-01 9.42E-01 3.01E-01
MAP2K5 1.42E-01 9.96E-01 7.65E-01 3.24E-01
MAP2K5 1.42E-01 9.96E-01 7.65E-01 3.24E-01
MAP2K5 1.42E-01 9.96E-01 7.65E-01 3.24E-01
6.14E-01 2.01E-01 3.40E-01 3.06E-01
PLD6 5.08E-02 2.59E-01 7.66E-01 6.93E-01
PLD6 3.13E-02 1.43E-01 4.20E-01 9.84E-01
FLCN 3.13E-02 1.43E-01 4.20E-01 9.84E-01
- 8.48E-01 7.81E-01 4.72E-01 6.69E-01
CHD6 3.25E-01 2.06E-01 9.95E-01 1.51E-01
CHD6 3.26E-01 2.30E-01 8.60E-01 2.02E-01
C0L6A1 2.39E-03 4.79E-04 3.00E-01 5.64E-01
68
Table 4. Top five “diseases and disorders” gene functional categories that are significantly enriched in the top 97 ADHD candidate genes from the GWAS for motor 
coordination problems in children with ADHD (see Supplementary Table 1) using Ingenuity pathway analysis. The six genes containing at least one SNP that yielded a 
P- value < 10.00E-05 (see Table 3) are indicated in bold.
Category Genes Significance a Adjusted 
significance b
Cardiovascular disease 
(35/97 genes)
ACPP, AKAP6, BMPER, BRUNOL4, C30RF31, CDH13, CNTN3, CNTNAP2, 
DABI. ENPP1. EPB41L4A. FAM130A2. GMDS. MAML2. MAP2K5. MEF2B. 
MICAL2. NR3C1. PKD1L2. PKP2. PNPLA7. RBMS3. RELN. RYR2. RYR3. 
SASH1. SCAPER, SLC7A2. SORCS3. SOX5. SPAG16. THRB. TMEM132D. 
TRIO. UNC13B
5.96E-09 2.68E-06
Neurological disease 
(45/97 genes)
ACPP. ADCY2. ANXA6. ATP6V0A4. BRUNOL4. CAB39. CDH13. CNTNAP2. 
DABI. GAD2. GMDS. GPR88. GRM4. MAML2. MICAL2. MLLT3. NF1. 
NGFB. NR3C1. PIP4K2A. PKD1L2. PLA2G4A. PTPRG. RAG1. RBMS2. 
RBMS3. RELN. RYR2. RYR3. SCN11A. SLC1A3. SLC35C1. SLC6A1. SLC7A2. 
SNX27. SORCS3. SOX5. SPAG16. TCF7L1. THRB. TMEM132D. TRIO. 
TRIP12. TUFT1. WDFY3
3.84E-08 6.57E-06
Endocrine system disorders 
(31/97 genes)
ADCY2. AKAP6. CDH13. CNTN3. CNTNAP2. DABI. ENPP1. EPB41L4A. 
FARP2. FLCN. GMDS. MAML2. ME3. MICAL2. NR3C1. PIP4K2A. PTPRG. 
RBMS3. RYR2. RYR3. SASH1. SCN11A. SLC6A1. SORCS3. SOX5. SPAG16. 
TCF7L1. THRB. TMEM132D. TRIO. WDFY3
5.36E-06 2.19E-04
Gastrointestinal disease 
(21/97 genes)
ACPP. AKAP6. CDH13. CNTNAP2. DABI. EPB41L4A. GMDS. MAML2. 
MAP2K5. MICAL2. NR3C1. PKD1L2. PTPRG. RBMS3. RYR2. SLC6A1. 
SORCS3. SOX5. TMEM132D. TUFT1. WDFY3
1.74E-05 5.60E-04
Inflammatory disease 
(32/97 genes)
ACPP. ADCY2. AKAP6. BRUNOL4. CDH13. CNTNAP2. DABI. ELMOD2. 
ENPP1. EPB41L4A. FARP2. GAD2. GMDS. MAML2. MAP2K5. MICAL2. 
MLLT3. NGFB. NR3C1. PKD1L2. PTPRG. RBMS3. RYR2. RYR3. SCN11A. 
SLC1A3. SLC6A1. SORCS3. SOX5. SPAG16. TMEM132D. WDFY3
1.74E-05 5.60E-04
Abbreviations : GWAS, genome-wide association study; ADHD, attention-deficit hyperactivity disorder; SNP, single nucleotide polymorphism 
a Single test /'’values.
b Multiple test-corrected /'’values using the Benjamini-Hochberg correction.
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Table 5. Top five gene functional subcategories of the “neurological disease” category that are significantly enriched in the top 97 candidate genes from the GWAS for 
motor coordination problems in children with ADHD using Ingenuity pathway analysis. The four genes containing at least one SNP that yielded a /'’value < 10.00E-05 
are indicated in bold.
Subcategory Genes Significance a Adjusted 
significance b
Neurodegenerative disorder 
(22/97 genes)
ADCY2, ATP6V0A4. CDH13, CNTNAP2, DABI, GAD2, GMDS, GRM4, 
MICAL2. NR3C1, PLA2G4A. RELN, RYR2. RYR3. SCN11A, SLC1A3. SLC6A1 
SLC7A2, SORCS3, TMEM132D, TRIO, TUFT1
3.84E-08 6.57E-06
Progressive motor neuropathy 
(23/97 genes)
ADCY2, BRUNOL4, CDH13, DABI, GAD2, GMDS, MAML2, MLLT3, NF1, 
NR3C1, PKD1L2, RBMS2, SCN11A, SLC1A3, SLC35C1, SLC6A1, SOX5, 
SPAG16, THRB, TMEM132D, TRIP12, TUFT1, WDFY3
3.73E-07 2.10E-05
Amyotrophic lateral sclerosis 
(15/97 genes)
ADCY2, BRUNOL4, CDH13, DABI, GAD2, GMDS, RBMS2, SCN11A, 
SLC1A3, SLC35C1, SLC6A1, SPAG16, TMEM132D, TUFT1, WDFY3
1.09E-06 5.42E-05
Bipolar affective disorder 
(19/97 genes)
ACPP, CDH13, CNTNAP2, DABI, GAD2, GMDS, GRM4, NR3C1, PIP4K2A, 
PTPRG, RBMS3, RELN, SCN11A. SLC1A3, SNX27, SOX5, TCF7L1, THRB, 
TMEM132D
2.64E-05 7.40E-04
Schizophrenia 
(10/97 genes)
CNTNAP2, DABI, GAD2, GRM4, NR3C1, PIP4K2A, PLA2G4A, RELN, 
SLC6A1, SNX27
5.78E-04 1.01E-02
Abbreviations : GWAS, genome-wide association study, ADHD, attention-deficit hyperactivity disorder, SNP, single nucleotide polymorphism. 
a Single test /'’values.
b Multiple test-corrected /'’values using the Benjamini-Hochberg correction.
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Table 6. Top five “canonical pathways” (1) and “physiological system development and function” (2) gene functional categories that are significantly enriched in the 
top 97 candidate genes from the GWAS for motor coordination problems in children with ADHD using Ingenuity pathway analysis. The ADCY2 gene is indicated in 
bold because it contains three SNPs that yielded a /'’-value < 10.00E-05.
Category Genes Significance3 Adjusted significance1
Synaptic long term depression (1) ADCY2, ADCY6, GRM4, PLA2G4A, RYR2, RYR3 1.29E-04 1.54E-02
(6/97 genes)
Behaviour (2) GAD2, NGFB 5.79E-03 4.00E-02
(2/97 genes)
Embryonic development (2) EZR, FARP2, SCN11A 5.79E-03 4.00E-02
(3/97 genes)
Hematological system development and function (2) GAD2, NGFB 5.79E-03 4.00E-02
(2/97 genes)
Nervous system development and function (2) FARP2, GAD2, GRM4, NGFB, SLC1A3, SLC6A1 5.79E-03 4.00E-02
(6/97 genes)
Abbreviations : GWAS, genome-wide association study, ADHD, attention-deficit hyperactivity disorder, DCD, developmental coordination disorder, 
SNP, single nucleotide polymorphism. 
a Single test /'’values.
b Multiple test-corrected /'’values using the Benjamini-Hochberg correction.
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Figure 1. Schematic representation of a gene/protein network potentially contributing to 
motor coordination problems in children with ADHD by influencing skeletal muscle cell 
(SMC) function. The eight proteins encoded by genes containing at least one SNP yielding a 
P  value < 10.00E-05 in the GWAS for motor coordination problems in children with ADHD 
are indicated in yellow. The proteins that are encoded by A KA P6, M E F 2B  - two genes that 
contain at least one SNP associated at P  < 10.00E-04 (see Supplementary Table 1) - and 
N O S1  - a gene found associated with ADHD in the GWAS by Lasky-Su et al. (2008) - are 
indicated in orange. A more elaborate description of the network can be found in 
Supplementary File 1.
(a) cell membrane; (b) cytoplasm; (c) nucleus; (d) mitochondrion; (e) extracellular 
matrix/compartment.
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Supplem entary file 1
Signalling through the proposed network can be initiated at the skeletal muscle cell membrane 
(Fig.1, a) by ADCY2 (adenylate cyclase 2), a cell membrane protein (Uniprot Consortium 
2010) that is also found in the cytoplasm and that is expressed in skeletal muscle and brain 
(Sunahara and Taussig 2002). ADCY2 is activated by the binding of hormones such as 
dopamine and prostaglandin to cell surface receptors which interact with intracellular G 
proteins (Sunahara and Taussig 2002) (not shown in Fig. 1). ADCY2 produces cAMP (Jones 
and Kuhar 2006), which subsequently activates PKA (protein kinase A) (Fig.1, b) and can be 
negatively regulated by the inhibitory G protein subunit GNAI2 (Grishina and Berlot 1997). 
In skeletal muscle, PKA activates the transcription factor function of catenin beta (CTNNB) 
(Hino et al. 2005) and inhibits AMPK (Djouder et al. 2010) and MAPK7 (Pearson and others 
2006) (see below) (Fig.1, b). PKA is targeted to the proteins it activates or inhibits by the 
PKA anchoring protein AKAP6 (Fig.1, c), expressed in the nucleus membrane of skeletal 
muscle and brain cells, and encoded by A K A P 6  (Dodge-Kafka and Kapiloff 2006; Uniprot 
Consortium 2010), one of the 97 candidate genes containing at least one GWAS SNP with P  
< 10.00E-04 (see Supplementary Table 1).
CTNNB can also be bound and transactivated by TCF7L1, another transcription factor 
(Uniprot Consortium 2010) (Fig.1, c). In the nucleus of skeletal muscle cells, CTNNB 
functions as a transcription factor (Fig.1, c) that promotes the self-renewal of these cells 
(Perez-Ruiz et al. 2008). The kinase MAPK7 (also known as: ERK5), which is highly 
expressed in brain and skeletal muscle (Fig.1, b), is activated by MAP2K5 (Uniprot 
Consortium 2010). MAP2K5 is itself a cytoplasmic kinase (Fig.1, b) that is expressed in 
many tissues, including skeletal muscle - where it is particularly abundant - and brain
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(Uniprot Consortium 2010), and that is activated in a signalling cascade downstream of IGF-
2, a growth factor that initiates important signals in myogenesis (Carter et al. 2009). Upon 
activation, MAPK7 translocates to the nucleus where it activates/phosphorylates transcription 
factors of the MEF2 (myocyte enhancer factor 2) protein family (Uniprot Consortium 2010) 
(Fig.1, c). The MEF2 proteins, in turn, upregulate the transcription and expression of 
numerous muscle-specific genes by specifically binding to the MEF element/domain in these 
genes (Uniprot Consortium 2010) (Fig.1, c). In this way, the MEF2 proteins are e.g. involved 
in skeletal muscle glucose uptake by upregulating the expression of the GLUT4 glucose 
transporter (Zorzano et al. 2005; Lira et al. 2007; Wright 2007).
Another ubiquitously expressed transcription factor in the network is CHD6 (Uniprot 
Consortium 2010). CHD6 activates NRF2 (Nioi et al. 2005), another transcription factor that 
is also widely expressed, with highest expression in (adult and fetal) muscle (Uniprot 
Consortium 2010) (Fig.1, c). NRF2 upregulates the expression of GNAI2, the negative 
regulator of ADCY2 (see above), by transactivating the G N A I2  promoter (Arinze and Kawai
2005).
Also contributing to the network is SLC7A2, a membrane transporter (Fig.1, a) for the 
cationic amino acids (arginine, lysine and ornithine) (Uniprot Consortium 2010) that is 
(highly) expressed in skeletal muscle (Uniprot Consortium 2010) and brain (Colton et al.
2006). One of the major products of intracellular arginine is nitric oxide (NO) (Fig.1, b and 
Fig.1, e), which is synthesized by the NOS1 enzyme in skeletal muscle (Grozdanovic 2001; 
Harris et al. 2008) (Fig.1, b). NO stimulates the expression of the G L U T 4  glucose transporter 
in skeletal muscle through AMPK and MEF2 proteins (Zorzano et al. 2005; Lira et al. 2007; 
Wright 2007) (Fig.1, b and Fig.1, c). F L C N  encodes the cytoplasmic folliculin (Fig.1, b),
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which is expressed in many tissues including skeletal muscle and brain (Uniprot Consortium 
2010) and is directly activated by the AMPK kinase (Wang et al. 2010). FLCN is also directly 
involved in mTOR kinase signalling pathways (not shown in Fig. 1), which are important for 
skeletal muscle protein synthesis and hence skeletal muscle mass (Fujita et al. 2007; Uniprot 
Consortium 2010).
In addition to the network involved in muscle maintenance and function as described above, 
two additional genes from the top findings play a role in muscle function: PLD6 is a protein 
that is located in the (outer) membrane of mitochondria (Fig.1, b and Fig.1, d). It induces 
mitochondrial fusion through the formation of a dimer with a PLD6 protein on the outer 
membrane of a nearby mitochondrion (Choi et al. 2006). W DFY3  is highly expressed in 
skeletal muscle and brain and encodes WD repeat and FYVE domain-containing protein 3, a 
membrane protein that targets cytosolic protein aggregates for autophagic degradation 
(Simonsen et al. 2004). Both mitochondrial fusion (Zorzano 2009; Ding et al. 2010; Zorzano 
et al. 2010) and autophagic degradation (Raben et al. 2009; Schoser 2009) play important 
roles in (ab)normal skeletal muscle function.
Importantly, most of the genes and signalling cascades described above, and most notably the 
GNAI2-ADCY2-PKA-CTNNB (Grishina and Berlot 1997; Sunahara and Taussig 2002; Hino 
et al. 2005; Votin et al. 2005; Jones and Kuhar 2006) and MAP2K5-MAPK7-MEF2 (Li et al. 
2001; Liu et al. 2003; Lam and Chawla 2007) cascades and NRF2 (Kosaka et al. 2010) also 
function in neurite outgrowth (Poelmans et al. 2011).
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Supplementary Table 1. List of 97 genes harboring at least one SNP located in an exonic, intronic or 
untranslated region of the gene and with association at P  < 10.00E-04 (after correction for multiple testing)
Gene Full name
A2BP1 ataxin-2-binding protein 1
ACACA acetyl-coenzyme A carboxylase alpha
ACPP acid phosphatase, prostate
ADCY2 adenylate cyclase 2
ADCY6 adenylate cyclase 6
AKAP6 A kinase anchor protein 6
ANXA6 annexin A6
ARMC3 Armadillo repeat containing 3
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4
BFSP1 beaded filament structural protein 1, filensin
BMPER BMP binding endothelial regulator
BRUNOL4 bruno-like 4, RNA binding protein (Drosophila)
C3orf31 chromosome 3 open reading frame 31
C8A complement component 8, alpha polypeptide
CAB39 calcium binding protein 39
CAPN9 calpain 9
CDH13 cadherin 13, H-cadherin
CHD6 chromodomain helicase DNA binding protein 6
CNTN3 contactin 3
CNTNAP2 contactin associated protein-like 2
CRYGN crystallin, gamma N
DAB1 disabled homolog 1 (Drosophila)
DCPS decapping enzyme, scavenger
DIP encodes mitochondrial protein DIP
ELMOD2 ELMO/CED-12 domain containing 2
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1
EPB41L4A erythrocyte membrane protein band 4.1 like 4A
EZR Ezrin
FAM130A2 cysteine-serine-rich nuclear protein 3
FAM155A family with sequence similarity 155, member A
FARP2 FERM, RhoGEF and pleckstrin domain protein 2
FLCN Folliculin
FLJ45455 -
FLJ45994 -
GAD2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa)
GMDS GDP-mannose 4,6-dehydratase
GORASP1 golgi reassembly stacking protein 1, 65kDa
GPR88 G protein-coupled receptor 88
GRM4 glutamate receptor, metabotropic 4
LCMT2 leucine carboxyl methyltransferase 2
LIPA lipase A, lysosomal acid, cholesterol esterase
LRRC50 leucine rich repeat containing 50
MACROD2 MACRO domain containing 2
MAML2 mastermind-like 2 (Drosophila)
MAP2K5 mitogen-activated protein kinase kinase 5
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial
MEF2B myocyte enhancer factor 2B
MICAL2 microtubule associated monoxygenase, calponin and LIM domain containing 2
MLLT3 myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3
MYO1B myosin IB
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Supplementary Table 1. (Continued).
Gene Full name
NCKAP1L NCK-associated protein 1 -like
NF1 neurofibromin 1
NGFB nerve growth factor (beta polypeptide)
NIP30 -
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, alpha
PKD1L2 polycystic kidney disease 1 -like 2
PKP2 plakophilin 2
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent)
PLD6 phospholipase D6
PNPLA7 patatin-like phospholipase domain containing 7
PTPRG protein tyrosine phosphatase, receptor type, G
PTPRQ protein tyrosine phosphatase, receptor type, Q
RAG1 recombination activating gene 1
RBMS2 RNA binding motif, single stranded interacting protein 2
RBMS3 RNA binding motif, single stranded interacting protein
RELN Reelin
RNF20 ring finger protein 20
RYR2 ryanodine receptor 2
RYR3 ryanodine receptor 3
SASH1 SAM and SH3 domain containing 1
SCAPER S-phase cyclin A-associated protein in the ER
SCN11A sodium channel, voltage-gated, type XI, alpha subunit
SH3D19 SH3 domain containing 19
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3
SLC35C1 solute carrier family 35, member C1
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2
SNX27 sorting nexin family member 27
SORCS3 sortilin-related VPS10 domain containing receptor 3
SOX5 SRY (sex determining region Y)-box 5
SPAG16 sperm associated antigen 16
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4
SVOPL SVOP-like
TBCA tubulin folding cofactor A
TCF7L1 transcription factor 7-like 1
THRB thyroid hormone receptor, beta
TMEM132D transmembrane protein 13 2D
TMPRSS5 transmembrane protease, serine 5
TNRC4 trinucleotide repeat containing 4
TRIO triple functional domain (PTPRF interacting)
TRIP12 thyroid hormone receptor interactor 12
TUFT1 tuftelin 1
TYW1B tRNA-yW synthesizing protein 1 homolog B (S. cerevisiae)
UCP1 uncoupling protein 1 (mitochondrial, proton carrier)
UNC13B unc-13 homolog B (C. elegans)
WDFY3 WD repeat and FYVE domain containing 3
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Supplementary Table 2. Additional information about the nine genes harbouring SNPs with 
P  < 10.00E-05 from the GWAS for motor coordination problems in children with ADHD.
Gene Full name Locus Gene description Disorder SLEP *
SLC7A2 solute carrier 
family 7 member 
2
8p22 encodes a membrane 
transporter for the cationic 
amino acids (arginine, lysine 
and ornithine); highly 
expressed in brain and skeletal 
muscle
CHD6 chromodomain 
helicase DNA 
binding protein 6
20q12 encodes an ubiquitously 
expressed transcription factor
lies within linkage region 
for autism
(NPL 5.56, P=2.9E-7) 
(Allen-Brady et al., 
2008); was found in 
GWAS for SCZ,
(P  =0.0004771)
(Sullivan et al., 2008)
TCF7L1 transcription 
factor 7-like 1
2p11.2 encodes transcription factor 
that is involved in the self­
renewal of skeletal muscle 
cells
lies within linkage region 
for eating disorder (LOD 
2.22; P  =0.0007)
(Devlin et al., 2002)
CRYGN crystallin, 
gamma N
7q36.1 encodes an eye lens protein, is 
very probably a pseudogene
lies within linkage meta­
analysis region for 
autism (HEGESMA 3.9, 
P  =0.0027) (Trikalinos et 
al., 2005); was found in 
GWAS for depression 
(Muglia et al., 2009)
PLD6 phospholipase
D6
17p11.2 encodes a protein that is 
located in the mitochondrial 
membrane and that is involved 
in mitochondrial fusion
WDFY3 WD repeat and 
FYVE domain 
containing 3
4q21.23 encodes a protein with WD 
repeats and a FYVE domain; 
highly expressed in brain and 
skeletal muscle
lies within linkage region 
for SCZ (NPL 2), 
(Faraone et al., 2006); 
bipolar disorder (LOD 
2), (McAuley et al.,
2008)
MAP2K5 MAP kinase 
kinase 5
15q23 encodes the dual specificity 
mitogen-activated protein 
kinase kinase 5; expressed in 
brain and skeletal muscle
related to Restless Legs 
Syndrome
(Schimmelmann et al., 
2009)
FLCN folliculin 17p11.2 encodes a protein that is 
expressed in many tissues 
including brain and skeletal 
muscle
ADCY2 adenylate 
cyclase 2
5p15.31 encodes a cell membrane 
protein that is expressed in 
brain and skeletal muscle
-
* SLEP: Sullivan Lab Evidence Project.
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A bstract
Developmental dyslexia is a common specific childhood learning disorder with a strong 
heritable component. Previous studies using different genetic approaches have identified 
several genetic loci and candidate genes for dyslexia. In this article, we have integrated the 
current knowledge on 14 dyslexia candidate genes suggested by cytogenetic findings, 
linkage and association studies. We found that 10 of the 14 dyslexia candidate genes 
(ROBO1, KIAA0319, KIAA0319L, S100B, DOCK4, FMR1, DIP2A, GTF2I, DYX1C1, 
D C D C2) fit into a theoretical molecular network involved in neuronal migration and 
neurite outgrowth. Based on this, we also propose three novel dyslexia candidate genes 
(SLIT2, HMGB1 and VAPA) from known linkage regions and we discuss the possible 
involvement of genes emerging from the two reported genome-wide association studies 
for reading impairment-related phenotypes in the identified network.
Keywords: dyslexia; genetics; neurodevelopment; molecular network; bioinformatics
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Introduction
Developmental dyslexia (or specific reading disability) is defined as a specific and 
significant impairment in reading ability that cannot be explained by deficits in either 
intelligence, learning opportunity, motivation or sensory acuity. Dyslexia is the most 
common childhood learning disorder (1-3).
The prevalence of dyslexia ranges from 3,6 % in primary school children in The 
Netherlands (4) to as high as 10 % in US school-aged children (5), which is likely due to 
the fact that many different psychometric tests and diagnostic criteria for dyslexia exist 
(Box 1) (2, 3, 6). Twice as many boys as girls are affected with dyslexia (4, 7, 8).
Results from functional Magnetic Resonance Imaging (fMRI) studies and studies using 
other functional brain imaging modalities (such as event-related potentials and 
magnetoencephalography), indicate that three regions in the left brain hemisphere are 
important for fluent reading (for recent reviews, see Shaywitz and Shaywitz (9) and 
Hoskyn (10)). These regions are an ‘anterior’ system, that is the inferior frontal gyrus 
(Broca’s area), and two ‘posterior’ systems, the dorsal parietotemporal and ventral 
occipitotemporal systems. Functional brain imaging studies have repeatedly demonstrated 
that dyslexic readers are characterised by a so-called ‘neural signature’, in that the anterior 
system of their left brain hemisphere is slightly overactivated during reading tasks whilst, 
in contrast, the two posterior systems are underactivated (9, 10).
Evidence from family and twin studies shows that dyslexia is a highly heritable disorder, 
and up to 75 % of the phenotypic variance can be explained by genetic factors (2-4). 
Dyslexia behaves as a multifactorial (or complex) disorder, in which combinations of 
genetic and environmental factors contribute to disease risk. This article will concentrate 
on the genetic factors involved in dyslexia etiology. The genetic model underlying most 
cases of dyslexia is likely one in which several to multiple genetic factors, all of small or 
moderate individual effect size, contribute to disease risk (3, 5). In the current study, we 
reviewed the available evidence for dyslexia loci and genes, including linkage studies, 
(candidate gene based) association studies and reports of chromosomal aberrations 
cosegregating with dyslexia. We found that 10 of the 14 dyslexia candidate genes that 
were suggested by the literature had been shown to directly or indirectly interact and could 
be integrated into a molecular signalling network contributing to dyslexia etiology, 
responsible for regulating neuronal migration and neurite outgrowth.
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Our work builds on findings of other researchers in the field of dyslexia genetics (5, 11­
13), as well as existing knowledge about genes involved in neuronal migration disorders 
and the KEGG pathway for axon guidance (http://www.genome.jp/dbget- 
bin/show_pathway?map043600). Moreover, based on the signalling network, we propose 
three novel dyslexia candidate genes from linkage regions.
Linkage and association studies
As shown in Table 1, a substantial number of genetic linkage studies for developmental 
dyslexia have been carried out. At least 11 loci have been repeatedly linked to dyslexia 
and/or measures of the reading process known to be disturbed in dyslexia (Box 1), on 
chromosomes 1p35-1p36 (DYX8) (14-18), 2p11-2p16 (DYX3) (2, 17, 19-24), 2q22.3 (25, 
26), 3p12-3q13 (DYX5) (2, 18, 27), 6p22 (DYX2) (1, 2, 18, 28-30), 6q12-q15 (DYX4) (31,
32), 7q32 (22, 31), 11q13.4 (25, 26),15q15-15q21 (DYX1) (1, 18, 33-37), 18p11.2 (DYX6) 
(2, 31, 38) and Xq26-Xq28 (DYX9) (2, 4, 18, 31). Additional (suggestive) linkage findings 
for chromosome regions 4p15.33-4p15.32 (31), 11p15.5 (DYX7) (39), 12q13.13-12q21.33 
(26), 13q12.13-12q12.3 (26), 13q22.1 (2), 17p13.3 (31), 18q22.2-18q22.3 (2) and 21q21- 
21q22 (2) still await replication (Table 1). Considerable effort has been spent in trying to 
identify the dyslexia genes in a number of these regions by conducting candidate gene 
association studies, which will be discussed below and in Tables 2 and 3. For additional 
reviews of the candidate gene association literature of dyslexia, we also refer to Petryshen 
and Pauls (5), Scerri and Schulte-Korne (8) and Schumacher e t al. (40).
Until now, no genome-wide association studies (GWAS) for developmental dyslexia have 
been published. However, Meaburn e t al. (41) reported a GWAS of early reading 
(dis)ability in the general population using a quantitative trait loci approach. In addition, 
the results of a GWAS for an electrophysiological endophenotype of dyslexia were 
reported (42)
D YX 1 locu s (15q21)
Although located approximately 7 Mb distal of the maximal linkage peak in the DYX1 
locus (43, 44), the DYX1C1 gene was identified as the dyslexia candidate in the 15q21 
locus.
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In 2003, Taipale et al. (43,45) reported the mapping of DYX1C1 from the breakpoint of a 
translocation (t(2; 15)(q11;q21)) in four dyslexic members of an earlier described family 
(43, 45). In the original article describing the mapping, nominally significant genetic 
association was also reported between alleles of two single nucleotide polymorphisms 
(SNPs) in the gene (rs3743205A and rs57809907T) and dyslexia. A haplotype of these 
two alleles was associated with dyslexia as well (43). However, efforts to replicate these 
original associations have produced mixed and sometimes conflicting results (Table 2). 
Four subsequent association studies failed to replicate an association of any allele of 
rs3743205 and rs57809907 with dyslexia (46-49) whereas three other studies found a 
(nominally) significant association between dyslexia and/or specific reading measures and 
the opposite allele of rs3743205 (50, 51) and/or rs57809907 (50-52). One study reported 
association for the two-SNP-haplotype that was reported in the original mapping study of 
DYX1C1 (53), and more recently, a haplotype of three SNPs including rs3743205 was 
found associated with dyslexia in female probands (54). (Nominally) significant genetic 
association between the DYX1C1 missense variant rs17819126 and three reading and 
spelling measures was also reported (55) (Table 2). Because of the above described 
association results, several researchers in the dyslexia genetics field now submit that either 
another dyslexia candidate gene in DYX1 exists that remains to be discovered or that 
different causative variants in DYX1C1 might exist between different (language) 
populations (8, 56).
Nevertheless, functional evidence points to DYX1C1 as a viable candidate for dyslexia 
etiology: DYX1C1 encodes DYX1C1 (alternative name: EKN1), a cytoplasmic and 
nuclear protein containing three tetratricopeptide repeat domains, known protein-protein 
interaction modules. DYX1C1 is expressed in several tissues, including the brain, where it 
localizes to cortical neurons and white matter glial cells (43, 57). In the promoter region of 
DYX1C1, a binding site for the ELK1 and TFII-I transcription factors is present (43). 
This binding site contains rs3743205 (44), one of the SNPs associated with dyslexia in the 
original DYX1C1 study (43). Experiments in rats using in utero RNA interference against 
D yx1c1  showed that the gene product has a role in neuronal migration (that is the 
migration of whole neurons to target regions during cerebral cortex development) in the 
developing neocortex. For this, the C-terminus of Dyx1c1 (which contains the three 
tetratricopeptide repeat domains) is necessary and sufficient (57).
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The neuronal migration anomalies resulting from the in utero RNA interference in rats 
appeared similar to those observed in a relatively small set (n=8) of postmortem brains in 
humans with dyslexia (see Rosen e t al. (58) and references herein). Moreover, in rats, 
these neuronal migration anomalies were shown to lead to distinct impairments in auditory 
processing and spatial learning that have also been suggested to have a role in dyslexia 
(58, 59). Apart from its clear role in neuronal migration, several alternatively spliced 
transcript variants of DYX1C1  appear to be biomarkers for colorectal cancer (60).
In addition, through one of its tetratricopeptide repeat domains, the DYX1C1 protein 
functions as a co-chaperone by interacting with the HSP70 (heat shock protein 70) and 
HSP90 (heat shock protein 90) proteins in breast cancer cells (61).
Finally, in hippocampal neurons, DYX1C1 interacts with both the nuclear and 
cytoplasmic estrogen receptors a  (ESR1) and P (ESR2) (62) (see below). ESR1 and ESR2 
have been recognized to be important in brain development and neuronal processes such 
as neuronal migration and synaptic plasticity (62). In addition, ERS1 and ERS2 are 
thought to be involved in cognitive processes such as learning and memory (62), which 
seem partially impaired in dyslexia (63).
D Y X 2 locu s (6p22)
A cluster of five genes at this locus (VMP, DCDC2, KIAA0319, TTR APand THEM2) has 
been associated with dyslexia (30, 64). Of these five genes, genetic variants in DCDC2, 
KIAA0319  and TTRAP were reported to be associated with the disorder more than once (3,
52, 65-77) (Table 3).
In 2005, D C D C 2  was identified as a dyslexia candidate gene in a fine mapping association 
study of the D YX2  locus (65). The study reported a 2445-bp deletion in intron 2 of 
D C D C 2  that harbours a compound short tandem repeat polymorphism consisting of 
variable copy numbers of repeat units. Moreover, the combined allele of the deletion and 
minor alleles of the compound short tandem repeat marker (that is alleles with frequencies 
of < 5%) yielded significant association with reading performance (65). However, a later 
association study failed to replicate this finding in a German dyslexia sample (66). 
Another study reported a haplotype consisting of specific alleles of two SNPs in intron 7 
of D C D C 2  (rs793862 and rs807701) to be associated with dyslexia (67) (Table 3).
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In 2007, the 2445-bp deletion in intron 2 of D C D C 2  was reported to be nominally 
associated with single word reading efficiency and spelling (52), and subsequently, 
healthy individuals heterozygous for the 2445-bp deletion were reported to exhibit 
significantly larger gray matter volumes in reading/language-related brain regions (68). 
More recently, the association findings for the intron 2 deletion as well as the two intron 7 
SNPs were replicated in an independent case-control cohort (69). The same study also 
reported an association with dyslexia for another SNP, in intron 6 of D C D C 2  (rs807724), 
and for a risk-haplotype consisting of the deletion in D C D C 2  and specific alleles of 
rs807724, rs793862 and rs807701 (69). Very recently, two other intronic SNPs in D C D C 2  
(rs1419228 and rs1091047) were also reported to be associated with reading and spelling 
measures in a general population sample (70) (Table 3).
D C D C 2  is part of an 11-member doublecortin(DCX)-repeat gene family, including the 
D C X  gene, which is involved in neuronal migration and mutated in X-linked lissencephaly 
and double cortex syndrome, two neuronal migration disorders (65, 78, 79).
D C D C 2  encodes a protein with two DCX domains. The known function of DCX domains 
is that they associate with, bundle and stabilize neuronal microtubules, which are essential 
for neurite outgrowth and neuronal migration (12, 13, 69, 78-80). The DCX domains are 
also ‘regulated’ through phosphorylation by MAP kinase proteins such as the extracellular 
signal-regulated kinase 1 (ERK1) and 2 (ERK2) proteins (80). D C D C 2  is expressed in 
many organs and tissues, including the brain. Within the human brain, D C D C 2  is 
expressed, among others, in regions that are implicated in reading ability (65, 78, 79, 81). 
Finally, as with DYX1C1 (see above), in utero RNA interference against the rat homolog 
of D C D C 2  results in neuronal migration anomalies that are similar to those seen in a small 
set of postmortem brains in humans with dyslexia (see Rosen e t al. (58) and references 
herein (65, 81)).
K IA A 0319  was identified as a dyslexia candidate gene in two independent positional 
association studies of the 6p22 D YX2  locus (3, 71). Francks e t al. (3) identified a three- 
SNP risk haplotype consisting of specific alleles of two SNPs (rs4504469 and rs2038137) 
in KIAA0319  and rs2143340 in intron 2 of TTRAP that yielded association with several 
reading measures in UK and US samples of families with dyslexic individuals (Table 3). 
Association with rs4504469, rs2038137 (71, 72) and the three-SNP risk haplotype (73) 
was replicated in subsequent studies whereas the rs2143340 SNP was also shown to be 
associated with normal variation in reading and spelling ability in the general population
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(74) (Table 3) . In addition, the risk haplotype containing rs2143340 was associated with > 
40% lower expression of KIAA0319 in lymphoblastoid cell lines from unaffected 
individuals and in neuroblastoma cell lines (75). Recently, an SNP in the promoter region 
of KIAA0319, rs9461045, that is in complete linkage disequilibrium with rs2143340 (and 
hence the risk haplotype for dyslexia) was shown to create a protein-binding site for the 
silencing transcription factor OCT-1 (76). KIAA0319  expression from the risk haplotype 
increased upon small interfering (si-)RNA-mediated knock-down of the OCT-1 gene in a 
neuronal cell line, which implies that rs9461045 is the functional variant causing reduced 
expression of KIAA0319  (76). Interestingly, nominally significant genetic interaction 
effects for the D C D C 2  and KIAA0319 genes were reported and replicated, which suggests 
that both genes independently contribute to dyslexia risk (72, 77).
KIAA0319  encodes a protein that consists of an extracellular part with a MANSC (motif at 
N-terminus with seven cysteines) domain and several overlapping fibronectin type III (FN 
III) and polycystic kidney disease (PKD) domains, a transmembrane domain and a 
cytoplasmic part (http://www.ensembl.org/homo_sapiens). Expression of KIAA0319 is 
specific to the brain, with highest levels in the cerebral cortex, hippocampus CA3 and 
dentate gyrus, putamen, amygdala and cerebellum of the adult human brain (75, 76, 82). 
PKD domains have been implicated in cell-cell adhesion processes, which led to the 
hypothesis that the KIAA0319 PKD domains have a role in the adhesion between neurons 
and glial fibres during neuronal migration (11, 13, 82).
In utero RNA interference against the rat homolog of KIAA0319 indeed results in neuronal 
migration anomalies (75). Recently, embryonic knockdown of K iaa0319  in rats was found 
to result in significant arrest of neuronal migration and subsequently causes specific types 
of neuronal migration anomalies in the postnatal rat brain whereas, in contrast, embryonic 
overexpression of K iaa0319  does not cause gross neuronal migration anomalies (83). 
Lastly, apart from a main variant (variant A) of KIAA0319, two alternatively spliced 
products of the gene exist (variants B and C), which encode KIAA0319 isoforms that lack 
a transmembrane domain. Isoform B was found to be secreted, suggesting that KIAA0319 
could be involved not only in cell-cell interactions, but also in extracellular signalling (82, 
84).
An additional putative dyslexia gene on 6p22 is TTRAP. As indicated above and in 
Table 3, rs2143340, an SNP in intron 2 of TTRAP, has yielded association with variation 
in spelling (73) and reading (73, 74) ability in the general population.
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Moreover, this SNP is a part of a three-SNP risk haplotype associated with dyslexia in 
studies of the KIAA0319  gene (3, 75). However, as the association findings for rs2143340 
now seem to be due to its linkage disequilibrium with rs9461045 affecting the expression 
of KIAA0319  (76) (see above), a role of TTRAP in dyslexia etiology has become unlikely.
The two other genes in the cluster of five genes at the DYX2  locus, that is VMP and 
THEM2, have not been repeatedly associated with developmental dyslexia.
D Y X 3 locu s (2p11-p16)
In 2002, Francks et al. (21) tested the SEMA4F  and OTX1 genes in the D YX3  locus for 
association with dyslexia. SEMA4F belongs to a protein family with a role in axonal 
guidance, and the OTX1 protein is a transcription factor involved in forebrain 
morphogenesis and cortex differentiation (21). However, no association with dyslexia was 
found (21).
In 2007, the C2ORF3 and M RPL19 genes were identified by positional candidate 
association mapping of the D YX3  locus (24), though these data still await replication. 
Both the C2ORF3 and M RPL19  genes are highly expressed in the adult and fetal human 
brain and although the function of both genes is unknown, it is interesting to note that 
C2ORF3 expression was found to correlate across brain regions with that of DYX1C1, 
DCDC2, and ROBO1, whereas M RPL19  expression was most highly correlated with the 
expression of KIAA0319  (24).
D Y X 5 locu s (3p12-q13)
The ROBO1 gene was identified as the dyslexia candidate gene in this locus through its 
position at the 3p12 translocation breakpoint of an individual with dyslexia carrying a 
translocation between chromosomes 3 and 8 (t(3;8)(p12;q11)) (85). Further examination 
of ROBO1 SNPs and haplotypes in a four-generation family determined that a haplotype 
cosegregated with dyslexia in 19 of 21 genotyped dyslexic family members (85). To date, 
there has been no independent replication of this finding.
The function of ROBO1 - a gene that is highly expressed in the brain - in brain 
development and neuronal migration is well established. ROBO1 encodes a member of the 
ROBO family of axonal guidance receptors.
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ROBO1 and other ROBO family proteins consist of an extracellular part with five 
immunoglobulin (Ig) and three FN III domains, a transmembrane domain and a 
cytoplasmic part (http://www.ensembl.org/homo_sapiens). The ROBO (or Roundabout 
homolog) proteins are receptors for so-called SLIT proteins. These interact with the netrin 
proteins and their receptor, DCC (deleted in colorectal carcinoma), to regulate the 
direction and rate of axon/neurite outgrowth (85, 86) (see below).
D Y X 8 locu s (1p35-p36)
So far, only one candidate gene in this locus was investigated. An association study of the 
KIAA0319L  gene using five tagging SNPs in a Canadian sample of 291 nuclear families 
ascertained through a proband with reading difficulties found nominally significant 
evidence for association with dyslexia for one SNP (rs7523017; P=0.042) and a haplotype 
(P=0.032) in KIAA0319L  in a subset of the sample (n=156 families) (87). This finding still 
awaits replication. KIAA0319L  is expressed in several brain regions 
(http://biogps.gnf.org/#goto=genereport&id=79932) and although its function is still 
unknown, the gene has a high protein sequence identity to KIAA0319  
(http://www.ensembl.org/homo_sapiens), and may therefore have similar functions.
D Y X 9 locu s (Xq26-Xq28)
This chromosome region contains 15 known protein-coding genes 
(http://www.ensembl.org/homo_sapiens) and due to their very high homology to the SLIT 
proteins (88) that bind ROBO1 (see above), SLITRK2 and SLITRK4 in the region have 
been hypothesized to be dyslexia candidate genes (85). However, no mutations in the 
coding regions of these genes nor those of CXORF1 or FMR1, two other brain-expressed 
genes in the region, were identified in a family showing linkage to the DXS1227- 
DXS8091 region (4). That being said, the 5’ UTR trinucleotide repeat in FMR1 , which - 
when expanded - leads to Fragile X syndrome, the most common inherited form of 
intellectual disability, was not investigated in this family. Fragile X syndrome is often 
accompanied by deficient reading skills (89). Moreover, 8 of 15 investigated females with 
fragile X syndrome and a normal intelligence were reported to have dyslexia (90), and 
males carrying a so-called FMR1 ‘premutation’ - who are normally intelligent as well - 
display specific verbal working memory deficits (91) often found to be present in 
dyslexics (63).
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FMR1 activates/phosphorylates the MAP kinase proteins ERK1 and ERK2 in 
hippocampal neurons (92). In addition, FMR1 acts as an RNA-binding protein involved in 
the localization and regulated translation of specific neuronal messenger RNAs (mRNAs) 
encoding key molecules for neurodevelopmental processes such as synaptic plasticity and 
neurite outgrowth (93-95), including the mRNA of RAC1 (96), a protein that has an 
important role in our putative dyslexia network (see below). Very recently, direct genetic 
interaction was also reported between the Drosophila homologs of the FMR1 and FLNA 
genes (97). The human FLNA gene encodes filamin A, a protein that directly binds and 
modulates the actin filaments in the neuronal cytoskeleton (95, 98). Mutations in FLNA 
cause periventricular nodular heterotopia type 1, a neuronal migration disorder that - apart 
from neurological symptoms such as epilepsy - has been associated with dyslexia in the 
context of a normal intelligence (99, 100).
Chromosomal aberrations
Several chromosomal aberrations have been reported to cosegregate with dyslexia. As 
reported above, the DYX1C1 and ROBO1 genes in the DYX1 and D YX5  loci, respectively, 
were identified through their position in the breakpoints of translocations in dyslexic 
individuals.
Our own group recently reported PCNT, DIP2A, S100B  and PRM T2 to be (partially) 
deleted in a small deletion of chromosome band 21q22.3 that cosegregated with dyslexia 
in a father and his three affected sons (56). Two of these genes seem valid candidate genes 
for dyslexia.
DIP2A  encodes the ‘disco-interacting protein 2 homolog A ’ (DIP2A) (95). (In our original 
report (56), based on incorrect gene annotation information, we identified this gene as 
encoding the ‘DLX-interacting protein 2’, which is an alternatively spliced human variant 
of glutamate receptor interacting protein 1 (101)). The Drosophila homolog of DIP2A  is 
involved in neuronal connectivity in the visual system (102). In humans, DIP2A is a 
nuclear protein that is ubiquitously expressed. In a complex with the transcription factors 
DMAP1 (95, 103), DNMT1 and HDAC2 (103), it negatively regulates neurite outgrowth 
(104) and synaptic plasticity (105). Synaptic plasticity is crucial for cognitive processes 
such as learning and memory (105), which seem partially impaired in dyslexia (see above) 
(63).
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The S100B  gene is mainly and highly expressed in the brain (especially in the 
hippocampus) (106). S100B  encodes a calcium-binding peptide that is mainly produced by 
astrocytes and that exerts paracrine and autocrine effects on neurons and glial cells. 
S100B is known to bind to the receptor for advanced glycation end products (RAGE) 
protein in (hippocampal) neurons, which activates a signalling pathway resulting in 
neurite outgrowth (107). The protein has been reported to be involved in modulating 
synaptic plasticity (108), although the mechanism by which this is brought about is 
currently unknown (106). The concentration of the S100B peptide is increased in blood 
and cerebrospinal fluid in various clinical brain conditions, including psychiatric disorders 
such as schizophrenia and Tourette syndrome (106).
In a very recent study, a microdeletion of the D O C K 4  gene was found to co-segregate - 
though imperfectly - with dyslexia in individuals from two independent families in a study 
on rare structural DNA variants predisposing to autism and/or reading 
impairment/dyslexia (109). D O C K 4  encodes a peripheral membrane protein (95) that 
regulates dendritic growth and branching of hippocampal neurons (110) and (neuronal) 
cell migration (111) through the activation of RAC1.
A deletion of chromosome 7q11.23 results in Williams-Beuren syndrome (WBS), a 
human neurodevelopmental syndrome that has multisystemic manifestations including 
mild-to-moderate mental retardation and cognitive deficits. WBS has also been associated 
with reading difficulties and ‘full’ dyslexia (112-114). The deletion of GTF2I as part of 
the WBS deletion is responsible for the rather typical neurocognitive profile associated 
with WBS and, more specifically, for the visuospatial construction deficits that are very 
often seen in individuals with WBS (115, 116). Visuospatial construction deficits are also 
found in people with dyslexia (117). Another indication that GTF2I is involved in the 
etiology of language-related disorders is the fact that in a recent study of people with a 
7q11.23 microduplication syndrome involving GTF2I, all 13 subjects investigated in the 
study also had some degree of specific language impairment (SLI) (118), a disorder that is 
comorbid with dyslexia (8). In these individuals, the expression of only two genes in the 
duplicated region was upregulated, that is GTF2I and CYLN2 (118). Interestingly, mice 
with haploinsufficiency for Cyln2, the other gene that was upregulated in the duplicated 
region, have features of WBS, including mild growth deficiency and deficits in motor 
coordination (119).
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GTF2I is highly expressed in the brain, where it has a role in normal brain development. It 
encodes the transcription factor TFII-I (44). As indicated above, TFII-I binds to the 
promoter of the DYX1C1 gene at a binding site containing rs3743205 (44), the SNP 
associated with dyslexia (43, 50, 51, 53, 54). TFII-I acts as an enhancer or suppressor of 
the transcription of DYX1C1 depending on the context of other transcription factors (44).
From  single candidate genes to an integrated m olecular network
As discussed earlier, 14 genes from the literature had (at least some) evidence for 
involvement in the etiology of dyslexia, that is DYX1C1, DCDC2, KIAA0319, C2ORF3, 
MRPL19, ROBO1, KIAA0319L, FMR1,PCNT, DIP2A, S100B, PRMT2, D O C K 4  and 
GTF2I. An analysis with the GOstat bioinformatics tool (http://gostat.wehi.edu.au/) (120) 
showed that after correction for multiple testing, 6 of the 10 most significantly enriched 
gene ontology terms in these 14 candidate genes are related to nervous system 
development in general and/or neurite outgrowth in particular, that is generation of 
neurons, neurogenesis, axonogenesis, neuron projection  morphogenesis, neuron 
projection  developm ent and neuron developm ent (Table 4). Whereas three genes from the 
set carried gene ontology terms implicating them in neurite outgrowth (that is DCDC2, 
ROBO1 and S100B), it was clear from the above review that more genes could be linked 
to this process and the related neurodevelopmental process of neuronal migration. 
Therefore, we systematically searched PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) 
and the Uniprot Protein Knowledgebase (UniProtKB) (http://www.uniprot.org/uniprot)
(95) for the (proposed) function of the proteins that are encoded by the 14 dyslexia 
candidate genes that were described above.
As shown and described in (the legends of) Figures 1 and 2, 10 of the 14 proposed 
dyslexia candidate genes (that is ROBO1, KIAA0319, KIAA0319L, S100B, DOCK4, 
FMR1, DIP2A, GTF2I, DYX1C1 and D CD C2) fit into a neurodevelopmental and 
theoretical molecular network. All the corresponding proteins could be directly or 
indirectly linked to processes regulating and modulating cytoskeletal microtubules and 
actin filaments that are involved in neuronal migration and/or the directed outgrowth of 
neurites/axons. The proposed network therefore fits and extends the currently dominating 
hypothesis of dyslexia as a neuronal migration disorder (5, 11-13, 57-59, 65, 75, 81-83).
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In addition to the 14 candidate genes described above, the delineation of the molecular 
network enabled us to propose three additional dyslexia candidate genes from linkage 
regions in which no candidates had been described thus far.
In the DYX6  locus on 18p 11.2, marker D18S464 - which showed genetic linkage with 
(single word) reading in two dyslexia linkage studies (2, 31) (Table 1) - is located 
immediately downstream from the VAPA  gene, in a linkage disequilibrium block that 
contains part of the VAPA gene (http://www.broad.mit.edu/mpg/haploview/). The VAPA 
gene is highly expressed in the brain. The VAPA protein (other names: VAP-33 or 
VAMP-associated protein A) is an integral membrane protein found in the (neuronal) cell 
membrane, membranes of cellular organelles (such as the Golgi apparatus) and associated 
with microtubules (121, 122). VAPA was reported to have an important role in stimulating 
neurite outgrowth (123). In addition, it is involved in synaptic plasticity (124) and 
necessary for vesicular neurotransmission at the synapse (121, 122, 125). Like DYX1C1
(61), VAPA binds and forms a complex with HSP90, a protein with many functions 
including a role in intracellular vesicle transport (122). Recently, genetic association 
between several SNPs in VAPA and bipolar disorder has been reported (125).
Suggestive genetic linkage of ‘irregular word spelling’ near marker D4S2633 on 
chromosome 4p15.32 was reported in the dyslexia linkage study by Bates e t al. (31) 
(Table 1). The gene nearest to this marker is SLIT2, which maps approximately 1.3 Mb 
proximally. SLIT2 encodes a ligand of the ROBO family of axonal guidance receptors of 
which the dyslexia candidate ROBO1 is a member (86, 126).
In the study by Igo et al. (26), linkage with ‘single word reading efficiency’ was reported 
for marker ATA5A09 on 13q12.3 (Table 1). ATA5A09 is located within the HMGB1 gene 
(http://www.ensembl.org/homo_sapiens). Like S100B, the encoded protein (HMGB1 or 
Amphoterin) binds to the RAGE receptor and is involved in neurite outgrowth (107, 127). 
HMGB1 can also directly activate the ETS1 transcription factor (128), which upregulates 
another SLIT gene, that is SLIT3 (129). In addition, HMGB1 enhances the ESR1-induced 
expression of genes containing estrogen response elements (130)(see below).
In Figures 1 and 2, we have used a colour code indicating the level of ‘evidence’ that 
implicates the above-described/proposed dyslexia candidates in the etiology of dyslexia. 
Proteins with relatively robust evidence for involvement in dyslexia are indicated in 
orange.
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These proteins are encoded by genes that were disrupted by translocation breakpoints in 
dyslexic individuals (DYX1C1 and ROBO1) and/or found associated with dyslexia, 
requiring repeated association findings for those genes not implicated by translocations 
(DYX1C1, DCDC2, KIAA0319  and ROBO1). Indicated in yellow are proteins with less 
robust evidence of their involvement in dyslexia. These proteins are encoded by genes that 
were repeatedly found to be deleted in people with dyslexia (PCNT, DIP2A, S100B, 
PRMT2, GTF2I and D O CK4), genes that showed (nominal) association with dyslexia in 
only one study (C2ORF3, M RPL19  and KIAA0319L) and FMR1 that was mutated in 
people with dyslexia. The proteins indicated in purple are encoded by the three novel 
dyslexia candidate genes we propose based on their location in reported dyslexia linkage 
regions (VAPA, SLIT2and HMGB1).
Signalling through the network can be initiated at the neuronal cell membrane by the 
interacting SLIT and netrin axonal guidance pathways, which regulate the direction and 
rate of axon/neurite outgrowth (Figures 1a and 2). The molecular guidance ‘cues’ SLIT 
(including the dyslexia candidate SLIT2) and Netrin (mainly the Netrin-1 protein) bind to 
ROBO1 and DCC, respectively (86, 126). As shown and described in more detail in (the 
legend of) Figure 2, the rate and direction of outgrowth is critically dependent on the exact 
receptor composition in the plasma membrane. As they have fibronectin type III domains 
very similar to those of the DCC receptor protein 
(http://www.ensembl.org/homo_sapiens), the KIAA0319 and KIAA0319L proteins may 
function as receptors for netrin-like molecules. However, these interactions are 
hypothetical and have not yet been confirmed by experimental data, and therefore are not 
shown in Figures 1 and 2. Moreover, as suggested by others, KIAA0319 (11, 13, 82), and 
possibly KIAA0319L, might alternatively/additionally function in the direct adhesion 
between neurons and glial fibres during neuronal migration through their polycystic 
kidney disease domains.
As indicated in Figure 2, the activation of the ROBO1 and DCC receptors leads to 
signalling via CDC42 (131) and cytoplasmic ERK1 and ERK2 proteins (132) resulting in 
changes in the cytoskeletal organization of microtubules and actin filaments and 
(eventually) in neurite outgrowth (86, 126, 133, 134). Two other dyslexia candidates, 
S100B and HMGB1, can also result in CDC42 (135) and ERK1/2 (132) activation and 
neurite outgrowth by binding to RAGE (106, 127) (Figure 1b).
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In addition, S100B or HMGB1 binding to RAGE also activates RAC1 (136, 137) (Figure 
1b). This latter pathway is also activated by DOCK4, a peripheral membrane protein (95) 
that regulates dendritic growth and branching of hippocampal neurons (110) (Figure 1b). 
In the cytoplasm of hippocampal neurons, FMR1 also activates ERK1 and ERK2 (92) 
(Figures 1d and e). Moreover, FMR1 is involved in the translation of the mRNA of RAC1 
(96) (Figure 1d).
Activated ERK1 and ERK2 activate/phosphorylate the NF-kB (nuclear factor kappa-B) 
(138), ETS1 (139), ELK1 (140) and TFII-I (141) transcription factors (Figure 1c). NF-kB 
is also activated downstream of RAC1 (136). All four transcription factor seem to have a 
role in the dyslexia neurodevelopmental network. Activated NF-kB upregulates the 
transcription of the Netrin-1 (142) and H SP90  (143) genes. It also upregulates the 
transcription of the ELK1 gene (144), a transcriptional activator of DYX1C1 (43). ELK1 is 
a brain-expressed transcription factor, and its activation has been associated with neurite 
outgrowth and hippocampus-dependent learning in rats (43). The ETS1 transcription 
factor regulates the transcription and expression of the SLIT3 gene (129). Activated 
(nuclear) TFII-I (141) up- or downregulates the transcription and expression of the 
DYX1C1 gene, depending on the context of other transcription factors (43, 44).
The nuclear protein DIP2A binds DMAP1 (102), which is a part of the DMAP1-DNMT1- 
HDAC2 repressive transcription complex (103) (Figure 1c). HDAC2 - through which the 
DMAP1-DNMT1-HDAC2 complex negatively regulates neurite outgrowth (104) - is 
involved in repressing the transcriptional activity of ELK1 (95), which results in a reduced 
expression of DYX1C1. HDAC2 also directly inhibits ESR1, the nuclear estrogen receptor 
a  (145).
The nuclear ESR1 and ESR2 proteins - when activated - upregulate the expression of 
genes containing estrogen response elements by directly binding to the DNA sequences 
containing these elements (95) (Figure 1c). This process - that is important in brain 
development and neuronal processes such as neuronal migration and synaptic plasticity
(62) (see above) - is enhanced - for ESR1 - by HMGB1 (130) and suppressed - for both 
ESR1 and ESR2 - by DYX1C1 (62). DYX1C1 also binds directly to nuclear ESR1 and 
ESR2, which promotes their proteosomal degradation and hence negatively regulates the 
function of these proteins (62).
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In addition to their role in the cell nucleus, ESR1 and ESR2 are also found in the 
cytoplasm of hippocampal neurites, where they are involved in activating ERK1/2 (62, 
146) (Figure 1d). The ESR-DYX1C1-complexes that promote the proteosomal 
degradation of ESR1 and ESR2 are also found in the cytoplasm of hippocampal neurites 
(Figure 1d), which suggests the involvement of DYX1C1 in negatively regulating 
estrogen signalling cascades in these neurites (62). Moreover, as both DYX1C1 (61) and 
VAPA (122) bind to HSP90, this makes one speculate that a complex of VAPA, HSP90 
and DYX1C1 would be involved in degrading and negatively regulating cytoplasmic 
ESR1 and ESR2 (Figure 1d).
After being activated by any of the above described cascades, the ERK1/2 proteins also 
regulate the activity of the DCDC2 protein by phosphorylating its DCX domains (80) 
(Figure 1e). DCDC2 and FLNA - a protein that is encoded by a gene interacting with 
FMR1 (97) (see above) - directly bind and modulate neuronal microtubules and actin 
filaments that are involved in neurite outgrowth and neuronal migration (11-13, 65, 69, 
78-81, 95, 98-100) (Figure 1e).
As already stated above, two GWAS related to reading disability have been reported to 
date. The first was a GWAS using a quantitative trait loci approach comparing the two 
extremes of the reading ability spectrum of the normal population in 1502 children from 
the UK Twins Early Development Study TEDS (41). The authors used a pooled design 
and SNP arrays of only 100.000 SNPs, which greatly reduced the power of the study. 
Nevertheless, they nominally replicated some of their findings in 4258 additional samples 
from TEDS, resulting in 10 SNPs of interest for reading ability in early childhood (41). 
Six of these SNPs are located in introns of protein coding genes 
(http://www.ensembl.org/homo_sapiens), three of which could be directly linked to our 
molecular network for dyslexia: CDC42BPA  (rs1320490; P=0.030), TIAM1 (rs2409411; 
P=0.004) and D PF 3  (rs2192595; P=0.003) (41). CDC42BPA is a downstream effector of 
CDC42 involved in modulating the neuronal cytoskeleton (95) and hence neurite 
outgrowth (12). TIAM1 is a cytoplasmic protein that is involved in neurite outgrowth by 
directly activating RAC1 (147). DPF3 is a nuclear protein that belongs to the neuron- 
specific chromatin remodeling complex (also called the nBAF complex) (95), which has 
an important role in neural development and dendritic outgrowth of neurons (148).
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Recently, the results of a GWAS for an electrophysiological endophenotype of dyslexia 
(that is the so-called ‘mismatch negativity component’ or MMN) in a discovery sample of 
200 and a replication sample of 186 dyslexic children were reported (42). Genome-wide 
significance was reached for two SNPs in high linkage disequilibrium in CLSTN2 
(rs1365152 and rs2114167) in the discovery sample, though this finding was not 
replicated. As the replication sample was less strongly affected with dyslexia than the 
discovery sample, the authors suggest that CLSTN2 should not yet be discarded as a 
dyslexia candidate (42). The gene encodes calsyntenin 2, a brain-specific protein 
localizing to postsynaptic specializations of asymmetric synapses in the adult mouse brain 
(149) and shows association with verbal working memory (150), a cognitive process that 
is repeatedly found to be impaired in dyslexic subjects (42, 63). Although its function is 
currently unknown, in analogy with its homologue calsyntenin 1 (151), CLSTN2 might 
have a role in axonal transport, and may therefore fit well into our proposed neuronal 
migration and neurite outgrowth network.
In addition to the finding in CLSTN2, genome-wide significant association was reported in 
the combined discovery and replication sample between the late component of the MMN 
and rs4234898 on 4q32.1, a SNP in a gene desert, that ‘trans-regulates’ the expression of 
S L C 2A 3 (other name: GLUT3) on 12p13.31. SL C 2A 3encodes the predominant facilitative 
glucose transporter in the brain. Therefore, the authors suggest that the ‘trans-regulation ’ 
effect of rs4234898 (and a haplotype of this SNP with rs11100040) on SLC2A3 might lead 
to decreased glucose uptake in dyslexic children that could in turn explain their attenuated 
MMN results (42). The expression of the SLC2A3 gene is known to be upregulated by 
NF-kB (152) and through estradiol/ESR1 activation (153). Moreover, (glutamatargic) 
excitation of the neuronal cell membrane causes a translocation of SLC2A3 to the cell 
membrane leading to increased glucose uptake (154), which implies that SLC2A3 is a 
dyslexia candidate that may have an indirect role in neuronal migration and/or neurite 
outgrowth as an energy supplier.
Looking forw ard
In summary, we have comprehensively reviewed the literature related to the molecular 
genetic findings for developmental dyslexia. To our knowledge, this article constitutes the 
first attempt to integrate all reported genetic findings for dyslexia into a molecular 
signalling network.
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Furthermore, we have postulated a number of additional candidate genes for dyslexia that 
act in this network. The theoretical molecular/cellular model we have presented 
mechanistically links genes involved in directed neurite outgrowth and neuronal 
migration, two distinct neurodevelopmental processes that use an overlapping molecular 
(that is genetic) machinery. Our model does not provide further insights into which of 
these neurodevelopmental processes would be most relevant to the etiology of dyslexia, or 
where in the brain these processes are localized to selectively impact on neural circuitry 
determining reading and spelling performance. Although we were able to place 10 of the 
14 dyslexia candidate genes that were suggested by the literature in the theoretical 
network, it is unlikely that there would just be a single explanatory model that connects all 
dyslexia candidate genes and their corresponding proteins on the molecular level. Rather, 
several etiological cascades contributing to dyslexia are likely to exist.
That being said, we think that the model identified in this paper makes important 
predictions about genes and functional relationships between genes that need to be directly 
tested in future studies. Therefore, we think that a number of additional genetic association 
and mutation studies as well as functional studies - for example neuroimaging studies and 
studies in animal models - will be needed to sustain some of the claims made here. In this 
respect, we also hope that in the next few years, results of additional, large genome-wide 
studies of dyslexia and reading-related phenotypes will become available in order to 
provide more clues for further unraveling the genetic etiology of dyslexia.
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Box 1 Diagnosis o f  dyslexia
Many different psychometric tests and diagnostic criteria for dyslexia exist. For a 
recent review of the different definitions and tests for dyslexia, we refer to Fletcher (6). 
Most of the linkage and association studies we refer to in this article make use of five 
measures of the normal reading process, that is single word reading (SWR), spelling, 
phoneme awareness (PA), phonological decoding (PD) and orthographic coding (OC) 
(2, 3). Specific tests have been developed for each of these five reading measures (2) 
and are used for the diagnosis of dyslexia. PA is the ability to reflect on and 
manipulate the phonemes of words. PD could be defined as the skill to convert written 
sublexical letter units (or graphemes) into their corresponding phonemes. The OC 
reading component reflects the ability to recognize the specific letter patterns (or 
orthography) of whole words. OC is a particularly important skill in English, in which 
frequently the same word sounds can be represented by different letter patterns (2). 
It should be noted that orthographic coding is less difficult in Dutch (or another ‘open’ 
language like German or Italian) than in English, as the Dutch language contains 
(much) less irregularities of grapheme to phoneme correspondences than exist in 
English.
Based on the five reading measures mentioned above, one commonly used scheme for 
diagnosing dyslexia uses cut-offs of a standard score of below -2 s.d. in children and a 
standard score of below -1.5 s.d. in adults for at least two of the five measures. Apart 
from frequent impairments in SWR and/or spelling, dyslexics usually show deficits in 
one or more of PA, PD and OC skills. Dyslexia should therefore be regarded as a 
continuum in which often, several measures of the normal reading process are affected 
to some extent. Moreover, the different reading measures seem to be (genetically) 
correlated with one another and with IQ (2, 3).
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Table 1. Linkage studies for developmental dyslexia and/or different measures of the reading process (Box 1). The genetic markers and single nucleotide 
polymorphisms (SNPs) that were found in more than one linkage study are indicated in bold.
Locus Marker * Sample origin Phenotype Reported level of significance** Loci examined Reference
Ip35-lp36 (DYX8) D1S253 USA SWR significant Ip36-lq23, 6p21.3-6p23 (15)
D1S507, D1S199 USA PD significant Ip36-lq23, 6p21.3-6p23 (15)
D1S507 Canada Dyslexia replication Ip34-lp36 (16)
D1S507, D1S199 South Africa*** Dyslexia replication Replication study (18)
D1S552-D1S1622 Canada Dyslexia significant Ip34-lp36 (16)
D1S199-D1S478 USA Dyslexia suggestive Various loci (14)
D1S199 The Netherlands Dyslexia replication Replication study (17)
MATN1 USA PA significant Ip36-lq23 (15)
2pll-2pl6 (DYX3) D2S2352-D2S378-D2S1337 Norway Dyslexia significant Genome scan (19)
D2S2352-D2S378-D2S1337 Canada PD replication Replication study (20)
D2S378 The Netherlands NWR replication Replication study (17)
D2S337-D2S286 USA Dyslexia suggestive 2pl2-2pl6 (21)
D2S2368 USA PA suggestive QTL genome scan (2)
D2S286 Finland Dyslexia replication Genome scan (22)
rs917235 Finland Dyslexia significant 2pl2 (24)
rs917235 Germany Dyslexia significant 2pl2 (24)
D2S2114 USA PA,PD,OC suggestive 2pl2-2pl6 (21)
rs730148 Finland Dyslexia significant 2pl2 (24)
rs730148 Germany Dyslexia significant 2pl2 (24)
D2S2216 Finland Dyslexia significant Genome scan (22)
D2S2216 Finland Dyslexia replication 2pll-2pl2 (23)
2q22.3 D2S1399 USA PDE significant Genome scan (25)
D2S1399 USA SWE replication Genome scan (26)
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3pl2-3ql3 (DYX5) D3S1595-D3S3655 Finland Dyslexia
D3S1278 USA PD
D3S1278 South Africa*** Dyslexia
4pl5.33-4pl5.32 D4S403 Australia IWR
D4S2633 Australia IWS
6p22 (DYX2) D6S461, D6S299 USA PA
D6S461 USA Dyslexia
D6S299 UK PD
D6S299 South Africa*** Dyslexia
JA04 USA Dyslexia
D6S1554 USA Dyslexia
6ql2-6ql5 (DYX4) D6S965 Canada PD
D6S462 Australia IWS
7q32 D7S530 Finland Dyslexia
D7S530 Australia NWS
llpl5.5 (DYX7) HRAS-DRD4 Canada PD
llql3.4 D11S1314 USA PDE
D11S1314 USA SWE
12ql3.13-12q21.33 D12S297 USA WID
D12S1064 USA SWE
13ql2.13-13ql2.3 D13S1304-ATA5A09 USA SWE
13q22.1 D13S156 USA o c
15ql5-15q21 (DYX1) D15S994 UK Dyslexia
D15S143 USA SWR
D15S143 Germany Spelling
D15S143 USA WID
significant Genome scan (27)
significant QTL genome scan (2)
replication Replication study (18)
suggestive Genome scan (31)
suggestive Genome scan (31)
significant Ip36-lq23,6p21.3-6p23 (1)
replication 6p21.3-6p22 (29)
suggestive QTL genome scan (2)
replication Replication study (18)
significant 6p21.3-6p22 (29)
significant 6p22.3 (30)
significant Chromosome 6 (32)
suggestive Genome scan (31)
significant Genome scan (22)
replication Genome scan (31)
significant llpl5.5 (39)
suggestive Genome scan (25)
replication Genome scan (26)
suggestive Genome scan (26)
suggestive Genome scan (26)
significant Genome scan (26)
suggestive QTL genome scan (2)
significant 15q (35)
significant 15pter-15qter (1)
replication Chromosome 15 (34)
replication Replication study (36)
15ql5-15q21 (DYX1) D15S143 Germany Dyslexia replication Replication study (37)
D15S143 South Africa*** Dyslexia replication Replication study (18)
17pl3.3 D17S831 Australia IWS suggestive Genome scan (31)
18pl 1.2 (DYX6) D18S464 UK SWR significant QTL genome scan (2)
D18S464 Australia RWR replication Genome scan (31)
D18S53 USA SWR significant QTL genome scan (2)
D18S53 USA Reading ability replication Genome scan**** (38)
18q22.2-18q22.3 D18S61-D18S1161 USA SWR significant QTL genome scan (2)
D18S61-D18S1161 USA PD, OC suggestive QTL genome scan (2)
21q21-21q22 D21S1899-D21S266 USA OC significant QTL genome scan (2)
Xq26-Xq28 (DYX9) DXS1047 UK SWR suggestive QTL genome scan (2)
DXS1047 South Africa*** Dyslexia replication Replication study (18)
DXS1227-DXS8091 The Netherlands Dyslexia significant Genome scan (4)
DXS1227, DXS8091 Australia NWS replication Genome scan (31)
DXS1227 South Africa*** Dyslexia Replication Replication study (18)
Abbreviations: IWR, irregular word reading ; IWS, irregular word spelling ;
NWR, nonword reading ; NWS, nonword spelling ;
OC, orthographic coding ; PA, phoneme awareness ;
PD, phonological decoding ; PDE, phonological decoding efficiency ;
QTL, quantitative trait loci; RWR, regular word reading ;
SWE, single word reading efficiency ; SWR, single word reading ;
WID, word identification, which is a measure of single word reading accuracy.
* All markers are presented in the order they are localized on the chromosome (i.e. from centromeric to telomeric).
** Replication indicates that at least suggestive evidence of linkage was found for the marker(s) that were identified in the original linkage study.
This linkage study was conducted on a sample of Afrikaans-speaking/reading children with dyslexia of Dutch descent.
Performance on the Wide-Range Achievement Test (WRAT), a test of reading ability, was linked to D18S53 in the Framingham sample.
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Table 2. Reported associations of DYX1C1 at DYX1 with reading measures and dyslexia.
Gene Study population Sample Phenotype SNP and/or haplotype Reported level of Reference
origin significance
D  YX1 C l F inland 109 cases and 195 
controls
Dyslexia rs3743205 (-3A) P=0.016 (43)
Dyslexia rs57809907(1249T) P=0.048 (43)
Dyslexia rs3743205 (-3A):rs57809907(1249T) P=0.015 (43)
UK 264 families Dyslexia rs3743205 (-3G>A) not significant (50)
OC rs57809907(1249G) P=0.021 (50)
OC rs3743205 (-3G):rs57809907(1249G) P=0.014 (50)
Canada 148 families SWR rs3743205 (-3G) P=0.027 (51)
WID rs3743205 (-3G) P= 0.032 (51)
Spelling rs3743205 (-3G) P=0.027 (51)
PA rs3743205 (-3G) P= 0.023 (51)
PD rs3743205 (-3G) P=0.023 (51)
Dyslexia rs57809907(1249G>T) not significant (51)
Dyslexia rs3743205 (-3G):rs57809907(1249G) P= 0.026 (51)
UK 247 trios Dyslexia rs3743205;rs57809907;rs3743205:rs57809907 not significant (46)
Italy 158 families Dyslexia rs3743205;rs57809907;rs3743205:rs57809907 not significant (47)
USA 150 families Dyslexia rs3743205;rs57809907;rs3743205:rs57809907 not significant (48)
Italy 57 cases and 97 controls Dyslexia rs3743205;rs57809907;rs3743205:rs57809907 not significant (49)
USA 191 trios Dyslexia rs3743205 (-3G>A) not significant (52)
Dyslexia rs57809907(1249G) P=0.040 (52)
Dyslexia rs3743205 (-3G>A):rs57809907(1249G>T) not significant (52)
Italy 212 families Dyslexia rs3743205 (-3G>A) not significant (53)
Dyslexia rs57809907(1249G>T) not significant (53)
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Italy 212 families Dyslexia rs3743205 (-3A):rs57809907(1249T) P=0.047 (53)
Germany 366 trios Dyslexia rs3743205(-3G) P=0.006 (54)
Australia 790 families IWR rsl7819126 P=0.020 (55)
NWR rsl7819126 P=0.0003 (55)
IWS rsl7819126 P=0.009 (55)
Abbreviations: IWR, irregular word reading ; IWS, irregular word spelling ;
NWR, nonword reading ; OC, orthographic coding ;
PA, phoneme awareness ; PD, phonological decoding ; SNP, single nucleotide polymorphism ;
SWR, single word reading ; WID, word identification, which is a measure of single word reading accuracy.
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Table 3. Reported associations of DCDC2, KIAA0319 and TTRAP at DYX2 with reading measures and dyslexia.
Gene Study population 
origin
Sample Phenotype SNP and/or haplotype Reported level of 
significance
Reference
DCDC2 USA 153 families Reading 2,445 bp del:compound STR minor alleles P=0.00002 (65)
Gemían 396 trios Dyslexia 2,445 bp del:compound STR minor alleles not significant (66)
Gemían 239 trios Dyslexia rs793862:rs807701 P=0.001 (67)
USA 191 trios SWE 2,445 bp del P=0.046 (52)
Spelling 2,445 bp del P=0.035 (52)
Gemían 72 cases and 184 controls Dyslexia 2,445 bp del P< 0.001 (69)
Dyslexia rs807724 P=0.044 (69)
Dyslexia rs793862 P=0.038 (69)
Dyslexia rs807701 P=0.019 (69)
Dyslexia 2,445 bp del:rs807724:rs793862:rs807701 P<0.050 (69)
Australian 522 families RWR rsl419228 P=0.002 (70)
IWR rsl419228 P=0.004 (70)
Spelling rsl419228 P=0.002 (70)
IWR rsl091047 P=0.003 (70)
KIAA0319 UK 126 families SWR rs4504469:rs2038137:rs2143340 P=0.0024 (3)
Spelling rs4504469:rs2038137:rs2143340 P=0.025 (3)
o c rs4504469:rs2038137:rs2143340 P=0.00007 (3)
US 124 families SWR rs4504469:rs2038137:rs2143340 P=0.017 (3)
Spelling rs4504469:rs2038137:rs2143340 P=0.037 (3)
PA rs4504469:rs2038137:rs2143340 P= 0.018 (3)
UK 248 cases and 273 controls Dyslexia rs4504469 P= 0.002 (71)
Dyslexia rs2038137 P=0.001 (71)
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UK 126 families SWR rs4504469 P=0.004 (72)
PA rs4504469 P= 0.010 (72)
PD rs4504469 P=0.008 (72)
OC rs4504469 P=0.001 (72)
SWR rs2038137 P=0.0002 (72)
Spelling rs2038137 P= 0.006 (72)
PD rs2038137 P= 0.003 (72)
OC rs2038137 P=0.001 (72)
UK 350 cases and 273 controls Dyslexia rs4504469 P= 0.005 (72)
Dyslexia rs2038137 P= 0.005 (72)
Australia 440 families SWR rs4504469:rs2038137:rs2143340 P=0.04 (73)
TTRAP UK ~ 6000 children * Reading rs2143340 P=0.001 (74)
Spelling rs2143340 P=0.008 (74)
Abbreviations: IWR, irregular word reading ; OC, orthographic coding ;
PA, phoneme awareness ; PD, phonological decoding ; RWR, regular word reading ;
SNP, single nucleotide polymorphism ; SWE, single word reading efficiency ; SWR, single word reading.
* Tested for reading and spelling ; sample ranges from 5254 to 7090 children depending on phenotype measured.
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Table 4. Top 10 gene ontology (GO) terms significantly enriched in the 14 dyslexia candidate genes from the literature using the GOstat bioinformatics 
tool (http://gostat.wehi.edu.au/) (120). For each GO term, the total number out of all currently annotated human genes (n=33972) that could be linked to 
this term (TAG) is indicated. The eight genes encoding proteins that could be directly placed in the theoretical molecular network for dyslexia are 
indicated in bold.
GO term Genes TAG Significance3 Adjusted
significance1
Cell projection morphogenesis and organization PCNT, ROBOl, SIOOB 204 5.84E-05 4.05E-03
Generation of neurons DCDC2, ROBOl, SIOOB 242 9.69E-05 5.04E-03
Neurogenesis DCDC2, ROBOl, SIOOB 262 1.22E-04 5.10E-03
Identical protein binding PRMT2, ROBOl, SIOOB
C20RF3, DIP2A.DYX1 Cl, FMR1, GTF2I, MRPL19, PRMT2,
364 3.22E-04 1.12E-02
Nucleus SIOOB 6058 5.56E-04 1.37E-02
Axonogenesis ROBOl, SIOOB 114 8.50E-04 1.37E-02
Neuron projection morphogenesis ROBOl, SIOOB
C20RF3. DIP2A DOCK4, DYX1C1, FMR1, GTF2I,
120 9.41E-04 1.37E-02
Intracellular organelle MRPL19, PCNT, PRMT2, SIOOB 10763 1.05E-03 1.37E-02
Neuron projection development ROBOl, SIOOB 135 1.19E-03 1.37E-02
Neuron development ROBOl, SIOOB 154 1.54E-03 1.53E-02
a Single test /'’-values.
b Multiple test-corrected /'’-values using the Benjaniini-Hochberg correction; only the 10 most significantly enriched GO terms with more than one gene and reaching a 
corrected statistical significance of P<  0.05 are shown.
117
Figure 1. Schematic representation of the dyslexia molecular signalling network for neurite 
outgrowth and neuronal migration. The colour code we have used in Figures 1 and 2 to indicate 
the level of evidence that implicates the dyslexia candidate genes/proteins in the etiology of 
dyslexia is described in more detail in the article text. In short, the orange proteins are encoded by 
genes for which there is relatively robust evidence . The yellow proteins represent genes for which 
we found less robust evidence and the purple proteins are encoded by genes we proposed as 
dyslexia candidates based on their location in dyslexia linkage regions. SLIT and Netrin axonal 
guidance pathways at the neuronal cell membrane regulate the CDC42-extracellular signal­
regulated kinase (ERK)1/2 cascade (a). This process is shown and described in more detail in (the 
legend of) Figure 2. Binding of S100B and HMGB1 to receptor for advanced glycation end 
products (RAGE) results in CDC42 (135) and ERK1/2 (132) activation (b). The latter is also 
induced by FMR1 (92). DOCK4 (110), S100B and HMGB1 binding to RAGE (136, 137) activate 
RAC1 (b), which in turn activates the transcriptional activity of NF-kB (136) (c). FMR1 also 
activates ERK1 and ERK2 (92) (d, e) and it is involved in the translation of the mRNA of RAC1
(96) (d). Activated ERK1 and ERK2 (also) activate/phosphorylate the NF-kB (nuclear factor 
kappa-B) (138), ETS1 (139), ELK1 (140) and TFII-I (141) transcription factors (c). ERK1 and 
ERK2 also activate/regulate DCDC2 (80)(e). Activated NF-kB upregulates the transcription and 
expression of Netrin-1 (NTN1) (142) and HSP90 (143). It also upregulates the transcription of 
ELK1 (144), a transcriptional activator of DYX1C1 (43). ETS1 regulates the transcription of SLIT3 
(129) and is directly activated by HMGB1 (128) (c). Activated (nuclear) TFII-I (141) upregulates 
or downregulates the transcription of DYX1C1, depending on the context of other transcription 
factors (43, 44). DIP2A binds DMAP1 (102), which itself is a part of the DMAP1-DNMT1- 
HDAC2 repressive transcription complex (103). HDAC2 inhibits ELK1 (95) and ESR1, the 
nuclear estrogen receptor a (145) (c). When bound by their endogenous ligand 17p-estradiol, the 
nuclear ESR1 and ESR2 (estrogen receptor P) proteins - which form heterodimers - upregulate the 
expression of reporter genes containing estrogen response elements (ERE) by directly binding to 
the DNA sequences containing these ERE (95) (c). This process is enhanced - for ESR1 - by 
HMGB1 (130) and suppressed - for both ESR1 and ESR2 - by DYX1C1 (62). DYX1C1 also binds 
directly to nuclear ESR1 and ESR2, which promotes their proteosomal degradation (62) (c). ESR1 
and ESR2 are also found in the cytoplasm, where they are involved in activating ERK1/2 (62, 146) 
(d). The ESR-DYX1C1-complexes that promote the proteosomal degradation of ESR1 and ESR2 
are also found in the cytoplasm (62), and we hypothesize that a complex of VAPA (VAMP- 
associated protein A) (122), HSP90 (heat shock protein 90) and DYX1C1 (61) would be involved 
in degrading cytoplasmic ESR1 and ESR2 (d). Lastly, (activated) DCDC2 as well as FLNA 
directly bind and modulate neuronal microtubules and actin filaments (65, 69, 78-81, 95, 98) (e).
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Figure 2. Schematic representation of how the proteins from the Netrin and SLIT molecular 
guidance pathways interact to regulate the direction and rate of axon/neurite outgrowth. The colour 
code we have used in Figures 1 and 2 to indicate the level of evidence that implicates the dyslexia 
candidate genes/proteins in the etiology of dyslexia is described in detail in the article text. In 
short, the orange proteins are encoded by genes for which there is relatively robust evidence . The 
yellow proteins represent genes for which we found less robust evidence and the purple proteins 
are encoded by genes we proposed as dyslexia candidates based on their location in dyslexia 
linkage regions.
In a simplified model of the interaction between the SLIT and Netrin ligands with their receptors, 
Netrin-1 binding to the DCC (deleted in colorectal carcinoma) receptor leads to the activation of 
CDC42 (131), which in turn phosphorylates and activates the cytoplasmic Extracellular signal­
regulated kinase (ERK) 1 and 2 proteins (132) (2). The activation of ERK1 and ERK2 leads to 
further downstream signalling through different second messenger systems resulting in changes in 
the cytoskeletal organization of microtubules and actin filaments. This, in turn, results in neurite 
attraction towards the netrin guidance cues and stimulation of neurite outgrowth (86). However, 
when both a ROBO1 and DCC receptor are present in the neuronal plasma membrane (1), the 
binding of Netrin-1 to DCC still leads to the activation of CDC42 and subsequently of ERK1/2, 
but SLIT(2) binding to one of the immunoglobulin (Ig) domains of the ROBO1 receptor (86) 
results in the cytoplasmic domains of ROBO1 and DCC interacting (86) and in binding of a srGAP 
protein to the cytoplasmic domain of ROBO1.This in turn reduces/inhibits the activity of CDC42 
(133, 134). The end result of the interaction between ROBO1 and DCC is still stimulation of 
neurite outgrowth but the neurite attraction towards the Netrin guidance cues is silenced (86). 
When only a ROBO1 receptor is present in the neuronal plasma membrane (3), binding of SLIT(2) 
to one of the Ig domains of the ROBO1 receptor (86) eventually leads - through the inhibition of 
CDC42 - to stimulation of neurite outgrowth but repulsion away from the SLIT guidance cues (86,
126, 133, 134).
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A bstract
Objective:
Attention Deficit Hyperactivity Disorder (ADHD) is a highly heritable neuropsychiatric 
disorder. In the present study, the authors investigated the presence of genomic 
convergence in the top findings of the five published genome-wide association studies 
(GWASs) of ADHD.
Method:
The authors carried out bioinformatics pathway analyses using the Ingenuity and BiNGO 
tools, as well as a systematic literature analysis of 85 genes from the five published 
GWASs containing single nucleotide polymorphisms associated with ADHD at a p value 
< 0.0001.
Results:
Findings revealed that 45 of the 85 top-ranked ADHD candidate genes encode proteins 
that fit into a neurodevelopmental network involved in directed neurite outgrowth. Data on 
copy number variations in patients with ADHD and data from animal studies provide 
further support for the involvement of this network in ADHD etiology. Several network 
proteins are also directly modulated by stimulants, the most commonly used 
psychopharmacological treatment for ADHD.
Conclusions:
The authors have identified a protein network for ADHD that contributes to our 
understanding of the molecular basis of the disorder. In addition, the data suggest new 
candidate genes for ADHD and provide clues to future research into 
psychopharmacological ADHD treatments.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder 
that is observed in children and adults. ADHD is characterised by age-inappropriate levels 
of hyperactive, impulsive and inattentive behaviours and leads to significant clinical and 
psychosocial impairments (DSM-IV-TR). The disorder has a worldwide prevalence of 
5 %-6 % in children (1) and 1 %-4 % in adults (2,3). The most effective and commonly 
used medications for ADHD are the stimulants methylphenidate and amphetamine and the 
nonstimulant drug atomoxetine, which (predominantly) modulate dopaminergic and 
noradrenergic neurotransmission (4,5).
Converging neurobiological evidence suggests that ADHD involves alterations of 
catecholaminergic brain circuits (6). Neuroimaging studies in children with ADHD also 
show neurodevelopmental brain anomalies, such as reduced cortical volume and folding, 
and gray matter heterotopia (7-10) which indicate that neuroanatomically, ADHD is a 
disorder of early brain development. In addition, specific neuroimaging modalities, such 
as diffusion tensor imaging (11-13), (resting-state) functional magnetic resonance imaging 
(fMRI) (14-16), and EEG (17), have shown that both structural and functional brain 
connectivity are impaired in ADHD patients.
Evidence from family and twin studies shows that ADHD is a highly heritable disorder, 
and approximately 76 % of the phenotypic variance can be explained by genetic factors 
(18). ADHD behaves as a multifactorial (or complex) disorder, in which different 
combinations of genetic and environmental factors contribute to the overall risk of 
developing the disorder. The genetic model underlying most cases of ADHD is likely one 
in which multiple genetic factors of small-to-moderate effect size contribute to the disease 
etiology (19). Recent data indicate that rare copy number variations of genes may also be 
relevant to the etiology of ADHD (20-22), but pending further studies, it is unclear which 
proportion of ADHD cases could be explained by these variants.
To date, eight independent genome-wide linkage scans have been conducted for ADHD 
(23,24). A recent meta-analysis of seven of these studies identified genome-wide 
significant linkage for a chromosomal region on 16q (23). In addition, a large number of 
candidate gene association studies have been published, and these have primarily focussed 
on genes involved in catecholaminergic neurotransmission.
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Recent meta-analyses of these studies have yielded significant meta-association for six 
ADHD candidate genes (i.e., the dopamine and serotonin transporter genes DAT1/SLC6A3  
and 5-HTT/SLC6A4, the D R D 4  and D R D 5  dopamine receptor genes, the HTR1B  serotonin 
receptor gene, and the SNAP25 gene involved in neurotransmission) (25,26). In 2008, the 
results of three genome-wide association studies (GWASs) for ADHD were published 
(27-29) in two independent data sets. Lasky-Su et al. (28) reported the following two 
findings that reached (trait-specific) genome-wide significance: 1) a single nucleotide 
polymorphism (SNP) in CDH 13 and 2) a SNP in GFOD1.
Very recently, the results of two additional GWASs for ADHD in two independent 
samples were reported (30,31). Apart from CDH13, which maps to the only chromosomal 
region that yielded genome-wide significant linkage for ADHD in a recent meta-analysis 
(23), overlap between GWAS findings and any of the reported linkage or candidate gene- 
based association findings has been limited (32), although this is probably due in part to 
the fact that the published GWASs for ADHD are strongly underpowered.
In the present study, we attempted to integrate the most significant findings from the five 
reported GWASs for ADHD into protein signalling networks that would not only increase 
our understanding of the genetic etiology of ADHD but also provide clues for future 
research into more effective (psychopharmacological) treatments for the disorder. 
Based on bioinformatics analyses and a systematic literature analysis of the (putative) 
function of the proteins encoded by the 85 top-ranked genes emerging from the five 
GWASs for ADHD, we describe a signalling network involved in neurite outgrowth that 
includes 45 of these proteins. The other 40 proteins could not be convincingly linked to 
the network. Corroborating evidence for the involvement of this gene network from 
chromosomal aberrations in humans, from animal models and from 
psychopharmacological studies is also presented.
Method
Identification  o f  A D H D  Candidate Genes from  GW ASs
To date, the results of five GWASs of ADHD have been reported. Neale et al. (27) 
reported GWAS results for a categorical ADHD phenotype in 909 Caucasian case-parent 
trios that were collected as part of the International Multicentre ADHD Genetics 
(IMAGE) study in children. Lasky-Su et al. (28) performed a GWAS on the same sample 
using quantitative phenotypes of ADHD.
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Lesch et al. (29) conducted a GWAS for a categorically defined ADHD phenotype using 
pooled DNA from 343 ADHD-affected adults and 304 comparison subjects.
Recently, Mick et al. (30) also reported the results of a GWAS of a categorical ADHD 
phenotype in a sample of 735 trios from three different US clinical sites. In addition, the 
IMAGE II consortium reported the results of a GWAS using a case-control design in 896 
unrelated participants with ADHD and 2,455 comparison subjects (31). From these five 
GWASs, we compiled a list of top SNPs, taking into account SNPs located within exonic, 
intronic, or untranslated regions of genes and in association with the ADHD phenotype at 
p < 1.00E-04 (Table 1).
In gen u ity  a n d  B iN G O  P a th w ay A nalyses
In order to detect significantly enriched gene categories in the selected ADHD candidate 
genes from the five GWASs, we performed analyses using the Ingenuity Pathway 
Analysis software package (http://www.ingenuity.com) and the BiNGO (Biological 
Network Gene Ontology) bioinformatics tool (33). We performed similar analyses on a set 
of top genes from four GWASs for diabetes type I and Crohn’s disease and compared the 
results with those for ADHD in order to identify possible overrepresentation bias of large 
(brain-expressed) genes in the top findings of the ADHD GWASs.
The Ingenuity software package (http://www.ingenuity.com) uses the Ingenuity 
Knowledge Base, which is based on information from the published literature as well as 
many other sources, including gene expression and gene annotation databases, to assign 
genes to different groups and categories of functionally related genes. Each of these 
categories can be further divided into many subcategories. Ingenuity calculates single p 
values for the enrichment of each gene category with the right-tailed Fisher’s exact test 
and taking into consideration both the total number of molecules from the analyzed data 
set and the total number of molecules that is linked to the same gene category according to 
the Ingenuity Knowledge Base. Furthermore, for each gene category, a multiple testing 
corrected p value of enrichment, calculated using the Benjamini-Hochberg correction, is 
provided.
The BiNGO tool also assigns genes to different functional categories, but these are 
specifically linked to gene ontology terms that group functionally related genes (33) and 
can be found in the Gene Ontology database (http://www.geneontology.org/).
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The gene ontology terms can be further assigned to three main gene ontology subgroups 
or domains (i.e., cellular component, biological process, and molecular function). As with 
Ingenuity, the BiNGO tool provides single p values, calculated with the hypergeometric 
test and taking into consideration both the total number of molecules from the analyzed 
data set and the total number of molecules that is linked to the same gene ontology term, 
as well as multiple testing corrected p values, calculated using the Benjamini-Hochberg 
correction, for the enrichment of each gene ontology term (33).
In the presentation of the results of the Ingenuity and BiNGO analyses for ADHD, only 
categories/processes with significant enrichment (i.e., multiple testing corrected p <0.05) 
and containing more than one gene were taken into account. Only in the comparison 
between ADHD, diabetes type I, and Crohn’s disease were the functional categories that 
only contain one gene also considered.
L itera tu re A n alysis
Subsequent to the bioinformatics analysis, we systematically searched the literature for the 
(proposed) function of all 85 proteins derived from the ADHD candidate genes using 
PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) and the Uniprot Protein 
Knowledgebase (UniProtKB), a comprehensive catalogue of protein sequences and 
functional annotations that is updated every 3 weeks and can be accessed online 
(http://www.uniprot.org/uniprot (34)). For each ADHD candidate, we firstly looked at the 
available information in UniProtKB, which in several cases already provided a general 
indication of the (putative) function of the gene/protein in question. Subsequently, we 
searched PubMed using the search terms “brain”, “neuron” and “neurite” in combination 
with the name of each of the candidate genes/proteins from the GWASs. Lastly, guided by 
the literature we found, we searched Pubmed for functional interactions between several 
of the candidate genes/proteins.
Results
Table 1 shows the 85 genes from the five GWASs for ADHD fulfilling the inclusion 
criteria of the present study. When more than one SNP in a single gene was found among 
the top findings, only the SNP yielding the lowest p value for association with (a 
quantitative phenotype of) ADHD is presented.
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As can be derived from Table 1, the only overlap between the top findings of the five 
published GWASs was for CDH13, in which (three different) SNPs were associated with 
ADHD at p < 1.00E-04 in three GWAS (28,29,31).
Analysis of these 85 top ADHD candidate genes using the Ingenuity pathway software 
revealed a significant enrichment (p = 4.11E-08 after correction for multiple testing) of the 
functional gene category neurological disease, with 44 of the 85 genes falling into this 
category (Table 2). Furthermore, analysis with the BiNGO bioinformatics tool revealed 
that the gene ontology processes (calcium) ion binding and hexokinase activity were 
significantly enriched in the 85 ADHD genes (2.94E-03 < p < 5.43E-03 and p = 2.69E-02, 
respectively) (Table 2). Further literature analysis of the (putative) function of the proteins 
encoded by the genes in the enriched BiNGO-terms revealed that 21 out of 36 genes in the 
(calcium) ion binding category and two out of two hexokinase activity genes play a role in 
neurite outgrowth. Subsequently, we investigated the function of the entire set of 85 genes 
further and found that a total of 45 of the 85 included genes (indicated in bold in tables, 
figure legend, and throughout this article) fit into a neurodevelopmental network that is 
involved in directed neurite outgrowth, which is illustrated in Figure 1. The proposed 
signalling network links axonal guidance and neuronal cell adhesion proteins at the 
neuronal cell membrane with downstream acting adaptor proteins and neuronal 
cytoskeleton/extracellular matrix-associated proteins. A detailed description of the 
evidence linking the genes in the network to neurite outgrowth is provided in the data 
supplement accompanying the online version of this article.
Involvement of the identified network in ADHD is also supported by the finding that 
several of the identified genes (i.e., CTNNA2, NRXN 1, NAP5, SERPINI1, NOS1, ERK1, 
ZN F423, N E D D 4L, and BMP2) are located within copy number variations - and are 
hence deleted or duplicated - in people with AD(H)D (20-22, 35-41) (Table 3, Figure 1).
Moreover, partial knockout models of the NOS1, ERK1, M AP1B, and R O RA  genes in 
mice provide further evidence of the involvement of these genes in ADHD etiology 
(Figure 1). Mice in which the Nos1 and Erk1 genes have been knocked out display 
hyperactive behavior (42,43), while, in contrast, M ap1b- (44) and Rora-knockout mice 
(45) show hypoactivity.
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Lastly, several proteins from the network appear to be under control of the stimulants 
methylphenidate and amphetamine that are used to treat ADHD symptoms (4,5). 
Both stimulants have been shown to stimulate neurite outgrowth (46,47) and directly or 
indirectly regulate the expression and/or function of several genes/proteins implicated in 
neurite outgrowth, including a number of genes/proteins from the identified network 
(Figure 1). Methylphenidate exposure upregulates the expression of AV P  (48) and C R EB 5  
(49) (Figure 1). In addition, methylphenidate upregulates the expression of a large number 
of other genes not directly found in the identified network but functionally implicated in 
neurite outgrowth (50). Examples of these genes are M M P14, TIMP2, and TIMP3.
The M M P14  gene encodes a neuronal extracellular matrix metalloproteinase, such as 
MMP24, and TIMP2 and TIMP3 encode two direct inhibitors of MMP14 (34,50). 
Amphetamine upregulates the expression of UN C5B  (51) and PAK1  (52) and 
downregulates the expression of CTNNB  (53). Amphetamine also activates neuronal 
ERK1 and ERK2 (54) and increases the level of arachidonic acid (AA) in neocortical, 
extrapyramidal, and limbic brain regions (55). Deficiencies or imbalances of arachidonic 
acid have been shown to be associated with ADHD (56). Lastly, the adenylate 
cyclase/cAMP/protein kinase A/CREB-signalling cascade (including protein kinase A 
activating CREB5) is also activated by amphetamine (57).
An important potential bias of which to be aware in the analysis of the top findings from 
the reported GWASs of ADHD is the fact that large genes, which are often brain 
expressed, may be more likely found as associated with a phenotype in a GWAS as a 
result of chance, since more SNPs are present in these large genes (58). Indeed, the genes 
found among the top findings of the ADHD GWASs were considerably larger than the 
average gene size of the human genome ((Table 1) average size of 85 ADHD genes: 373 
kb versus average gene size in human genome: 27 kb (59)). If large genes are more likely 
found to be associated with a phenotype of a GWAS because of chance, this would be 
expected to be the case for GWASs of both nonpsychiatric disorders and ADHD, and 
therefore, we compared the results of our analyses with the Ingenuity and BiNGO 
software tools for the 20 top ADHD candidate genes with those for the top 20 candidate 
genes from four published GWASs for diabetes mellitus type I and Crohn’s disease (Table
4, Table 5; also see the data supplement).
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This comparison showed that the neurological disease category was not enriched in 
Crohn’s disease and only contained a single gene in diabetes type I (Table 4). In addition, 
the gene ontology processes that were enriched in the top GWAS findings were clearly 
different for the three diseases (Table 5).
Discussion
In the present study, we used both bioinformatics tools and manual literature mining to 
attempt to integrate the top findings of the currently available GWAS data for ADHD. 
We found that 45 of the 85 top ADHD candidate genes (or approximately 53%) fit into a 
network that is involved in neurite outgrowth. It should be noted that our decision to only 
include SNPs within exonic or intronic regions of genes and those with association at 
p < 1.00E-04 is essentially arbitrary. By only including genes with SNPs in exons and 
introns, we have ignored the possible role of upstream and downstream regulatory 
sequences (61), which could have increased the number of (potentially relevant) genes to 
be included in the study. However, we do not expect that this would have altered the 
general tendency in our results (i.e., the considerable overrepresentation of neurite 
outgrowth-related genes).
Surprisingly, the enrichment of neurite outgrowth-related genes was not reflected by the 
finding of gene functional categories and/or gene ontology terms directly related to neurite 
outgrowth with the bioinformatics tools used in this study (Table 2). This shows the 
limitations of the currently available bioinformatics software, which is a result of the 
current incompleteness of the annotation of the human genome. Therefore, use of 
bioinformatics tools should always be accompanied by manual and systematic literature 
and database mining in order to fully understand the processes involved in the etiology of 
multifactorial disorders. Moreover, the enrichment of neurite outgrowth-related genes in 
the ADHD GWAS data (53%) should be viewed from the perspective that only 3% 
(N=576) of all currently annotated human genes (N=18,589) are involved in neurogenesis 
(gene ontology term:GO:0022008).
Several additional lines of evidence suggest that the identified network provides an 
important contribution to the etiology of ADHD.
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Apart from implicating the same genes as the GWASs, these other lines of evidence point 
to involvement of several other genes (and their corresponding proteins) that were not 
found (at the p < 1.00E-04 level) in the GWASs but that functionally connect the genes 
from the GWAS findings. First, nine proteins that act in the identified neurite outgrowth 
network are encoded by genes that were also found in copy number variations in people 
with ADHD (20-22, 35-41) (Table 3). Second, knockout mouse models of four network 
genes reveal ADHD-related behavior (42-45). Third, and most importantly, the expression 
and/or function of a number of genes/proteins in the identified network is regulated by the 
stimulants methylphenidate (48-50) and amphetamine (51-55, 57), which are the most 
commonly used psychopharmacological treatments for ADHD symptoms (4,5) and 
directly regulate neurite outgrowth (46,47). The latter finding might not only increase our 
understanding of the working mechanism of these drugs but also provide directions for 
future research into new and more effective psychopharmacological ADHD treatments.
The fact that stimulants regulate neurite outgrowth potentially implicates a number of 
classic ADHD candidate genes in our network. Methylphenidate and amphetamine 
mediate effects on both dopaminergic and serotonergic neurotransmission in the brain 
(4,5,62). In this respect, the genes encoding the SLC6A3, DRD4, DRD5, SLC6A4, and 
HTR1B proteins could be putatively linked to the identified network. In addition, the link 
of these classic candidate genes with the neurite outgrowth network may help to localize 
the network to dopaminergic and serotonergic brain regions.
The findings from this study fit very well with literature about disturbed brain structure 
and function in ADHD patients (7-10) and, even more so, with recent reports describing 
aberrant structural and functional brain connectivity in these patients (11-17). 
Because differences in brain connectivity have been shown to underlie interindividual 
variability in complex cognition-related processes, including ADHD (63,64), relatively 
minor alterations in neurite outgrowth efficiency or direction may provide a major 
contribution to the cognitive deficits observed in ADHD.
A possibly important bias in our study may arise from the fact that the brain-expressed 
genes in the top findings of the ADHD GWASs are substantially larger than the average 
gene size in the human genome, and seven of the nine very large genes (i.e., genes with a 
size of > 1 Mb) from the list of 85 ADHD genes indeed encode proteins that fit into the 
proposed ADHD network.
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It has been argued that the overrepresentation of large genes in the top of GWASs might 
result from bias because one is more likely to find an associated SNP in a larger, usually 
brain-expressed gene (58). If this is the case, it would be expected that similar results 
would be found in GWASs of polygenic disorders that are assumed not to primarily 
originate in the brain, such as diabetes mellitus and Crohn’s disease. However, our 
Ingenuity and BiNGO analyses on the 20 top candidate genes from the GWASs for 
ADHD, diabetes mellitus type I, and Crohn’s disease (Table 4, Table 5) show that this 
bias does not likely explain the findings for ADHD. In this respect, we would like to 
submit that the strong enrichment of neurite outgrowth-related genes in the top findings 
from the five ADHD GWASs, with 45 out of 85 genes fitting into our proposed network, 
also argues against the fact that these genes are spurious association findings. 
Nevertheless, we cannot completely exclude the possibility that some of the genes placed 
in the network still might have been chance findings.
Is the involvement of neurite outgrowth genes specific to the etiology of ADHD? 
This seems rather unlikely, since we recently also found neurite outgrowth to be 
implicated in dyslexia (65). Following an approach similar to the one used in the present 
study, we found that 10 of 14 dyslexia candidate genes reported to date (i.e., DCDC2, 
DIP2A, DO CK4, DYX1C1, FMR1, GTF2I, KIAA0319, KIAA0319L, ROBO1, S100B) fit 
into a protein network that is involved in neurite outgrowth and neuronal migration.
As shown in Figure 2 and explained in further detail in the data supplement, the proteins 
encoded by six of these genes (i.e., DCDC2, DYX1C1, FMR1, TFII-I (encoded by 
GTF2I), ROBO1, and S100B) fit directly in the identified network for ADHD. It is also 
interesting to note that decreased serum concentrations of S100B correlate with increasing 
hyperactivity symptoms in children with ADHD compared to normal comparison subjects 
(66) and that knockout mouse models of the FMR1 (67) and GTF2I (68) genes show 
ADHD-like behavior. One possible explanation for the observed genetic overlap between 
ADHD and dyslexia is that these neurodevelopmental disorders are highly comorbid and 
genetically correlated with one another (69-71). The same also holds true for autism (72), 
and recent evidence suggests involvement of neurite outgrowth genes in this 
neurodevelopmental disorder as well (73).
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The different functional consequences of disturbed or abnormal neurite outgrowth in the 
different brain regions that are most affected in ADHD, dyslexia, and autism, respectively, 
could help to explain why a disturbance of the same neurodevelopmental process could 
lead to these partially overlapping but still distinct clinical phenotypes.
Several genes that are major players in the identified neurite outgrowth network have not 
been directly observed in the top findings of the GWASs. An example of such a gene is 
ERK1, which not only has an important function in the network but has also been 
implicated in ADHD through its location in ADHD-related copy number variations 
(22,38) as well as the fact that E rk l-knockout mice display hyperactive behaviour (43) 
and that amphetamine directly activates neuronal ERK1 (54). Other examples are CTNNB 
and CD C42 . These and other genes from the network may be strong candidates for future 
association studies.
Lastly, our data make a compelling case for the use of polygenic types of association 
analyses to explain a higher percentage of the heritability of ADHD through the GWAS 
findings. In this respect, all the individually associated genes from the identified neurite 
outgrowth network could be fitted simultaneously into one polygenic risk test, as 
illustrated in the recent study by Yang et al. (74) of all SNPs that have been individually 
associated in GWASs of variation in human height as well as in two other recent studies 
applying similar approaches to GWAS data for schizophrenia (75) and functional gene 
groups for cognitive ability in ADHD (76).
In conclusion, by integrating the top findings of the five GWASs for ADHD with copy 
number variation data, (psychopharmacologically induced) expression data, and data from 
animal studies, we have identified a protein signalling network for ADHD that results in 
directed neurite outgrowth. Systems biology approaches like those used in this study are 
needed to yield genetic findings that are useful for clinical purposes, such as the prediction 
of disease prognosis and the identification of new treatment targets and strategies.
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Table 1. Top single nucleotide polymorphisms (SNPs) from the five reported genome-wide association studies 
(GW ASs) of attention deficit hyperactivity disorder (ADHD)a.
GW AS SNP p Locus Gene Position ~ gene Gene size
Neale et al. (27)b rs9676447 1.00E-05 19q13.33 NUCB1 intronic 23 kb
rs876477 2.70E-05 4p 15.31 KCNIP4 intronic 1220 kb
rs7657608 3.00E-05 4q32.3 SPOCK3 intronic 501 kb
rs3782309 5.50E-05 12p 11.23 ITPR2 intronic 498 kb
rs922781 5.50E-05 15q22.2 RORA intronic 741 kb
rs12505502 5.60E-05 4q22.1 FAM 190A Intronic 1360 kb
rs1062793 7.00E-05 6q14.1 SH3BGRL2 3' UTR 72 kb
rs703965 9.20E-05 10q22.3 ZMIZ1 intronic 248 kb
rs4149601 9.30E-05 18q21.31 NEDD4L intronic 357 kb
Lasky-Su et al. (28)c rs6565113 d 16q23.3 CDH13 intronic 948 kb
rs552655 d 6p24.1 GFOD1 intronic 130 kb
rs4128767 1.28E-06 15q25.1 IL16 intronic 117 kb
rs11719664 2.48E-06 3p24.3 ZNF385D intronic 955 kb
rs7577925 2.55E-06 2q21.2 N AP5 intronic 897 kb
rs7495052 2.83E-06 15q26.1 SLCO3A1 intronic 319 kb
rs17281813 3.46E-06 16q12.1 ZNF423 intronic 336 kb
rs363512 3.89E-06 21q2 1.3 GRIK1 intronic 403 kb
rs8041675 3.98E-06 15q14 M E IS2 intronic 210 kb
rs17641078 4.73E-06 9p24.3 DMRT2
nonsynonymous,
coding 7 kb
rs930421 5.64E-06 2p21 MTA3 3' UTR 262 kb
rs17651978 6.05E-06 3p13 FOXP1 intronic 629 kb
rs478597 8.08E-06 12q24.22 NOS1 intronic 163 kb
rs6791644 8.32E-06 3p14.2 F H IT intronic 1502 kb
rs260461 8.38E-06 19q13.43 ZNF544 intronic 35 kb
rs2290416 8.51E-06 8q24.3 NAPRT1
synonymous,
coding 4 kb
rs1202199 8.52E-06 6p22.3 M BOAT1 intronic 110 kb
Lesch et al. (29)e rs864643 1.30E-08 3p22.2 M O BP 3' UTR 59 kb
rs7995215 1.35E-08 13 q31.3 GPC6 intronic 1180 kb
rs11243897 5.63E-08 9q34.13 C9orf98 intronic 153 kb
rs7164335 1.30E-07 15q23 ITGA11 intronic 130 kb
rs220470 1.34E-07 17p13.2 ITGAE intronic 87 kb
rs10983238 1.37E-07 9 q3 3.1 A STN 2 intronic 990 kb
rs2587695 2.73E-07 2q14.2 PCDP1 intronic 118 kb
rs2281597 5.41E-07 1p3 5.1 CSMD2 intronic 652 kb
rs10514604 8.06E-07 16q24.1 ATP2C2 intronic 96 kb
rs2677744 9.69E-07 15q26.1 M AN 2A2 intronic 18 kb
rs2502731 1.58E-06 9 q3 4.11 DNM1 intronic 52 kb
rs2199161 1.62E-06 5q13.2 M AP1B intronic 100 kb
rs10786284 1.96E-06 10q24.1 TLL2 intronic 149 kb
rs1555322 3.60E-06 20q11.22 M M P24 intronic 50 kb
rs16928529 3.90E-06 10q22.1 UNC5B intronic 90 kb
rs515910 4.36E-06 10q25.1 C10orf79 intronic 102 kb
rs2237349 4.63E-06 7p15.1 CREB5 intronic 527 kb
rs4964805 4.74E-06 12q23.3 NT5DC3 intronic 71 kb
rs3799977 4.90E-06 6p2 1.1 SU PT3H intronic 569 kb
rs11646411 7.40E-06 16q23.3 CDH13 intronic 948 kb
rs469727 7.54E-06 5q22.2 REEP5 intronic 46 kb
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Table 1 - continued.
Lesch et al. (29)e rs2241685 8.11E-06 2p25.3 M YT1L intronic 542 kb
rs2242073 8.27E-06 2q33.3 CRYGC intronic 2 kb
rs13395022 9.68E-06 2p12 CTNNA2 intronic 1460 kb
rs11594082 1.00E-05 10q22.1 CDH23 intronic 419 kb
rs3893215 2.56E-05 11p15.1 KCNC1 intronic 47 kb
Mick et al. (30)f rs2823819 6.70E-07 21q21.1 C21orf34 intronic 539 kb
rs11074889 6.71E-07 16p 13.13 EM P2 intronic 52 kb
rs8074751 1.18E-06 17q24.1 CCDC46 intronic 556 kb
rs1859156 2.05E-06 4q22.3 BM PR1B intronic 400 kb
rs438259 3.71E-06 6p24.3 AL024506.1 intronic 122 kb
rs2602381 3.85E-06 2q37.1 UGT1A9 intronic 101 kb
rs10011926 8.07E-06 4q25 ELOVL6 intronic 153 kb
rs11953346 1.59E-05 5q15 MCTP1 intronic 578 kb
rs7702178 1.84E-05 5q35.1 DUSP1 intronic 3 kb
rs17023218 1.88E-05 3p24.1 RBMS3 intronic 1166 kb
rs6561686 2.08E-05 13q14.3 LECT1 intronic 37 kb
IM AGE II rs10823973 6.30E-07 10q21.1 PRKG1 intronic 1307 kb
consortium (31 )g rs2291567 2.00E-06 7q32.1 FLN C intronic 29 kb
rs13238831 5.60E-06 7q32.1 KCP intronic 48 kb
rs11593241 5.70E-06 10q26.3 TCERG1L intronic 219 kb
rs12317552 9.10E-06 12q14.1 PPM 1H 3' UTR 291 kb
rs17151821 1.10E-05 7p21.3 NXPH1 intronic 319 kb
rs17095690 1.60E-05 1p31.1 C1orf173 intronic 106 kb
rs8045006 2.30E-05 16q23.3 CDH13 intronic 948 kb
rs1023556 2.60E-05 7p14.3 AC005493.1 intronic 14 kb
rs2394538 2.80E-05 10q22.1 HK1 intronic 132 kb
rs1278776 2.90E-05 13q34 ATP11A intronic 197 kb
rs17495366 3.10E-05 2p16.3 NRXN1 intronic 1114 kb
nonsynonymous,
rs906219 3.70E-05 10q22.1 HKDC1 coding 47 kb
rs1472147 4.10E-05 7q32.1 ATP6V1F intronic 3 kb
rs589943 4.90E-05 11q22.3 DYNC2H1 intronic 370 kb
rs2962393 5.60E-05 5q34 GABRB2 intronic 260 kb
rs846971 5.60E-05 6q21 SOBP intronic 170 kb
rs10445861 6.50E-05 2q14.3 CNTNAP5 intronic 890 kb
rs4261672 7.20E-05 2q22.2 LRP1B intronic 1900 kb
rs6986578 7.30E-05 8q13.2 PREX2 intronic 280 kb
rs12090000 7.40E-05 1q25.2 FAM5B intronic 111 kb
rs1565630 8.00E-05 7q32.1 CCDC136 intronic 31 kb
rs4533267 8.30E-05 15q26.3 AD AM TS17 intronic 370 kb
rs2979307 9.00E-05 3q21.2 OSBPL11 intronic 66 kb
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a Data show SNPs from the GWASs (27-31) located within genes and with a p value < 1.00E-04 for
association with ADHD after correction for linkage disequilibrium. The 45 (different) genes encoding 
proteins that could be directly placed in the putative ADHD network are indicated in bold
b GWAS of a categorical DSM-IV ADHD phenotype in 909 Caucasian case-parent-trios collected as part of the
International Multicentre ADHD Genetics (IM AG E) study in children.
c GWAS of quantitative phenotypes of ADHD that carried out in the same IM AGE sample used in the GWAS
conducted by Neale et al. (27).
d Findings revealed genome-wide significance for a single quantitative trait using family-based association
testing principal component algorithm.
e GWAS of a categorical DSM-IV ADHD phenotype using pooled DNA from 343 ADHD-affected adults and
304 comparison subjects. (Reported p values in this study were ranked according to the mean rank calculated 
across three statistics).
f GWAS of DSM-IV-TR ADHD in a combined sample of 735 trios from three US clinical sites.
g GWAS conducted in 896 unrelated case patients with DSM-IV ADHD and 2,455 comparison subjects using
a case-control design.
Abbreviations: UTR, untranslated region.
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Table 2. Nervous system related gene functional categories that are significantly enriched in the top 85 ADHD candidate genes from the five published GWASs (27-31) using 
Ingenuity pathway analysis (www.ingenuity.com) . The genes encoding proteins that could be directly placed in the putative ADHD network are indicated in bold.
Category Genes Significance3 Adjusted significance0
Neurological disease ADAMTS17, ASTN2, ATP2C2, BMPR1B, C100RF79, C210RF34, C90RF98, 4.67E-10 4.11E-08
(44/85 genes) CCDC46. CDH13, CDH23. CNTNAP5, CREB5, CSMD2, CTNNA2, DYNC2H1, 
FAM190A, FHIT. FOXP1. GABRB2. GFOD1. GRIK1. ITGA11. ITPR2. KCNIP4. 
LRP1B, MAP1B, MCTP1, MEIS2, MOBP, MYT1L. NAPRT1, NOS1, NRXN1, 
NXPH1, PPM1H, PRKG1, RBMS3, RORA, SLC03A1, SPOCK3, TLL2, UNC5B, 
ZNF385D, ZNF423
Top gene functional categories that are significantly enriched in the top 85 ADHD candidate genes from the five published GWASs (27-31) using BiNGO (Biological 
Network Gene Ontology) analysis (33). The genes encoding proteins that could be directly placed in the putative ADHD network are indicated in bold.
GO term d Genes Significance15 Adjusted significance0
Ion binding ADAMTS17, ATP 11 A, ATP2C2, BMPR1B, CDH13, CDH23, CREB5, DMRT2, 
DUSP1, FHIT, FOXP1. GABRB2, HK1, ITGA11, ITGAE. ITPR2. KCNC1, KCNIP4. 
LRP1B, MAN2A2, MCTP1.MMP24. MTA3. MYT1L. NOS1, NRXN1, NT5DC3, 
NUCB1, RORA, SOBP. SPOCK3, TLL2, ZMIZ1, ZNF385D, ZNF423, ZNF544
4.10E-06 2.94E-03
Metal ion binding ADAMTS17. ATP11A. ATP2C2. BMPR1B. CDH13, CDH23. CREB5, DMRT2, 
DUSP1, FHIT. FOXP1. HK1, ITGA11, ITGAE. ITPR2. KCNC1. KCNIP4, LRP1B, 
MAN2A2.MCTP1 MMP24. MTA3. MYT1L. NOS1, NRXN1, NT5DC3, NUCB1, 
RORA. SOBP. SPOCK3, TLL2, ZMIZ1, ZNF385D. ZNF423, ZNF544
7.45E-06 2.94E-03
Cation binding ADAMTS17. ATP2C2. BMPR1B. CDH13, CDH23. CREB5, DMRT2, DUSP1, FHIT. 
FOXP1. HK1. ITGA11, ITGAE. ITPR2. KCNC1. KCNIP4. LRP1B, MAN2A2. 
MCTP1.MMP24. MTA3. MYT1L. NOS1, NRXN1, NUCB1, RORA, SOBP. SPOCK3, 
TLL2, ZMIZ1, ZNF385D. ZNF423, ZNF544
1.19E-05 3.14E-03
Calcium ion binding ATP2C2, CDH13, CDH23, ITGA11, ITGAE,ITPR2.KCNIP4.LRP1B, MCTP1.MMP24, 
NRXN1, NUCB1, SPOCK3, TLL2
2.76E-05 5.43E-03
Hexokinase activity HK1, HKDC1 1.71E-04 2.69E-02
Abbreviations: ADHD, attention deficit hyperactivity disorder; GO, gene ontology; GWASs, genome-wide association studies.
a Single test p value calculated with the right-tailed Fisher’s exact test and taking into consideration both the total number of molecules from the analyzed data set and the total 
number of molecules linked to the same gene category according to the Ingenuity Knowledge Base.
b Single test p value calculated using the hypergeometric test and taking into consideration both the total number of molecules from the analyzed data set and the total number of 
molecules linked to the same GO term.
0 Multiple test-corrected p values using the Benjamini-Hochberg correction (only categories reaching a corrected statistical significance of < 0.05 are shown). 
d A ll significantly enriched GO terms can be further assigned to the molecular function GO subgroup/domain.
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Table 3. Genes encoding proteins from the putative ADHD network and reported to be deleted (del) 
and/or duplicated (dup) in (genome-wide) copy number variations (CNVs) in people with AD(H)D.
The six genes from the reported GWASs (Table 1) encoding proteins that could be directly placed in the 
putative ADHD network are indicated in bold.
Locus Gene CNV Phenotype Additional remarks Reference
2p12 CTNNA2 del ADHD genome-wide CNV analysis (20)
2p16.3 N RXN1 del ADHD genome-wide CNV analysis (35)
2q21.2 N AP5 del ADD - (36)
3q26.1 SERPINI1 dup ADHD genome-wide CNV analysis (20)
3q26.1 SERPINI1 del ADHD genome-wide CNV analysis (21)
12q24.22 NOS1 dup ADHD - (37)
16p 11.2 ERK1 dup ADHD 6/8 unrelated people with ADHD (38)
16p 11.2 ERK1 dup ADHD genome-wide CNV analysis (22)
16p 11.2 ERK1 del ADHD 4/15 unrelated people with ADHD (38)
16p 11.2 ERK1 del ADHD genome-wide CNV analysis (22)
16q12.1 ZNF423 dup ADHD - (39)
18q21. 31 NEDD4L dup ADD 2 siblings with ADD (40)
20p12.3 BMP2 del ADD - (41)
Abbreviations: ADD, attention deficit disorder; ADHD, attention deficit hyperactivity disorder.
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Table 4. Nervous system-related gene functional categories that are significantly enriched in the top 20 ADHD candidate genes from the published GWASs 
(Supplementary Table 1) using Ingenuity pathway analysis (www.ingenuity.com). The genes encoding proteins that could be directly placed in the putative ADHD 
network are indicated in bold.
Category
Neurological disease (13/20 genes)
Genes Significance3
ASTN2. ATP2C2, C210RF34, C90RF98, CCDC46, CDH13, 1.53E-04 
CSMD2, GFOD1, ITGA11, M AP1B, MOBP, PRKG1, TLL2
Adjusted significance 
7.55E-03
Biogenesis of lamellipodia ( CDH13 5.49E-03 2.10E-02
Nervous system related gene functional categories that are significantly enriched in the top 20 candidate genes from four published GWASs for diabetes type I 
(Supplementary Table 1) using Ingenuity pathway analysis (www.ingenuity.com) .____________________________________________________________________________
Category
Neurological disease (1/20 genes)
Genes
TH
Significance 1 
1.42E-02
Adjusted significance 
3.02E-02
Long temi depression INS 1.30E-03 8.11E-03
Nervous system related gene functional categories that are significantly enriched in the top 20 candidate genes from four published GWASs for Crohn’s disease 
(Supplementary Table 1) using Ingenuity pathway analysis (www.ingenuity.com)._____________________________________________________________________________
Category
Neurological disease (0/20 genes)
Genes Significance 3 Adjusted significance
Abbreviations: ADHD, attention deficit hyperactivity disorder; GWASs, genome-wide association studies.
3 Single test p value calculated with the right-tailed Fisher’s exact test and taking into consideration both the total number of molecules from the analyzed data set and the total 
number of molecules linked to the same gene category according to the Ingenuity Knowledge Base.
b Multiple test-corrected p values using the Benjamini-Hochberg correction (only categories reaching a corrected statistical significance of < 0.05 are shown). 
c Refers to protrusions of the neuronal growth cone that are formed during the process of neurite outgrowth (60).
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Table 5. Top five gene functional categories that are significantly enriched in the top 20 ADHD candidate genes from the published GWASs (Supplementary table 
1) using BiNGO (Biological Network Gene Ontology) analysis (33). The genes encoding proteins that could be directly placed in the putative ADHD network are 
indicated in bold.
GO term Genes Significance3 Adjusted significance15
Regulation of chemotaxis CDH13.IL16 3.58E-05 4.40E-03
Regulation of behavior CDH13.IL16 5.25E-05 4.40E-03
Regulation of response to external stimulus CDH13.IL16 2.77E-04 1.32E-02
Integrin complex ITGA11, ITGAE 2.98E-04 1.32E-02
Cell migration CDH13, IL16. ITGA11 6.38E-04 2.34E-02
Top five gene functional categories that are significantly enriched in the top 20 candidate genes from four published GWASs for diabetes type 1 (Supplementary
table 1) using BiNGO analysis (33).
GO term Genes Significance3 Adjusted significance15
Growth factor binding ERBB3, IL7R, INS 4.46E-05 2.27E-02
Regulation of secretion ERBB3. INS 3.35E-04 3.54E-02
Anion transport C1QTNF6. CFTR. COL1A2 4.75E-04 3.54E-02
Regulation of insulin receptor signaling INS 9.76E-04 3.54E-02
Tyrosine 3-monooxygenase activity TH 9.76E-04 3.54E-02
Top five gene functional categories that are significantly enriched in the top 20 candidate genes from four published GWASs for Crohn’s disease (Supplementary
table 1) using BiNGO analysis (33).***
GO term Genes Significance3 Adjusted significance15
Protein kinase cascade GCKR, LRRK2, MST1, STAT3, TNFSF15 5.10E-06 2.28E-03
Intracellular signaling cascade GCKR. LRRK2. MST1. NOD2, STAT3. TNFSF15 6.10E-04 2.42E-02
Cell communication ATG16L1, BSN. GCKR. ITLN1.LRRK2. MST1. NOD2.PTPN22. 7.95E-04 2.42E-02
STAT3. TNFSF15
Protein amino acid autophosphorylation LRRK2, MST1 9.08E-04 2.42E-02
Macrophage activation during immune response SBN 02 9.76E-04 2.42E-02
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Abbreviations: ADHD, attention deficit hyperactivity disorder; GO, gene ontology; GWASs, genome-wide association studies.
a Single test p value calculated using the hypergeo metric test and taking into consideration both the total number of molecules from the analyzed data set and the total 
number of molecules that is linked to the same GO term.
b Multiple test-corrected p values using the Benjamini-Hochberg correction.
*
The GO terms regulation of chemotaxis, regulation of behavior, regulation of response to external stimulus, and cell migration can be further assigned to the biological 
process GO sub group/do main, while integrin complex falls under the cellular component domain.
The GO terms growth factor binding and tyrosine 3-monooxygenase activity can be further assigned to the molecular function GO sub group/do main, while regulation 
of secretion, anion transport, and regulation of insulin receptor signaling fall under the biological process domain.
A ll GO terms can be further assigned to the biological process GO sub group/do main.
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Figure 1. Schematic representation of the ADHD neurodevelopmental signalling network 
for directed neurite outgrowth. The genes/proteins that emerged from the five reported 
genome-wide association studies for ADHD are indicated in yellow. The proteins 
encoded by genes found in copy number variations in patients with ADHD are indicated 
by a blue border. The proteins encoded by genes implicated in the etiology of ADHD 
through gene knockout studies in mice are indicated by a green border. The genes/proteins 
of which the expression and/or function is regulated by stimulants are indicated by a red 
border. Evidence placing the genes/proteins into this network is presented in the data 
supplement.
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Figure 2. Schematic representation of how six neurite outgrowth-related dyslexia 
candidate genes (65) - indicated in orange - can be directly placed in the signalling 
network for ADHD shown in Figure 1. The genes/proteins that emerged from the five 
reported genome-wide association studies for ADHD are indicated in yellow. The proteins 
encoded by genes found in copy number variations in patients with ADHD are indicated 
by a blue border. The proteins encoded by genes implicated in the etiology of ADHD 
through gene knockout studies in mice are indicated by a green border. The genes/proteins 
of which the expression and/or function is regulated by stimulants are indicated by a red 
border. Evidence placing the six dyslexia candidate genes/proteins into the ADHD 
network is presented in the data supplement.
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Supplementary Table 1.
Top 20 single SNPs within genes from the published GWASs for ADHD (1-5). For each gene, the SNP
yielding the lowest p value in any of the GWASs is shown.
The 12 genes encoding proteins that could be directly placed in the putative ADHD network are indicated
in bold.
SNP p value Locus Gene Position within gene Reference GW AS
rs6565113 * 16q23.3 CDH13 intronic (2)
rs552655 * 6p24.1 GFOD1 intronic (2)
rs864643 1.30E-08 3p22.2 M O BP 3' UTR (3)
rs7995215 1.35E-08 13 q31 3 GPC6 intronic (3)
rs11243897 5.63E-08 9q34.13 C9orf98 intronic (3)
rs7164335 1.30E-07 15q23 ITGA11 intronic (3)
rs220470 1.34E-07 17p13.2 ITGAE intronic (3)
rs10983238 1.37E-07 9q33.1 A STN 2 intronic (3)
rs2587695 2.73E-07 2q14.2 PCDP1 intronic (3)
rs2281597 5.41E-07 1p35.1 CSMD2 intronic (3)
rs10823973 6.30E-07 10 q2 1 1 PRKG1 intronic (5)
rs2823819 6.70E-07 21 q2 1 1 C21orf34 intronic (4)
rs11074889 6.71E-07 16p 13.13 EM P2 intronic (4)
rs10514604 8.06E-07 16q24.1 ATP2C2 intronic (3)
rs2677744 9.69E-07 15q26.1 M AN 2A2 intronic (3)
rs8074751 1.18E-06 17q24.1 CCDC46 intronic (4)
rs4128767 1.28E-06 15q25.1 IL16 intronic (2)
rs2502731 1.58E-06 9q34.11 DNM1 intronic (3)
rs2199161 1.62E-06 5q13.2 M AP1B intronic (3)
rs10786284 1.96E-06 10q24.1 TLL2 intronic (3)
Top 20 single SNPs within genes from four published GWASs for type 1 diabetes (6-9). For each gene, the
SNP yielding the lowest p value in any of the four GWASs is shown.
SNP p value Locus Gene Position within gene Reference GW AS
rs2476601 2.07E-80 1p13.2 PTPN22 nonsyn, coding (7)
rs2292239 1.52E-20 12q13.2 ERBB3 intronic (7)
rs12708716 2.57E-18 16p 13.13 CLEC16A intronic (7)
rs17696736 2.31E-16 12q24.13 C12orf30 intronic (7)
rs3825932 3.17E-15 15q25.1 CTSH intronic (9)
rs11755527 4.66E-12 6q15 BACH2 intronic (9)
rs1990760 1.77E-11 2q24.2 IFIH1 nonsyn, coding (7)
rs100446 6.75E-11 11p15.5 INS intronic (8)
rs6356 2.70E-09 11p15.5 TH nonsyn, coding (8)
rs763361 1.38E-08 18q22.2 CD226 nonsyn, coding (7)
rs1445898 1.45E-08 5p13.2 CAPSL nonsyn, coding (7)
rs10255021 1.71E-08 7q21.3 COL1A2 intronic (8)
rs229541 1.98E-08 22q12.3 C1QTNF6 intronic (9)
rs3764021 5.80E-08 12p 13.31 CLEC2D nonsyn, coding (6)
rs17388568 6.35E-07 4q27 ADA1 intronic (6)
rs380421 8.84E-07 20q13.12 SPINT2 nonsyn, coding (7)
rs6017667 1.78E-06 20q13.12 SPINT4 nonsyn, coding (7)
rs6897932 7.70E-06 5p13.2 IL7R nonsyn, coding (7)
rs6546909 8.53E-06 2p 13.1 DQX1 syn, coding (6)
rs213950 1.95E-05 7q31.2 CFTR nonsyn, coding (7)
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Supplementary Table 1 - continued.
Top 20 single SNPs within genes from four published GWASs for Crohn’s 
gene, the SNP yielding the lowest p value in any of the four GWASs is shown.
disease (6,10-12). For each
SNP p value Locus Gene Position ~ gene Reference GW AS
rs11465804 6.66E-63 1p31.3 IL23R intronic (12)
rs3828309 2.36E-32 2q37.1 ATG16L1 intronic (12)
rs2076756 7.01E-14 16q12.1 NOD2 intronic (10)
rs2301436 1.04E-12 6q27 FGFR1OP intronic (12)
rs3197999 1.15E-12 3p21.31 MST1 nonsyn, coding (12)
rs744166 6.82E-12 17 q2 1. 2 STAT3 intronic (12)
rs4263839 2.60E-10 9q32 TNFSF15 intronic (12)
rs11175593 3.08E-10 12q12 LRRK2 intronic (12)
rs6908425 8.96E-10 6p22.3 CDKAL1 intronic (12)
rs2274910 1.46E-09 1q23.3 ITLN1 intronic (12)
rs4807569 2.12E-09 19p 13.3 SBNO2 intronic (12)
rs3763313 5.20E-09 6p21.32 BTNL2 intronic (12)
rs2476601 1.46E-08 1p13.2 PTPN22 nonsyn, coding (12)
rs780094 3.14E-07 2p23.3 GCKR intronic (12)
rs12529198 6.96E-07 6p25.1 LYRM4 intronic (12)
rs9858542 7.70E-07 3p21.31 BSN syn, coding (6)
rs1131095 1.21E-06 3p21.31 APEH syn, coding (11)
rs17309827 2.08E-06 6p25.2 SLC22A23 intronic (12)
rs1925411 3.58E-06 1p31.3 WDR78 intronic (11)
rs13003464 4.60E-06 2p 16.1 PUS10 intronic (12)
Abbreviations: ADHD, attention deficit hyperactivity disorder; GWASs, genome-wide association studies; 
SNPs, single nucleotide polymorphisms
* genome-wide significant for a single quantitative trait using family-based association testing (FBAT) 
principal component algorithm
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Description of figures
Figure 1:
Signalling through the network can be initiated at the neuronal cell membrane by the netrin axonal 
guidance ‘cues’ binding to the netrin receptor UNC5B, which (eventually) results in neurite 
repulsion from the netrin guidance cues (13). EMP2 (Epithelial membrane protein 2) is a neuronal 
cell membrane protein that interacts with FAK (Focal Adhesion Kinase) (14), which 
phosporylates/activates UNC5B upon netrin binding (15). Upon binding netrin, UNC5B also 
inhibits GNAI2 (16), which itself interacts with NUCB1 (17) and inhibits adenylate cyclase 
(ADCY) (17). ADCY produces cyclic AMP (cAMP) (18) and cAMP subsequently activates 
protein kinase A (PKA) (18), which activates CDC42 (19). CDC42 is a GTP-hydrolyzing 
(GTPase) protein that is a central mediator of directed neurite outgrowth (20,21) through its key 
function in regulating the remodelling of the cytoskeleton of the neural growth cone, which in turn 
results in the formation of growth cone protrusions called filopodia and lamellipodia (22).
Several other signalling cascades lead to CDC42 activation.
Firstly, CDH13 is anchored in the (neuronal) cell membrane through glycosylphosphatidylinositol 
(GPI) molecules (17) and is an atypical member of the cadherin protein family because, as 
opposed to e.g. the CDH2 and CDH23 proteins (see below), it doesn’t have a cytoplasmic domain 
(http://www.ensembl.org/homo_sapiens). CDH13 acts as a regulator of neural cell growth and 
guidance (23,24) and it activates CDC42 (25). In addition, integrin beta-1 (ITGB1) is involved in 
upregulating the expression of CDH13 (26).
CDC42 activation is also mediated by arachidonic acid (AA) (27) and AVP (Arg-vasopressin) 
(28). MBOAT1 is involved in the production of AA (17) whereas UGT1A9 degrades AA and its 
metabolites (29). SLCO3A1 is a neuronal cell membrane transporter for AVP, a cerebral 
neuropeptide that functions as a neurotransmitter (17,30) and promotes neurite outgrowth (31). 
After being bound by its ligands BMP2 or BMP7, the neuronal cell membrane receptor BMPR1B 
(17) also activates CDC42 and contributes to the neuronal cytoskeletal remodelling necessary for 
neurite outgrowth (see below) (32-35). The secreted KCP proteins interact with BMP7 and 
enhance its binding to BMPR1B (17).
A CDC42-independent signalling cascade that leads to neurite outgrowth starts at the neuronal cell 
membrane protein NRXN1 (neurexin 1), which functions as a cell adhesion molecule and receptor 
(17). After being bound by its specific ligand, the secreted neuropeptide NXPH1 (neurexophilin 1) 
(17), the cytoplasmic domain of NRXN1 binds the CASK kinase protein (17).
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CASK directly links NRXN1 signalling with remodelling of the neuronal (actin) cytoskeleton 
mediating neurite outgrowth (17).
A second CDC42-independent pathway leading to neurite outgrowth centers around the 
N(euronal)-cadherin CDH2, a protein that - like CDH13 (see above) - is a member of the cadherin 
protein family (17). CDH2 is anchored in the neuronal cell membrane and the neuronal 
cytoskeleton through binding to a complex consisting of catenin beta (CTNNB) and catenin alpha 
2 (CTNNA2) (36,37). Inactivation of CDH2 leads to the dissolution of the CDH2-CTNNB- 
CTNNA2 complex and the CTNNB protein being released and targeted to the nucleus, where it 
functions as a transcription factor (36). CDH2 is degraded through MMP24 (38), and its 
expression is upregulated through CDC42 (39) (not shown in Figure 1). SERPINI1 (or 
Neuroserpin), a secreted protein (17) that is involved in neurite outgrowth (40), also upregulates 
the expression of CDH2 (41). LRP1B is a neuronal cell membrane receptor that binds and 
internalises SERPINI1, after which SERPINI1 is degraded (17,42). CDH2 also mediates neurite 
outgrowth that is induced by nitric oxide (NO) (43), which is produced by NOS1, the brain- 
specific nitric oxide synthase (17).
CDC42 regulates a number of downstream effectors to facilitate neurite outgrowth. Activated 
CDC42 either directly activates the cytoplasmic ERK (Extracellular signal related kinase) 1 and 2 
proteins (44) or through activation of PAK1 (p21-activated kinase 1) (17,45). ERK2 can be 
dephosphorylated/inactivated by DUSP1 (Dual specificity protein phosphatase 1) (17). CDC42 
also activates the Activated CDC42 kinase 1 (ACK1) (17) which is degraded by NEDD4L (46).
A number of other cytoplasmic proteins link cell surface signals with cytoskeleton-mediated 
responses involved in neurite outgrowth. NAP5, through its association with the NCK proteins 
(17), is such a protein (47). DYNC2H1, a member of the family of cytoplasmic dynein proteins 
localised in the axon growth cone and playing a prominent role in microtubule advance during 
neuronal cytoskeleton remodelling associated with neurite outgrowth (48), is another example. 
This may involve the FAM190A protein (17) directly associating and interacting with NDEL1 
(Nuclear distribution protein nudE-like 1) (49), which promotes neurite outgrowth by activating 
dynein proteins such as DYNC2H1 (50). After being activated, ERK1/2 subsequently 
phosphorylate/activate the microtubule-associated MAP1B (51), a protein that is involved in 
cytoskeletal changes that lead to neurite outgrowth (51,52). In addition, DNM1 (Dynamin 1) 
(17,53), FLNC - through actin filaments (17) - and - through the microtubules - the hexokinase 
domain-proteins HK1 and HKDC1 (54,55) as well as MOBP (Myelin-associated oligodendrocyte 
basic protein) (56) associate directly with and modulate the neuronal cytoskeleton to facilitate 
neurite outgrowth.
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ATP2C2 is a brain-expressed ATPase transporter that moves calcium and manganese (Mn) ions 
into cytoplasmic vescicles derived from the trans-Golgi network, and is in this way involved in 
manganese detoxification in neuronal cells (17,57). Mn induces neurite outgrowth by activating 
ERK1/2 (58) and upregulating the expression of MAP1B  (59). Interestingly, elevated serum 
concentrations of Mn were found in children with ADHD compared to normal controls (60).
The cell nucleus is another important compartment in the neurite/axon outgrowth network. PKA 
activates the transcription factor function of CTNNB (61). In the nucleus of (dopaminergic) 
neurons, CTNNB upregulates the expression of OTX2 (62). OTX2, a neuronal transcription factor 
that is involved in early brain development (63), directly binds and interacts with MEIS2 (64), 
another neuronal transcription factor (17). CTNNB also upregulates the expression of NEDD4L 
(65), an E3 ubiquitin-protein ligase (17) that is involved in cellular processes regulating neurite 
outgrowth (66) through degradation of several neuronal proteins, including ACK1 (46) (see 
above). SUPT3H is a transcription factor that forms part of the PCAF transcription factor 
complex (17) that both increases the transcriptional activity and upregulates the expression of 
CTNNB (67). Conversely, both KCNIP4, a potassium channel-interacting membrane protein (17) 
and the cytoplasmic FHIT inhibit the transcriptional activity of CTNNB (68,69). RORA, a 
transcription factor involved in neurite outgrowth (17,70), also inhibits the transcriptional activity 
of CTNNB (71). In addition, PKA regulates the expression of a number of relevant genes by 
phosphorylating/activating the transcription factors of the CREB family (18), such as CREB5. 
Furthermore, MYT1L, a transcription factor of the MYT1 (myelin transcription factor 1) family 
(17), upregulates the expression of neuregulin-1 (NRG1) (72), a protein that is both secreted into 
the (neuronal) extracellular compartment/matrix and found in the nucleus (17), and induces neurite 
outgrowth (73). In response to BMP2 signalling, ZNF423, another brain transcription factor, 
upregulates the expression of BMP target genes/proteins such as BMPR1B (17).
In order to not only allow the axon/neurite to grow through modulating (i.e degrading or 
‘building’) the neuronal cytoskeleton but also to grow in a certain direction, it is necessary for the 
extracellular matrix to be equally modulated (i.e. degraded or produced) (74). In this respect, the 
matrix metalloproteinase MMP24 not only degrades CDH2 (see above) but also the neuronal 
extracellular matrix (38) and it is specifically involved in neurite outgrowth (75). The extracellular 
matrix protein SPOCK3 (17) is a negative regulator of MMP24 (76). Furthermore, the 
metalloproteinases TLL2 and ADAMTS17 degrade the neuronal extracellular matrix (17,30). The 
mannosidase MAN2A2 is a neuronal cell membrane protein that catalyzes the first step in the 
biosynthesis of the complex N-glycans (17) necessary for the formation of the neuronal 
extracellular matrix proteins (77).
181
The GPC6 protein can be located in the neuronal cell membrane and secreted in the neuronal 
extracellular compartiment, where it forms an integral part of the extracellular matrix (17) and acts 
as a receptor for other extracellular matrix proteins. Together with ITGA11, ITGB1 also forms a 
receptor that binds collagen in the extracellular matrix (17).
Lastly, four other neuronal proteins can be putatively placed in the network. ASTN2 is a cell 
membrane protein that is involved in calcium-dependent cell-cell adhesion and, more specifically, 
in neuron-glia binding during brain development (17,30). CDH23, another cadherin protein such 
as CDH2 and CDH13, may fit into the network by binding to the cell membrane-associated (17) 
kinase MAGI1 (78), which in turn binds and ‘anchors’ CTNNB into the neuronal cell membrane 
(79) (not shown in Figure 1). CSMD2 is a protein enriched in axonal growth cones and is also 
involved in neuronal outgrowth (30). PPM1H is a cytoplasmic phosphatase that is involved in 
neurite outgrowth through an as yet unknown mechanism (80).
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Figure 2:
The proteins encoded by six neurite outgrowth-related candidate genes from our recent review of 
the genetic findings for dyslexia (ROBO1, S100B, FMR1, DYX1C1, GTF2Iand DCDC2) (81) can 
be placed directly in the protein network shown in Figure 1, mainly through functioning either 
upstream or downstream of CDC42 and ERK1/2.
When the molecular guidance cues SLIT bind to the ROBO1 membrane receptor (not shown in 
Figure 2), a signalling cascade is initiated that leads to the inhibition of CDC42 and eventually 
results in neurite outgrowth away from the SLIT guidance cues (13, 82). S100B binding to RAGE 
(receptor for advanced glycosylation end products) results in CDC42 (83) and ERK1/2 (44) 
activation and neurite outgrowth (84). Interestingly, decreased serum concentrations of S100B 
were found to correlate with increasing hyperactivity symptoms in children with ADHD compared 
to normal controls (85).
FMR1 - the protein associated with Fragile X syndrome, the most common inherited form of 
intellectual disability - either activates/phosphorylates neuronal ERK1/2, directly (86), or through 
binding and activating PAK1 (45,87). FMR1 also acts as an RNA-binding protein involved in the 
localization and regulated translation of specific neuronal messenger RNAs (mRNAs) encoding 
key molecules for neurite outgrowth (88), including the mRNA of the ADHD candidate MAP1B 
(89) (not shown in Figure 2). DYX1C1 is also involved in activating neuronal ERK1/2 (90,91) and 
depending on the context of other transcription factors, the expression of DYX1C1 is up- or 
downregulated by the transcription factor TFII-I, which itself is encoded by the GTF2I gene 
(92,93).
Lastly, the ERK1/2 proteins also regulate the activity of the DCDC2 protein by phosphorylating its 
doublecortin (DCX) domains (94). Like several ADHD candidates (see above), DCDC2 directly 
binds and modulates the neuronal cytoskeleton to facilitate neurite outgrowth (95).
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Abstract
Autism spectrum disorders (ASDs) are highly heritable. In recent years, six genome-wide 
association studies (GWASs) of ASDs were published. In order to identify genetic 
networks, bioinformatics and systematic literature analyses were conducted for 200 genes 
from five published GWASs that yielded association with ASDs through single nucleotide 
polymorphisms at P  < 0.0001. The sixth published GWAS was used to validate the 
findings. We also searched for overlap between the identified candidate genes and genes 
located in copy number variations (CNVs) in people with ASDs and we identified 
microRNAs that downregulate the expression of candidate genes and are dysregulated in 
ASDs. A total of 117 of the 200 ASD candidate genes encode proteins fitting into three 
signalling networks regulating steroidogenesis, neurite outgrowth and synaptic function. 
Thirty-five other ASD candidate genes could be placed in these networks. We also found 
that 82 of the 200 ASD candidate genes were found in CNVs in people with ASDs and 
100 genes were targets of ASD-implicated microRNAs. Notably, the proteins encoded by 
10 ASD-linked AKAP (A-kinase anchor protein) genes functionally integrate signalling 
cascades within and between the identified networks, with literature data pointing towards 
these AKAPs as possible targets for novel psychopharmacological treatment of ASDs.
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Introduction
Autism spectrum disorders (ASDs) are a group of pervasive neurodevelopmental disorders 
that are characterized by qualitative impairments in reciprocal social interaction and 
communication as well as restricted, repetitive and stereotyped patterns of behaviour, 
interests and activities. The ASDs include autism, Asperger’s syndrome (AS) and 
pervasive developmental disorder not otherwise specified (PDD-NOS) 1. Individuals with 
autism show impairments in all three core symptom domains and an onset of symptoms 
before age 3 years, whilst AS is characterized by impairment in social interaction and 
restricted, repetitive and stereotyped patterns of behaviour, interests and activities but a 
normal language and cognitive language development before age 3 years. PDD-NOS is 
diagnosed in people who do not meet autism criteria for all three symptom domains and/or 
show a late age of onset u . The prevalence of ASDs is estimated to be 0.5-1% 3-5 and 
approximately 4 times more males than females have an ASD 2,e.
Family and twin studies show that ASDs are highly heritable, and approximately 90% of 
the phenotypic variance can be explained by genetic factors 6-8. However, despite their 
high heritability, the genetic architecture of ASDs is very heterogeneous 9, which has 
hindered the identification and replication of genetic susceptibility factors (see recent 
reviews 9"u ). Rare genetic variants predisposing to ASDs are currently thought to account 
for 10-20% of all ASD cases 9,n. They include rare mutations in single genes - which can 
lead to monogenic disorders that are frequently associated with ASDs, such as fragile X 
syndrome and tuberous sclerosis - and copy number variations (CNVs) that constitute 
deletions or duplications of a large variety of genes and may contribute to oligogenic 
forms of ASDs 9-11. Common genetic variants for ASDs, e.g. single nucleotide 
polymorphism (SNPs), are identified through candidate gene and genome-wide 
association studies (GWASs) and are assumed to each contribute a (very) small increase in
8 10 12 17disease risk ' . Thus far, six GWASs for ASDs have been published ' . In addition to 
many protein-coding genes implicated in ASDs through genetic variation, there is 
increasing evidence for the involvement of so-called microRNAs in ASD etiology 18-21.
In recent years, three main biological ‘themes’ have emerged that link genetic ASD 
findings at the level of biological function, namely steroid synthesis 22,23, growth and 
neurite outgrowth of developing neurons 10,16,22-24, and synaptic function 9,10,24‘26. In the 
present study, we attempted to integrate the most significant findings from five reported 
GWASs of ASDs into protein signalling networks linked to these biological themes.
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Based on a bioinformatics analysis and a systematic literature review of the 200 top- 
ranked GWAS genes, we describe three signalling networks involved in steroidogenesis, 
neurite outgrowth and synaptic function that include 117 of these genes and 35 additional 
ASD candidates. Data from a sixth GWAS validate these findings. We also found 
corroborating evidence for the identified ASD networks through CNV and microRNA 
data. Importantly, signalling cascades within and between the three networks are 
functionally integrated by AKAPs (A-kinase anchor proteins), which seem promising 
targets for the development of psychopharmacological treatment of ASDs.
Results 
Identification of candidate genes from five GWASs
Supplementary Table 1 shows the 200 genes from the five GWASs of ASDs fulfilling the 
inclusion criteria of the study. When more than one SNP within a gene region was found 
among the top-ranked association findings, only the SNP yielding the lowest P  value is 
presented. Twelve genes (6%) are also implicated in ASDs through additional evidence.
C orroborating evidence
As is also indicated in Supplementary Table 1, 82 of the 200 candidate genes (41%) were 
observed in CNVs in people with ASDs and 100 of the candidates (50%) were targets of 
ASD-implicated microRNAs (Supplementary Table 2).
Bioinformatics analysis
Further analysis of the 200 top-ranked ASD candidate genes using the Ingenuity pathway 
software revealed a significant enrichment (multiple testing corrected P=1.64E-04) of the 
gene category “neurological disease”, with 81 of the 200 genes falling into this category. 
Moreover, 8 of the 9 other significant categories in the top 10 of nervous system-related 
gene categories can be directly linked to neurite outgrowth or synaptic function (Table 2).
Systematic literature  analysis and identification of protein networks 
Based on the three main biological themes linked to ASDs (see above) and integrating the 
findings from the Ingenuity analysis and our systematic literature analysis, we found that 
the proteins encoded by 117 of the 200 ASD candidate genes (58.5%) fit into three distinct 
signalling networks.
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The first network is involved in steroidogenesis by regulating the production and 
metabolism of the steroid hormones testosterone and estradiol in testicular Leydig cells 
(Figure 1). The second network leads to directed neurite outgrowth through the integration 
of molecular signalling cascades in the extracellular matrix, cell membrane, cytoplasm and 
nucleus of developing neurons (Figure 2a) with cascades modulating the cytoskeleton in 
and the extracellular matrix surrounding the growth cone of these neurons (Figure 2b). 
The third network regulates and modulates (glutamatergic) neurotransmission across the 
synapse (Figure 3). The proteins encoded by 35 additional ASD candidate genes, 
including strong ASD candidates such as CNTNAP2, M ET  and NRXN1 (Supplementary 
Table 3), could also be placed in the three networks. A detailed description of the evidence 
linking all the genes/proteins in the networks is provided in the Supplementary 
Information. Importantly, signalling cascades within all three networks are modulated and 
regulated by the proteins encoded by 10 ASD-implicated AKAP (A-kinase anchoring 
protein) genes (Supplementary Table 4).
Discussion
In this study, we used both bioinformatics and extensive manual literature mining to 
integrate the top-ranked findings of five published GWASs of ASDs. Of the 200 top- 
ranked candidates, a total of 144 genes were also implicated in the etiology of ASDs 
through CNVs and/or microRNAs and/or additional ‘other’ evidence. There is also a 
strong overlap between rare and common ASD-implicated genetic variants - with 41% of 
the ASD candidate genes identified through common SNPs also being found in rare ASD- 
linked CNVs - which implies that multifactorial and oligogenic forms of ASDs partially 
share etiologic pathways.
We were able to place the proteins encoded by 117 of the 200 ASD candidate genes and 
35 additional ASD candidates into three signalling networks regulating steroidogenesis in 
Leydig cells, neurite outgrowth and (glutamatergic) synaptic function. Importantly, the 
sixth published GWAS of ASDs 17 validates the identified networks because 11 of the 13 
genes overlapping between GWASs 1-5 and GWAS 6 could be placed into these 
networks. A total of 15 genes from GWASs 1-5 (7.5% of the 200 ASD candidate genes) 
were implicated through SNPs associated with ASDs at P  < 1.00E-04 in two of the six 
published GWASs (Supplementary Table 5).
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The proteins encoded by the 10 AKAP genes shown in Supplementary Table 4 constitute 
a common functional theme within the identified networks. The AKAPs (A-kinase 
anchoring proteins) constitute a growing protein family of currently more than 50 
members that shares an ability to bind protein kinase A (PKA) to its substrates, i.e. the 
proteins that are phosphorylated and hence regulated in their activity by PKA. AKAPs are 
found in many subcellular locations and expressed in many tissues, including testis and 
brain. Apart from anchoring PKA, AKAPs can also directly bind and/or regulate many 
other proteins, including kinases/phosphatases other than PKA 27 As described in the 
descriptions of the protein networks in Figures 1-3, ASD-implicated AKAPs are involved 
in signalling cascades regulating Leydig cell-based steroidogenesis, neurite outgrowth of 
developing neurons, and glutamatergic synaptic transmission. Within the neurite 
outgrowth network, AKAPs also regulate the two main signalling ‘hubs’, by activating 
both CDC42 and (the transcription factor function of) CTNNB.
There is ample genetic evidence for the involvement of AKAPs in the etiology of ASDs 
(Supplementary Table 4). First, five AKAP genes (AKAP7, AKAP11, MAP2, M SN  and 
NBEA) are implicated through SNPs associated at P  < 1.00E-04 in the published GWASs 
12,17 In this respect, rs5918959, a SNP located 66 kb downstream of the M SN  gene 
showed a genome-wide significant P  value of 1.22E-10 for association with ASD in the 
combined discovery samples from the GWAS by Wang et al. 12 (see Methods). Three 
other AKAP genes (AKAP5, AK AP8  and AKAP13) are implicated in ASDs through SNPs 
associated at P  < 1.00E-03 17. Further, six AKAP genes are found in CNVs in people with 
ASDs (AKAP8, AKAP9, A K A P 10,, AKAP13, M AP2  and NBEA), and NBEA was disrupted 
by a chromosomal translocation in a male with autism 28. AKAP9  is also present in a locus 
linked to autism 29. Moreover, several AKAPs are the target of ASD-implicated 
microRNAs (AKAP5, AKAP8, AKAP11, A K A P13  and NBEA) or expressed differentially 
in lymphoblastoid cells of people with ASDs (AKAP7) (Supplementary Table 4). 
Expression studies also implicate M SN  and M AP2, with increased 30 respectively 
decreased 31 expression found in the postmortem brain of autistic people. In addition, 
exposure to low levels of polychlorinated biphenyls (PCBs) leads to an increased
32 33 thcerebellar expression of Akap11 and autism-like behaviour in rats . An 11 AK AP  
gene could be implicated in ASDs, in that rs10038113, a SNP yielding genetic association 
with ASDs in the GWASs by Wang et al. 12 (P  = 7.40E-08) and Ma et al. 13 (P  = 3.40E-06) 
maps only 7 kb upstream of the M SN-like 1 (MSNL1) gene (http://www.ensembl.org).
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MSNL1 is the only gene in a linkage disequilibrium (LD) block of approximately 100 kb 
in size that contains several SNPs yielding genome-wide significant association with ASD 
for the combined discovery and replication samples in the GWAS by Wang et al. 12. This 
LD block is located within the intergenic region between the cadherin 10 (CDH 10) and 
cadherin 9 (CDH 9) genes and although Wang et al. speculate that one of these genes may 
be involved in ASDs, none of the SNPs in the block was shown to affect the brain 
expression levels of CD H 10  and/or CDH9 12. MSNL1 shows a very high degree of 
sequence homology to the M SN  gene 34, and although it is currently annotated as a 
pseudogene (http://www.ncbi.nlm.nih.gov/sites/entrez), there is literature evidence that a 
pseudogene can be transcribed and can regulate the expression of other genes 35. 
Interestingly, rs10038113 and rs1896731, a SNP present in the same LD block and 
mapping 11 kb upstream of MSNL1, were recently also found to be nominally associated 
with a quantitative ASD subphenotype 36, whereas rs4307059, a SNP from the LD block 
located 56 kb downstream of MSNL1, associates with ASD-like social communication 
difficulties in the general population 37. Therefore, we would like to submit that instead of 
CDH10/CDH9, the genome-wide significant SNPs from the study by Wang et al. may 
implicate MSNL1 in the etiology of ASDs.
Additional evidence points to a role for the A K A P  genes (and the encoded proteins) in the 
etiology of ASDs. AKAP10 38, AKAP13 39 and MSN 40 are involved in innate immunity, 
known to be disturbed in at least a subset of people with ASDs 41,42, through regulating the 
activity of Toll-like receptors (TLRs). AKAP5 and AKAP8 are both involved in the 
biosynthesis of the circadian hormone melatonin 43, which is markedly disturbed in people 
with ASDs 44 Therefore, it is interesting that both anti-inflammatory treatments and 
melatonin have been proposed as possible new treatments of ASDs 45. Neuronal AKAPs 
also play an important role in the serotonin-induced release of neurotransmitters 46. 
AKAP5 is involved in the recycling of postsynaptic AMPA glutamate receptors (Figure 3 
and Supplementary Information) and regulating longterm potentiation and depression 
through glutamate-bound NMDA receptors 47,48. AKAP7 regulates signalling cascades 
downstream of D1-like dopamine receptors 49,50. Hence, it is very interesting and 
intriguing that Risperidone, one of only two drugs approved by the Food and Drug 
Administration (FDA) for the treatment of ASDs (http://www.fda.gov/), functions both as 
a modulator of AMPA and NMDA glutamate receptor expression 51 and regulates the 
serotonin-induced release of glutamate and dopamine 52,53.
204
Risperidone is also involved in upregulating the brain expression of MAP2 54 - an AKAP 
implicated in neurite outgrowth (Figure 2b) - as well as CTNNB and GSK3B 55, two 
proteins that are regulated by AKAP8 and AKAP11, respectively (Figure 2a). RHOA, a 
protein that is positively regulated by AKAP13 and has an important role in the neurite 
outgrowth and synaptic networks (Figures 2 and 3), also modulates the effects of 
Risperidone treatment for autistic symptoms 56. In other words, 8 of the 10 ASD- 
implicated AKAPs we identified (i.e. AKAP5, AKAP7, AKAP8, AKAP10, AKAP11, 
AKAP13, MAP2 and MSN) regulate two ASD-implicated biological processes for which 
new treatments have been proposed (innate immunity and melatonin synthesis) and/or are 
involved in (in)directly modulating the downstream effects of Risperidone treatment for 
ASDs. Therefore, the effects of existing ASD drugs on these and other AKAPs should be 
investigated in future studies. Several AKAP-dependent protein-protein interactions or the 
AKAPs themselves are also increasingly considered and investigated as potential drug 
targets 27, and several molecules that specifically inhibit the binding of PKA to its AKAP 
binding site have been patented (http://www.wipo.int/patentscope/search/en/search.jsf). 
One of these molecules is Ht31, a peptide derived from AKAP13, and interestingly, 
transgenic mice that conditionally express Ht31 in their hippocampus show spatial 
learning and memory impairments 57 that resemble cognitive deficits in ASDs 58,59. For 
these reasons, we think that the ASD-implicated AKAPs and/or protein-protein 
interactions dependent on these AKAPs are excellent targets for developing novel ASD 
drugs.
The identified testicular steroidogenesis network (Figure 1) provides additional proof for 
both the excess of males in ASDs (see above) and the ‘extreme male brain’ theory of 
ASDs. This theory integrates several lines of evidence and states that ASD behaviours are 
associated with increased fetal testosterone levels and are therefore more common in 
males as well as females with disorders characterised by an overproduction of testosterone 
60,61. Interestingly, administering the AKAP-inhibiting peptide Ht31 (see above) to rats 
effectively blocks the ‘masculinization’ of a part of the rodent brain 62, which suggests a 
additional and more direct role of AKAPs in mediating the masculinizing effects of 
testosterone - or rather, estradiol, which is converted from testosterone in the brain (see 
Supplementary Information) - on brain development. Furthermore, our findings about the 
involvement of (disturbed) neurite outgrowth and synaptic function in the genetic etiology 
of ASDs fit very well with literature reports describing aberrant structural and functional
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brain connectivity in people with ASDs 63. Hence, ASDs can be seen as disorders of 
‘neuronal communication’ that - at the level of individual neurons - could be caused by 
disturbances or alterations in the efficiency, direction and/or timing of neurite outgrowth 
(during brain development) and/or synaptic function (throughout adult life).
This is further corroborated by a recent study reporting enrichment of several neurite 
outgrowth-related and ASD-implicated genes in a set of genes that were correlated with 
structural connectivity in the adult rat brain through gene expression patterns during brain 
development 64 In addition, in a very recent study using weighted gene co-expression 
analysis in human neuronal progenitor cells, it was reported that AKAP7, AKAP11 and 
AKAP12 are co-expressed in a ‘co-expression module’ containing genes - including four 
previously implicated ASD candidate genes - that are likely involved in the onset of 
differentiation as well as the cessation of proliferation of these cells 65, which provides an 
additional indication of the involvement of (specific) AKAPs in early brain development. 
However, neurobiological processes like neurite outgrowth and synaptic function are not 
specific to the etiology of ASDs, and our research group recently reported that neurite 
outgrowth is also important in the genetic etiology of dyslexia 66 and ADHD 67, two 
neurodevelopmental disorders that are highly comorbid and genetically correlated with 
each other 68 and with ASDs 69-71. Disturbed synaptic function is also involved in the 
etiology of schizophrenia 72, a neurodevelopmental disorder that only manifests itself in 
late adolescence or adulthood and shares genetic factors with ASDs 73. That being said, we 
think that the clinical specificity of these neurodevelopmental disorders could be at least 
partially explained by the different functional consequences of a disturbed or abnormal 
neurite outgrowth and/or synaptic function in the most affected brain region(s) for each 
disorder. For ASDs, a consistently replicated finding is that the cerebellum and, more 
specifically, cerebellar Purkinje cells, are amongst the most affected brain regions, often 
resulting in an actual loss of these cells 74,75. As several of the ASD-implicated 
microRNAs show dysregulated expression in postmortem cerebellar cortex of people with 
ASDs 18 and many of the identified ASD candidate genes/proteins - including AKAP5, 
AKAP9 and AKAP11 - are highly expressed and/or have a specific function in cerebellar 
Purkinje cells (see Supplementary Information), cerebellar dysfunction of the identified 
genetic networks may be very important in the etiology of ASDs.
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Table 1. Overview of the clinical samples from six published GWASs for ASDs 12-17
GWAS Clinical sample Genotyping
platform
Phenotype Diagnosis
Wang et al. 12 Combined discovery sample (AE):
*
AGRE (943 families)
+
ACC cohort (1453 cases and 7070 
controls) from CHOP and several other 
U.S. clinical sites
Illumina ASD ADOS + ADI-R
Ma et al. 13 CAP discovery sample (AE):
four U.S. clinical sites 
(438 families)
Illumina Autism ADI-R + DSM-IV
Weiss et al. 14 Combined discovery sample (AE), 
consisting of 1031 multiplex families 
with 1553 affected offspring from: 
AGRE (801 families) *
+
NIMH (341 families)
Affymetrix ASD ADI-R
Salyakina et al. 15 Combined sample:
Discovery sample from two U.S. 
clinical sites (124 families)
+
AGRE validation sample (110 
families)
Illumina ASP ADI-R + DSM-IV
Hussman et al. 16 Combined sample:
Sample from two U.S. clinical sites 
(597 families)
+
AGRE sample 
(696 families)
Illumina Autism ADI-R + DSM-IV
Anney et al. 17 AGP Consortium discovery sample 
(AE):
Autism (809 families)
+
ASD (1369 families)
Illumina Autism + 
ASD
ADOS + ADI-R
Abbreviations: ACC, Autism Case Control; ADOS, Autism Diagnostic Observation Schedule;
ADI-R, Autism Diagnostic Interview-Revised; AE, all ethnicities; AGP, Autism Genome 
Project; AGRE, Autism Genetic Resource Exchange; ASD(s), autism spectrum 
disorder(s); ASP, Asperger’s syndrome; CAP, Collaborative Autism Project; CHOP, 
Children’s Hospital of Philadelphia; DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders-4th edition; GWAS, genome-wide association study; GWASs, genome- 
wide association studies; NIMH, National Institute for Mental Health
there is considerable overlap between these two clinical samples 12,14
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Table 2. Top 10 nervous system-related gene functional categories that are significantly enriched in the top 200 ASD candidate genes from GWASs 1-5 1216 (Supplementary table 1) 
using Ingenuity pathway analysis (www.ingenuity.com) . The genes encoding proteins that could be directly placed in one or more of the three networks involved in ASDs (Figures 1-3) 
are indicated in bold. The functional categories that are directly involved in neurite outgrowth or synaptic function are underlined.
Category Genes Significance3 Adj. significance13
Neurological disease 
(81/200 genes)
ABCC1,ACTN2,ADA,ADAMTS3,AKAP7,APP,ATPIB1.ATXN2L.BAG5,ClOORF11, CADPS, CDCA7.CNGA3,
COLEC12,CRBN, CRIM1, CTNNA2, CTNNA3, CUGBP2, DAB1, DCC, DHRS3, DMD, DNER, DYNLT1, FAM171A1, 
FGF1, FHIT, GALNT13, GALNTL4, GANG, GDAP1, GDNF, GPR98, GRIN2A,HRH2,IQGAP2,JARID2,KCNA1, KCNB1, 
KLC1, LRP1B, MAML2, MARCKS, MAST3, MEIS2, MY05A,MY05B, NDRG1, NEFM, NGF, NIDI, NPAS3, NTM, 
OR5211. OTX2,P2RYl,PIK3Rl, PTPRE, PTPRN2,RIMS1,SEMA4D,SEMA5A,SGCD,SGCZ,SGEF,SHH,SIPA1L2.SKAP1. 
SORCS2,SOX2,SPATA16,SRGAP3,ST8SIA2,SUCLG2,SYT17,SYTL3,THOCl, TMEM132D, TOX. TSHZ1
9.79E-07 1.64E-04
Development of CNS APP, CTNNA2, DAB1, FEZF2, JARID2, MARCKS, MY05A, OTX2, SH3GL3, SHH, SIX3, SOX2, ST8SIA2, TLX1 8.03E-06 9.17E-04
Development of neurites APP, DCC, DMD, FEZF2, GDNF, MSN, NGF, PTPRE, SHH, SLITRK5, THBS4 3.28E-05 3.29E-03
Shaue change of neurites APP, DCC, DYNLT1, GDNF, NGF 3.44E-05 3.32E-03
Sprouting of neurites APP, DYNLT1, GDNF, NGF 7.63E-05 6.39E-03
Neurological process of axons APP, DCC, FEZF2, GDNF, OTX2, PTPRE, SEMA5A, SHH 1.33E-04 8.78E-03
Ouantitv of svnautic vesicles APP, MY05A, RIMS1 1.53E-04 9.87E-03
Growth of axons APP, DCC, GDNF, NGF, PLXNA4, SEMA5A 2.14E-04 1.31E-02
Neuro genesis APP, CRIM1, DCC, FEZF2, FGF1, GDNF, NGF, OTX2, PLXNA4, SEMA5A, SHH, SOX2, ST8SIA2, THBS4 8.32E-04 3.87E-02
Outgrowth of neurites APP, DCC, FRK, GDNF, MARCKS, NGF, PLXNA4, SEMA5A, SH2B1 8.56E-04 3.91E-02
Abbreviations: ASD(s), autism spectrum disorder(s); CNS, central nervous system; GWASs, genome-wide association studies
a Single test P value calculated with the right-tailed Fisher’s exact test and taking into consideration both the total number of molecules from the analysed dataset and the total 
number of molecules that is linked to the same gene category according to the Ingenuity Knowledge Base.; b Multiple test-corrected P  values using the Benjamini-Hochberg 
correction; only categories with more than one gene are shown.
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Figure 1. Schematic representation of a protein network that is implicated in the etiology of autism spectrum disorders (ASDs) and involved in the production and 
metabolism of the steroid hormones testosterone and estradiol in (fetal and adult) testicular Leydig cells. The proteins encoded by genes emerging from five 
published genome-wide association studies (GWASs) for ASDs (Supplementary Table 1) are indicated in yellow. The other proteins and the AKAPs (Anchoring 
Kinase A Proteins) encoded by genes that were implicated in the etiology of ASDs through other evidence (Supplementary Tables 3 and 4) are indicated in orange. 
ABCC1 is indicated by a black border because the ABCC1 gene was implicated through two of the six published GWASs of ASDs (Supplementary Table 5). All 
AKAPs are also indicated by a green border. In the Supplementary Information, the current knowledge about the function of the proteins in the network is presented.
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Figure 2a. Schematic representation of a protein network that is implicated in the etiology of autism spectrum disorders (ASDs) and leads to neurite outgrowth 
through molecular signalling cascades located in the extracellular matrix/compartment, cell membrane, cytoplasm and nucleus of developing neurons. The proteins 
encoded by genes emerging from five published genome-wide association studies (GWASs) for ASDs (Supplementary Table 1) are indicated in yellow. The other 
proteins and the AKAPs (Anchoring Kinase A Proteins) encoded by genes that were implicated in the etiology of ASDs through other evidence (Supplementary 
Tables 3 and 4) are indicated in orange. The proteins encoded by genes that were implicated through two of the six published GWASs of ASDs (Supplementary 
Table 5) are indicated by a black border. All AKAPs are also indicated by a green border. In the Supplementary Information, the current knowledge about the 
function of the proteins in the network is presented.
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Figure 2b. Schematic representation of a protein network that is implicated in the etiology of autism spectrum disorders (ASDs) and leads to neurite outgrowth 
through molecular signalling cascades located in the growth cone and surrounding extracellular matrix/compartment of developing neurons. The proteins encoded by 
genes emerging from five published genome-wide association studies (GWASs) for ASDs (Supplementary Table 1) are indicated in yellow. The other proteins and 
the AKAPs (Anchoring Kinase A Proteins) encoded by genes that were implicated in the etiology of ASDs through other evidence (Supplementary Tables 3 and 4) 
are indicated in orange. All AKAPs are also indicated by a green border. In the Supplementary Information, the current knowledge about the function of the proteins 
in the network is presented.
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Figure 3. Schematic representation of a protein network that is located in the neuronal synapse and is involved in the etiology of autism spectrum disorders (ASDs) 
by modulating glutamatergic neurotransmission. The proteins encoded by genes emerging from five published genome-wide association studies (GWASs) for ASDs 
(Supplementary Table 1) are indicated in yellow. The other proteins and the AKAPs (Anchoring Kinase A Proteins) encoded by genes that were implicated in the 
etiology of ASDs through other evidence (Supplementary Tables 3 and 4) are indicated in orange. NEDD4L is indicated by a black border because the NEDD4L 
gene was implicated through two of the six published GWASs of ASDs (Supplementary Table 5). All AKAPs are also indicated by a green border. In the 
Supplementary Information, the current knowledge about the function of the proteins in the network is presented.
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Methods
Identification of candidate genes from  five GWASs
The main characteristics of the six GWASs of ASDs published to date are presented in 
Table 1. Data from GWASs 1-5 12-16 were used for constructing protein gene/protein 
networks and the sixth published GWAS 17 was used for validation. From GWASs 1-5, we 
compiled a list of top-ranked single nucleotide polymorphisms (SNPs), taking into account 
SNPs that are located within exonic, intronic or untranslated regions of genes or found 
within 100 kilobase (kb) of downstream and/or upstream (potentially regulatory 76-79) 
sequences flanking the gene, and that yielded association with ASDs at P  < 1.00E-04. It 
should be noted that, for the selection of SNPs from GWASs 1 12 and 3 14, we used the 
complete and detailed association results for the combined discovery samples that were 
kindly provided by Drs Wang and Hakonarson, and Dr Weiss, respectively, rather than the 
lists including replication samples as published.
Using the same SNP selection criteria, we searched for overlapping genes between 
GWASs 1-5 and GWAS 6. The reason for choosing GWAS 6 for validation was that this 
GWAS was conducted on a discovery sample that is independent from all discovery 
samples used in the other GWASs. Our chosen statistical cut-off of P  < 1.00E-04 remains 
essentially arbitrary, but was also used in four of the six ASD GWASs to designate 
‘suggestive’ evidence of association 12-14,17, and applying this cut-off provided us with a 
manageable number of genes for our subsequent analyses.
C orroborating evidence
Subsequently, we searched the literature on copy number variations (CNVs) found in 
people with ASDs for overlap with each of the genes from the five GWASs. We searched 
for overlapping CNVs that were identified in people with ASDs through a genome-wide 
array-based hybridization approach and/or that were ‘recurrent’, i.e. observed in case 
studies of at least two unrelated people with ASDs.
In addition, we searched for targets of ASD-implicated microRNAs amongst the candidate 
genes from the five GWASs. MicroRNAs are very small RNAs that negatively regulate the 
expression of multiple genes 18-21. We first compiled a list of microRNAs that have been 
repeatedly implicated in the etiology of ASDs, after which we used Targetscan to identify 
which of the ASD candidate genes are targeted and hence downregulated by ASD- 
implicated microRNAs. Targetscan is a web-based tool (http://www.targetscan.org/) that
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predicts possible gene targets of microRNAs and ranks the predicted efficacy of 
microRNA targeting using a calculated context score.
We also compiled a list of additional candidate genes/proteins that were not directly 
observed in the top-ranked GWAS findings but are implicated in ASDs through at least 
two lines of ‘other’ evidence, including ‘classic’ candidate gene-based association studies, 
top-ranked genes from the sixth reported GWAS of ASDs 17, CNV studies and microRNA 
studies.
Bioinformatics analysis
To detect significantly enriched gene categories in the selected candidate genes from the 
five GWASs, we performed a bioinformatics analysis using the Ingenuity Pathway 
Analysis software package (http://www.ingenuity.com). Based on the Ingenuity 
Knowledge Base and using information from the published literature as well as many other 
sources, including gene expression and gene annotation databases, genes are assigned to 
different categories and subcategories of functionally related genes. Ingenuity calculates 
single P  values for the enrichment of each gene (sub)category using the right-tailed 
Fisher’s exact test. For each (sub)category, a multiple testing corrected P  value, calculated 
using the Benjamini-Hochberg correction, is also provided (http://www.ingenuity.com).
Systematic literature analysis and identification of protein networks
We then systematically searched the literature for the (proposed) function of all proteins 
derived from the ASD candidate genes using the Uniprot Protein Knowledgebase 
(UniProtKB), a comprehensive catalogue of protein sequences and functional annotations 
that is updated every 3 weeks and can be accessed online (http://www.uniprot.org/uniprot) 
80, and PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez). For each ASD candidate from 
the five GWASs, we first looked at the available information in UniProtKB, which in most 
cases already provided a general indication of the (putative) function of the gene/protein in 
question. Based on the Ingenuity analysis, UniProtKB and the three main biological 
‘themes’ linking the genetic ASD findings (see Introduction), we subsequently searched 
PubMed using the search terms “Leydig”, “steroid”, “steroid synthesis”, “steroidogenesis”, 
“testosterone”, “estradiol”, “estrogen”, “brain”, “neuron”, “neuronal growth”, “neurite”, 
“neurite outgrowth”, “synapse”, “synaptic”, “glutamate” and “glutamate receptor” in 
combination with the name of each of the candidate genes/proteins. Guided by the 
literature we found, we also searched Pubmed for functional interactions between the 
candidate genes/proteins.
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Supplementary Table 1. Top single SNPs located in gene regions (including 100 kb of flanking downstream and/or upstream sequences) and with P  < 1.00E-04 for 
association with autism spectrum disorders (ASDs) from the genome-wide association studies (GWASs) reported by Wang et al. (GWAS 1) 1. Ma et al. (GWAS 2) 2, 
Weiss et al. (GWAS 3) 3 and Salyakina et al (GWAS 4) 4. The genes belonging to an LD block of SNPs with P <  1.00E-04 for association with autism in the GWAS by 
Hussman et al. (GWAS 5) 5 are also shown. In addition, it is indicated which genes were reported to be deleted (del) and/or duplicated (dup) in copy number variations 
(CNVs) in people with ASDs 7 29 and which of the microRNA(s) that were repeatedly implicated in ASDs (Supplementary table 2) downregulate(s) the expression of 
one or more genes according to the Targetscan prediction tool (http://www.targetscan.org/). The genes encoding proteins that could be directly placed in one or more of 
the three networks involved in ASDs (Figures 1-3) are indicated in bold and the genes encoding AKAPs (A-kinase anchor proteins) are underlined.
GWAS 1 (Wang et al. ) 1
SNP P  value Locus
*
Gene
* *
Position ~ gene CNV(s) Micro RNA(s)
rs5918959 1.22E-10 Xql2 MSN  m 66 kb downstream -
rs6529461 6.40E-09 Xq26.1 ARHGAP36 42 kb downstream del7
rsl2392447 5.64E-08 Xq28 FAM3A 10 kb downstream del . dup 8 MIR93, MIR106B, MIR128, MIR148B, MIR193B, 
MIR484, MIR486
rsl2392447 5.64E-08 Xq28 SLC10A3 5 kb upstream
00fr~- MIR146B
rs9932538 1.94E-07 16pl2.3 SYT17 intronic - MIR320
rs5972577 2.67E-07 Xp21.1 DMD (2) intronic
00fQ\r~- MIR320
rs6646569 9.75E-07 Xq24 RHOXF1 1.2 kb downstream del7
rs6646569 9.75E-07 Xq24 RHOXF2 51 kb upstream del7 MIR23A, MIR23B, MIR146B
rs793094 1.29E-06 10p l l .22 ZNF438 66 kb upstream t 00
rs3755827 3.54E-06 3pl4.2 CADPS 24 kb downstream -
rs3755827 3.54E-06 3pl4.2 FEZF2 5 ’ near gene -
rsl0774538 6.22E-06 12q24.23 CCDC64 24 kb upstream t o
rs6131030 6.46E-06 20ql3.12 CDH22 intronic - MIR455
rsl 1715476 7.17E-06 3pl4.1 SUCLG2 50 kb upstream del9'11
rs807023 7.77E-06 10q24.31 AL133215.1 nonsyn, coding -
rs9349688 8.08E-06 6p l2.1 LRRC1 nonsyn, coding - MIR577
rs4058287 1.05E-05 18q21.31 NEDD4L intronic del1012 MIR23A, MIR23B, MIR93, MIR106B
rsl 7687319 1.08E-05 6p22.1 PRSS16 14 kb downstream - MIR23A, MIR23B, MIR148B, MIR185, MIR320, MIR577
rs891989 1.11E-05 5q31.3 NDFIP1 13 kb upstream - -
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Supplementary Table 1 - continued.
GWAS1 (Wang et al. ) 1
SNP P  value Locus
*
Gene
* *
Position ~ gene CNV(s) Micro RNA(s)
rs4936059 1.13E-05 llq24.3 F L U 61 kb upstream d e l7 8 MIR193B
rsl0997574 1.23E-05 10q21.3 CTNNA3 intronic d e l810, dup 8
rs4911811 1.36E-05 Xq23 LRCH2 20 kb upstream
00fr~- MIR23A, MIR23B
rs6546183 1.42E-05 2p23.3 D TN B intronic t
o
rs6602977 1.54E-05 15q25.2 SH3GL3 intronic - MIR93, MIR106B
rs902726 1.59E-05 17q25.1 ICT1 intronic -
rs6759954 1.71E-05 2p l l .2 C2orf51 40 kb upstream -
rs4759808 1.77E-05 12q24.33 TMEM132D intronic del9, dup 7’8’10
rs4901741 1.93E-05 14q22.3 OTX2 83 kb upstream - MIR128, MIR148B
rs7139183 2.06E-05 12pl3.2 TAS2R7 29 kb downstream -
rs537111 2.10E-05 Xq23 GUCY2F 2.6 kb upstream d e l7
rs2830038 2.43E-05 21q21.3 AP P  (3) intronic
00
MIR93, MIR 106A, MIR106B
rsl859569 2.47E-05 7q34 TBXAS1 intronic -
rs2181572 2.77E-05 6q23.2 AK AP7  (4) 62 kb downstream -
rsl 1656071 3.08E-05 17pl 1.2 EPN2 3' UTR/intronic del \  dup 13’14 MIR23A, MIR23B, MIR148B, MIR320, MIR455, MIR577
rs861544 3.28E-05 14q32.33 KLC1 intronic - MIR 185
rsl6946714 3.29E-05 15q26.1 ST8SIA 2 79 kb upstream - MIR93, MIR106B, MIR500, MIR502-3p
rs4689606 3.45E-05 4pl6.1 GRPEL1 67 kb upstream - MIR146B, MIR148B, MIR500
rsl3032106 3.49E-05 2q24.1 GALNT13 intronic del11 MIR455
rs4877464 3.62E-05 9q22.1 NXNL2 39 kb downstream - MIR23A, MIR23B, MIR146B, MIR193B, MIR199B
rs500294 3.90E-05 Xq28 M AM LD1 intronic
00
rs2726555 3.90E-05 8q l2.1 TOX intronic - MIR23A, MIR23B
rsl6844401 4.02E-05 4pl6.3 H G FAC non syn, coding dup15
rs7746447 4.02E-05 6q25.3 DYNLT1 3' near gene -
rs7746447 4.02E-05 6q25.3 SYTL3 14 kb upstream -
rs4911249 4.14E-05 20q l l .21 C20orf203 6 kb downstream dup15 -
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Supplementary Table 1 -  continued.
GWAS1 (Wang et al. ) 1
SNP P  value Locus
*
Gene
* *
Position ~ gene CNV(s) Micro RNA(s)
rs4911249 4.14E-05 20q l l .21 C 20orfll2 41 kb upstream dup 15
rsl279313 4.15E-05 14ql3.1 NPAS3 intronic
00
MIR93, MIR106B
rs2246219 4.29E-05 3ql3 .13 GUCA1C intronic -
rs 17804647 4.30E-05 17pl3.1 TEKT1 syn, coding del 8 ’ 1 3
rs2593943 4.42E-05 3ql3 .13 MORC1 nonsyn, coding - MIR23A, MIR23B, MIR146B, MIR199B, MIR577
rs6556217 4.52E-05 5q35.2 SFXN1 73 kb downstream -
rs6556217 4.52E-05 5q35.2 H R H 2 55 kb upstream - MIR93, MIR106B, MIR199B
rs4659660 4.56E-05 lq42.3 EDARADD intronic
00f
MIR23A, MIR23B
rs752624 4.71E-05 14q32.33 BAG 5 2.4 kb downstream -
rs966864 5.06E-05 12p l2.2 SLC01C1 intronic - MIR93, MIR106B, MIR486
rsl2924488 5.26E-05 16p13.11 ABCC1 18 kb upstream del8, dup7’8’15’16 MIR 185, MIR199B, MIR486
rs7060889 5.29E-05 X pll.4 U SP9X 57 kb upstream del7 MIR132, MIR199B
rsl022249 5.37E-05 6p25.1 CDYL 51 kb upstream -
rsl529869 5.37E-05 2q22.2 LRP1B intronic
00
rs 11760399 5.46E-05 7q36.1 CUL1 intronic d e l7
rsl040503 5.67E-05 lq24.2 ATP IB  1 intronic -
rsl0836331 5.73E-05 llp l5 .4 C llorf40 1.6 kb downstream -
rsl0836331 5.73E-05 llp l5 .4 OR52I1 19 kb upstream -
rsl2620553 5.81E-05 2ql3 FBLN7 intronic -
rs967963 5.94E-05 3p26.2 C RBN 16 kb upstream del 8 ? dup 1 3
rsl 1221322 5.96E-05 llq24.3 ETS1 intronic del 7 ’ 8 MIR193B, MIR199B, MIR455? MIR650
rsl2229563 6.06E-05 12q21.33 LUM  (5) 37 kb downstream del9
rsl2229563 6.06E-05 12q21.33 KERA 8 kb upstream del9
rsl467662 6.39E-05 lq23.1 ETV3 26 kb downstream -
rsl467662 6.39E-05 lq23.1 ARHGEF11 50 kb upstream - MIR93, MIR106B, MIR132
rsl812886 6.43E-05 10q26.2 PTPRE intronic - MIR185, MIR199B, MIR484
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GWAS 1 (Wang et al. ) 1
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rs3 744203 6.46E-05 17q25.1 CDR2L syn, coding - MIR128
rsl0072475 6.61E-05 5ql3.1 PIK3R1 (6) intronic - MIR93, MIR106B, MIR 128. MIR199B, MIR320, 
MIR455,MIR486, MIR650
rs280502 6.75E-05 19pl3.2 CDC37 10 kb downstream - MIR185, MIR486
rs280502 6.75E-05 19pl3.2 TYK2 2.3 kb upstream -
rs2975186 6.90E-05 8p21.2 N E F 3 26 kb upstream dup 1718
rs8108738 7.23E-05 19pl3.11 M AST3 nonsyn, coding - MIR93, MIR106B
rs4689835 7.24E-05 4pl6.1 SORCS2 intronic 1
c MIR146B, MIR 185. MIR211, MIR320, MIR455, MIR484, 
MIR486
rsl999930 7.57E-05 6q22.1 F R K 5 kb upstream -
rs2675186 7.86E-05 3p25.3 SRGAP3 intronic dup 13 MIR23A, MIR23B, MIR93, MIR106B, MIR199B, MIR486
rs8049439 7.87E-05 16pll.2 ATXN2L intronic dup8-10
rs279722 8.18E-05 20ql3.12 ZNF663 intronic -
rs940970 8.22E-05 15q21.2 M Y 05A intronic - MIR199B
rs268379 8.29E-05 8p22 SG CZ intronic dup9
rs9307938 8.32E-05 4q32.1 CTSO intronic - MIR128, MIR320, MIR500
rsl7807087 8.54E-05 lq42.2 SIPA1L2 91 kb upstream - MIR577
rs6779908 8.66E-05 3q26.33 SOX2 65 kb downstream -
rs2241046 8.83E-05 22qpericentromeric IL17RA intronic del7-8-1,:’dup7-8-li:u3 MIR148B, MIR199B, MIR320
rs7498665 8.95E-05 16pll.2 SH2B1 intronic del 19,dup 8-10 MIR577
rs2606063 9.02E-05 2q31.1 PDK1 34 kb downstream - MIR148B
rs4916821 9.04E-05 5ql4.3 GPR98 intronic dup8-10 MIR320
rsl2439749 9.05E-05 15ql4 M E IS2 intronic - MIR23A, MIR23B, MIR128, MIR199B, MIR320
rs5922226 9.19E-05 Xq21.2 DACH 2 19 kb upstream d e l7-10
rslll75194 9.22E-05 12ql4.2 SRGAP1 intronic -
rs530490 9.27E-05 1 lq2 1 M A M L2 intronic - MIR211
rs6986474 9.58E-05 8q24.22 NDRG1 14 kb upstream - -
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GWAS 1 (Wang et al. ) 1
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rsl7530 9.72E-05 12q22 CLLU1 19 kb downstream -
rsl 1119953 9.77E-05 lq32.3 N E N F 51 kb downstream -
rsl 1119953 9.77E-05 lq32.3 ATF 3 68 kb upstream - MIR93, MIR106B, MIR650
GWAS 2 (Ma et al.) 2
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rs9822786 2.98E-07 3ql3.2 SLC9A10 intronic - MIR93, MIR106B, MIR132
rs9919560 1.13E-06 llpl5.3 G ALNTL4 intronic -
rs43 94668 4.89E-06 lp36.22 DHRS3 intronic -
rsl2622496 9.66E-06 2q32.2 TMEM194B intronic/5' UTR -
rsl2155975 1.10E-05 8p22 PSD3 intronic delx. dup MIR500, MIR502-3p
rs742759 1.52E-05 20ql3.13 KCNB1 intronic - MIR153-1
rsl811763 1.65E-05 3q26.31 SPATA16 intronic -
rs6436915 1.67E-05 2q37.1 SP110 intronic -
rsl529813 1.78E-05 7ql 1.21 ZNF679 70 kb upstream -
rsl 1001685 2.34E-05 10q22.3 C lO orfll intronic del9 MIR211
rsl55288 2.84E-05 lp32.2 DAB1 intronic dup 8-10
rs315717 3.06E-05 5q35.1 LCP2 syn, coding - MIR148B, MIR455
rs3731723 3.20E-05 2q37.1 SLC16A14 97 kb upstream -
rsl 1636552 3.27E-05 15ql2 ATP10A 25 kb upstream del7,11 dup7,8,10,11’15’20’24
rsl467068 3.35E-05 2p l6.1 BCL11A 82 kb upstream del24, dup 10 MIR146B, MIR148B, MIR211, MIR486, MIR577
rsl0444509 3.36E-05 12q23.2 GNPTAB intronic -
rsl0840070 3.36E-05 llp l5 .4 STK33 intronic - MIR93, MIR106B
rs4129081 3.56E-05 2q32.2 MFSD6 intronic -
rsl 1689493 4.31E-05 2q31.1 CDCA7 26 kb dowstream - MIR93, MIR106B
rsl 130496 4.70E-05 7q36.3 PTPRN2 nonsyn, coding del 7’8’25,d u p 8 MIR577
rsl 1117003 4.75E-05 12q21.31 RASSF9 83 kb downstream del9 -
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GWAS 2 (Ma et al.) 2
SNP P value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rsl 149558 5.11E-05 7q33 EXOC4 intronic
00
rsl2491012 5.44E-05 3q25.2 SGEF intronic
00
rs7910491 5.51E-05 10q24.31 KAZALD1 25 kb downstream - MIR146B, MIR185, MIR193B, MIR577
rs7910491 5.51E-05 10q24.31 TLX1 37 kb upstream - MIR128
rsl423435 5.70E-05 5pl3.2 GDNF 65 kb upstream -
rs4852531 5.93E-05 2p l2 CTNNA2 intronic -
rs8088001 6.23E-05 18pl 1.32 COLEC12 32 kb downstream de l1, dup MIR148B, MIR455
rs8088001 6.23E-05 18pl 1.32 THOC1 20 kb upstream de l1, dup
rsl 144093 6.34E-05 18q21.2 DCC intronic - MIR486
rs7325257 6.51E-05 13q31.2 SLITRK5 73 kb downstream -
rs2082804 6.68E-05 8ql2.3 YTHDF3 60 kb downstream - MIR93, MIR106B, MIR484
rs201171 6.74E-05 lp36.31 KLHL21 3 'UTR - MIR128, MIR146B, MIR148B, MIR320, MIR484, MIR486, 
MIR650
rsl 1055784 6.74E-05 12pl3.31 NANOG intronic -
rsl6833075 6.81E-05 lq42.3 NIDI intronic
00f
rs891754 6.96E-05 17ql2 C17orfl02 91 kb downstream dup7’9
rsl936022 7.10E-05 6ql3 RIMS1 intronic - MIR199B
rsl000058 7.11E-05 7q32.3 PLXNA4 (7) intronic
00f
rs6049129 7.18E-05 20p l l .21 CST2 29 kb downstream - MIR455
rs6049129 7.18E-05 20p l l .21 CST1 44 kb upstream
00
MIR455
rs7523086 7.27E-05 lpl3.2 NGF 5 kb downstream -
rsl2414590 7.66E-05 10q26.2 FOXI2 54 kb upstream - MIR132, MIR484, MIR486
rs2528795 7.78E-05 7qll.23 ELN intronic del7’26,dup7,15,27
rsl0748804 8.07E-05 10q24.31 SFXN3 40 kb downstream -
rs4456502 8.33E-05 16pl3.2 GRIN2A (8) 73 kb upstream del 9, dup 9 MIR577
rs4148358 8.50E-05 16p13.11 ABCC1 intronic d e l8, d up 781516 MIR185, MIR199B, MIR486
rs547668 8.50E-05 18pll.22 APCDD1 intronic dup 28 MIR93, MIR106B
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GWAS 2 (Ma et al.) 2
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rs492780 8.78E-05 2p21 SIX 3 25 kb upstream f O
GWAS 3 (Weiss et al. ) 3
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rs7766973 2.14E-06 6p22.3 JA R ID 2 intronic - MIR23A, MIR23B, MIR148B, MIR211
rs6886828 3.20E-06 5q33.3 SGCD intronic dup9 MIR23A, MIR23B, MIR 128. MIR199B, MIR211
rs7923367 6.81E-06 10q21.3 CTNNA3 intronic d e l8'10, dup8
rsl 1757604 8.25E-06 6q21 HDAC2 92 kb downstream - MIR455
rsl 1757604 8.25E-06 6q21 M ARC K S 16 kb upstream - MIR23A, MIR23B, MIR 128. MIR500, MIR502-3p
rsl0513025 9.58E-06 5pl5.31 TAS2R1 5 kb downstream d e l10 MIR484
rsl0513025 9.58E-06 5pl5.31 SEM A5A  (9) 77 kb upstream d e l10 MIR93, MIR106B, MIR650
rsl2293188 1.19E-05 llp l4 .3 GAS2 intronic -
rsl2329903 1.57E-05 21q21.3 AD AM TS5 90 kb upstream dup9 MIR23A, MIR23B, MIR93, MIR106B, MIR128, MIR148B
rs4742409 1.58E-05 9p24.1 C9orfl23 22 kb downstream -
rs642349 2.23E-05 10pl4 CUGBP2 intronic - MIR146B, MIR199B, MIR486
rsl3133437 3.11E-05 4q34.3 VEGFC 25 kb upstream - MIR128
rs311121 4.35E-05 Xp22.33 XG intronic del 7’8’10’29,dup7’ 8 MIR23A, MIR23B, MIR320, MIR455, MIR500
rs6901216 4.68E-05 6p21.31 M LN 35 kb upstream - MIR484
rsl2516809 4.95E-05 5pl5.1 ZNF622 43 kb downstream -
rs6888419 5.14E-05 5ql3.3 SV2C 73 kb downstream -
rs6888419 5.14E-05 5ql3.3 IQGAP2 5 kb upstream d e l9 MIR199B
rsl0849170 5.29E-05 12pl3.32 KCNA6 32 kb downstream - MIR132
rsl0849170 5.29E-05 12pl3.32 KCNA1 27 kb upstream - MIR128, MIR146B, MIR211, MIR455, MIR500, MIR502- 
3p, MIR650
rs6453278 5.97E-05 5ql3.3 ZBED 3 34 kb upstream -
rsl6848434 6.21E-05 4ql3.3 AD AM TS3 85 kb upstream - MIR199B, MIR500, MIR502-3p, MIR577
rs249729 6.55E-05 5q31.3 FGF1 92 kb downstream - MIR484
rs3763947 6.81E-05 llp l4 .3 SVIP 9 kb downstream
00
-
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GWAS 3 (Weiss et al.)3
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
rsl2329482 8.35E-05 20pl3 ZNF343 5 kb upstream
00f
MIR23A, MIR23B, MIR 128. MIR 132. MIR320
rs2299692 8.74E-05 20ql3.12 AD A  (10) intronic -
rs4670551 9.37E-05 2p22.2 CRIM1 intronic d e l8, dup 10 MIR93, MIR106B, MIR199B
rs2297956 9.62E-05 lq43 AC TN 2 intronic
001
MIR23A, MIR23B
GWAS 4 (Salyakina et al.) 4
SNP P  value Locus
*
Gene
* *
Position ~ gene CNV(s) Micro RNA(s)
rsl550976 2.30E-06 llq25 N T M intronic d e l7
rsl0510837 3.56E-06 3pl4.2 F H IT intronic del 8A20,dup8-10-20
rs892055 4.70E-06 19ql3.2 RASGRP4 non syn, coding - MIR146B, MIR577, MIR650
rs7179456 7.34E-06 15q22.1 SLTM intronic - MIR132
rsl425761 9.72E-06 8q2 1 . 1 1 GDAP1 86 kb downstream -
rsl0796285 2.00E-05 10pl3 FAM 171A1 intronic -
rs7218167 2.00E-05 17q21.32 SKAP1 intronic -
rs6022419 2.00E-05 20qll.23 KIAA0406 intronic -
rsl7133163 3.00E-05 7q32.2 KLHDC10 intronic - MIR132
rs7786445 4.00E-05 7q36.3 S H H  (11) 73 kb upstream d e l7
rs7136780 4.00E-05 12p 1 1 .2 1 C12orf35 52 kb downstream f 00 MIR128
rs7136780 4.00E-05 12p 1 1 .2 1 BICD1 62 kb upstream -
rs2581644 4.00E-05 18q22.3 TSHZ1 intronic d e l12’13
rs4599356 5.00E-05 4q31.21 GYPA 49 kb upstream - MIR128, MIR 132, MIR146B, MIR148B, MIR211, MIR455
rsl2903690 5.00E-05 15ql5.1 GANC intronic -
rsl0935907 6.00E-05 3q25.2 P2RY1 76 kb downstream - MIR132, MIR484, MIR486, MIR577, MIR650
rs 13 74520 6.00E-05 8q22.3 R IM S2 40 kb downstream t o MIR146B
rs 13 74520 6.00E-05 8q22.3 TM7SF4 23 kb upstream - MIR650
rs404375 8.00E-05 5ql4.1 THBS4 intronic d e l10 MIR23A, MIR23B
rs2457965 9.00E-05 18q21.1 M Y 0 5 B intronic d e l12 MIR93, MIR106B
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GWAS 5 (Hussman et al. ) 5
SNP P  value Locus
*
Gene
**
Position ~ gene CNV(s) Micro RNA(s)
LD block 1.80E-05 22ql3.1 CACNA1I - -
LD block 2.70E-05 2q26.3 D N ER - - MIR23A, MIR23B, MIR148B, MIR320, MIR577
LD block 3.60E-05 16pl3.3 A2BP1  (12) - d e l8-9-20, dup 8,9
LD block 9.09E-05 2q l l .2 CNGA3 - -
LD block 9.09E-05 4q31.1 SETD 7 - - MIR 128
LD block 9.09E-05 9q22.2 SEM A4D - -
LD block 9.91E-05 2p l2 LR R TM 4 -
00
LD block 9.91E-05 8q22.1 CDH17 - - MIR23A, MIR23B, MIR199B
Abbreviations: LD, linkage disequilibrium; nonsyn, nonsynonymous; syn, synonymous; SNP(s), single nucleotide polymorphism(s); UTR, untranslated region
Additional evidence for an involvement in the etiology of ASDs was found for the following genes/proteins:
(1) The expression of M S N  was found to be increased in the postmortem brain of autistic people 3". MSN is also involved in innate immunity, a process that is disturbed
31 32 * * 33in a subset of people with ASDs • ~, through regulating Toll-like Receptor 4 (TLR4) activity
(2) Genetic defects in DM D  cause Duchemie muscular dystrophy, a neuromuscular disorder that is associated with an increased frequency of ASDs 34.
(3) High levels of APP were also found in the plasma of children with severely autistic behavior35.
(4) A K A P 7 is differentially expressed in lymphoblastoid cell lines of people with ASDs 36.
(5) Exposure to low levels of polychlorinated biphenyls (PCBs) leads to a decreased expression of Luni in the cerebellum of rats 37 and the inhibition of cerebellar
38 ' . . .  . . . 'XQ A~\Purkinje cell development . Loss of cerebellar Purkinje cell function is involved in the etiology of autism " , and perinatal exposure to PCBs indeed leads to 
autism-like behaviour in rats 42.
(6) PIK3R1 encodes the regulatory subunit that together with the catalytic subunit forms the Phosphatidylinositol 3-kinase or PI3K protein. PI3K signalling has been 
implicated in the etiology of ASDs 28-43-44
235
(7) Genetic association between rs4731863, an intronic SNP in PLXNA4, and ASDs was reported 45.
(8) Genetic association between SNPs in GRIN2A  and autism was reported 46
(9) The expression of SEM A5A  was reported to be downregulated in people with autism 47.
(10) The G22A polymorphism in the AD A  gene was found to be associated with ASDs 48.
(11) SHH is involved in preventing the effects of in utero exposure to valproic acid (valproate) on the serotonergic neurons - and, linked to this, autism-like behaviour - of 
rats 49'50.
(12) Genetic association between SNPs in A2BP1 and autism was reported and the expression of A2BP1 was found to be decreased in the postmortem brain of autistic 
people 30
* *
Genetic position according to the Ensembl Human Genome Browser (http://www.ensembl.org/Homo_sapiens/).
***** 7111315 20 22 25 26 28Copy number variations (CNVs) that were either identified in people with ASDs through a genome-wide array-based hybridization approach ■ • • • • • •  and/or are
121416 19 23 24 27 29‘recurrent’ in that they were found in at least two unrelated people with ASDs . . . . .
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Supplementary Table 2. Twenty microRNAs that were repeatedly implicated in autism spectrum disorders (ASDs) with at least two studies reporting dysregulated
51 * 36 52 53expression of the encoding microRNA gene in postmortem cerebellar cortex tissue ~ or lymphoblastoid cells ~ of people with ASDs and/or the encoding microRNA 
gene being deleted and/or duplicated in copy number variations (CNVs) in people with ASDs 7-81111316-54-56
MicroRNA Expression in people with ASDs Tissue CNV Reference
MIR23A upregulated postmortem cerebellar cortex tissue - 51
upregulated lymphoblastoid cell line - 52
upregulated lymphoblastoid cell line - 53
MIR23B upregulated lymphoblastoid cell line - 52
upregulated lymphoblastoid cell line - 53
MIR93 downregulated and upregulated postmortem cerebellar cortex tissue - 51
upregulated lymphoblastoid cell line - 53
MIR106B downregulated postmortem cerebellar cortex tissue - 53
downregulated and upregulated lymphoblastoid cell line - 53
MIR128 upregulated postmortem cerebellar cortex tissue - 51
duplication 8
MIR132 upregulated postmortem cerebellar cortex tissue - 51
upregulated lymphoblastoid cell line - 52
downregulated lymphoblastoid cell line - 53
MIR146B downregulated postmortem cerebellar cortex tissue - 51
upregulated lymphoblastoid cell line - 52
MIR148B upregulated postmortem cerebellar cortex tissue - 51
upregulated lymphoblastoid cell line - 53
duplication 8
MIR185 upregulated lymphoblastoid cell line - 53
duplication 10
deletion 13
MIR193B downregulated postmortem cerebellar cortex tissue - 51
duplication 13
MIR199B downregulated and upregulated lymphoblastoid cell line - 36
downregulated lymphoblastoid cell line - 53
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Supplementary Table 2 - continued.
Micro RNA Expression in people with ASDs Tissue CNV Reference
MIR211 downregulated lymphoblastoid cell line - 53
deletion 54
duplication 55
duplication 56
MIR320 downregulated postmortem cerebellar cortex tissue - 51
downregulated lymphoblastoid cell line - 52
MIR455 downregulated and upregulated lymphoblastoid cell line - 36
downregulated lymphoblastoid cell line - 53
MIR484
upregulated postmortem cerebellar cortex tissue - 51
duplication 7
duplication 8
duplication 16
deletion 8
MIR486 differentially regulated in two independent ASD samples - 36
MIR500 upregulated lymphoblastoid cell line - 36
duplication 10
MIR502-3p upregulated lymphoblastoid cell line - 36
duplication 10
MIR577 downregulated and upregulated lymphoblastoid cell line - 36
duplication 8
MIR650 downregulated and upregulated lymphoblastoid cell line - 36
- - duplication 8
* * * ' * 78 1013Copy number variations (CNVs) that were either identified in people with ASDs through a genome-wide array-based hybridization approach ’ ’ ’ and/or are 
‘recurrent’ in that they were found in at least two unrelated people with ASDs 16-54-56
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Supplementary Table 3. Thirty-five additional candidate genes encoding proteins that could be directly placed in one or more of the three networks involved in ASDs 
(Figures 1-3). These genes were reported to be deleted (del) and/or duplicated (dup) in copy number variations (CNVs) in people with ASDs 7111315- 21.22.26.27.58.67,so,si 
downregulated by one or more microRNAs repeatedly implicated in ASDs (Supplementary Table 2) and/or implicated in ASDs through other evidence ( ‘classic’ 
candidate gene association and gene mutation studies, SNPs at P  < 1.00E-04 level from ASD GWAS 6 6, gene expression studies, animal studies, and pharmacological 
studies ).
Gene Locus CNV(s) Micro RNA(s) Other evidence
CACNA1C 12pl3.33 d e l10 MIR320, MIR455, MIR577 G406R missense mutation in GAGNA1 (', causes autism57
CD44 1 Ip 13 d e l58 MIR577
CD44 is involved cerebellar Purkinje cell loss yj: loss of 
cerebellar Purkinje cell function is involved in the 
etiology of autism 39 41
CDC42 lp36.12 MIR185
CDC42 mediates dendritic outgrowth and branch 
formation of cerebellar Purkinje cells 6"; loss of 
cerebellar Purkinje cell function is involved in the 
etiology of autism 39 41
CNTNAP2 7q35-7q36.1 d e l1-9' 13, dup 8 MIR211 genetic association with ASDs 61,62
CYP19A1 15q21.2
00
genetic association with ASDs 63; male C ypl9al 
knockout mice display severe deficits in social 
recognition and memory that resemble symptoms of 
ASDs 6 L 65; the expression of CYP19A1 is decresed in 
the brain of people with autism 66
ERK1 16pll.2
del
dup sa i3- is. 21.67 MIR132, MIR486
ESR1 6q25.1 - MIR146B, MIR148B, MIR211 genetic association with ASDs 63
ESR2 14q23.2 - MIR199B genetic association with ASDs 63
GATA1 Xp 11.23 d e l1, dup 111
GATA4 8p23.1 MIR577
rs2029969, an intronic SNP in G ATA4 , showed a 
/ -8.58E-05 for association with ASD in the GWAS by 
Anney et al. (GWAS 6) 6
GRIA1 5q33.2 MIR128
GRIA1 shows abnormal expression levels in postmortem 
brains of autistic people 68
GRIK2 6ql6.3 MIR455
genetic linkage and association of GRIK2 with autism
69,70
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Gene Locus CNV(s) Micro RNA(s) O ther evidence
GSK3B 3ql3 .33 - MIR199B Gsk3b is involved in ASD-like beliaviour in mice 71,72
HGF 7q21.11 MIR23A, MIR23B, MIR 132. MIR199B
decreased serum HGF levels were found in children and 
adults with autism 73,74
JARID 1C Xp 11.22 d e l7 MIR185, MIR193B mutation in JARID1C  causes ASDs 75
KCNMA1 10q22.3 dup9 MIR132, MIR211, MIR484 genetic association with autism 76
M ET 7q31.2 d e l10 MIR128, MIR148B
genetic association with ASDs : decreased M ET  
expression was found in postmortem brain of autistic 
people 78
NMDAR1 9q34.3 dup 13
mice with reduced expression of Nm darl display autism­
like beliaviour79
N Q 02 6p25.2 dup 13
rs2071004, an intronic SNP in NQ 02, showed a 
/-2.00E-15 for association with ASD in GWAS 6 6
NRXN1 2pl6.3
^  j  8-11,13,5180,81 
dup89
NTRK1 lq23.1
00
genetic association with autism 63
PARK2 6q26 d e l8-9 1 3  22, dup 8 9
MIR93, MIR106B, MIR146B. MIR199B. 
MIR211, MIR3 20
rs9365410, an intronic SNP in PARK2, showed a 
/ -4.34E-05 for association with ASD in GWAS 6 6
PLXNB3 Xq28 d e l1, dup 713 - -
PTEN 10q23.31
MIR23A, MIR23B, MIR93. MIR106B, 
MIR148B, MIR320, MIR486. MIR577
Pten regulates social interaction in mice 1 and mutations 
in PTEN  cause autism 82
RHOA 3p21.31 MIR577
RHOA is involved in modulating the effects of 
Risperidone treatment for autistic symptoms 83
RO BO l 3pl2.3-3pl2.2 1 O MIR146B, MIR148B
rsl3087498, an intronic SNP in ROBOl, showed a 
/-4 .0 1 E-05 for association with ASD in people who are 
‘verbal’- i.e. they have developed speech -  from GWAS 
6 6 ; RO BO l expression is reduced in lymphocytes of 
autistic patients 84
RORA 15q22.2
Rora knockout mice display autistic features 8~; the 
expression of RORA is decreased in the postmortem 
brain of autistic people 86
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Gene Locus CNV(s) Micro RNA(s) O ther evidence
SCN2A 2q24.3
MIR23A, MIR23B, MIR106B, MIR132, 
MIR500, MIR502-3p genetic association with autism 45,87
SEMA3A 7q21.11 MIR199B, MIR320, MIR486
SEMA3 A is involved in cerebellar Purkinje cell function 
and loss 88,89 ; loss of cerebellar Purkinje cell function is 
involved in the etiology of autism 39 41
SLC1A2 1 Ip 13 d e l58 MIR93, MIR106B, MIR132, MIR455
SLC1A3 5pl3.2 MIR23A, MIR23B, MIR455
Slclri'Sknockout mice have social withdrawal symptoms 
90; SLC1A3 expression is increased in postmortem brain 
of individuals with autism 68
STAR 8pll.23 f 00
MIR93, MIR106B, MIR132, MIR146B, 
MIR148B, MIR199B, MIR484
STAT3 17q21.2 MIR93, MIR106B, MIR650
STAT3 signalling is implicated in the etiology of autism
91
STX1A 7qll.23 d e l7 26, d up715-27 MIR128 • i • 92 93genetic association with autism ’
WNT2 7q31.2 d e l10 MIR199B . , . 94genetic association with autism
Abbreviations: ASD(s), autism spectrum disorder(s); GWAS, genome-wide association study; GWASs, genome-wide association studies, SNP(s), single nucleotide 
polymorphism(s)
* * * * * * 7111315 21 22Copy number variations (CNVs) that were either identified in people with ASDs through a genome-wide array-based hybridization approach • • • - — and/or are
26 27 67 80 81‘recurrent’ in that they were found in at least two unrelated people with ASDs ~ ~ ’
* * ,
According to the Targetscan prediction tool (http://www.targetscan.org/), the expression of the gene is downregulated by one or more microRNAs that have been
repeatedly implicated in ASDs (Supplementary table 2)
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Supplementary Table 4. Overview of the genetic and other evidence implicating 10 genes encoding AKAPs (A-kinase anchor proteins) in the etiology of ASDs.
Locus Gene GWAS CNV(s) Micro RNA(s) Other evidence
2q34 MAP2
rs6742553, a SNP 91 kb downstream of MAP2, 
showed a / -4.55E-05 for association with 
autism in people of Western European ancestry 
from the GWAS by Amiey et al. 6 d e l7
decreased MAP2 expression was found in the 
postmortem brain of autistic people 95
6q23.2 AKAP7
rs2181572, a SNP 62 kb downstream of AKAP7, 
showed a P= 2.77E-05 for association with ASD 
in the GWAS by Wang et al. 1
AKAP7 is differentially expressed in 
lymphoblastoid cell lines of people with ASDs 36
7q21.2 AKAP9 d e l10
D7S1813, a genetic marker showing genetic 
linkage with autism (MLS=2.2) 96, is located in an 
LD block containing the AKAP9 gene 
(http ://www.broad. mit.edu/ mpg/haploview/); 
AKAP9 is involved in cerebellar Purkinje cell 
function 97 and loss of cerebellar Purkinje cell 
function is involved in the etiology of autism 39 41
13ql3.3 NBEA
rsl461965, an intronic SNP in NBEA, showed a 
/ -8.37E-05 for association with autism in the 
GWAS by Amiey et al.6 d e l98
MIRN93,
MIRN106B, MIR211
NBEA was disrupted by a chromosomal 
translocation in a male with autism {NBEA) 99
13ql4 .11 AKAP11
rs912099, a SNP 12 kb upstream of AKAP11, 
showed a / - 1.15E-06 for association with ASD 
in people who are ‘verbal’ - i.e. they have 
developed speech - from the GWAS by Anney 
et al. 6 MIRN93, MIR106B
Exposure to low levels of polychlorinated 
biphenyls (PCBs) leads to a decreased 
expression of A kapl 1 in the cerebellum of rats 37 
and the inhibition of cerebellar Purkinje cell 
development38; loss of cerebellar Purkinje cell 
function is involved in the etiology of autism39-41, 
and perinatal exposure to PCBs leads to autism-like 
behaviour in rats 42.
14q23.3 AKAP5
rsl7824591, a SNP 44 kb upstream of AKAP5, 
showed a / -8.05E-04 for association with ASD 
in people who are ‘verbal’ from the GWAS by 
Amiey et al. 6 MIRN106B
AKAP5 is involved in melatonin synthesis 1"", 
which is markedly disturbed in people with ASDs 
1111 ; AKAP5 is involved in cerebellar Purkinje cell
102 103function and loss and loss of cerebellar 
Purkinje cell function is involved in the etiology of 
autism 39 41
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Supplementary Table 4 - continued.
Locus Gene GWAS CNV(s) Micro RNA(s) O ther evidence
15q25.3 AKAP13
Four intronic SNPs in AKAP13 were associated 
with autism at P  < 1.00E-03 in the GWAS by 
Amiey et al. 6
00f MIRN93,
MIRN106B, MIR577
AKAP13 is involved in innate inununity, a process 
that is disturbed in a subset of people with ASDs 
31’32, through regulating Toll-like Receptor 2 
(TLR2) activity 104
17pll.2 AKAP10
d e l7, dup
13,14
AKAP10 is involved in innate inununity, a process 
that is disturbed in a subset of people with ASDs 
31’32, through regulating Toll-like Receptor 4 
(TLR4) activity 104
19pl3.12 AKAP8
rsl0405035, a SNP 16 kb downstream of 
AKAP8, showed a / -9.26E-04 for association 
with ASD in people who are ‘verbal’ from the 
GWAS by Amiey et al. 6 dup 15
MIR146B,MIR148B, 
MIR199B, MIR211
AKAP8 is involved in melatonin synthesis 1111’,
which is markedly disturbed in people with ASDs
101
Xql2 M SN
rs5918959, a SNP 66 kb downstream of MSN, 
showed a / - 1.22E-10 for association with ASD 
in the GWAS by Wang et al. 1
The expression of M SN  was found to be 
upregulated in the postmortem brain of autistic 
people 3"; MSN is also involved in innate 
inununity, a process that is disturbed in a subset of 
people with ASDs 3132, through regulating TLR4 
activity 33
Abbreviations: ASD(s), autism spectrum disorder(s); GWAS, genome-wide association study; LD, linkage disequilibrium; MLS, multipoint lod score; SNP, single 
nucleotide polymorphism
* * * * * * 78101315Copy number variations (CNVs) that were either identified in people with ASDs through a genome-wide array-based hybridization approach ’ ’ ’ or and/or are 
‘recurrent’ in that they were found in at least two unrelated people with ASDs IL9X. AKAP10 is located within the ‘common’ chromosomal region of 17pl 1.2 that is 
typically duplicated in Potocki-Lupski syndrome 14, which in approximately 90 % of the cases is accompanied by (features of) an ASD 14.
* * ,
According to the Targetscan prediction tool (http://www.targetscan.org/), the expression of the gene is downregulated by one or more microRNAs that have been
repeatedly implicated in ASDs (Supplementary table 2).
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Supplementary Table 5. Fifteen genes that were implicated through SNPs associated with ASDs at P <  1.00E-04 in two of the six published GWASs of ASDs 16. The 
genes encoding proteins that could be directly placed in one or more of the three networks involved in ASDs (Figures 1-3) are indicated in bold.
Gene Locus SNP
*
Position ~ gene P  value Phenotype GWAS
ABCC1 16p13.11 rsl2924488 18 kb upstream 5.26E-05 ASD GWAS 1 (Wang et al. ) 1
ABCC1 16p13.11 rs4148358 intronic 8.50E-05 Autism GWAS 2 (Ma et al.) 2
CTNNA3 10q21.3 rsl0997574 intronic 1.23E-05 ASD GWAS 1 (Wang et al. ) 1
CTNNA3 10q21.3 rs7923367 intronic 6.81E-06 ASD GWAS 3 (Weiss et al. ) 3
F H IT 3pl4.2 rsl0510837 intronic 3.56E-06 ASP GWAS 4 (Salyakina et al.) 4
F H IT 3pl4.2 rs2361333 intronic 5.54E-06 ASD GWAS 6 (Anney et al.) 6
F R K 6q22.1 rsl999930 5 kb upstream 7.57E-05 ASD GWAS 1 (Wang et al. ) 1
F R K 6q22.1 rsl95495 76 kb downstream 2.95E-05 Autism GWAS 6 (Anney et al.) 6
GALNT13 2q24.1 rsl3032106 intronic 3.49E-05 ASD GWAS 1 (Wang et al. ) 1
GALNT13 2q24.1 rs6750412 13 kb downstream 8.38E-05 ASD GWAS 6 (Anney et al.) 6
LRP1B 2q22.2 rsl529869 intronic 5.37E-05 ASD GWAS 1 (Wang et al. ) 1
LRP1B 2q22.1 rs2052910 intronic 5.39E-05 Autism GWAS 6 (Anney et al.) 6
NEDD4L 18q21.31 rs4058287 intronic 1.05E-05 ASD GWAS 1 (Wang et al. ) 1
NEDD4L 18q21.31 rs9953923 92 kb downstream 4.11E-05 ASD GWAS 6 (Anney et al.) 6
NPAS3 14ql3.1 rsl279313 intronic 4.15E-05 ASD GWAS 1 (Wang et al. ) 1
NPAS3 14ql3.1 rsl303473 intronic 2.81E-05 Autism GWAS 6 (Anney et al.) 6
N T M llq25 rsl550976 intronic 2.30E-06 ASP GWAS 4 (Salyakina et al.) 4
N T M llq25 rsl0894473 intronic 2.96E-05 Autism GWAS 6 (Anney et al.) 6
NXNL2 9q22.1 rs4877464 39 kb downstream 3.62E-05 ASD GWAS 1 (Wang et al. ) 1
NXNL2 9q22.1 rs4242610 40 kb downstream 4.36E-05 ASD GWAS 6 (Anney et al.) 6
SETD 7 4q31.1 LD block - 9.09E-05 Autism GWAS 5 (Hussman et al. ) 5
SETD 7 4q31.1 rs4863655 3'UTR 8.72E-05 Autism GWAS 6 (Anney et al.) 6
SFXN1 5q35.2 rs6556217 73 kb downstream 4.52E-05 ASD GWAS 1 (Wang et al. ) 1
SFXN1 5q35.2 rs267381 intronic 6.00E-05 Autism GWAS 6 (Anney et al.) 6
SP110 2q37.1 rs6436915 intronic 1.67E-05 Autism GWAS 2 (Ma et al.) 2
SP110 2q37.1 rs3 769847 59 kb upstream 1.77E-05 ASD GWAS 6 (Anney et al.) 6
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Supplementary Table 5 - continued.
Gene Locus SNP
*
Position ~ gene P  value Phenotype GWAS
ST8SIA 2 15q26.1 rsl6946714 79 kb upstream 3.29E-05 ASD GWAS 1 (Wang et al. ) 1
ST8SIA 2 15q26.1 rs3784730 intronic 5.38E-06 ASD GWAS 6 (Anney et al.) 6
U SP9X X pll.4 rs7060889 57 kb upstream 5.29E-05 ASD GWAS 1 (Wang et al. ) 1
U SP9X X pll.4 rs7060889 57 kb upstream 4.24E-05 ASD GWAS 6 (Anney et al.) 6
Abbreviations: ASD(s), autism spectrum disorder(s); ASP, Asperger’s syndrome; GWAS, genome-wide association study; GWASs, genome-wide association studies; 
SNP, single nucleotide polymorphism; UTR, untranslated region
Genetic position according to the Ensembl Human Genome Browser (http://www.ensembl.org/Homo_sapiens/); same SNP
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Description of protein networks in Figures 1-3
In the description of the three protein networks regulating steroidogenesis, neurite 
outgrowth and synaptic function in Figures 1, 2 and 3, all ASD candidate genes/proteins 
that were implicated through GWASs 1-5 (Supplementary Table 1) - which are indicated 
in yellow in the figures - and the other candidate genes/proteins (Supplementary Tables 3 
and 4) - which are indicated in orange in the figures - are indicated in bold. Moreover, the 
10 (genes encoding) AKAPs (A-kinase anchor proteins) (Supplementary Table 4) are 
underlined.
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Description of protein network in Figure 1 :
When histamine molecules bind to the histamine h2 receptor (HRH2), a signalling 
cascade is initiated that stimulates steroidogenesis in Leydig cells through the activation of 
adenylate cyclase (ADCY) 106. ADCY produces cyclic AMP (cAMP) 107 which 
subsequently activates protein kinase A (PKA) 107 PKA is recruited and bound by 
cytoplasmic AKAP10, AKAP11, AKAP13 or NBEA - all expressed in Leydig cells 
(http://biogps.gnf.org/) - to regulate the activity of the L-type calcium channel CACNA1C 
108. This channel is highly expressed in Leydig cells and transports calcium ions into these 
cells 109. An increased intracellular concentration of calcium is necessary for 
downregulating the expression of the mitochondrial steroidogenic acute regulatory protein 
(STAR) 109, which plays a key role in steroid hormone synthesis by enhancing the 
transformation of cholesterol into pregnenolone 110. In addition, PKA bound to AKAP10 - 
which is also found in the mitochondria 108 - can positively regulate STAR activity 111. 
TBXAS1, a cell membrane protein, downregulates the expression of STAR and hence 
inhibits steroidogenesis in Leydig cells 112 (not shown). The transport of cholesterol 
molecules into the mitochondria of Leydig cells is facilitated by vimentin (VIM) 113, a 
protein that itself is activated/phosphorylated by the STK33 kinase 114
The produced pregnenolone is subsequently transported from the mitochondria into the 
smooth endoplasmic reticulum (SER), where it undergoes a series of metabolic reactions, 
resulting in the production of testosterone 115. Testosterone is then either further 
transformed into estradiol by the CYP19A1 (or aromatase) enzyme - which is found in the 
(membrane) of the SER 108 - or diffuses to the cytoplasm 115. From there, testosterone is 
secreted into the extracellular compartment and further transported in the blood circulation 
and across the blood brain barrier by passive diffusion as ‘free’ testosterone or through 
binding to several proteins, including sex hormone-binding globuline (SHBG) and 
albumin 108, 116-118 (not shown). The secretion of testosterone by Leydig cells is stimulated 
by an increased intracellular calcium concentration - which could be e.g. achieved by 
CACNA1C activity (see above) 119 - and downstream of a cascade that involves the M ET 
membrane receptor. M ET is activated by its ligand, hepatocyte growth factor (HGF) 108,
which itself is activated by extracellular hepatocyte growth factor activator (HGFA)
108, 120 proteins .
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Like testosterone, the produced estradiol diffuses from the SER to the cytoplasm, where it 
can be degraded to toxic metabolites, such as estrogen quinones (EQ) and estradiol
glucuronides (EG) 108, 121, 122. The NQO2 reductase enzyme is involved in the 
detoxification and hence degradation of EQ 121, whilst ABCC1 is a testis-expressed
membrane protein that transports EG out of the cell, and is in this way involved in the
108,122detoxification of these estradiol metabolites , . One of the effects of EG is the 
inhibition of the activity of SLCO1C1, which transports the thyroid hormones T4 (full 
name: thyroxine) and - to a lesser extent - T3 (full name: triiodothyronine) into Leydig
108,123cells , . T4 is further metabolised into the more active T3 by the membrane-located 
DIO2 enzyme 108. T3 is involved in upregulating the expression of STAR 124 (see above).
The cell nucleus is an important compartment in the steroidogenesis network, as the 
expression of many network proteins is regulated from here. Dachshund homolog 2 
(DACH2) is a transcription factor that downregulates the expression of CDKN1B 125, a 
cytoplasmic protein that is involved in steroidogenesis by upregulating the expression of 
STAR 126. Conversely, HDAC2 belongs to a repressive transcription factor complex 108 
that downregulates the expression of STAR 127 The RORA transcription factor 
upregulates the expression of CYP19A1 128, and GATA4 is involved in activating the 
transcription of both STAR and CYP19A1 129. In turn, the transcriptional activity of 
GATA4 is repressed by the DNA-binding protein JARID2 130 and positively regulated by 
PKA 131 bound/anchored to nuclear AKAP8 108 . In addition, AKAP8 directly binds
132 133nuclear CASP3 , which in turn degrades GATA1 , a transcription factor involved in 
regulating streoidogenesis in Leydig cells 134 THOC1, a component of the nuclear TREX 
complex, upregulates the expression of GATA1 135.
Lastly, although as yet, they cannot be directly linked to the above described network, 
RHOXF1, RHOXF2 108, 136, MAMLD1 and MAML2 137 are all nuclear 
proteins/transcription factors that are expressed in Leydig cells and are involved in 
steroidogenesis.
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Description of protein network in Figure 2a :
Signalling through the network can be initiated at the neuronal cell membrane where the 
binding of ligands from the extracellular matrix/compartment to their respective receptors 
leads to the modulation of several downstream molecular cascades in the cytoplasm and 
nucleus that are involved in neurite outgrowth:
An important signalling cascade in the network is involved in regulating the activity of 
CDC42, a GTP-hydrolyzing (GTPase) protein that is an important mediator of directed
138,139neurite outgrowth , . Activated CDC42 regulates a number of downstream effectors to 
facilitate neurite outgrowth, such as the cytoplasmic extracellular signal related kinase 
(ERK)1 140, which in turn phosphorylates/activates a number of cytoskeleton-associated 
proteins in the neuronal growth cone (see Figure 2b). Netrin axonal guidance ‘cues’ bind 
to the netrin receptor DCC which activates CDC42 and (eventually) results in neurite 
attraction towards the netrin guidance cues 141. In this respect, sonic hedgehog (SHH) 
molecules act as guidance cues that can mimic and supplement the chemoattractive effect 
of netrin on axons/neurites 142 . In addition, GDNF binding to the GFRA1 receptor 
activates CDC42 143, as does the membrane-located RHOG 144, which itself is activated by 
SGEF 108. NGF binding to NTRK1 activates the regulatory kinase PI3K  108,145, which in 
turn activates CDC42 146 as well as MSN 147,148. PI3K  is also activated downstream of 
FGF1 binding to the FGFR1 membrane receptor 149,150 (not shown) and inhibited by 
PTEN 151, a protein that is regulated/activated by the MAST3 152 and FR K  153 kinases and 
degraded by cytoplasmic caspase-3 (CASP3) 154, which also degrades CDC42 itself 155. 
NTRK1 can also be bound by the peripheral membrane adaptor protein SH2B1, which 
acts as an enhancer/positive regulator of NGF-induced 156 and also FGFl-induced 157 
neurite outgrowth. NEDD4L, a cytoplasmic E3 ubiquitin-protein ligase, binds and 
degrades NTRK1 158. Adenosine deaminase (ADA) catalyzes the hydrolysis of adenosine 
to inosine and is located in the cell membrane 108. ADA binding ADORA1 promotes its 
activation by enhancing the binding of adenosine to this receptor 159. Activation of 
ADORA1 triggers a signalling cascade that leads to the inhibition of NGF-induced neurite 
outgrowth 160,161. When the SLIT guidance cues bind the ROBO1 receptor, the peripheral
membrane proteins SRGAP1 and SRGAP3 associate with ROBO1 and inhibit CDC42
108, 162
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SLITRK5 is a neuronal membrane protein that is involved in suppressing neurite 
outgrowth 108 and may also feed into the network because it shows a very high homology 
to the SLIT proteins 163 that bind ROBO1 108, 164
Another important upstream regulator of CDC42 is protein kinase A (PKA), which itself 
has been repeatedly linked to regulating neurite outgrowth 165-167 PKA can be recruited by 
and bound to cytoplasmic AKAP7, AKAP10, AKAP11, AKAP13 or MSN 108,168, 
subsequently activating CDC42 169. MSN is positively regulated/activated by RHOA 170 
which, like CDC42, is a GTP-hydrolyzing (GTPase) protein and a mediator of neurite 
outgrowth 171,172. RHOA itself can be activated by AKAP13 104,108 as well as 
ARHGEF11 108 and is inhibited by ARHGAP36 108.
A second important signalling pathway in the network leading to neurite outgrowth is 
CDC42-independent and centers around catenin beta (CTNNB). The N(euronal)-cadherin 
CDH2, which is anchored in the neuronal cell membrane and the neuronal cytoskeleton, 
binds to a complex consisting of CTNNB and catenin alpha 2 (CTNNA2) or catenin alpha 
3 (CTNNA3) 108, 173-175. CDH2 is functionally modulated by and stably associated with 
cell surface N-acetylgalactosaminyltransferases such as GALNT13 and GALNTL4 108,176. 
In addition to inhibiting CDC42 (see above), SLIT binding to ROBO1 can inactivate 
CDH2, which leads to the dissolution of the CDH2-CTNNB-CTNNA2/3 complex and the 
CTNNB protein being released and targeted to the nucleus, where it functions as a 
transcription factor 173 (see below). Similar to CDH2, the neuronal cadherin CDH22 - 
which is mainly expressed in developing brain regions 177 - is anchored in the cell
108 173 175membrane and cytoskeleton and forms the same this complex . The nuclear
translocation and hence transcriptional activity of CTNNB can be inhibited by the 
cytoplasmic FH IT protein 178. APCDD1 is a membrane protein that functions upstream of 
CTNNB and that is involved in neurogenesis during brain development by inhibiting
179 180WNT3A (not shown), which itself regulates neurite outgrowth . Another membrane 
protein functioning upstream of CTNNB is LRP1B, a receptor that forms a complex with 
and inhibits the degradation of APP 181, a neuronal membrane protein that modulates the 
degradation of cytoplasmic CTNNB 182 and plays an important role in both the etiology of 
Alzheimer's disease 181 and that is involved in neurite outgrowth 183. The cytoplasmic 
DAB1 184 and the membrane protein COLEC12 (collectin-12) 185 bind APP and modulate 
its degradation and clearance. APP is also degraded by cytoplasmic CASP3 186 and it 
regulates the expression of N EN F  187, which encodes neudesin, a secreted neurotrophic
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factor that is involved in the differentiation and growth of developing neurons through 
ERK1-, PKA- and PI3K-dependent signaling 108, 188 (not shown). Furthermore, CUL1 189 
and CASP3 190 enhance the ubiquination/degradation of cytoplasmic CTNNB, whilst 
USP9X inhibits this process 191. Hyperphosphorylation and subsequent degradation of 
CTNNB can be achieved by the kinase GSK3B 192, which itself can be inhibited by 
ZBED3 193. Moreover, GSK3B can bind to AKAP11 together with PKA, after which the 
bound PKA inhibits GSK3B activity 194 After having been activated and having 
translocated to the nucleus (see above), CTNNB upregulates the expression of several 
genes from the three networks (not shown), i.e. GATA1 195 (Figure 1), EPN 2  195, 
NEDD4L  196 and OTX2 197 (this figure), PTPRN2 (Figure 3) 195 and RHOA  195 (this 
figure, Figure 2b and Figure 3). The nuclear proteins/transcription factors FLI1 198 and 
RORA 199 negatively regulate the transcription factor function of CTNNB, whilst 
C lO O R F ll enhances this function 200. In addition, PKA bound/anchored to nuclear 
AKAP8 108 enhances the transcription factor function of CTNNB 201. Furthermore, OTX2, 
a neuronal transcription factor involved in early brain development 202 and a direct
203 108interactor of M EIS2 , another neuronal transcription factor , contributes to CTNNB 
regulation by upregulating the expression of the transcription factor SIX3 204 In turn, 
SIX3 is a negative regulator of the expression of WNT1 205, which itself activates the 
transcription factor function of CTNNB 206. The related WNT2 also activates CTNNB 207 
Lastly, the expression of CTNNB is upregulated by STAT3 208, a transcription factor that 
plays a role in neurite outgrowth 157 after having been activated downstream of PTEN 
activity 209 and having translocated from the cytoplasm to the nucleus, a process that is 
enhanced by the cytoplasmic EPN2 108, 210,211.
A third major signalling cascade in the network centers around the estradiol-activated 
ESR1 and ESR2 receptors and indirectly feeds into the above described CDC42- and 
CTNNB-dependent signalling cascades.
As shown in Figure 1, testosterone is produced in Leydig cells and then transported via the 
blood circulation, across the blood brain barrier and into developing neurons by passive 
diffusion as ‘free’ testosterone or through binding to several proteins, including sex 
hormone-binding globuline (SHBG) and albumin 108, 116-118 (not shown). Subsequently, the 
testosterone produced in the testis is further transformed to estradiol by the CYP19A1 (or 
aromatase) enzyme, which is found in the (membrane) of the smooth endoplasmic 
reticulum (SER) 108.
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In addition, a variable amount of testosterone can be produced and converted to estradiol
212 213in developing cerebellar Purkinje neurons and the adult cerebral cortex . SLC10A3
108 214is a membrane-located bile acid transporter that is highly expressed in the brain ’ , and 
bile acid - that is present in its bioactive state in brain cells 215 - is involved in 
downregulating the expression of CYP19A1 216, 217 (not shown). Furthermore, the RORA 
66,128 and GATA4 129 transcription factors upregulate the expression of brain CYP19A1. 
GATA4 also upregulates the expression of CTNNA3 218 (not shown). The transcriptional 
activity of GATA4 is repressed by the DNA-binding protein JARID2 130 and its 
expression is negatively regulated by the transcription factor NANOG 219. The expression 
of NANOG  is upregulated by SOX2 220, another transcription factor that can also be 
placed in the neurite outgrowth network because it regulates the expression of CDH2 221 
(not shown). Estradiol produced in the SER diffuses to the cytoplasm, where it can either 
bind and activate the ESR1 and ESR2 receptors 108, which are found in both the 
cytoplasm and nucleus 108 (see below), or be degraded to toxic metabolites, such as 
estrogen quinones (EQ) and estradiol glucuronides (EG) 108,121,122. The NQO2 reductase 
enzyme is involved in the detoxification degradation of EQ by degradation 121, whilst
ABCC1 is a brain-expressed membrane protein that transports EG out of the cell, and is in
108,122this way involved in the detoxification of estradiol metabolites , . One of the effects of 
intracellular EG is the inhibition of the activity of SLCO1C1, which transports the thyroid 
hormones T4 (full name: thyroxine) and - to a lesser extent - T3 (full name:
108, 123triiodothyronine) into neurons , . T4 is further metabolised into the more active T3 by 
the membrane-located DIO2 enzyme 108. T3 is involved in upregulating the expression of 
ESR1 and ESR2 222,223. Cytoplasmic ESR1 and ESR2 bound/activated by estradiol are 
functionally linked to the above described CDC42-dependent cascade through being 
regulated by AKAP13 224,225 and activating both RHOA 170 and ERK1 226. In the nucleus, 
ESR1/2 activated/bound by estradiol function as transcription factors that feed into both 
the CDC42- and CTNNB-dependent signalling cascades by upregulating the expression 
of GDNF  227 (not shown) and WNT2 228, and downregulating the expression of the AKAP  
genes M SN  229 and AKAP11 230. Alpha-actinin-2 (ACTN2) and SETD7 are nuclear 
proteins that act as coactivators of ESR1 231,232 and/or ESR2 231 whilst HDAC2, a 
repressive transcription factor that negatively regulates neurite outgrowth 233, directly 
inhibits ESR1 234.
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Apart from the three major signalling ‘hubs’ that are dependent on the 
activation/regulation of CDC42, CTNNB, and ESR1/ESR2, additional signalling 
cascades leading to neurite outgrowth are present in the network. First, SCN2A is a 
neuronal cell membrane protein and a member of a protein family of voltage-gated sodium 
channels that are involved in neurite outgrowth 235. The expression of SCN2A  is 
downregulated by the transcription factor JARID1C 236 (not shown) and SCN2A is 
specifically activated by PKA associated with/bound by membrane-located AKAP7 108, 
237 SCN2A is also specifically degraded by NEDD4L 108. NEDD4L itself interacts with 
and is activated by NDFIP1 108, which binds to and controls the ubiquitination and 
abundance of PTEN 238. NDRG1, a cytoplasmic protein that is highly expressed in 
cerebellar Purkinje cells 239, can be upregulated by PTEN 240 (not shown) whilst NDRG1 
itself downregulates the expression of A TF3  241 (not shown), encoding a transcription 
factor that promotes neurite outgrowth 242. NDRG1 is also involved in activating 
cytoplasmic CASP3 243 (not shown). AKAP8 also directly binds nuclear CASP3 132, which 
in turn degrades ETS1 244, a transcription factor that can be placed in the identified neurite 
outgrowth network because it enhances the transcription of SLIT3 245, a ligand of the 
ROBO1 axonal guidance receptor 246 (see above). ETS1 also regulates the expression of 
BCL11A  247, which codes for another transcription factor that is involved in neurite 
outgrowth through regulating the expression of D C C  248 (not shown).
Lastly, although as yet, they cannot be directly linked to the above described network, 
several other proteins can be placed in the network. First, ST8SIA2 is a neuronal 
membrane protein that polysialylates the neural cell adhesion molecule (NCAM) 249 and in 
this way supports neurite outgrowth 250. LRRTM 4 is membrane protein that plays a role 
in neuronal development 251. LRRTM 4  is also downregulated by the REST transcription
252 253factor complex that contains CDYL and that is involved in regulating neurite
254 255,256outgrowth . In addition, the membrane proteins neurotrimin (NTM) , and DNER
257, the cytoplasmic proteins CDC37 258 and GDAP1 259, and the nuclear
proteins/transcription factors FEZF2 108, 260 and NPAS3 108, 261 are all involved in neurite
outgrowth.
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Description of protein network in Figure 2b :
Signalling through the network in the growth cone of developing neurons is initiated at the 
neuronal cell membrane by SEMA3A guidance cues binding to the membrane-located 
PLXNA4 108. This leads to the inhibition of PI3K  147, a kinase that activates CDC42 146, a
138,139central mediator of directed neurite outgrowth , (as described in Figure 2a), either 
directly or by activating Moesin (MSN) 145,146 and recruitment of PKA 166,167 MSN can be 
regulated in several additional ways in the neuronal growth cone. First, it can be activated 
by LRRK2 262, a cytoplasmic kinase that interacts with the PARK2 kinase 108, which itself 
is bound and modulated by BAG5 108. Through binding and activating its receptor, 
PLXNB1, the membrane protein and guidance cue SEMA4D also mediates activation of
RHOA 108,263, which activates MSN 170 and is a mediator of neurite outgrowth 171,172. 
MSN is also activated by a signalling cascade downstream of SEMA5A and HGF 
(hepatocyte growth factor): the membrane protein and guidance cue SEMA5A binds 
PLXNB3, which interacts with the M ET membrane receptor 264. M ET, activated by 
HGFA-activated HGF 108, binds and modulates CD44, a membrane protein that links the 
SEMA5A-PLXNB3-MET-complex to the cytoskeleton by activating and binding 
cytoskeleton-associated MSN 264,265.
After being activated (see above and description of protein network in Figure 2a), CDC42 
activates ERK1 140, a kinase that in turn phosphorylates/activates microtubule-associated 
protein 2 (MAP2) 108, a cytoskeleton-associated AKAP 108, as well as NEF3 266 and 
MARCKS 267, two other proteins that are involved in neurite outgrowth through binding 
and modulating the neuronal cytoskeleton 108,268. BICD1 and BICDR1 (encoded by the 
CCDC64 gene) are proteins that bind and modulate DYNLT1 269,270, which itself is a key 
component of the cytoplasmic dynein complex that is involved in neurite outgrowth by
271,272regulating the actin cytoskeleton , . Kinesin light chain KLC1 (kinesin light chain 1) 
273, TYK2 108 and GAS2 108 are three other proteins that directly associate with and 
modulate the neuronal cytoskeleton in order to facilitate neurite outgrowth.
Furthermore, PKA associated with MAP2 and MSN binds and regulates the activity of the 
cytoskeleton-associated dystrobrevin beta (DTNB) 274. Together with the dystrophin 
(DMD), delta-sarcoglycan (SGCD) and zeta-sarcoglycan (SGCZ) proteins, DTNB forms 
a part of the dystrophin-associated protein complex 108, which is involved in neurite 
outgrowth by directly linking signalling cascades in the cytoplasm of the growth cone to
275, 276modulation of both the neuronal cytoskeleton and extracellular matrix , .
254
Modulating the neuronal extracelllar matrix is necessary for the neuron to grow in a 
certain direction 277 . In this respect, the brain-expressed metalloproteinases ADAMTS3
108,278and ADAMTS5 degrade the neuronal extracellular matrix . Moreover, lumican 
(LUM) proteins are secreted into the extracellular matrix and bind (and modulate the
108 279,280function of) laminin molecules that have an important role in neurite outgrowth , . 
Lastly, although they cannot be directly linked to the above described network, the 
THBS4 extracellular matrix proteins are also involved in regulating neurite outgrowth 281.
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Description of protein network in Figure 3 :
This network contains both presynaptic and postsynaptic components.
In the presynaptic terminal, SYT17, a neuronal membrane protein and member of the 
synaptotagmin protein family that is involved in the exocytosis of presynaptic vesicles
282 283filled with neurotransmitters such as glutamate ’ , is phosphorylated/activated by PKA 
284, which itself can be bound and recruited by cytoplasmic and membrane-associated 
AKAP7 108. CACNA1A, a member of the L-type calcium channel family, transports
285 286calcium ions into the presynaptic cytoplasm upon activation of the neuron , . Calcium 
influx activates KCNMA1 108, a potassium channel regulated by the cytoplasmic 
cerebelon (CRBN) protein 287, and CADPS, a protein that is associated with presynaptic 
vesicles 108. Both KCNMA1 and CADPS are involved in presynaptic vesicle exocytosis
288 291
- . Other proteins that have a role in this process are STX1A and SV2C, which are 
both associated with presynaptic vesicles 108, 292,293. STX1A also inhibits KCNB1, a 
potassium channel located in the presynaptic membrane 108, 294, which can also be 
inhibited by cytoplasmic protein tyrosine phosphatase epsilon (PTPRE) 295. In addition, 
STX1A interacts with and regulates the activity of KCNA1 296, a presynaptic potassium 
channel that - like KCNMA1 - is involved in the presynaptic release of glutamate-filled 
vesicles 297 KCNA1 function can also be modulated by direct binding of CNTNAP2, a 
synaptic membrane protein of the neurexin family 298. Synaptic vesicular trafficking is 
also regulated by another member of the neurexin family, the presynaptic membrane 
protein neurexin 1 (NRXN1), which is bound to the peripheral membrane protein 
synaptotagmin-like protein 3 (SYTL3) 299. PTPRN2, and RIMS1 and RIM S2 are three 
other presynaptic membrane proteins that regulate presynaptic vesicle endo- and
. • . - i  108, 300, 301exocytosis respectively .
Neurotransmitters - especially glutamate - are then released into the synaptic cleft that 
contains several extracellular matrix proteins that shape synaptic plasticity and 
excitability, such as nidogen 1 (NID1) 302.
Most of the postsynaptic components of the identified network seem to be involved in 
glutamate signalling and (related) endosome trafficking.
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Synaptic/extracellular glutamate is either transported into the postsynaptic neuron by the 
EAAT1 and EAAT2 glutamate transporters - which are encoded by the SLC1A3 and 
SLC1A2  genes 108 - or binds to postsynaptic glutamate receptors, including GRIA1 (other 
name: AMPA1), the subunits of the NMDA receptor NMDAR1 and NMDAR2A, and 
GRIK2 108, which can be degraded by the E3 ubiquitin-protein ligase complex of CUL3 
303 and KLHL21 108, 304 EAAT1/2 are activated/regulated by ARHGEF11 305 and 
degraded by NEDD4L 306,307. Postsynaptic NMDAR1 is inhibited by an activated P2RY1 
membrane receptor 308. Furthermore, GRIA1 glutamate receptors are internalised and 
translocated into endosomes by endocytosis and reinserted into the postsynaptic cell 
membrane by exocytosis, and this process is called the ‘AMPA receptor recycling 
pathway’ 309,310. ARF6, a protein that is found in the membrane of postsynaptic endosomes 
108 and involved in promoting neurite outgrowth 311, is also involved in the endocytic
108, 312recycling of AMPA glutamate receptors , downstream of PSD3, a postsynaptic 
membrane protein and a guanine nucleotide exchange factor (GEF) for/activator of ARF6 
108. SH3GL3 (other name: endophilin-A3) is another brain-expressed protein found in the 
membrane of postsynaptic endosomes 108 and involved in the endocytosis of AMPA 
receptors 108, 313. Conversely, EXOC4 108, 314, MYO5A 315, 316 and MYO5B 108, 317 are 
cytoplasmic proteins that positively regulate the exoxytosis and re-insertion of AMPA 
glutamate receptors into the postsynaptic membrane. AKAP5 has an important role in
318 319regulating this recycling of postsynaptic AMPA receptors . Furthermore, when 
glutamate binds to the GRIA1 receptor, a signalling cascade is initiated in which the 
RHOA GTPase, activated by the guanine nucleotide exchange factor (GEF) ARHGEF11
108 320, is involved and that leads to the activation of MSN . Active PKA associated with 
cytoplasmic MSN 166, NBEA 108 (which is also found in the postsynaptic membrane and is 
involved in membrane protein traffic 98, ,321) and AKAP7 108 activates CDC42 167 , a 
protein that is not only an important mediator of neurite outgrowth (see Figure 2a and
322-324Figure 2b) but that is also involved in synapse formation and maintenance 322-324. CDC42 
can also be activated downstream of glutamate binding and activating of (subunits of the 
NMDA glutamate receptor such as) NMDAR1 and NMDAR2A 108. Activated NMDAR1, 
which forms a postsynaptic signalling complex with the membrane protein FAM171A1
108, 325(other name: astroprincin) , and is linked to the actin cytoskeleton by cytoplasmic 
alpha-actinin-2 (ACTN2) 326, binds the synapse-specific cytoplasmic isoform of AKAP9
108, 327, which in turn recruits PKA to activate CDC42 167”328.
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In addition, PKA bound to membrane-located AKAP5 329 and AKAP7 330 activates the L- 
type calcium channel CACNA1C that increases the intracellular calcium. An increased 
intracellular concentration of calcium is necessary for upregulating the expression of 
CDC42 331.
Lastly, A2BP1 and CUGBP2 can be placed in the (post)synaptic network because these 
proteins - that are found in both the cytoplasm and nucleus 108 - function as RNA-binding
108, 332proteins that regulate the processing of the NMDAR1 pre-mRNA ’ (not shown). In 
addition, TLX1 is a transcription factor that is required for glutamatergic differentiation of 
neurons by regulating the expression of several glutamatergic genes, including GRIK2 333 
(not shown).
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Chapter 7
Summary and general discussion

In this chapter, the studies presented in this thesis are briefly summarized, followed by an 
integration and discussion of the main findings from the thesis and, linked to this, 
suggestions for future research.
Identification of genes and functional protein networks
In Chapter 2, we reported the identification of four novel DD candidate genes (PCNT, 
DIP2A, S100B and PRMT2) through the thorough cytogenetic and molecular genetic 
analysis of a rare CNV, i.e. a very small deletion of chromosome region 21q22.3, that 
cosegregated with DD in a father and his three sons. Of the genes in the deletion, DIP2A 
and S100B seemed the most likely candidates for DD.
Chapter 3 described the findings of the first GWAS for MCP that was conducted in a 
clinical sample of children with ADHD from the International Multicentre ADHD 
Genetics (IMAGE) project. Based on bioinformatics and systematic literature analyses of 
the top-ranked findings, we found that nine genes were associated with MCP through 
SNPs at P  < 1.00E-04. The proteins encoded by eight of these genes function in a 
signalling network that is both involved in regulating neurite outgrowth and skeletal 
muscle cell function.
In Chapters 4, 5 and 6, a similar “gene/protein network building” approach as the one 
described in Chapter 3 was used to build functional protein networks for DD, ADHD and 
ASDs, respectively:
For DD (Chapter 4), we integrated the current knowledge on 14 dyslexia candidate genes 
suggested by cytogenetic findings as well as linkage and association studies, and we were 
able to fit the proteins encoded by 10 of these genes into a functional network involved in 
neuronal migration as well as neurite outgrowth. Based on the identified network, we 
could also propose three novel DD candidate genes from known linkage regions.
In Chapter 5, we presented our bioinformatics and systematic literature analyses of 85 
genes from the five published GWASs containing SNPs associated with ADHD at P  < 
1.00E-04. The proteins encoded by 45 of these 85 top-ranked ADHD candidate genes 
fitted into a network that regulates directed neurite outgrowth.
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Corroborating evidence for the involvement of this network in ADHD etiology comes 
from CNV studies in ADHD patients, gene knockout studies in mice, and data about gene 
expression modulation by stimulants, the most effective and commonly used 
psychopharmacological treatments for ADHD. Since the publication of this paper, 
literature findings have implicated two more genes from the list of 85 GWAS genes in 
(dopaminergic) neurite outgrowth, i.e. the FOXP1 (Lasky-Su et al., 2008; Konstantoulas 
et al., 2010; Hedlund et al., 2008) and PRKG1 (Neale et al., 2010; Tedeschi et al., 2009) 
genes. In addition, a recent paper has provided evidence for GIT1, another gene involved 
in neurite outgrowth, as an ADHD candidate gene (Won et al., 2011).
Lastly, in Chapter 6, the analysis of 200 genes from five published GWASs that yielded 
association with ASDs through SNPs at P  < 1.00E-04, with a validation in a sixth 
published GWAS of ASDs, was presented. In total, 117 of the 200 top-ranked ASD 
candidate genes, many of which were also implicated in ASDs through additional lines of 
genetic evidence (CNVs and microRNAs) and 35 additional strong candidates encode 
proteins fitting into three distinct signalling networks that functionally regulate 
steroidogenesis, neurite outgrowth and synaptic function. Most importantly, the proteins 
encoded by 10 ASD-linked AKAP (A-kinase anchor protein) genes functionally integrate 
signalling cascades within and between the three identified networks, with literature data 
pointing towards these AKAPs as possible novel “druggable targets” for ASDs.
On a general note, we would like to say that to a certain extent, the bioinformatics 
analyses we conducted for the different disorders were indicative of possible functional 
relationships between the candidate genes/proteins, but that it was only through systematic 
manual literature analysis as well as the integration/addition of corroborating evidence 
(see above) that the actual networks could be built.
Underlying shared and specific biological processes
In comparing the findings for the different neurodevelopmental disorders, we noticed that 
certain genes and molecular signalling cascades as well as underlying biological processes 
seem to be shared between disorders, while others appear specific to a single 
neurodevelopmental disorder.
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Pleiotropy
Table 1 summarizes the genetic findings for 55 genes that are pleiotropic between the four 
studied disorders, in that they have been implicated in the etiology of at least two of the 
four disorders through “strong” genetic evidence, which includes: SNPs from one or more 
GWASs associated at P  < 1.00E-04, location in CNVs that were either identified using a 
genome-wide array-based hybridization approach or through being associated with the 
disorder in (families with) multiple affected individuals, cytogenetic studies, candidate 
gene-based association studies, gene mutation studies, gene expression studies, and gene 
knockout studies in rodents. As can be derived from Table 1, six genes are implicated in 
DD, ADHD and ASDs (DCDC2, GTF2I, SLC2A3, NEDD4L, S100B, FMR1) and one 
gene is implicated in ADHD, MCP and ASDs (NOS1). In addition, the FOXP1 and 
ATP2C2 genes are involved in the etiology of ADHD, ASDs as well as speech and 
language impairments that are (highly) comorbid with and genetically related to DD 
(Sharma et al., 2009; Kang and Drayna, 2011).
Furthermore, the proteins encoded by all 55 pleiotropic genes could be placed in a 
functional network involved in neurite outgrowth of developing neurons, which is indeed 
the underlying neurobiological process that is shared between all four studied 
neurodevelopmental disorders (Chapters 3-6). Several pleiotropic network proteins and a 
number of genes/proteins that are not directly implicated in any of the disorders but that 
functionally “link” network proteins are also modulated by the stimulant drugs 
methylphenidate (MPH) and/or amphetamine (AMPH) - the most commonly used 
medications for treating ADHD - and/or one or both of the two drugs that are currently 
approved for the treatment of (severe irritability associated with) ASDs, the neuroleptics 
risperidone (RISP) and aripiprazole (ARIP). In Figure 1 and its accompanying legend, this 
network is shown and the functional evidence placing the 55 pleiotropic genes/proteins 
into the network is presented. In Table 2, the evidence for the modulation of a number of 
network proteins by ADHD-and/or ASD-drugs is shown.
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Apart from overlap at the gene and biological process level, there exists some overlap at 
the level of molecular signalling cascades that contain a (relatively) limited number of 
proteins and form a part of the larger functional protein networks contributing to the 
underlying biological processes for the different disorders. For example, CTNNB- and 
NRXN1-dependent cascades are shared between the identified ADHD and ASD networks 
(Chapters 5 and 6) whilst ESR1/ESR2-dependent molecular signalling is implicated in DD 
and ASDs (Chapters 4 and 6), and the CDC42-ERK1-mediated signalling cascade is 
important in the functional networks for DD, ADHD and ASDs (Chapters 4-6).
As already indicated in Chapter 1 of this thesis, the four studied disorders are highly 
comorbid with each other, which means that children (or adults) with one disorder often 
also have symptoms of one or more of the three other disorders. Several explanatory 
models for this clinical overlap have been proposed. First, as also already mentioned in 
Chapter 1, the observed comorbidity could be (partially) “artificial”, in that it may be 
partially due to the fact that the currently used diagnostic instruments and classification 
systems for the different disorders measure or consider certain symptoms or “traits” that 
are shared between these disorders. Second, one disorder may represent an early 
manifestation of/lead to another disorder or be part of another disorder. The third and most 
plausible explanatory model for the observed comorbidity is that the different 
neurodevelopmental disorders share a common underlying (genetic and environmental) 
etiology (Caron and Rutter, 1991; Rommelse et al., 2009; Rommelse et al., 2010). In this 
respect, the fact that we found a considerable amount of pleiotropic genes between the 
studied disorders further strengthens the idea that the observed clinical 
overlap/comorbidity would be - at least in part - due to shared genetic factors. Moreover, 
our findings of shared/overlapping molecular signalling cascades as well as one shared 
underlying neurobiological process between the four disorders (i.e. neurite outgrowth) 
corroborate the notion of a common (genetic) etiology of these disorders.
Specificity
Despite the observed overlap between the four neurodevelopmental disorders, there 
remains a considerable amount of apparent disorder-related specificity. However, we need 
to be careful in interpreting these findings.
288
There are considerable differences in the amount and “robustness” of the available genetic 
evidence that was used to build the functional protein networks for each disorder. For DD, 
there are no data from GWASs, and the evidence for all genes/proteins that could be 
placed in the identified network for neuronal migration and neurite outgrowth (Chapter 4) 
ranges from - at best - repeated candidate-gene based association (e.g. DYX1C1, DCDC2, 
KIAA0319) or mutation findings (FMR1) to genes that are only implicated through 
chromosomal anomalies in a (very) limited number of affected individuals (e.g. DIP2A, 
S100B, DOCK4). In contrast, the functional networks for ADHD and ASDs (Chapters 5 
and 6) contain proteins encoded by genes that were implicated through highly ranked 
SNPs derived from several GWASs and especially for ASDs, there is also a considerable 
amount of corroborating evidence for the involvement of a (large) number of GWAS 
genes in these networks (see above). Therefore, it is entirely possible and likely that genes 
that seem to be disorder-specific at the moment will turn out to be pleiotropic once gene 
identification approaches with sufficient detection power (such as GWASs and whole 
genome/exome sequencing methods) will have been applied to all neurodevelopmental 
disorders that are studied in this thesis.
At the genetic level, the disorder-related specificity is reflected by the fact that some 
genes/proteins and molecular signalling cascades seem to be implicated in only one of the 
neurodevelopmental disorders investigated in this thesis. For example, the binding of 
netrin axonal guidance ‘cues’ to UNC5B and DCC, two receptor proteins that seem to be 
specifically implicated in ADHD and ASDs, respectively, has opposite effects on the 
direction of neurite outgrowth, with netrin binding to UNC5B leading to neurite repulsion 
away from the netrin cues (Chapter 5) and the formation of the netrin-DCC complex 
resulting in neurite attraction towards these cues (Chapter 6). In addition, the AKAPs are a 
group of proteins that apparently are not only specifically implicated in ASDs at the 
genetic level but also functionally regulate several “ASD-specific” proteins such as 
CACNA1C, GATA4, RHOA, SCN2A, STAR and SYT17 (Chapter 6). Other examples of 
(apparent) disorder-specific signalling cascades include BMPR1B-dependent signalling 
and the HGFA-HGF-MET cascade in the ADHD and ASD networks, respectively 
(Chapters 5 and 6). Moreover, although the neurobiological process of neurite outgrowth 
is shared between all four studied disorders, synaptic function and steroidogenesis seem to 
be specifically underlying ASDs (Chapter 5).
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Three additional factors can contribute to disorder-related specificity, i.e. the location, 
(environmental) modulation and timing of gene expression.
First, functional consequences of disturbed or abnormal neurite outgrowth in the different 
brain regions that are predominantly affected in either DD, MCP, ADHD or ASDs - see 
Chapter 1 - could help to explain why a disturbance of the same underlying 
neurobiological process could lead to these partially overlapping but still distinct clinical 
phenotypes.
Second, even when the same genes are shared between different neurodevelopmental 
disorders, the expression and/or function of the proteins they encode can be modulated 
differently by the environment, which e.g. becomes apparent when looking at the effects 
of drugs used to treat different neurodevelopmental disorders on the expression of genes 
that are pleiotropic between these disorders. For instance, as can be derived from Table 2, 
the neuronal production of nitric oxide (NO) is positively regulated by the ADHD 
medications MPH and AMPH that upregulate the expression of the NO-producing enzyme 
Nos1 in rodent striatum and negatively regulated by ARIP, an ASD drug. Another 
example is the downregulation of Ctnnb and N gf expression by AMPH in rat brain, while 
RISP upregulates the expression of both genes.
Third, specificity can occur when pleiotropic genes are co-expressed with genes that are 
(apparently) specific to one disorder within a brain region that is predominantly affected in 
this disorder. An analysis of gene expression correlation indices (denoted by r) for 
pleiotropic candidate genes in different brain regions and using BrainSpan, an online atlas 
of the developing human brain (http://www.developinghumanbrain.org/), shows how this 
would work. For example, although CDH13 has been strongly implicated in both ADHD 
and ASDs (see Table 1), genes that show a (very) high “expression correlation index” with 
CDH13 in the striatum and the cerebellum, two brain regions (predominantly) implicated 
in ADHD and ASDs, respectively, seem to be disorder-specific: the “ADHD-specific” 
MYT1L (r=0.860) and MAP1B genes (r=0.773) (Chapter 5) are highly co-expressed with 
CDH13 in the striatum, and the “ASD-specific” D C C  (r=0.919) and SLITRK5 (r=0.917) 
(Chapter 6) show very high expression correlation with CDH13 in the cerebellum.
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NEDD4L and NRXN1, two other genes that are implicated in both ADHD and ASDs 
(Table 1), are also highly co-expressed with MYT1L (r=0.895 for NEDD4L and r=0.883 
for NRXN1) and MAP1B (r=0.927 for NEDD4L and r=0.930 for NRXN1) in the striatum 
while interestingly, both genes are very highly co-expressed with the ASD-implicated 
AKAP genes MAP2 (r=0.938 for NEDD4L and r=0.953 for NRXN1) and NBEA (r=0.922 
for NEDD4L and r=0.975 for NRXN1) (Chapter 6) in the cerebellum.
Treatment targets
As indicated in the introduction of this thesis (Chapter 1), the ultimate goal of identifying 
novel genes, protein networks and the core underlying biological processes contributing to 
each of the four neurodevelopmental disorders is to find protein targets for the 
development of disorder-specific and novel pharmacological and/or non-pharmacological 
treatments. That being said, neurite outgrowth, neuronal migration and steroidogenesis 
(Chapters 3-6) essentially occur prenatally, which makes these biological processes not 
really suitable for modulation by - existing and to be newly developed - postnatal 
treatments. However, biological processes that are still important after birth such as 
skeletal muscle cell function and glutamatergic synaptic transmission - which were 
identified as underlying processes for MCP (Chapter 3) and ASDs (Chapter 6), 
respectively - provide more interesting prospects for developing novel treatments. In this 
respect, it is interesting that for ASDs, the disorder with most genetic data, 8 of the 10 
ASD-implicated AKAPs we identified are (in)directly regulated in their function or 
expression by the ASD-drug RISP and/or involved in ASD-linked biological processes for 
which novel pharmacological treatments have been developed, such as innate immunity 
and melatonin synthesis (Chapter 6). Hence, these findings not only provide additional 
insights into the working mechanism of existing drugs, but they also give clues towards 
developing novel and disorder-specific drugs.
Future research
Based on the findings from this thesis, we would like to address the following three main 
issues/questions in future research:
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First, we would like to study the pleiotropy and specificity between the different 
neurodevelopmental disorders in much greater detail, which we think would point towards 
additional disorder-specific targets for novel (non-)pharmacological treatments. The 
ultimate goal of this approach would be to develop treatments that are aimed at directly 
modulating the core (neuro)biological deficits underlying the different disorders rather 
than - as is the case with virtually all of the extisting treatments - the visible and detectable 
symptoms of each disorder.
Second and more specifically, we would like to find additional genetic evidence for the 
involvement of the AKAPs in the etiology of ASDs through e.g. the targeted sequencing 
of all AKAP genes in ASD patients.
Third, given the fact that the currently used bioinformatics tools and approaches provide 
only (very) limited indications as to the true functional relationships between the 
candidate genes for the different disorders (see above), we would like to develop novel 
bioinformatics approaches that better and much more systematically exploit the existing 
functional gene annotation data and literature. However, for this to be fully effective, it 
would be essential that much more fundamental research studies - including not only 
(additional) GWASs but e.g. also whole genome/ exome sequencing, (in vivo) gene 
expression and epigenetics studies - would be conducted for all disorders. In addition, 
more investment in the collection of postmortem materials - i.e. the development of “brain 
banks” - for these disorders is necessary. As for conducting (more) GWASs and/or 
applying other “genome-wide” approaches such as whole genome/exome sequencing, the 
usefulness and validity of these types of studies for finding new candidate genes for 
polygenic disorders has been the subject of recent debate (Lander, 2011a; Lander, 2011b; 
Evans et al., 2011). In this respect, we think that by rigorously applying as well as 
extending and refining the “network building” approach that we used in this thesis, further 
progress can definitely be made through these approaches in elucidating the core 
underlying biological deficits for not just neurodevelopmental disorders but in principle 
any polygenic/multifactorial disorder.
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Table 1. Genes that are implicated through strong genetic evidence in at least two of the four neurodevelopmental disorders that are studied in this thesis: DD, ADHD, MCP and/or 
ASDs. The seven genes that are implicated in three of the four disorders are indicated in bold.
Locus Gene DD ADHD ± MCP ASDs
lpl3.2 NGF
candidate gene-based association (Syed et al., 
2007) GWAS (Ma et al., 2009)
2pl6.3 NRXN1
GWAS (Neale et al., 2010) ; 
CNV: del (Bradley et al., 2010)
CNVs : del (Pinto et al., 2010; Gai et al.,
2011; Marshall et al., 2008; Bucan et al.,
2009; Bremer et al., 2011; Glessner et al., 
2009), dup (Pinto et al., 2010; Gai et al., 2011)
2pl2 CTNNA2
GWAS (Lesch et al., 2008); 
CNV : del (Elia et al., 2010) GWAS (Ma et al., 2009)
2q21.2 NAP5 GWAS (Lasky-Su et al., 2008)
GWAS (Anney et al., 2010); 
CNV: del (Pinto et al., 2010)
2q22.2 LRP1B GWAS (Neale et al., 2010)
GWASs (Wang et al., 2009a; Anney et al., 
2010); CNV : del (Pinto et al., 2010)
2q23.3-q24.1 GALNT13 CNV : dup (Williams et al., 2010)
GWASs (Wang et al., 2009a; Anney et al., 
2010) ; CNV : del (Bucan et al., 2009)
2q37.1 UGT1A9 GWAS (Mick et al., 2010)
GWAS (Anney et al., 2010); 
CNV: del (Gai et al., 2011)
3p26.2 CRBN CNV : del (Williams et al., 2010)
GWAS (Wang et al., 2009a); CNVs : del 
(Pinto et al., 2010), dup (Bremer et al., 2011)
3p22.2 MOBP GWAS (Lesch etal., 2008) CNV : dup (Pinto et al., 2010)
3pl4.2 FHIT GWAS (Lasky-Su et al., 2008)
GWASs (Salyakina et al., 2010; Anney et al., 
2010) ; CNVs : del (Pinto et al., 2010; Sebat 
et al., 2007; Gai et al., 2011), dup (Pinto et al., 
2010; Sebat et al., 2007; Marshall et al., 2008)
3pl3 FOXP1
CNV: FOXP1 deletions have been associated 
with speech and language deficits (Horn et al., 
2010) GWAS (Lasky-Su et al., 2008)
CNV : del (Sanders et al., 2011) ; 
de novo mutations in FOXP1 cause autism 
(Hamdan et al., 2010; O'Roak et al., 2011)
3pl2.3-pl2.2 ROBOl
disrupted by familial translocation 
cosegregating with dyslexia ; candidate gene- 
based association (Poelmans et al., 2011; 
Bates et al., 2011)
GWAS (Anney et al., 2010); CNV : dup 
(Marshall et al., 2008); ROBOl expression is 
reduced in lymphocytes of autistic patients 
(Anitha et al., 2008)
4pl5.31 KCNIP4 GWAS (Neale et al., 2008) CNV : del (Pinto et al., 2010)
4q22.1 FAM190A GWAS (Neale et al., 2008)
CNV : del (Marshall et al., 2008), dup (Pinto 
etal., 2010)
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Table 1 - continued.
Locus Gene DD ADHD ASDs
4q32.3 SPOCK3 GWAS (Neale et al., 2008)
CNV : del (Rosenfeld et al., 2010; Gai et al., 
2011)
5pl5.31 ADCY2
GWAS for MCP in children with ADHD (Fliers 
etal., 2011) CNV : del (Pinto et al., 2010)
6p22.3 MBOAT1 GWAS (Lasky-Su et al., 2008) CNV : del (Pinto et al., 2010)
6p22.3 DCDC2
repeated candidate gene-based association 
(Poelnians et al., 2011)
candidate gene-based association (Couto et al., 
2009) CNV : del (Pinto et al., 2010)
6p22.3 KIAA0319
repeated candidate gene-based association 
(Poelnians et al., 2011) CNV : dup (Pinto et al., 2010)
6p21.32 RAGE
Rage knockout mice show ADHD-like 
behaviour (Sakatani et al., 2009)
plasma levels of RAGE are decreased in ASD 
patients (Boso et al., 2006)
6q26 PARK2
CNVs : del (Bradley et al., 2010; Elia et al., 
2010), dup (Elia et al., 2010)
GWAS (Anney et al., 2010); CNVs : 
del (Glessner et al., 2009; Pinto et al., 2010; 
Bremer et al., 2011; Gai et al., 2011), dup 
(Pinto et al., 2010; Gai et al., 2011)
7p21.3 NXPH1 GWAS (Mick 2010) CNV: dup (Gai etal., 2011)
7pl5.1 CREB5 GWAS (Leschetal., 2008) CNV: del (Gai et al., 2011)
7qll.23 GTF2I
CNV: the typical deletion of 7ql 1.23 
associated with Williams-Beuren syndrome 
(WBS) contains GTF2I and WBS has been 
associated with dyslexia (Poelnians et al., 
2011)
CNV: the typical deletion of 7ql 1.23 associated 
with Williams-Beuren syndrome (WBS) 
contains GTF2Iand WBS lias been associated 
with ADHD (Leyfer et al., 2006; Lo-Castro et 
al., 2011)
CNVs : the reciprocal duplication of the 
typical WBS-deletion contains GTF2Iand is 
associated with a syndrome that is often 
characterised by ASD-like behaviour (Van der 
Aa et al., 2009); dup (Sanders et al., 2011);
7q31.1 DOCK4
CNV: located within familial deletion 
(incompletely) cosegregating with dyslexia 
(Pagnamenta et al., 2010)
candidate gene-based association (Maestrini et 
al., 2010)
7q32.1 FLNC GWAS (Neale et al., 2010) CNV : del (Rosenfeld et al., 2010)
7q32.1 KCP GWAS (Neale et al., 2010) CNV : del (Rosenfeld et al., 2010)
7q36.3 SHH
mutation in SHH  causes ADHD (Heussler et al., 
2002) GWAS (Salyakina et al., 2010)
9q33.1 ASTN2 GWAS (Leschetal., 2008)
GWAS (Anney et al., 2010); CNVs : del 
(Pinto et al., 2010; Bremer et al., 2011; Gai et 
al., 2011)
9q34.11 DNM1 GWAS (Leschetal., 2008) CNV : dup (Sanders et al., 2011)
10qll.23-q21.1 PRKG1 - GWAS (Neale et al., 2010) CNV : dup (Sanders et al., 2011)
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Table 1 - continued.
Locus Gene DD ADHD ± MCP ASDs
10q21.3 CTNNA3
CNVs : del (Bradley et al., 2010; Elia et al., 
2010)
GWASs (Wang et al., 2009a; Weiss et al., 
2009) ; CNVs : del (Marshall et al., 2008; 
Pinto et al., 2010; Gai et al., 2011), dup (Pinto 
etal., 2010)
10q22.1 HK1 GWAS (Neale et al., 2010)
antibodies against HK1 were found in children 
with autism (Gonzalez-Gronow et al., 2010)
llq22.3 DYNC2H1 GWAS (Neale et al., 2010) CNV: dup (Gai etal., 2011)
12p 13.31 SLC2A3
GWAS for a neurophysiological 
endophenotype of dyslexia (Roeske et al., 
2011) CNV : dup (Lesch et al., 2011)
Slc2a3 deficient mice display ASD-like 
behaviour (Zhao et al., 2010)
12q24.22 NOS1
GWAS (Lasky-Su et al., 2008); Nosl knockout 
mice show hyperactivity (Tanda et al., 2009; 
Zoubovsky et al., 2011); Nosl knockout mice 
show nocturnal MCP (Kriegsfeld et al., 1999)
CNV : dup (Marshall et al., 2008); 
Nosl knockout mice show ASD-like 
behaviour (Tanda et al., 2009)
13ql2.3 HMGB1
linked genetic marker is located within 
HMGB1 (Poelmans et al., 2011)
serum levels of HMGB1 were increased in 
adult patients with autism (Emanuele et al., 
2010)
13q31.3 GPC6 GWAS (Lesch etal., 2008)
CNVs : del (Pinto et al., 2010), dup (Pinto et 
al., 2010)
15ql4 MEIS2 GWAS (Lasky-Su et al., 2008) GWAS (Wang et al., 2009a)
15q21.3 DYX1C1
repeated candidate gene-based association 
(Poelmans et al., 2011)
candidate gene-based association (Wigg et al., 
2008)
15q22.2 RORA
GWAS (Neale et al., 2008) ; Rora knockout 
mice show hypoactivity (Deiss et al., 2000)
Rora knockout mice display autistic features 
(Doulazmi et al., 2006); the expression of 
RORA is decreased in the postmortem brain of 
autistic people (Nguyen et al., 2010)
15q26.1 SLC03A1 GWAS (Lasky-Su et al., 2008) GWAS (Anney et al., 2010)
16pl3.3 A2BP1
CNVs : del (Elia et al., 2010), dup (Elia et al., 
2010)
GWAS (Hussman et al., 2011);
CNVs : del (Sebat et al., 2007; Pinto et al., 
2010; Gai et al., 2011), dup (Pinto et al., 2010; 
Gai et al., 2011); candidate gene-based 
association (Martin et al., 2007); the 
expression of A2BP1 was found to be 
decreased in the postmortem brain of autistic 
people (Voineagu et al., 2011)
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Table 1 - continued.
Locus Gene DD ADHD ± MCP ASDs
16p 13.11 ABCC1 CNV : dup (Williams et al., 2010)
GWASs (Wang et al., 2009a; Ma et al., 2009) 
; CNVs : del (Pinto et al., 2010), dup (Pinto et 
al., 2010; Rosenfeld et al., 2010; Sanders et 
al., 2011)
16q23.3 CDH13
GWASs (Lasky-Su et al., 2008; Lesch et al., 
2008; Neale etal., 2010)
CNVs : del (Pinto et al., 2010; Gai et al., 
2011; Sanders et al., 2011), dup (Pinto et al., 
2010; Gai etal., 2011)
16q24.1 ATP2C2
candidate gene-based association with specific 
language impairment (Newbury et al., 2009)
GWAS (Lesch et al., 2008); CNV : del (Elia et 
al., 2010)
CNVs : del (Sanders et al., 2011), dup (Pinto 
etal., 2010)
17pl 1.2 PLD6
GWAS for MCP in children with ADHD (Fliers 
etal., 2011)
CNVs : del (Rosenfeld et al., 2010); dup 
(Bremer et al., 2011)
17pl 1.2 FLCN
GWAS for MCP in children with ADHD (Fliers 
etal., 2011)
CNVs : del (Rosenfeld et al., 2010); dup 
(Bremer et al., 2011)
18pl 1.32 COLEC12 CNV : del (Elia et al., 2010)
GWAS (Ma et al., 2009a); CNVs : del 
(Rosenfeld et al., 2010), dup (Rosenfeld et al., 
2010)
18pll.22 VAPA
gene in LD with linked genetic marker 
(Poelmans et al., 2011) CNV : dup (Rosenfeld et al., 2010)
18q21.31 NEDD4L
candidate gene-based association (Scerri et al., 
2010) GWAS (Neale et al., 2008)
GWASs (Wang et al., 2009a; Amiey et al., 
2010) ; CNV : del (Marshall et al., 2008)
20qll.22 MMP24 GWAS (Leschetal., 2008) CNV : dup (Sanders et al., 2011)
21q22.3 DIP2A
CNV: located within familial deletion 
cosegregating with dyslexia (Poelmans et al., 
2009)
CNVs: duplication (Pinto et al., 2010; Gai et 
al., 2011)
21q22.3 S100B
CNV: located within familial deletion 
cosegregating with dyslexia (Poelmans et al., 
2009)
decreased serum concentration of S100B 
correlates with increasing hyperactivity 
symptoms in children with ADHD (Oades et al., 
2010)
CNVs: duplication (Pinto et al., 2010; Gai et 
al., 2011)
Xq27.3 FMR1
FMR1 (pre)mutation has been associated with 
dyslexia (Poelmans et al., 2011)
FMR1 (pre)mutation has been associated with ADHD (Farzin et al., 2006; Lo-Castro et al., 2011; 
Boyle and Kaufmann, 2010) and ASDs (Farzin et al., 2006; Boyle and Kaufmami, 2010)
Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD(s), autism spectrum disorder(s); CNV(s), copy number variation(s); DD, developmental dyslexia; del, deletion; dup, 
duplication; GWAS, genome-wide association study; GWASs, genome-wide association studies; LD, linkage disequilibrium;
MCP, motor coordination problems
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Table 2. Proteins that could be placed in the network shown in Figure 1 and of which the expression and/or function is modulated by the stimulant drugs methylphenidate (MPH) and/or 
amphetamine (AMPH) - which are the most commonly used medications for treating ADHD - and/or one or both of the two drugs that are currently approved by the FDA for the 
treatment of (severe irritability associated with) ASDs, the neuroleptics risperidone (RISP) and aripiprazole (ARIP). The proteins that are modulated differently by drugs to treat ADHD 
and ASDs are indicated in bold.
Protein(s) Stimulant(s) Neuroleptic(s)
AA
AMPH increases the level of AA in several rat brain regions 
(Bhattachaijee et al., 2006)
RISP positively regulates biosynthesis of AA in rats (McNamara et al., 
2011)
AMPK ARIP activates AMPK (Takami et al., 2010)
AVP
MPH upregulates expression of Avp in rats (Appenrodt and 
Schwarzberg, 2003)
ADCY(2)
ARIP negatively regulates ADCY(2) activity (Rauly-Lestiemie et al., 
2007)
ADCY(2)-cAMP-PKA-CREB(5)
AMPH activates the ADCY(2)-cAMP-PKA-CREB(5) protein 
signalling cascade (Jones and Kuhar, 2006)
CREB5 MPH upregulates expression of Creb5 in rats (Andersen et al., 2002) -
CTNNB
AMPH downregulates expression of Ctnnb in rat brain (Alimohamad 
et al., 2005b)
RISP upregulates expression of Ctnnb in rat brain (Alimohamad et al., 
2005a)
ERK1 AMPH activates neuronal ERK1 (Choe and Wang, 2002) -
NGF
AMPH decreases expression of N gf in rat brain (Angelucci et al., 
2007)
RISP upregulates expression of Ngf in rat brain (Hassanzadeh and 
Rahimpour, 2011)
NO
RISP positively regulates NO production and secretion by glial cells 
(Quincozes-Santos et al., 2009); ARIP negatively regulates NO 
production and secretion by glial cells (Kato et al., 2008)
NOS1
MPH upregulates expression of Nosl in rat striatum (Cavaliere et al., 
2011); AMPH downregulates or upregulates expression of Nosl in 
mouse striatum, dependent on the administered dose of AMPH (Wang 
and Lau, 2001)
S100B
RISP stimulates S100B secretion by glial cells (Quincozes-Santos et 
al., 2008)
Abbreviations: AA, arachidonic acid; ADHD, attention deficit hyperactivity disorder; ASDs, autism spectrum disorders; AVP, arg-vasopressin; 
FDA, food and drug administration (http://www.fda.gov/); NO, nitric oxide
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Figure 1. Schematic representation of a functional network that contains the proteins 
encoded by 55 genes that are pleiotropic between at least two of the four 
neurodevelopmental disorders (Table 1) and that leads to neurite outgrowth through 
molecular signalling cascades located in the extracellular matrix, cell membrane, 
cytoplasm, cytoskeleton and nucleus of (the growth cone of) developing neurons. The 
proteins encoded by candidate genes for dyslexia are indicated in blue, whilst the proteins 
encoded by genes implicated in ADHD, MCP and ASDs are indicated in yellow, 
purple/by a purple border and in red/by a red border, respectively. The proteins indicated 
in green are implicated through their corresponding genes in dyslexia and ADHD, and the 
proteins indicated in dark grey/by a dark grey border are modulated by specific drugs for 
ADHD and/or ASDs (Table 2). In the network description below, all pleiotropic proteins 
are indicated in bold.
Signalling through the network can be initiated at the neuronal cell membrane by the 
binding of extracellular S100B and HMGB1 proteins to the RAGE receptor, which 
results in the activation of cytoplasmic CDC42 and (eventually) neurite outgrowth 
(Rothermundt et al., 2003; Chou et al., 2004; Wang et al., 2008a). Several other signalling 
cascades lead to CDC42 activation. Firstly, CDH13, a member of the cadherin protein 
family that is anchored in the neuronal cell membrane, acts as a regulator of neural cell 
growth and guidance (Takeuchi et al., 2000; Philippova et al., 2009) and activates CDC42 
(Semina et al., 2009). CDC42 activation is also mediated by AVP (Arg-vasopressin) 
(Rosso et al., 2002), a cerebral neuropeptide that functions as a neurotransmitter (UniProt 
Consortium, 2010; Franke et al., 2009) and promotes neurite outgrowth (Brinton and 
Gruener, 1987), and arachidonic acid (AA) (Wen et al., 2000). SLCO3A1 is a neuronal 
cell membrane transporter for AVP while MBOAT1 is involved in the production of AA 
(Uniprot Consortium, 2010) and UGT1A9 degrades AA and its metabolites (Turgeon et 
al., 2003). Other extracellular proteins that are indirectly involved in the activation of 
CDC42 and neurite outgrowth are KCP (Chapter 5), NGF and SHH (Chapter 6). 
Furthermore, when the SLIT molecular guidance ‘cues’ bind to the ROBO1 membrane 
receptor, a signalling cascade is initiated that involves ROBO1 binding to cytoplasmic 
ASD-implicated srGAP proteins (Ghose and Van Vactor, 2002; Chapter 6) and that leads 
to the inhibition of CDC42 and eventually results in neurite outgrowth away from the 
SLIT guidance cues (Stein and Tessier-Lavigne, 2001; Wong et al., 2001).
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CDC42 is a GTP-hydrolyzing (GTPase) protein that is a central mediator of directed 
neurite outgrowth (Nikolic, 2002; Briancon-Marjollet et al., 2008) and it 
regulates/activates a number of downstream effectors to facilitate neurite outgrowth, such 
as the cytoplasmic ERK (Extracellular signal related kinase) 1 protein (Frost et al., 1997). 
ERK1, in turn, is activated/phosphorylated by cytoplasmic FMR1 (Shang et al., 2009) and 
activates both DCDC2 (Gleeson et al., 1999), a protein that directly binds and modulates 
the neuronal cytoskeleton to facilitate neurite outgrowth (Coquelle et al., 2006), and TFII- 
I (which is encoded by the GTF2I gene). After being activated, TFII-I translocates to the 
nucleus (Kim and Cochran, 2001), where it binds and interacts with nuclear PRKG1 
(Casteel et al., 2002) and, depending on the context of other transcription factors, 
functions as a transcription factor that up- or downregulates the expression of DYX1C1 
(Taipale et al., 2003; Tapia-Paez et al., 2008). Cytoplasmic DYX1C1, in turn, is involved 
in activating neuronal ERK1 (Massinen et al., 2009).
A CDC42-independent signalling cascade that leads to neurite outgrowth starts at the 
neuronal cell membrane protein NRXN1 (neurexin 1), which functions as a cell adhesion 
molecule and receptor. After being bound by its specific ligand, the secreted neuropeptide 
NXPH1 (neurexophilin 1), the cytoplasmic domain of NRXN1 binds the CASK kinase 
protein, which directly links NRXN1 signalling with remodelling of the neuronal (actin) 
cytoskeleton mediating neurite outgrowth (Uniprot Consortium, 2010). A second CDC42- 
independent pathway leading to neurite outgrowth centers around the N(euronal)-cadherin 
CDH2, a protein that - like CDH13 (see above) - is a member of the cadherin protein 
family (Uniprot Consortium, 2010). CDH2 is anchored in the neuronal cell membrane and 
the neuronal cytoskeleton through binding to a complex consisting of catenin beta 
(CTNNB) and catenin alpha 2 (CTNNA2) or catenin alpha 3 (CTNNA3) (Uniprot 
Consortium, 2010; Rhee et al., 2007; Abe et al., 2004; Janssens et al., 2001). CDH2 is 
functionally modulated by and stably associated with cell surface N- 
acetylgalactosaminyltransferases such as GALNT13 (Uniprot Consortium, 2010; Balsamo 
and Lilien, 1990). CDH2 also mediates neurite outgrowth that is induced by nitric oxide 
(NO) (Chen et al., 2006), which is produced by cytoplasmic NOS1, the brain-specific 
nitric oxide synthase (Uniprot Consortium, 2010). In addition, CDH2 is degraded through 
MMP24 (Monea et al., 2006) (see below), and its expression is upregulated through 
CDC42 (Laplante et al., 2004) (not shown in Figure 1).
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Lastly and in addition to inhibiting CDC42 (see above), SLIT binding to ROBO1 can 
inactivate CDH2, which leads to the dissolution of the CDH2-CTNNB-CTNNA2/3 
complex and the CTNNB protein being released and targeted to the nucleus, where it 
functions as a transcription factor (Rhee et al., 2007) (see below). The nuclear 
translocation and hence transcriptional activity of CTNNB can be inhibited by the 
cytoplasmic FH IT protein (Weiske et al., 2007) and KCNIP4, a potassium channel- 
interacting membrane protein (Uniprot Consortium, 2010; Kitagawa et al., 2007). 
Furthermore, the membrane-located adenylate cyclase 2 (ADCY2) protein produces cyclic 
AMP (cAMP) (Uniprot Consortium, 2010; Jones and Kuhar, 2006) and cAMP 
subsequently activates protein kinase A (PKA) (Jones and Kuhar, 2006) , which activates 
both (the transcription factor function of) CTNNB (Hino et al., 2005) (see below) and 
CDC42 (Chen et al., 2003). Together with CRBN (Lee et al., 2011), PKA also inhibits 
AMPK (Djouder et al., 2010), a kinase that promotes neurite outgrowth (Tan et al., 2011), 
is activated by NO (Bess et al., 2011) and itself activates the cytoplasmic FLCN protein 
(Wang et al., 2010).
A number of other cytoplasmic proteins link cell surface signals with cytoskeleton- 
mediated responses involved in neurite outgrowth. NAP5, through its association with the 
NCK proteins (Uniprot Consortium, 2010), is such a protein (Guan et al., 2007). 
DYNC2H1, a member of the family of cytoplasmic dynein proteins localised in the axon 
growth cone and playing a prominent role in microtubule advance during neuronal 
cytoskeleton remodelling associated with neurite outgrowth (Grabham et al., 2007), is 
another example. This may involve the FAM190A protein (Uniprot Consortium, 2010) 
directly associating and interacting with NDEL1 (Nuclear distribution protein nudE-like 
1) (Camargo et al., 2007), which promotes neurite outgrowth by activating dynein proteins 
such as DYNC2H1 (Shim et al., 2008). In addition, DNM1 (Dynamin 1) (Uniprot 
Consortium, 2010; Lackner et al., 2009), FLNC - through actin filaments (Uniprot 
Consortium, 2010) - and - through the microtubules - HK1 (Wagner et al., 2001; Wang et 
al., 2008b) and M OBP (Myelin-associated oligodendrocyte basic protein) (Montague et 
al., 1998) associate directly with and modulate the neuronal cytoskeleton to facilitate 
neurite outgrowth. ATP2C2 is a brain-expressed ATPase transporter that moves calcium 
and manganese (Mn) ions into cytoplasmic vescicles derived from the trans-Golgi network 
- such a vesicle is denoted as ‘CV’ in Figure 1- and is in this way involved in manganese 
detoxification in neuronal cells (2009; Xiang et al., 2005).
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Mn also induces neurite outgrowth by activating ERK1 (Walowitz and Roth, 1999) and 
being involved in downregulating the expression of the cytoplasmic PARK2 kinase 
(Wang et al., 2009b).
The cell nucleus is another important compartment in the neurite outgrowth network. In 
the neuronal nucleus, CTNNB - which is itself activated by PKA (see above) - upregulates 
the expression of the ASD-implicated OTX2 (Joksimovic et al., 2009). OTX2, a neuronal 
transcription factor that is involved in early brain development (Nguyen Ba-Charvet et al., 
1998), directly binds and interacts with MEIS2 (Agoston and Schulte, 2009), another 
neuronal transcription factor (Uniprot Consortium, 2010). CTNNB also upregulates the 
expression of NEDD4L (Lee et al., 2007), an E3 ubiquitin-protein ligase (Uniprot 
Consortium, 2010) that is involved in cellular processes regulating neurite outgrowth 
(Robinson et al., 2005) through the degradation of several proteins from the identified 
neurite outgrowth networks for ADHD and ASDs (Chapters 5 and 6). RORA, a 
transcription factor involved in neurite outgrowth (Uniprot Consortium, 2010; Jin et al., 
1998), also inhibits the transcriptional activity of CTNNB (Lee et al., 2010). Furthermore, 
nuclear PKA phosphorylates/activates the transcription factors of the CREB family (Jones 
and Kuhar, 2006) - such as CREB5 - which are involved in regulating neurite outgrowth 
(Moore and Goldberg, 2011). FOXP1 is a transcription factor that upregulates the 
expression of PITX3 (Konstantoulas et al., 2010) , another transcription factor that is 
involved in the neurite outgrowth of dopaminergic neurons (Hedlund et al., 2008) (not 
shown in Figure 1). Lastly, DIP2A forms a part of a transcription factor complex that 
negatively regulates neurite outgrowth (Chapter 4) and A2BP1 is an RNA-binding protein 
that can be found in both the cytoplasm and nucleus (Uniprot Consortium, 2010) and 
regulates the pre-mRNA processing of calcitonin (Zhou et al., 2007), a secreted protein 
that stimulates neurite outgrowth (Grimm-Jorgensen, 1987) (not shown in Figure 1).
In order to not only allow the axon/neurite to grow through modulating (i.e degrading or 
‘building’) the neuronal cytoskeleton but also to grow in a specific direction, it is 
necessary for the extracellular matrix to be equally modulated (i.e. degraded or produced) 
(Ma et al., 2008). In this respect, the matrix metalloproteinase MMP24 not only degrades 
CDH2 (see above) but also the neuronal extracellular matrix (Monea et al., 2006) and it is 
specifically involved in neurite outgrowth (Hayashita-Kinoh et al., 2001).
301
The extracellular matrix protein SPO CK 3 (Uniprot Consortium, 2010) is a negative 
regulator o f  M M P24 (Nakada et al., 2003). Furthermore, the G PC6 protein is located in 
the neuronal cell membrane or secreted in the neuronal extracellular compartiment, where 
it forms an integral part o f  the extracellular matrix (Uniprot Consortium, 2010) and acts as 
a receptor for other extracellular matrix proteins.
Lastly, although as yet, they cannot be directly linked to the above described neurite 
outgrowth network, the mitochondrial membrane-located PLD6 protein - a mitochondrion 
is denoted as ‘M C ’ in Figure 1 - (Chapter 3) as w ell as the cell membrane-located proteins 
DO CK 4, K IA A 0319, SLC2A3 and V A PA  (Chapter 4), A ST N 2 and LR P1B (Chapter 5), 
and ABCC 1 and C O LE C 12 (Chapter 6) can be functionally linked to neurite outgrowth.
— ► aetivates/rcgulatcs/produccs
— i inhibits/inactivates
—D* transports
- • ► upregulaies expression of 
— | dow n regulates expression of
......► translocates to
— £§► degrades
302
extracel]u l;
n x p h  1
M O B P
NX PH 1 S 1 0 0 B
MMP24
Fi-NC siooe
©
S L ITDNM1
FMR1
eytoskeIct c t h n a  2/3 f h i t
cytoplasm°yHC2Hl
NDEL1
D Y X 1 C 1
N E D D 4 L^nck
n a p s ME I S 2
C R B N
t f i i -i
PRKG1
N O S 1
FLCN
F O X P ,nucleus
r o r a
MMP24
303
A
B
C
C
1

References
Abe,K., Chisaka,O., Van,R.F., and Takeichi,M. (2004). Stability of dendritic spines and 
synaptic contacts is controlled by alpha N-catenin. Nat. Neurosci. 7, 357-363.
Agoston,Z. and Schulte,D. (2009). Meis2 competes with the Groucho co-repressor Tle4 
for binding to Otx2 and specifies tectal fate without induction of a secondary midbrain- 
hindbrain boundary organizer. Development 136, 3311-3322.
Alimohamad,H., Rajakumar,N., Seah,Y.H., and Rushlow,W. (2005a). Antipsychotics alter 
the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex 
and striatum. Biol. Psychiatry 57, 533-542.
Alimohamad,H., Sutton,L., Mouyal,J., Rajakumar,N., and Rushlow,W.J. (2005b). The 
effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in 
the ventral midbrain of rats. J. Neurochem. 95, 513-525.
Andersen,S.L., Arvanitogiannis,A., Pliakas,A.M., LeBlanc,C., and Carlezon,W.A., Jr.
(2002). Altered responsiveness to cocaine in rats exposed to methylphenidate during 
development. Nat. Neurosci. 5, 13-14.
Angelucci,F., Gruber,S.H., El,K.A., Tonali,P.A., and Mathe,A.A. (2007). Chronic 
amphetamine treatment reduces NGF and BDNF in the rat brain. Eur. 
Neuropsychopharmacol. 17, 756-762.
Anitha,A., Nakamura,K., Yamada,K., Suda,S., Thanseem,I., Tsujii,M., Iwayama,Y., 
Hattori,E., Toyota,T., Miyachi,T., Iwata,Y., Suzuki,K., Matsuzaki,H., Kawai,M., 
Sekine,Y., Tsuchiya,K., Sugihara,G., Ouchi,Y., Sugiyama,T., Koizumi,K., Higashida,H., 
Takei,N., Yoshikawa,T., and Mori,N. (2008). Genetic analyses of roundabout (ROBO) 
axon guidance receptors in autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 
1019-1027.
Anney,R., Klei,L., Pinto,D., Regan,R., Conroy,J., Magalhaes,T.R., Correia,C., 
Abrahams,B.S., Sykes,N., Pagnamenta,A.T., Almeida,J., Bacchelli,E., Bailey,A.J., 
Baird,G., Battaglia,A., Berney,T., Bolshakova,N., Bolte,S., Bolton,P.F., Bourgeron,T., 
Brennan,S., Brian,J., Carson,A.R., Casallo,G., Casey,J., Chu,S.H., Cochrane,L., 
Corsello,C., Crawford,E.L., Crossett,A., Dawson,G., de,J.M., Delorme,R., Drmic,I., 
Duketis,E., Duque,F., Estes,A., Farrar,P., Fernandez,B.A., Folstein,S.E., Fombonne,E., 
Freitag,C.M., Gilbert,J., Gillberg,C., Glessner,J.T., Goldberg,J., Green,J., Guter,S.J., 
Hakonarson,H., Heron,E.A., Hill,M., Holt,R., Howe,J.L., Hughes,G., Hus,V., Igliozzi,R., 
Kim,C., Klauck,S.M., Kolevzon,A., Korvatska,O., Kustanovich,V., Lajonchere,C.M., 
Lamb,J.A., Laskawiec,M., Leboyer,M., Le,C.A., Leventhal,B.L., Lionel,A.C., Liu,X.Q., 
Lord,C., Lotspeich,L., Lund,S.C., Maestrini,E., Mahoney,W., Mantoulan,C., 
Marshall,C.R., McConachie,H., McDougle,C.J., McGrath,J., McMahon,W.M., 
Melhem,N.M., Merikangas,A., Migita,O., Minshew,N.J., Mirza,G.K., Munson,J., 
Nelson,S.F., Noakes,C., Noor,A., Nygren,G., Oliveira,G., Papanikolaou,K., Parr,J.R., 
Parrini,B., Paton,T., Pickles,A., Piven,J., Posey,D.J., Poustka,A., Poustka,F., Prasad,A., 
Ragoussis,J., Renshaw,K., Rickaby,J., Roberts,W., Roeder,K., Roge,B., Rutter,M.L., 
Bierut,L.J., Rice,J.P., Salt,J., Sansom,K., Sato,D., Segurado,R., Senman,L., Shah,N., 
Sheffield,V.C., Soorya,L., Sousa,I., Stoppioni,V., Strawbridge,C., Tancredi,R., Tansey,K., 
Thiruvahindrapduram,B., Thompson,A.P., Thomson,S., Tryfon,A., Tsiantis,J., van,E.H.,
305
Vincent,J.B., Volkmar,F., Wallace,S., Wang,K., Wang,Z., Wassink,T.H., Wing,K., 
Wittemeyer,K., Wood,S., Yaspan,B.L., Zurawiecki,D., Zwaigenbaum,L., Betancur,C., 
Buxbaum,J.D., Cantor,R.M., Cook,E.H., Coon,H., Cuccaro,M.L., Gallagher,L., 
Geschwind,D.H., Gill,M., Haines,J.L., Miller,J., Monaco,A.P., Nurnberger,J.I., Jr., 
Paterson,A.D., Pericak-Vance,M.A., Schellenberg,G.D., Scherer,S.W., Sutcliffe,J.S., 
Szatmari,P., Vicente,A.M., Vieland,V.J., Wijsman,E.M., Devlin,B., Ennis,S., and 
Hallmayer,J. (2010). A genome-wide scan for common alleles affecting risk for autism. 
Hum. Mol. Genet. 19, 4072-4082.
Appenrodt,E. and Schwarzberg,H. (2003). Methylphenidate-induced motor activity in rats: 
modulation by melatonin and vasopressin. Pharmacol. Biochem. Behav. 75, 67-73.
Balsamo,J. and Lilien,J. (1990). N-cadherin is stably associated with and is an acceptor for 
a cell surface N-acetylgalactosaminylphosphotransferase. J. Biol. Chem. 265, 2923-2928.
Bates,T.C., Luciano,M., Medland,S.E., Montgomery,G.W., Wright,M.J., and Martin,N.G.
(2011). Genetic variance in a component of the language acquisition device: ROBO1 
polymorphisms associated with phonological buffer deficits. Behav. Genet. 41, 50-57.
Bess,E., Fisslthaler,B., Fromel,T., and Fleming,! (2011). Nitric Oxide-Induced Activation 
of the AMP-Activated Protein Kinase alpha2 Subunit Attenuates IkappaB Kinase Activity 
and Inflammatory Responses in Endothelial Cells. PLoS. One. 6, e20848.
Bhattacharjee,A.K., Chang,L., White,L., Bazinet,R.P., and Rapoport,S.I. (2006). D- 
Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving 
arachidonic acid in unanesthetized rats. J. Cereb. Blood Flow Metab 26, 1378-1388.
Boso,M., Emanuele,E., Minoretti,P., Arra,M., Politi,P., Ucelli di,N.S., and Barale,F. 
(2006). Alterations of circulating endogenous secretory RAGE and S100A9 levels 
indicating dysfunction of the AGE-RAGE axis in autism. Neurosci. Lett. 410, 169-173.
Boyle,L. and Kaufmann,W.E. (2010). The behavioral phenotype of FMR1 mutations. Am. 
J. Med. Genet. C. Semin. Med. Genet. 154C, 469-476.
Bradley,W.E., Raelson,J.V., Dubois,D.Y., Godin,E., Fournier,H., Prive,C., Allard,R., 
Pinchuk,V., Lapalme,M., Paulussen,R.J., and Belouchi,A. (2010). Hotspots of large rare 
deletions in the human genome. PLoS. One. 5, e9401.
Bremer,A., Giacobini,M., Eriksson,M., Gustavsson,P., Nordin,V., Fernell,E., Gillberg,C., 
Nordgren,A., Uppstromer,A., Anderlid,B.M., Nordenskjold,M., and Schoumans,J. (2011). 
Copy number variation characteristics in subpopulations of patients with autism spectrum 
disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156, 115-124.
Briancon-Marjollet,A., Ghogha,A., Nawabi,H., Triki,I., Auziol,C., Fromont,S., Piche,C., 
Enslen,H., Chebli,K., Cloutier,J.F., Castellani,V., Debant,A., and Lamarche-Vane,N.
(2008). Trio mediates netrin-1-induced Rac1 activation in axon outgrowth and guidance. 
Mol. Cell Biol. 28, 2314-2323.
Brinton,R.E. and Gruener,R. (1987). Vasopressin promotes neurite growth in cultured 
embryonic neurons. Synapse 1, 329-334.
306
Bucan,M., Abrahams,B.S., Wang,K., Glessner,J.T., Herman,E.I., Sonnenblick,L.I., varez 
Retuerto,A.I., Imielinski,M., Hadley,D., Bradfield,J.P., Kim,C., Gidaya,N.B., Lindquist,I., 
Hutman,T., Sigman,M., Kustanovich,V., Lajonchere,C.M., Singleton,A., Kim,J., 
Wassink,T.H., McMahon,W.M., Owley,T., Sweeney,J.A., Coon,H., Nurnberger,J.I., 
Li,M., Cantor,R.M., Minshew,N.J., Sutcliffe,J.S., Cook,E.H., Dawson,G., Buxbaum,J.D., 
Grant,S.F., Schellenberg,G.D., Geschwind,D.H., and Hakonarson,H. (2009). Genome- 
wide analyses of exonic copy number variants in a family-based study point to novel 
autism susceptibility genes. PLoS. Genet. 5, e1000536.
Camargo,L.M., Collura,V., Rain,J.C., Mizuguchi,K., Hermjakob,H., Kerrien,S., 
Bonnert,T.P., Whiting,P.J., and Brandon,N.J. (2007). Disrupted in Schizophrenia 1 
Interactome: evidence for the close connectivity of risk genes and a potential synaptic 
basis for schizophrenia. Mol. Psychiatry 12, 74-86.
Caron,C. and Rutter,M. (1991). Comorbidity in child psychopathology: concepts, issues 
and research strategies. J. Child Psychol. Psychiatry 32, 1063-1080.
Casteel,D.E., Zhuang,S., Gudi,T., Tang,J., Vuica,M., Desiderio,S., and Pilz,R.B. (2002). 
cGMP-dependent protein kinase I beta physically and functionally interacts with the 
transcriptional regulator TFII-I. J. Biol. Chem. 277, 32003-32014.
Cavaliere,C., Cirillo,G., Bianco,M.R., Adriani,W., De,S.A., Leo,D., Perrone-Capano,C., 
and Papa,M. (2011). Methylphenidate administration determines enduring changes in 
neuroglial network in rats. Eur. Neuropsychopharmacol.
Chen,J., Zacharek,A., Li,Y., Li,A., Wang,L., Katakowski,M., Roberts,C., Lu,M., and 
Chopp,M. (2006). N-cadherin mediates nitric oxide-induced neurogenesis in young and 
retired breeder neurospheres. Neuroscience 140, 377-388.
Chen,N., Furuya,S., Shinoda,Y., Yumoto,M., Ohtake,A., Sato,K., Doi,H., Hashimoto,Y., 
Kudo,Y., and Higashi,H. (2003). Extracellular carbohydrate-signal triggering cAMP- 
dependent protein kinase-dependent neuronal actin-reorganization. Neuroscience 122, 
985-995.
Choe,E.S. and Wang,J.Q. (2002). CaMKII regulates amphetamine-induced ERK1/2 
phosphorylation in striatal neurons. Neuroreport 13, 1013-1016.
Chou,D.K., Zhang,J., Smith,F.I., McCaffery,P., and Jungalwala,F.B. (2004). 
Developmental expression of receptor for advanced glycation end products (RAGE), 
amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their 
role in neurite outgrowth and cell migration. J. Neurochem. 90, 1389-1401.
Coquelle,F.M., Levy,T., Bergmann,S., Wolf,S.G., Bar-El,D., Sapir,T., Brody,Y., Orr,I., 
Barkai,N., Eichele,G., and Reiner,O. (2006). Common and divergent roles for members of 
the mouse DCX superfamily. Cell Cycle 5, 976-983.
Couto,J.M., Gomez,L., Wigg,K., Ickowicz,A., Pathare,T., Malone,M., Kennedy,J.L., 
Schachar,R., and Barr,C.L. (2009). Association of attention-deficit/hyperactivity disorder 
with a candidate region for reading disabilities on chromosome 6p. Biol. Psychiatry 66, 
368-375.
307
Deiss,V., Strazielle,C., and Lalonde,R. (2000). Regional brain variations of cytochrome 
oxidase activity and motor co-ordination in staggerer mutant mice. Neuroscience 95, 903­
911.
Djouder,N., Tuerk,R.D., Suter,M., Salvioni,P., Thali,R.F., Scholz,R., Vaahtomeri,K., 
Auchli,Y., Rechsteiner,H., Brunisholz,R.A., Viollet,B., Makela,T.P., Wallimann,T., 
Neumann,D., and Krek,W. (2010). PKA phosphorylates and inactivates AMPKalpha to 
promote efficient lipolysis. EMBO J. 29, 469-481.
Doulazmi,M., Capone,F., Frederic,F., Bakouche,J., Lemaigre-Dubreuil,Y., and Mariani,J. 
(2006). Cerebellar purkinje cell loss in heterozygous rora+/- mice: a longitudinal study. J. 
Neurogenet. 20, 1-17.
Elia,J., Gai,X., Xie,H.M., Perin,J.C., Geiger,E., Glessner,J.T., D'arcy,M., Deberardinis,R., 
Frackelton,E., Kim,C., Lantieri,F., Muganga,B.M., Wang,L., Takeda,T., Rappaport,E.F., 
Grant,S.F., Berrettini,W., Devoto,M., Shaikh,T.H., Hakonarson,H., and White,P.S. (2010). 
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially 
associated with neurodevelopmental genes. Mol. Psychiatry 15, 637-646.
Emanuele,E., Boso,M., Brondino,N., Pietra,S., Barale,F., Ucelli di,N.S., and Politi,P.
(2010). Increased serum levels of high mobility group box 1 protein in patients with 
autistic disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 681-683.
Evans,J.P., Meslin,E.M., Marteau,T.M., and Caulfield,T. (2011). Genomics. Deflating the 
genomic bubble. Science 331, 861-862.
Farzin,F., Perry,H., Hessl,D., Loesch,D., Cohen,J., Bacalman,S., Gane,L., Tassone,F., 
Hagerman,P., and Hagerman,R. (2006). Autism spectrum disorders and attention- 
deficit/hyperactivity disorder in boys with the fragile X premutation. J. Dev. Behav. 
Pediatr. 27, S137-S144.
Fliers,E.A., Vasquez,A.A., Poelmans,G., Rommelse,N., Altink,M., Buschgens,C., 
Asherson,P., Banaschewski,T., Ebstein,R., Gill,M., Miranda,A., Mulas,F., Oades,R.D., 
Roeyers,H., Rothenberger,A., Sergeant,J., Sonuga-Barke,E., Steinhausen,H.C., 
Faraone,S.V., Buitelaar,J.K., and Franke,B. (2011). Genome-wide association study of 
motor coordination problems in ADHD identifies genes for brain and muscle function. 
World J. Biol. Psychiatry.
Franke,B., Neale,B.M., and Faraone,S.V. (2009). Genome-wide association studies in 
ADHD. Hum. Genet. 126, 13-50.
Frost,J.A., Steen,H., Shapiro,P., Lewis,T., Ahn,N., Shaw,P.E., and Cobb,M.H. (1997). 
Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. 
EMBO J. 16, 6426-6438.
Gai,X., Xie,H.M., Perin,J.C., Takahashi,N., Murphy,K., Wenocur,A.S., D'arcy,M., 
O'Hara,R.J., Goldmuntz,E., Grice,D.E., Shaikh,T.H., Hakonarson,H., Buxbaum,J.D., 
Elia,J., and White,P.S. (2011). Rare structural variation of synapse and neurotransmission 
genes in autism. Mol. Psychiatry.
Ghose,A. and VanVactor,.D. (2002). GAPs in Slit-Robo signaling. Bioessays 24, 401-404.
308
Gleeson,J.G., Lin,P.T., Flanagan,L.A., and Walsh,C.A. (1999). Doublecortin is a 
microtubule-associated protein and is expressed widely by migrating neurons. Neuron 23, 
257-271.
Glessner,J.T., Wang,K., Cai,G., Korvatska,O., Kim,C.E., Wood,S., Zhang,H., Estes,A., 
Brune,C.W., Bradfield,J.P., Imielinski,M., Frackelton,E.C., Reichert,J., Crawford,E.L., 
Munson,J., Sleiman,P.M., Chiavacci,R., Annaiah,K., Thomas,K., Hou,C., Glaberson,W., 
Flory,J., Otieno,F., Garris,M., Soorya,L., Klei,L., Piven,J., Meyer,K.J., Anagnostou,E., 
Sakurai,T., Game,R.M., Rudd,D.S., Zurawiecki,D., McDougle,C.J., Davis,L.K., Miller,J., 
Posey,D.J., Michaels,S., Kolevzon,A., Silverman,J.M., Bernier,R., Levy,S.E., 
Schultz,R.T., Dawson,G., Owley,T., McMahon,W.M., Wassink,T.H., Sweeney,J.A., 
Nurnberger,J.I., Coon,H., Sutcliffe,J.S., Minshew,N.J., Grant,S.F., Bucan,M., Cook,E.H., 
Buxbaum,J.D., Devlin,B., Schellenberg,G.D., and Hakonarson,H. (2009). Autism 
genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459, 
569-573.
Gonzalez-Gronow,M., Cuchacovich,M., Francos,R., Cuchacovich,S., Fernandez,M.P., 
Blanco,A., Bowers,E.V., Kaczowka,S., and Pizzo,S.V. (2010). Antibodies against the 
voltage-dependent anion channel (VDAC) and its protective ligand hexokinase-I in 
children with autism. J. Neuroimmunol. 227, 153-161.
Grabham,P.W., Seale,G.E., Bennecib,M., Goldberg,D.J., and Vallee,R.B. (2007). 
Cytoplasmic dynein and LIS1 are required for microtubule advance during growth cone 
remodeling and fast axonal outgrowth. J. Neurosci. 27, 5823-5834.
Grimm-Jorgensen,Y. (1987). Somatostatin and calcitonin stimulate neurite regeneration of 
molluscan neurons in vitro. Brain Res. 403, 121-126.
Guan,S., Chen,M., Woodley,D., and Li,W. (2007). Nckbeta adapter controls 
neuritogenesis by maintaining the cellular paxillin level. Mol. Cell Biol. 27, 6001-6011.
Hamdan,F.F., Daoud,H., Rochefort,D., Piton,A., Gauthier,J., Langlois,M., Foomani,G., 
Dobrzeniecka,S., Krebs,M.O., Joober,R., Lafreniere,R.G., Lacaille,J.C., Mottron,L., 
Drapeau,P., Beauchamp,M.H., Phillips,M.S., Fombonne,E., Rouleau,G.A., and 
Michaud,J.L. (2010). De novo mutations in FOXP1 in cases with intellectual disability, 
autism, and language impairment. Am. J. Hum. Genet. 87, 671-678.
Hassanzadeh,P. and Rahimpour,S. (2011). The cannabinergic system is implicated in the 
upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl)
215, 129-141.
Hayashita-Kinoh,H., Kinoh,H., Okada,A., Komori,K., Itoh,Y., Chiba,T., Kajita,M., 
Yana,I., and Seiki,M. (2001). Membrane-type 5 matrix metalloproteinase is expressed in 
differentiated neurons and regulates axonal growth. Cell Growth Differ. 12, 573-580.
Hedlund,E., Pruszak,J., Lardaro,T., Ludwig,W., Vinuela,A., Kim,K.S., and Isacson,O.
(2008). Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain 
dopamine neurons survive enrichment by fluorescence-activated cell sorting and function 
in an animal model of Parkinson's disease. Stem Cells 26, 1526-1536.
309
Heussler,H.S., Suri,M., Young,I.D., and Muenke,M. (2002). Extreme variability of 
expression of a Sonic Hedgehog mutation: attention difficulties and holoprosencephaly. 
Arch. Dis. Child 86, 293-296.
Hino,S., Tanji,C., Nakayama,K.I., and Kikuchi,A. (2005). Phosphorylation of beta-catenin 
by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its 
ubiquitination. Mol. Cell Biol. 25, 9063-9072.
Horn,D., Kapeller,J., Rivera-Brugues,N., Moog,U., Lorenz-Depiereux,B., Eck,S., 
Hempel,M., Wagenstaller,J., Gawthrope,A., Monaco,A.P., Bonin,M., Riess,O., 
Wohlleber,E., Illig,T., Bezzina,C.R., Franke,A., Spranger,S., Villavicencio-Lorini,P., 
Seifert,W., Rosenfeld,J., Klopocki,E., Rappold,G.A., and Strom,T.M. (2010). 
Identification of FOXP1 deletions in three unrelated patients with mental retardation and 
significant speech and language deficits. Hum. Mutat. 31, E1851-E1860.
Hussman,J.P., Chung,R.H., Griswold,A.J., Jaworkski,J.M., Salyakina,D., Ma,D., 
Konidari,I., Whitehead,P.L., Vance,J.M., Martin,E.R., Cuccaro,M.L., Gilbert,J.R., 
Haines,J.L., and Pericak-Vance,M.A. (2011). A noise-reduction GWAS analysis 
implicates altered regulation of neurite outgrowth and guidance in autism. Mol. Autism 2,
1.
Janssens,B., Goossens,S., Staes,K., Gilbert,B., van,H.J., Colpaert,C., Bruyneel,E., 
Mareel,M., and Van,R.F. (2001). alphaT-catenin: a novel tissue-specific beta-catenin- 
binding protein mediating strong cell-cell adhesion. J. Cell Sci. 114, 3177-3188.
Jin,P., Sun,Y., and Grabowski,G.A. (1998). Role of Sp proteins and RORalpha in 
transcription regulation of murine prosaposin. J. Biol. Chem. 273, 13208-13216.
Joksimovic,M., Yun,B.A., Kittappa,R., Anderegg,A.M., Chang,W.W., Taketo,M.M., 
McKay,R.D., and Awatramani,R.B. (2009). Wnt antagonism of Shh facilitates midbrain 
floor plate neurogenesis. Nat. Neurosci. 12, 125-131.
Jones,D.C. and Kuhar,M.J. (2006). Cocaine-amphetamine-regulated transcript expression 
in the rat nucleus accumbens is regulated by adenylyl cyclase and the cyclic adenosine 5'- 
monophosphate/protein kinase a second messenger system. J. Pharmacol. Exp. Ther. 317, 
454-461.
Kang,C. and Drayna,D. (2011). Genetics of Speech and Language Disorders. Annu. Rev. 
Genomics Hum. Genet.
Kato,T., Mizoguchi,Y., Monji,A., Horikawa,H., Suzuki,S.O., Seki,Y., Iwaki,T., 
Hashioka,S., and Kanba,S. (2008). Inhibitory effects of aripiprazole on interferon-gamma- 
induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem. 
106, 815-825.
Kim,D.W. and Cochran,B.H. (2001). JAK2 activates TFII-I and regulates its interaction 
with extracellular signal-regulated kinase. Mol. Cell Biol. 21, 3387-3397.
Kitagawa,H., Ray,W.J., Glantschnig,H., Nantermet,P.V., Yu,Y., Leu,C.T., Harada,S., 
Kato,S., and Freedman,L.P. (2007). A regulatory circuit mediating convergence between 
Nurr1 transcriptional regulation and Wnt signaling. Mol. Cell Biol. 27, 7486-7496.
310
Konstantoulas,C.J., Parmar,M., and Li,M. (2010). FoxPl promotes midbrain identity in 
embryonic stem cell-derived dopamine neurons by regulating Pitx3. J. Neurochem. 113, 
836-847.
Kriegsfeld,L.J., Eliasson,M.J., Demas,G.E., Blackshaw,S., Dawson,T.M., Nelson,R.J., and 
Snyder,S.H. (1999). Nocturnal motor coordination deficits in neuronal nitric oxide 
synthase knock-out mice. Neuroscience 89, 311-315.
Lackner,L.L., Horner,J.S., and Nunnari,J. (2009). Mechanistic analysis of a dynamin 
effector. Science 325, 874-877.
Lander,E.S. (2011a). Genome-sequencing anniversary. The accelerator. Science 331, 
1024.
Lander,E.S. (2011b). Initial impact of the sequencing of the human genome. Nature 470, 
187-197.
Laplante,I., Beliveau,R., and Paquin,J. (2004). RhoA/ROCK and Cdc42 regulate cell-cell 
contact and N-cadherin protein level during neurodetermination of P19 embryonal stem 
cells. J. Neurobiol. 60, 289-307.
Lasky-Su,J., Neale,B.M., Franke,B., Anney,R.J., Zhou,K., Maller,J.B., Vasquez,A.A., 
Chen,W., Asherson,P., Buitelaar,J., Banaschewski,T., Ebstein,R., Gill,M., Miranda,A., 
Mulas,F., Oades,R.D., Roeyers,H., Rothenberger,A., Sergeant,J., Sonuga-Barke,E., 
Steinhausen,H.C., Taylor,E., Daly,M., Laird,N., Lange,C., and Faraone,S.V. (2008). 
Genome-wide association scan of quantitative traits for attention deficit hyperactivity 
disorder identifies novel associations and confirms candidate gene associations. Am. J. 
Med. Genet. B Neuropsychiatr. Genet. 147B, 1345-1354.
Lee,H.S., Park,M.H., Yang,S.J., Park,K.C., Kim,N.S., Kim,Y.S., Kim,D.I., Yoo,H.S., 
Choi,E.J., and Yeom,Y.I. (2007). Novel candidate targets of Wnt/beta-catenin signaling in 
hepatoma cells. Life Sci. 80, 690-698.
Lee,J.M., Kim,I.S., Kim,H., Lee,J.S., Kim,K., Yim,H.Y., Jeong,J., Kim,J.H., Kim,J.Y., 
Lee,H., Seo,S.B., Kim,H., Rosenfeld,M.G., Kim,K.I., and Baek,S.H. (2010). RORalpha 
attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon 
cancer. Mol. Cell 37, 183-195.
Lee,K.M., Jo,S., Kim,H., Lee,J., and Park,C.S. (2011). Functional modulation of AMP- 
activated protein kinase by cereblon. Biochim. Biophys. Acta 1813, 448-455.
Lesch,K.P., Timmesfeld,N., Renner,T.J., Halperin,R., Roser,C., Nguyen,T.T., Craig,D.W., 
Romanos,J., Heine,M., Meyer,J., Freitag,C., Warnke,A., Romanos,M., Schafer,H., 
Walitza,S., Reif,A., Stephan,D.A., and Jacob,C. (2008). Molecular genetics of adult 
ADHD: converging evidence from genome-wide association and extended pedigree 
linkage studies. J. Neural Transm. 115, 1573-1585.
Lesch,K.P., Selch,S., Renner,T.J., Jacob,C., Nguyen,T.T., Hahn,T., Romanos,M., 
Walitza,S., Shoichet,S., Dempfle,A., Heine,M., Boreatti-Hummer,A., Romanos,J., Gross- 
Lesch,S., Zerlaut,H., Wultsch,T., Heinzel,S., Fassnacht,M., Fallgatter,A., Allolio,B., 
Schafer,H., Warnke,A., Reif,A., Ropers,H.H., and Ullmann,R. (2011). Genome-wide copy
311
number variation analysis in attention-deficit/hyperactivity disorder: association with 
neuropeptide Y gene dosage in an extended pedigree. Mol. Psychiatry 16, 491-503.
Leyfer,O.T., Woodruff-Borden,J., Klein-Tasman,B.P., Fricke,J.S., and Mervis,C.B.
(2006). Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. 
Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 615-622.
Lo-Castro,A., D'Agati,E., and Curatolo,P. (2011). ADHD and genetic syndromes. Brain 
Dev. 33, 456-461.
Ma,W., Tavakoli,T., Derby,E., Serebryakova,Y., Rao,M.S., and Mattson,M.P. (2008). 
Cell-extracellular matrix interactions regulate neural differentiation of human embryonic 
stem cells. BMC. Dev. Biol. 8, 90.
Ma,D., Salyakina,D., Jaworski,J.M., Konidari,I., Whitehead,P.L., Andersen,A.N., 
Hoffman,J.D., Slifer,S.H., Hedges,D.J., Cukier,H.N., Griswold,A.J., McCauley,J.L., 
Beecham,G.W., Wright,H.H., Abramson,R.K., Martin,E.R., Hussman,J.P., Gilbert,J.R., 
Cuccaro,M.L., Haines,J.L., and Pericak-Vance,M.A. (2009). A genome-wide association 
study of autism reveals a common novel risk locus at 5p14.1. Ann. Hum. Genet. 73, 263­
273.
Maestrini,E., Pagnamenta,A.T., Lamb,J.A., Bacchelli,E., Sykes,N.H., Sousa,I., Toma,C., 
Barnby,G., Butler,H., Winchester,L., Scerri,T.S., Minopoli,F., Reichert,J., Cai,G., 
Buxbaum,J.D., Korvatska,O., Schellenberg,G.D., Dawson,G., de,B.A., Minderaa,R.B., 
Mulder,E.J., Morris,A.P., Bailey,A.J., and Monaco,A.P. (2010). High-density SNP 
association study and copy number variation analysis of the AUTS1 and AUTS5 loci 
implicate the IMMP2L-DOCK4 gene region in autism susceptibility. Mol. Psychiatry 15, 
954-968.
Marshall,C.R., Noor,A., Vincent,J.B., Lionel,A.C., Feuk,L., Skaug,J., Shago,M., 
Moessner,R., Pinto,D., Ren,Y., Thiruvahindrapduram,B., Fiebig,A., Schreiber,S., 
Friedman,J., Ketelaars,C.E., Vos,Y.J., Ficicioglu,C., Kirkpatrick,S., Nicolson,R., 
Sloman,L., Summers,A., Gibbons,C.A., Teebi,A., Chitayat,D., Weksberg,R., 
Thompson,A., Vardy,C., Crosbie,V., Luscombe,S., Baatjes,R., Zwaigenbaum,L., 
Roberts,W., Fernandez,B., Szatmari,P., and Scherer,S.W. (2008). Structural variation of 
chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 82, 477-488.
Martin,C.L., Duvall,J.A., Ilkin,Y., Simon,J.S., Arreaza,M.G., Wilkes,K., varez- 
Retuerto,A., Whichello,A., Powell,C.M., Rao,K., Cook,E., and Geschwind,D.H. (2007). 
Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for 
autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 869-876.
Massinen,S., Tammimies,K., Tapia-Paez,I., Matsson,H., Hokkanen,M.E., Soderberg,O., 
Landegren,U., Castren,E., Gustafsson,J.A., Treuter,E., and Kere,J. (2009). Functional 
interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal 
pathways in dyslexia. Hum. Mol. Genet. 18, 2802-2812.
McNamara,R.K., Jandacek,R., Rider,T., Tso,P., Cole-Strauss,A., and Lipton,J.W. (2011). 
Differential effects of antipsychotic medications on polyunsaturated fatty acid
312
biosynthesis in rats: Relationship with liver delta6-desaturase expression. Schizophr. Res.
129, 57-65.
Mick,E., Todorov,A., Smalley,S., Hu,X., Loo,S., Todd,R.D., Biederman,J., Byrne,D., 
Dechairo,B., Guiney,A., McCracken,J., McGough,J., Nelson,S.F., Reiersen,A.M., 
Wilens,T.E., Wozniak,J., Neale,B.M., and Faraone,S.V. (2010). Family-based genome- 
wide association scan of attention-deficit/hyperactivity disorder. J. Am. Acad. Child 
Adolesc. Psychiatry 49, 898-905.
Monea,S., Jordan,B.A., Srivastava,S., DeSouza,S., and Ziff,E.B. (2006). Membrane 
localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding 
protein and cleavage of cadherins. J. Neurosci. 26, 2300-2312.
Montague,P., Barrie,J.A., Thomson,C.E., Kirkham,D., McCallion,A.S., Davies,R.W., 
Kennedy,P.G., and Griffths,I.R. (1998). Cytoskeletal and nuclear localization of myelin 
oligodendrocytic basic protein isoforms. Eur. J. Neurosci. 10, 1321-1328.
Moore,D.L. and Goldberg,J.L. (2011). Multiple transcription factor families regulate axon 
growth and regeneration. Dev. Neurobiol.
Nakada,M., Miyamori,H., Yamashita,J., and Sato,H. (2003). Testican 2 abrogates 
inhibition of membrane-type matrix metalloproteinases by other testican family proteins. 
Cancer Res. 63, 3364-3369.
Neale,B.M., Lasky-Su,J., Anney,R., Franke,B., Zhou,K., Maller,J.B., Vasquez,A.A., 
Asherson,P., Chen,W., Banaschewski,T., Buitelaar,J., Ebstein,R., Gill,M., Miranda,A., 
Oades,R.D., Roeyers,H., Rothenberger,A., Sergeant,J., Steinhausen,H.C., Sonuga- 
Barke,E., Mulas,F., Taylor,E., Laird,N., Lange,C., Daly,M., and Faraone,S.V. (2008). 
Genome-wide association scan of attention deficit hyperactivity disorder. Am. J. Med. 
Genet. B Neuropsychiatr. Genet. 147B, 1337-1344.
Neale,B.M., Medland,S., Ripke,S., Anney,R.J., Asherson,P., Buitelaar,J., Franke,B., 
Gill,M., Kent,L., Holmans,P., Middleton,F., Thapar,A., Lesch,K.P., Faraone,S.V., 
Daly,M., Nguyen,T.T., Schafer,H., Steinhausen,H.C., Reif,A., Renner,T.J., Romanos,M., 
Romanos,J., Warnke,A., Walitza,S., Freitag,C., Meyer,J., Palmason,H., Rothenberger,A., 
Hawi,Z., Sergeant,J., Roeyers,H., Mick,E., and Biederman,J. (2010). Case-control 
genome-wide association study of attention-deficit/hyperactivity disorder. J. Am. Acad. 
Child Adolesc. Psychiatry 49, 906-920.
Newbury,D.F., Winchester,L., Addis,L., Paracchini,S., Buckingham,L.L., Clark,A., 
Cohen,W., Cowie,H., Dworzynski,K., Everitt,A., Goodyer,I.M., Hennessy,E., 
Kindley,A.D., Miller,L.L., Nasir,J., O'Hare,A., Shaw,D., Simkin,Z., Simonoff,E., 
Slonims,V., Watson,J., Ragoussis,J., Fisher,S.E., Seckl,J.R., Helms,P.J., Bolton,P.F., 
Pickles,A., Conti-Ramsden,G., Baird,G., Bishop,D.V., and Monaco,A.P. (2009). CMIP 
and ATP2C2 modulate phonological short-term memory in language impairment. Am. J. 
Hum. Genet. 85, 264-272.
Nguyen Ba-Charvet,K.T., von,B.Y., Guazzi,S., Boncinelli,E., and Godement,P. (1998). A 
potential role for the OTX2 homeoprotein in creating early 'highways' for axon extension 
in the rostral brain. Development 125, 4273-4282.
313
Nguyen,A., Rauch,T.A., Pfeifer,G.P., and Hu,V.W. (2010). Global methylation profiling 
of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders 
and a novel autism candidate gene, RORA, whose protein product is reduced in autistic 
brain. FASEB J. 24, 3036-3051.
Nikolic,M. (2002). The role of Rho GTPases and associated kinases in regulating neurite 
outgrowth. Int. J. Biochem. Cell Biol. 34, 731-745.
O'Roak,B.J., Deriziotis,P., Lee,C., Vives,L., Schwartz,J.J., Girirajan,S., Karakoc,E., 
Mackenzie,A.P., Ng,S.B., Baker,C., Rieder,M.J., Nickerson,D.A., Bernier,R., Fisher,S.E., 
Shendure,J., and Eichler,E.E. (2011). Exome sequencing in sporadic autism spectrum 
disorders identifies severe de novo mutations. Nat. Genet. 43, 585-589.
Oades,R.D., Myint,A.M., Dauvermann,M.R., Schimmelmann,B.G., and Schwarz,M.J.
(2010). Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration 
of associations of cytokines and kynurenine metabolites with symptoms and attention. 
Behav. Brain Funct. 6, 32.
Pagnamenta,A.T., Bacchelli,E., de Jonge,M.V., Mirza,G., Scerri,T.S., Minopoli,F., 
Chiocchetti,A., Ludwig,K.U., Hoffmann,P., Paracchini,S., Lowy,E., Harold,D.H., 
Chapman,J.A., Klauck,S.M., Poustka,F., Houben,R.H., Staal,W.G., Ophoff,R.A., 
O'Donovan,M.C., Williams,J., Nothen,M.M., Schulte-Korne,G., Deloukas,P., 
Ragoussis,J., Bailey,A.J., Maestrini,E., and Monaco,A.P. (2010). Characterization of a 
Family with Rare Deletions in CNTNAP5 and DOCK4 Suggests Novel Risk Loci for 
Autism and Dyslexia. Biol. Psychiatry.
Philippova,M., Joshi,M.B., Kyriakakis,E., Pfaff,D., Erne,P., and Resink,T.J. (2009). A 
guide and guard: the many faces of T-cadherin. Cell Signal. 21, 1035-1044.
Pinto,D., Pagnamenta,A.T., Klei,L., Anney,R., Merico,D., Regan,R., Conroy,J., 
Magalhaes,T.R., Correia,C., Abrahams,B.S., Almeida,J., Bacchelli,E., Bader,G.D., 
Bailey,A.J., Baird,G., Battaglia,A., Berney,T., Bolshakova,N., Bolte,S., Bolton,P.F., 
Bourgeron,T., Brennan,S., Brian,J., Bryson,S.E., Carson,A.R., Casallo,G., Casey,J., 
Chung,B.H., Cochrane,L., Corsello,C., Crawford,E.L., Crossett,A., Cytrynbaum,C., 
Dawson,G., de,J.M., Delorme,R., Drmic,I., Duketis,E., Duque,F., Estes,A., Farrar,P., 
Fernandez,B.A., Folstein,S.E., Fombonne,E., Freitag,C.M., Gilbert,J., Gillberg,C., 
Glessner,J.T., Goldberg,J., Green,A., Green,J., Guter,S.J., Hakonarson,H., Heron,E.A., 
Hill,M., Holt,R., Howe,J.L., Hughes,G., Hus,V., Igliozzi,R., Kim,C., Klauck,S.M., 
Kolevzon,A., Korvatska,O., Kustanovich,V., Lajonchere,C.M., Lamb,J.A., Laskawiec,M., 
Leboyer,M., Le,C.A., Leventhal,B.L., Lionel,A.C., Liu,X.Q., Lord,C., Lotspeich,L., 
Lund,S.C., Maestrini,E., Mahoney,W., Mantoulan,C., Marshall,C.R., McConachie,H., 
McDougle,C.J., McGrath,J., McMahon,W.M., Merikangas,A., Migita,O., Minshew,N.J., 
Mirza,G.K., Munson,J., Nelson,S.F., Noakes,C., Noor,A., Nygren,G., Oliveira,G., 
Papanikolaou,K., Parr,J.R., Parrini,B., Paton,T., Pickles,A., Pilorge,M., Piven,J., 
Ponting,C.P., Posey,D.J., Poustka,A., Poustka,F., Prasad,A., Ragoussis,J., Renshaw,K., 
Rickaby,J., Roberts,W., Roeder,K., Roge,B., Rutter,M.L., Bierut,L.J., Rice,J.P., Salt,J., 
Sansom,K., Sato,D., Segurado,R., Sequeira,A.F., Senman,L., Shah,N., Sheffield,V.C., 
Soorya,L., Sousa,I., Stein,O., Sykes,N., Stoppioni,V., Strawbridge,C., Tancredi,R., 
Tansey,K., Thiruvahindrapduram,B., Thompson,A.P., Thomson,S., Tryfon,A., Tsiantis,J., 
van,E.H., Vincent,J.B., Volkmar,F., Wallace,S., Wang,K., Wang,Z., Wassink,T.H., 
Webber,C., Weksberg,R., Wing,K., Wittemeyer,K., Wood,S., Wu,J., Yaspan,B.L.,
314
Zurawiecki,D., Zwaigenbaum,L., Buxbaum,J.D., Cantor,R.M., Cook,E.H., Coon,H., 
Cuccaro,M.L., Devlin,B., Ennis,S., Gallagher,L., Geschwind,D.H., Gill,M., Haines,J.L., 
Hallmayer,J., Miller,J., Monaco,A.P., Nurnberger,J.I., Jr., Paterson,A.D., Pericak- 
Vance,M.A., Schellenberg,G.D., Szatmari,P., Vicente,A.M., Vieland,V.J., Wijsman,E.M., 
Scherer,S.W., Sutcliffe,J.S., and Betancur,C. (2010). Functional impact of global rare 
copy number variation in autism spectrum disorders. Nature 466, 368-372.
Poelmans,G., Engelen,J.J., Van Lent-Albrechts,J., Smeets,H.J., Schoenmakers,E., 
Franke,B., Buitelaar,J.K., Wuisman-Frerker,M., Erens,W., Steyaert,J., and Schrander- 
Stumpel,C. (2009). Identification of novel dyslexia candidate genes through the analysis 
of a chromosomal deletion. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 140-147.
Poelmans,G., Buitelaar,J.K., Pauls,D.L., and Franke,B. (2011). A theoretical molecular 
network for dyslexia: integrating available genetic findings. Mol. Psychiatry 16, 365-382.
Quincozes-Santos,A., Abib,R.T., Leite,M.C., Bobermin,D., Bambini-Junior,V., 
Goncalves,C.A., Riesgo,R., and Gottfried,C. (2008). Effect of the atypical neuroleptic 
risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol. Cell 
Biochem. 314, 59-63.
Quincozes-Santos,A., Bobermin,L.D., Kleinkauf-Rocha,J., Souza,D.O., Riesgo,R., 
Goncalves,C.A., and Gottfried,C. (2009). Atypical neuroleptic risperidone modulates glial 
functions in C6 astroglial cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 11-15.
Rauly-Lestienne,I., Boutet-Robinet,E., Ailhaud,M.C., Newman-Tancredi,A., and 
Cussac,D. (2007). Differential profile of typical, atypical and third generation 
antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of 
agonist and inverse agonist properties. Naunyn Schmiedebergs Arch. Pharmacol. 376, 93­
105.
Rhee,J., Buchan,T., Zukerberg,L., Lilien,J., and Balsamo,J. (2007). Cables links Robo- 
bound Abl kinase to N-cadherin-bound beta-catenin to mediate Slit-induced modulation of 
adhesion and transcription. Nat. Cell Biol. 9, 883-892.
Robinson,K.N., Manto,K., Buchsbaum,R.J., MacDonald,J.I., and Meakin,S.O. (2005). 
Neurotrophin-dependent tyrosine phosphorylation of Ras guanine-releasing factor 1 and 
associated neurite outgrowth is dependent on the HIKE domain of TrkA. J. Biol. Chem.
280, 225-235.
Roeske,D., Ludwig,K.U., Neuhoff,N., Becker,J., Bartling,J., Bruder,J., Brockschmidt,F.F., 
Warnke,A., Remschmidt,H., Hoffmann,P., Muller-Myhsok,B., Nothen,M.M., and Schulte- 
Korne,G. (2011). First genome-wide association scan on neurophysiological 
endophenotypes points to trans-regulation effects on SLC2A3 in dyslexic children. Mol. 
Psychiatry 16, 97-107.
Rommelse,N.N., Altink,M.E., Fliers,E.A., Martin,N.C., Buschgens,C.J., Hartman,C.A., 
Buitelaar,J.K., Faraone,S.V., Sergeant,J.A., and Oosterlaan,J. (2009). Comorbid problems 
in ADHD: degree of association, shared endophenotypes, and formation of distinct 
subtypes. Implications for a future DSM. J. Abnorm. Child Psychol. 37, 793-804.
315
Rommelse,N.N., Franke,B., Geurts,H.M., Hartman,C.A., and Buitelaar,J.K. (2010). 
Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum 
disorder. Eur. Child Adolesc. Psychiatry 19, 281-295.
Rosenfeld,J.A., Ballif,B.C., Torchia,B.S., Sahoo,T., Ravnan,J.B., Schultz,R., Lamb,A., 
Bejjani,B.A., and Shaffer,L.G. (2010). Copy number variations associated with autism 
spectrum disorders contribute to a spectrum of neurodevelopmental disorders. Genet. 
Med.
Rosso,L., Peteri-Brunback,B., Vouret-Craviari,V., Deroanne,C., Van Obberghen- 
Schilling,E., and Mienville,J.M. (2002). Vasopressin and oxytocin reverse adenosine- 
induced pituicyte stellation via calcium-dependent activation of Cdc42. Eur. J. Neurosci.
16, 2324-2332.
Rothermundt,M., Peters,M., Prehn,J.H., and Arolt,V. (2003). S100B in brain damage and 
neurodegeneration. Microsc. Res. Tech. 60, 614-632.
Sakatani,S., Yamada,K., Homma,C., Munesue,S., Yamamoto,Y., Yamamoto,H., and 
Hirase,H. (2009). Deletion of RAGE causes hyperactivity and increased sensitivity to 
auditory stimuli in mice. PLoS. One. 4, e8309.
Salyakina,D., Ma,D.Q., Jaworski,J.M., Konidari,I., Whitehead,P.L., Henson,R., 
Martinez,D., Robinson,J.L., Sacharow,S., Wright,H.H., Abramson,R.K., Gilbert,J.R., 
Cuccaro,M.L., and Pericak-Vance,M.A. (2010). Variants in several genomic regions 
associated with asperger disorder. Autism Res. 3, 303-310.
Sanders,S.J., Ercan-Sencicek,A.G., Hus,V., Luo,R., Murtha,M.T., Moreno-De-Luca,D., 
Chu,S.H., Moreau,M.P., Gupta,A.R., Thomson,S.A., Mason,C.E., Bilguvar,K., Celestino- 
Soper,P.B., Choi,M., Crawford,E.L., Davis,L., vis Wright,N.R., Dhodapkar,R.M., 
Dicola,M., Dilullo,N.M., Fernandez,T.V., Fielding-Singh,V., Fishman,D.O., Frahm,S., 
Garagaloyan,R., Goh,G.S., Kammela,S., Klei,L., Lowe,J.K., Lund,S.C., McGrew,A.D., 
Meyer,K.A., Moffat,W.J., Murdoch,J.D., O'Roak,B.J., Ober,G.T., Pottenger,R.S., 
Raubeson,M.J., Song,Y., Wang,Q., Yaspan,B.L., Yu,T.W., Yurkiewicz,I.R., 
Beaudet,A.L., Cantor,R.M., Curland,M., Grice,D.E., Gunel,M., Lifton,R.P., Mane,S.M., 
Martin,D.M., Shaw,C.A., Sheldon,M., Tischfield,J.A., Walsh,C.A., Morrow,E.M., 
Ledbetter,D.H., Fombonne,E., Lord,C., Martin,C.L., Brooks,A.I., Sutcliffe,J.S., 
Cook,E.H., Jr., Geschwind,D., Roeder,K., Devlin,B., and State MW (2011). Multiple 
Recurrent De Novo CNVs, Including Duplications of the 7q11.23 Williams Syndrome 
Region, Are Strongly Associated with Autism. Neuron 70, 863-885.
Scerri,T.S., Paracchini,S., Morris,A., MacPhie,I.L., Talcott,J., Stein,J., Smith,S.D., 
Pennington,B.F., Olson,R.K., DeFries,J.C., Monaco,A.P., and Richardson,A.J. (2010). 
Identification of candidate genes for dyslexia susceptibility on chromosome 18. PLoS. 
One. 5, e13712.
Sebat,J., Lakshmi,B., Malhotra,D., Troge,J., Lese-Martin,C., Walsh,T., Yamrom,B., 
Yoon,S., Krasnitz,A., Kendall,J., Leotta,A., Pai,D., Zhang,R., Lee,Y.H., Hicks,J., 
Spence,S.J., Lee,A.T., Puura,K., Lehtimaki,T., Ledbetter,D., Gregersen,P.K., Bregman,J., 
Sutcliffe,J.S., Jobanputra,V., Chung,W., Warburton,D., King,M.C., Skuse,D., 
Geschwind,D.H., Gilliam,T.C., Ye,K., and Wigler,M. (2007). Strong association of de 
novo copy number mutations with autism. Science 316, 445-449.
316
Semina,E.V., Rubina,K.A., Rutkevich,P.N., Voyno-Yasenetskaya,T.A., Parfyonova,Y.V., 
and Tkachuk,V.A. (2009). T-cadherin activates Rac1 and Cdc42 and changes endothelial 
permeability. Biochemistry (Mosc. ) 74, 362-370.
Shang,Y., Wang,H., Mercaldo,V., Li,X., Chen,T., and Zhuo,M. (2009). Fragile X mental 
retardation protein is required for chemically-induced long-term potentiation of the 
hippocampus in adult mice. J. Neurochem. 111, 635-646.
Sharma,M., Purdy,S.C., and Kelly,A.S. (2009). Comorbidity of auditory processing, 
language, and reading disorders. J. Speech Lang Hear. Res. 52, 706-722.
Shim,S.Y., Samuels,B.A., Wang,J., Neumayer,G., Belzil,C., Ayala,R., Shi,Y., Shi,Y., 
Tsai,L.H., and Nguyen,M.D. (2008). Ndel1 controls the dynein-mediated transport of 
vimentin during neurite outgrowth. J. Biol. Chem. 283, 12232-12240.
Stein,E. and Tessier-Lavigne,M. (2001). Hierarchical organization of guidance receptors: 
silencing of netrin attraction by slit through a Robo/DCC receptor complex. Science 291, 
1928-1938.
Syed,Z., Dudbridge,F., and Kent,L. (2007). An investigation of the neurotrophic factor 
genes GDNF, NGF, and NT3 in susceptibility to ADHD. Am. J. Med. Genet. B 
Neuropsychiatr. Genet. 144B, 375-378.
Taipale,M., Kaminen,N., Nopola-Hemmi,J., Haltia,T., Myllyluoma,B., Lyytinen,H., 
Muller,K., Kaaranen,M., Lindsberg,P.J., Hannula-Jouppi,K., and Kere,J. (2003). A 
candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat 
domain protein dynamically regulated in brain. Proc. Natl. Acad. Sci. U. S. A 100, 11553­
11558.
Takami,G., Ota,M., Nakashima,A., Kaneko,Y.S., Mori,K., Nagatsu,T., and Ota,A. (2010). 
Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole 
phosphorylates AMP-activated protein kinase. J. Neural Transm. 117, 1139-1153.
Takeuchi,T., Misaki,A., Liang,S.B., Tachibana,A., Hayashi,N., Sonobe,H., and Ohtsuki,Y.
(2000). Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its 
characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma 
cells. J. Neurochem. 74, 1489-1497.
Tan,B., Luan,Z., Wei,X., He,Y., Wei,G., Johnstone,B.H., Farlow,M., and Du,Y. (2011). 
AMP-activated kinase mediates adipose stem cell-stimulated neuritogenesis of PC12 cells. 
Neuroscience 181, 40-47.
Tanda,K., Nishi,A., Matsuo,N., Nakanishi,K., Yamasaki,N., Sugimoto,T., Toyama,K., 
Takao,K., and Miyakawa,T. (2009). Abnormal social behavior, hyperactivity, impaired 
remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal 
nitric oxide synthase knockout mice. Mol. Brain 2, 19.
Tapia-Paez,I., Tammimies,K., Massinen,S., Roy,A.L., and Kere,J. (2008). The complex of 
TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal 
migration and dyslexia. FASEB J. 22, 3001-3009.
317
Tedeschi,A., Nguyen,T., Steele,S.U., Feil,S., Naumann,U., Feil,R., and Di,G.S. (2009). 
The tumor suppressor p53 transcriptionally regulates cGKI expression during neuronal 
maturation and is required for cGMP-dependent growth cone collapse. J. Neurosci. 29, 
15155-15160.
Turgeon,D., Chouinard,S., Belanger,P., Picard,S., Labbe,J.F., Borgeat,P., and Belanger,A.
(2003). Glucuronidation of arachidonic and linoleic acid metabolites by human UDP- 
glucuronosyltransferases. J. Lipid Res. 44, 1182-1191.
Uniprot Consortium (2010). The Universal Protein Resource (UniProt) in 2010. Nucleic 
Acids Res. 38, D142-D148.
Van der Aa, .N., Rooms,L., Vandeweyer,G., van den,E.J., Reyniers,E., Fichera,M., 
Romano,C., Delle,C.B., Mortier,G., Menten,B., Destree,A., Maystadt,I., Mannik,K., 
Kurg,A., Reimand,T., McMullan,D., Oley,C., Brueton,L., Bongers,E.M., van Bon,B.W., 
Pfund,R., Jacquemont,S., Ferrarini,A., Martinet,D., Schrander-Stumpel,C., 
Stegmann,A.P., Frints,S.G., de Vries,B.B., Ceulemans,B., and Kooy,R.F. (2009). Fourteen 
new cases contribute to the characterization of the 7q11.23 microduplication syndrome. 
Eur. J. Med. Genet. 52, 94-100.
Voineagu,I., Wang,X., Johnston,P., Lowe,J.K., Tian,Y., Horvath,S., Mill,J., Cantor,R.M., 
Blencowe,B.J., and Geschwind,D.H. (2011). Transcriptomic analysis of autistic brain 
reveals convergent molecular pathology. Nature.
Wagner,G., Kovacs,J., Low,P., Orosz,F., and Ovadi,J. (2001). Tubulin and microtubule 
are potential targets for brain hexokinase binding. FEBS Lett. 509, 81-84.
Walowitz,J.L. and Roth,J.A. (1999). Activation of ERK1 and ERK2 is required for 
manganese-induced neurite outgrowth in rat pheochromocytoma (PC12) cells. J. Neurosci. 
Res. 57, 847-854.
Wang,J.Q. and Lau,Y.S. (2001). Dose-related alteration in nitric oxide synthase mRNA 
expression induced by amphetamine and the full D1 dopamine receptor agonist SKF- 
82958 in mouse striatum. Neurosci. Lett. 311, 5-8.
Wang,L., Li,S., and Jungalwala,F.B. (2008a). Receptor for advanced glycation end 
products (RAGE) mediates neuronal differentiation and neurite outgrowth. J. Neurosci. 
Res. 86, 1254-1266.
Wang,Z., Gardiner,N.J., and Fernyhough,P. (2008b). Blockade of hexokinase activity and 
binding to mitochondria inhibits neurite outgrowth in cultured adult rat sensory neurons. 
Neurosci. Lett. 434, 6-11.
Wang,K., Zhang,H., Ma,D., Bucan,M., Glessner,J.T., Abrahams,B.S., Salyakina,D., 
Imielinski,M., Bradfield,J.P., Sleiman,P.M., Kim,C.E., Hou,C., Frackelton,E., 
Chiavacci,R., Takahashi,N., Sakurai,T., Rappaport,E., Lajonchere,C.M., Munson,J., 
Estes,A., Korvatska,O., Piven,J., Sonnenblick,L.I., varez Retuerto,A.I., Herman,E.I., 
Dong,H., Hutman,T., Sigman,M., Ozonoff,S., Klin,A., Owley,T., Sweeney,J.A., 
Brune,C.W., Cantor,R.M., Bernier,R., Gilbert,J.R., Cuccaro,M.L., McMahon,W.M., 
Miller,J., State MW, Wassink,T.H., Coon,H., Levy,S.E., Schultz,R.T., Nurnberger,J.I., 
Haines,J.L., Sutcliffe,J.S., Cook,E.H., Minshew,N.J., Buxbaum,J.D., Dawson,G.,
318
Grant,S.F., Geschwind,D.H., Pericak-Vance,M.A., Schellenberg,G.D., and Hakonarson,H. 
(2009a). Common genetic variants on 5p14.1 associate with autism spectrum disorders. 
Nature 459, 528-533.
Wang,J., Rahman,M.F., Duhart,H.M., Newport,G.D., Patterson,T.A., Murdock,R.C., 
Hussain,S.M., Schlager,J.J., and Ali,S.F. (2009b). Expression changes of dopaminergic 
system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. 
Neurotoxicology 30, 926-933.
Wang,L., Kobayashi,T., Piao,X., Shiono,M., Takagi,Y., Mineki,R., Taka,H., Zhang,D., 
Abe,M., Sun,G., Hagiwara,Y., Okimoto,K., Matsumoto,I., Kouchi,M., and Hino,O.
(2010). Serine 62 is a phosphorylation site in folliculin, the Birt-Hogg-Dube gene product. 
FEBS Lett. 584, 39-43.
Weiske,J., Albring,K.F., and Huber,O. (2007). The tumor suppressor Fhit acts as a 
repressor of beta-catenin transcriptional activity. Proc. Natl. Acad. Sci. U. S. A 104, 
20344-20349.
Weiss,L.A., Arking,D.E., Daly,M.J., and Chakravarti,A. (2009). A genome-wide linkage 
and association scan reveals novel loci for autism. Nature 461, 802-808.
Wen,Y., Gu,J., Knaus,U.G., Thomas,L., Gonzales,N., and Nadler,J.L. (2000). Evidence 
that 12-lipoxygenase product 12-hydroxyeicosatetraenoic acid activates p21-activated 
kinase. Biochem. J. 349, 481-487.
Wigg,K.G., Feng,Y., Crosbie,J., Tannock,R., Kennedy,J.L., Ickowicz,A., Malone,M., 
Schachar,R., and Barr,C.L. (2008). Association of ADHD and the Protogenin gene in the 
chromosome 15q21.3 reading disabilities linkage region. Genes Brain Behav. 7, 877-886.
Williams,N.M., Zaharieva,I., Martin,A., Langley,K., Mantripragada,K., Fossdal,R., 
Stefansson,H., Stefansson,K., Magnusson,P., Gudmundsson,O.O., Gustafsson,O., 
Holmans,P., Owen,M.J., O'Donovan,M., and Thapar,A. (2010). Rare chromosomal 
deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide 
analysis. Lancet.
Won,H., Mah,W., Kim,E., Kim,J.W., Hahm,E.K., Kim,M.H., Cho,S., Kim,J., Jang,H., 
Cho,S.C., Kim,B.N., Shin,M.S., Seo,J., Jeong,J., Choi,S.Y., Kim,D., Kang,C., and Kim,E.
(2011). GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. 
Nat. Med. 17, 566-572.
Wong,K., Ren,X.R., Huang,Y.Z., Xie,Y., Liu,G., Saito,H., Tang,H., Wen,L., Brady- 
Kalnay,S.M., Mei,L., Wu,J.Y., Xiong,W.C., and Rao,Y. (2001). Signal transduction in 
neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in 
the Slit-Robo pathway. Cell 107, 209-221.
Xiang,M., Mohamalawari,D., and Rao,R. (2005). A novel isoform of the secretory 
pathway Ca2+,Mn(2+)-ATPase, hSPCA2, has unusual properties and is expressed in the 
brain. J. Biol. Chem. 280, 11608-11614.
319
Zhao,Y., Fung,C., Shin,D., Shin,B.C., Thamotharan,S., Sankar,R., Ehninger,D., Silva,A., 
and Devaskar,S.U. (2010). Neuronal glucose transporter isoform 3 deficient mice 
demonstrate features of autism spectrum disorders. Mol. Psychiatry 15, 286-299.
Zhou,H.L., Baraniak,A.P., and Lou,H. (2007). Role for Fox-1/Fox-2 in mediating the 
neuronal pathway of calcitonin/calcitonin gene-related peptide alternative RNA 
processing. Mol. Cell Biol. 27, 830-841.
Zoubovsky,S.P., Pogorelov,V.M., Taniguchi,Y., Kim,S.H., Yoon,P., Nwulia,E., Sawa,A., 
Pletnikov,M.V., and Kamiya,A. (2011). Working memory deficits in neuronal nitric oxide 
synthase knockout mice: Potential impairments in prefrontal cortex mediated cognitive 
function. Biochem. Biophys. Res. Commun. 408, 707-712.
320
Chapter 8
Nederlandse samenvatting (Dutch summary) 
List of publications 
Acknowledgements 
Curriculum vitae
PhD thesis titles in Donders Graduate 
School of Cognitive Neuroscience series

Nederlandse samenvatting (Dutch summary)
Het belangrijkste doel van deze thesis bestaat erin om nieuwe genen en functionele 
eiwitnetwerken te identificeren voor vier neurologische ontwikkelingsstoornissen: 
dyslexie, aandachtstekort- en hyperactiviteitsstoornis - beter bekend onder de Engelse 
benaming attention deficit hyperactivity disorder of ADHD - motorische 
coördinatieproblemen en autisme spectrum stoornissen (ASS).
Hoofdstuk 1
In dit hoofdstuk wordt een overzicht gegeven van de klinische symptomen, de prevalentie, 
erfelijkheid, gen-identificatiemethoden en neuroanatomische bevindingen voor elk van de 
vier ontwikkelingsstoornissen. Daarnaast wordt kort ingegaan op de klinische en 
genetische overlap tussen deze stoornissen en worden de algemene en specifieke doelen 
van de thesis besproken.
Hoofdstuk 2
Een studie wordt beschreven waarin vier nieuwe kandidaatgenen voor dyslexie werden 
gevonden op basis van de doorgedreven genetische analyse van een zeer kleine deletie van 
het uiteinde van chromosoom 21, die samen met dyslexie gevonden werd bij een vader en 
zijn drie zonen.
Hoofdstuk 3
In dit hoofdstuk worden de resultaten besproken van de eerste genoom-wijde 
associatiestudie voor motorische coördinatieproblemen bij kinderen met ADHD uit het 
“International Multicentre ADHD Genetics” (IMAGE) project. Op basis van uitgebreide 
bioinformatica- en literatuuranalyses van de belangrijkste bevindingen uit deze studie, 
wordt er vervolgens een functioneel eiwitnetwerk “gebouwd” dat 8 van de 9 statistisch 
meest significant geassocieerde genen/eiwitten bevat en zowel betrokken is bij het 
reguleren van de uitgroei van zenuwcellen (of neuronen) tijdens de ontwikkeling van de 
hersenen (de zogenaamde “neurite outgrowth”) als de functie van skeletale spiercellen.
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Hoofdstuk 4
Zoals voor motorische coördinatieproblemen (Hoofdstuk 3), wordt er in dit hoofdstuk een 
netwerk voor dyslexie “gebouwd” door het integreren van de bestaande kennis over 14 
kandidaatgenen voor dyslexie. Hierbij blijkt dat 10 van deze 14 genen voor eiwitten 
coderen die samen een functioneel netwerk vormen dat niet alleen betrokken is bij 
“neurite outgrowth” maar ook bij “neuronal migration”, het zich verplaatsen of migreren 
van (groepen) neuronen naar een specifieke plaats in de hersenen tijdens de ontwikkeling.
Hoofdstuk 5
In dit hoofdstuk worden de resultaten gepresenteerd van bioinformatica- en 
literatuuranalyses van de 85 meest significant geassocieerde genen uit de vijf tot op heden 
gepubliceerde genoom-wijde studies voor ADHD. De eiwitten die gecodeerd worden door 
45 van deze genen passen in een netwerk dat - zoals ook het geval is voor motorische 
coördinatieproblemen en dyslexie - “neurite outgrowth” reguleert. Bovendien is er 
bijkomend bewijs voor de betrokkenheid van dit netwerk bij ADHD, aangezien een aantal 
van de genen uit het netwerk ook gevonden zijn - en daardoor dubbel voorkomen of 
ontbreken - in zogenaamde “copy number variations” of CNVs in mensen met ADHD. 
Daarnaast komen er aanwijzingen voor een rol van dit netwerk bij ADHD uit genetische 
studies in muizen en uit gegevens over hoe de expressie - m.a.w. de door het 
overeenkomstige gen geproduceerde hoeveelheid - van sommige netwerk-eiwitten 
beïnvloed wordt door de stimulantia, medicatie die vaak gebruikt wordt om ADHD te 
behandelen.
Hoofdstuk 6
Dit hoofdstuk van de thesis beschrijft de doorgedreven analyse van 200 kandidaatgenen 
voor ASS die uit vijf gepubliceerde genoom-wijde associatiestudies komen. Door het 
toepassen van een aanpak die erg lijkt op deze gebruikt in hoofdstukken 3,4 en 5, werd 
gevonden dat de eiwitten gecodeerd door 117 van de 200 belangrijkste ASS- 
kandidaatgenen functioneren in drie verschillende netwerken die betrokken zijn bij de 
synthese van steroidhormonen in de testis, “neurite outgrowth”, en het reguleren van de 
“synaps”, de verbinding tussen twee zenuwcellen. Zoals bij ADHD, bestaat er ook 
bijkomend bewijs voor de betrokkenheid van deze netwerken bij (het ontstaan van) ASS, 
zoals bv. het veelvuldig voorkomen van CNVs bij mensen met ASS.
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Daarnaast worden vele eiwitten uit de verschillende ASS-netwerken gemoduleerd en/of 
gereguleerd door de zogenaamde AKAP-eiwitten, en de AKAP-familie van eiwitten vormt 
daardoor een mogelijk doelwit voor het ontwikkelen van nieuwe behandelingen voor ASS.
Hoofdstuk 7
In het laatste hoofdstuk van de thesis wordt in meer detail gekeken naar en dieper 
ingegaan op de mogelijke onderliggende redenen voor zowel de overlap (of pleiotropie) - 
zoals bv. het feit dat “neurite outgrowth” een gemeenschappelijk, onderliggend biologisch 
proces lijkt te zijn voor alle vier de ontwikkelingsstoornissen - als de verschillen (of 
specificiteit) tussen de netwerken voor de verschillende aandoeningen. Bijkomend wordt 
besproken hoe sommige van de geïdentificeerde kandidaatgenen/eiwitten een mogelijk 
doelwit kunnen vormen voor het ontwikkelen van nieuwe behandelingen en worden er 
enkele suggesties gedaan voor toekomstig onderzoek.
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